#BEGIN_DRUGCARD DB02944

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
3458-28-4

# ChEBI_ID:
28729

# Chemical_Formula:
C6H12O6

# Chemical_IUPAC_Name:
(2S,3S,4R,5R,6S)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
A hexose or fermentable monosaccharide and isomer of glucose from manna, the ash Fraxinus ornus and related plants. (From Grant & Hackh&#39;s Chemical Dictionary, 5th ed & Random House Unabridged Dictionary, 2d ed)

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
7.13E+005 mg/L (at 17 °C)

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Alpha-D-Mannose

# HET_ID:
MAN

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3-,4+,5-,6-/m0/s1

# InChI_Key:
InChIKey=WQZGKKKJIJFFOK-QYESYBIKSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
C00936

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
2944

# Mechanism_Of_Action:
Not Available

# Melting_Point:
132 dec °C

# Molecular_Weight_Avg:
180.1559

# Molecular_Weight_Mono:
180.063388116

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1GAH

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-2.6

# Predicted_LogS:
0.64

# Predicted_Water_Solubility:
7.82e+02 g/l

# Primary_Accession_No:
DB02944

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
6992084

# PubChem_Substance_ID:
46504527

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT02113

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
OC[C@@H]1O[C@H](O)[C@@H](O)[C@H](O)[C@H]1O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:21:41 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
12.9 (at 0 °C)

# Drug_Target_10_Cellular_Location:
Secreted protein

# Drug_Target_10_Chromosome_Location:
Not Available

# Drug_Target_10_Drug_References:
Not Available

# Drug_Target_10_Essentiality:
Non-Essential

# Drug_Target_10_GenAtlas_ID:
APOH

# Drug_Target_10_GenBank_ID_Gene:
X53595

# Drug_Target_10_GenBank_ID_Protein:
Not Available

# Drug_Target_10_GeneCard_ID:
Not Available

# Drug_Target_10_Gene_Name:
APOH

# Drug_Target_10_Gene_Sequence:
>1038 bp
ATGATTTCTCCAGTGCTCATCTTGTTCTCGAGTTTTCTCTGCCATGTTGCTATTGCAGGA
CGGACCTGTCCCAAGCCAGATGATTTACCATTTTCCACAGTGGTCCCGTTAAAAACATTC
TATGAGCCAGGAGAAGAGATTACGTATTCCTGCAAGCCGGGCTATGTGTCCCGAGGAGGG
ATGAGAAAGTTTATCTGCCCTCTCACAGGACTGTGGCCCATCAACACTCTGAAATGTACA
CCCAGAGTATGTCCTTTTGCTGGAATCTTAGAAAATGGAGCCGTACGCTATACGACTTTT
GAATATCCCAACACGATCAGTTTTTCTTGTAACACTGGGTTTTATCTGAATGGCGCTGAT
TCTGCCAAGTGCACTGAGGAAGGAAAATGGAGCCCGGAGCTTCCTGTCTGTGCTCCCATC
ATCTGCCCTCCACCATCCATACCTACGTTTGCAACACTTCGTGTTTATAAGCCATCAGCT
GGAAACAATTCCCTCTATCGGGACACAGCAGTTTTTGAATGTTTGCCACAACATGCGATG
TTTGGAAATGATACAATTACCTGCACGACACATGGAAATTGGACTAAATTACCAGAATGC
AGGGAAGTAAAATGCCCATTCCCATCAAGACCAGACAATGGATTTGTGAACTATCCTGCA
AAACCAACACTTTATTACAAGGATAAAGCCACATTTGGCTGCCATGATGGATATTCTCTG
GATGGCCCGGAAGAAATAGAATGTACCAAACTGGGAAACTGGTCTGCCATGCCAAGTTGT
AAAGCATCTTGTAAATTACCTGTGAAAAAAGCCACTGTGGTGTACCAAGGAGAGAGAGTA
AAGATTCAGGAAAAATTTAAGAATGGAATGCTACATGGTGATAAAGTTTCTTTCTTCTGC
AAAAATAAGGAAAAGAAGTGTAGCTATACAGAGGATGCTCAGTGTATAGATGGCACTATC
GAAGTCCCCAAATGCTTCAAGGAACACAGTTCTCTGGCTTTTTGGAAAACTGATGCATCC
GATGTAAAGCCATGCTAA

# Drug_Target_10_General_Function:
Not Available

# Drug_Target_10_General_References:
1339416	Day JR, O'Hara PJ, Grant FJ, Lofton-Day C, Berkaw MN, Werner P, Arnaud P: Molecular cloning and sequence analysis of the cDNA encoding human apolipoprotein H (beta 2-glycoprotein I). Int J Clin Lab Res. 1992;21(3):256-63.
1650181	Steinkasserer A, Estaller C, Weiss EH, Sim RB, Day AJ: Complete nucleotide and deduced amino acid sequence of human beta 2-glycoprotein I. Biochem J. 1991 Jul 15;277 ( Pt 2):387-91.
1655523	Kristensen T, Schousboe I, Boel E, Mulvihill EM, Hansen RR, Moller KB, Moller NP, Sottrup-Jensen L: Molecular cloning and mammalian expression of human beta 2-glycoprotein I cDNA. FEBS Lett. 1991 Sep 9;289(2):183-6.
1748314	Mehdi H, Nunn M, Steel DM, Whitehead AS, Perez M, Walker L, Peeples ME: Nucleotide sequence and expression of the human gene encoding apolipoprotein H (beta 2-glycoprotein I). Gene. 1991 Dec 15;108(2):293-8.
1777418	Matsuura E, Igarashi M, Igarashi Y, Nagae H, Ichikawa K, Yasuda T, Koike T: Molecular definition of human beta 2-glycoprotein I (beta 2-GPI) by cDNA cloning and inter-species differences of beta 2-GPI in alternation of anticardiolipin binding. Int Immunol. 1991 Dec;3(12):1217-21.
6587378	Lozier J, Takahashi N, Putnam FW: Complete amino acid sequence of human plasma beta 2-glycoprotein I. Proc Natl Acad Sci U S A. 1984 Jun;81(12):3640-4.
9914524	Okkels H, Rasmussen TE, Sanghera DK, Kamboh MI, Kristensen T: Structure of the human beta2-glycoprotein I (apolipoprotein H) gene. Eur J Biochem. 1999 Jan;259(1-2):435-40.

# Drug_Target_10_HGNC_ID:
HGNC:616

# Drug_Target_10_HPRD_ID:
Not Available

# Drug_Target_10_ID:
4850

# Drug_Target_10_Locus:
17q23-qter

# Drug_Target_10_Molecular_Weight:
38298

# Drug_Target_10_Name:
Beta-2-glycoprotein 1

# Drug_Target_10_Number_of_Residues:
345

# Drug_Target_10_PDB_ID:
1C1Z

# Drug_Target_10_Pathway:
Not Available

# Drug_Target_10_Pfam_Domain_Function:
PF00084	Sushi
PF09014	Sushi_2

# Drug_Target_10_Protein_Sequence:
>Beta-2-glycoprotein 1
MISPVLILFSSFLCHVAIAGRTCPKPDDLPFSTVVPLKTFYEPGEEITYSCKPGYVSRGG
MRKFICPLTGLWPINTLKCTPRVCPFAGILENGAVRYTTFEYPNTISFSCNTGFYLNGAD
SAKCTEEGKWSPELPVCAPIICPPPSIPTFATLRVYKPSAGNNSLYRDTAVFECLPQHAM
FGNDTITCTTHGNWTKLPECREVKCPFPSRPDNGFVNYPAKPTLYYKDKATFGCHDGYSL
DGPEEIECTKLGNWSAMPSCKASCKVPVKKATVVYQGERVKIQEKFKNGMLHGDKVSFFC
KNKEKKCSYTEDAQCIDGTIEVPKCFKEHSSLAFWKTDASDVKPC

# Drug_Target_10_Reaction:
Not Available

# Drug_Target_10_Signals:
1-19

# Drug_Target_10_Specific_Function:
Binds to various kinds of negatively charged substances such as heparin, phospholipids, and dextran sulfate. May prevent activation of the intrinsic blood coagulation cascade by binding to phospholipids on the surface of damaged cells

# Drug_Target_10_SwissProt_ID:
P02749

# Drug_Target_10_SwissProt_Name:
APOH_HUMAN

# Drug_Target_10_Synonyms:
APC inhibitor
Activated protein C- binding protein
Anticardiolipin cofactor
Apo-H
Apolipoprotein H
B2GPI
Beta(2)GPI
Beta-2-glycoprotein 1 precursor
Beta-2-glycoprotein I

# Drug_Target_10_Theoretical_pI:
8.03

# Drug_Target_10_Transmembrane_Regions:
None

# Drug_Target_11_Cellular_Location:
Not Available

# Drug_Target_11_Chromosome_Location:
Not Available

# Drug_Target_11_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_11_Essentiality:
Non-Essential

# Drug_Target_11_GenAtlas_ID:
Not Available

# Drug_Target_11_GenBank_ID_Gene:
U27584

# Drug_Target_11_GenBank_ID_Protein:
1002527

# Drug_Target_11_GeneCard_ID:
Not Available

# Drug_Target_11_Gene_Name:
cslB

# Drug_Target_11_Gene_Sequence:
>1521 bp
ATGAAGATGCTGAATAAACTAGCCGGATACTTATTGCCGATCATGGTGCTGCTGAATGTG
GCACCATGCTTAGGTCAGGTTGTTGCTTCAAATGAAACTTTATACCAGGTTGTAAAGGAG
GTAAAACCCGGTGGTCTGGTACAGATTGCCGATGGGACTTATAAAGATGTTCAGCTGATT
GTCAGCAATTCAGGAAAATCTGGTTTGCCCATCACTATTAAAGCCCTGAACCCGGGTAAG
GTTTTTTTTACCGGAGATGCTAAAGTAGAGCTGAGGGGCGAGCACCTGATACTGGAAGGC
ATCTGGTTTAAAGACGGGAACAGAGCTATTCAGGCATGGAAATCACATGGACCCGGATTG
GTGGCTATATATGGTAGCTATAACCGCATTACCGCATGTGTATTTGATTGTTTTGATGAA
GCCAATTCTGCTTACATTACTACTTCGCTTACCGAAGACGGAAAGGTACCTCAACATTGC
CGCATAGACCATTGCAGTTTTACCGATAAGATCACTTTTGACCAGGTAATTAACCTGAAC
AATACAGCCAGAGCTATTAAAGACGGTTCGGTGGGAGGACCGGGGATGTACCATCGTGTT
GATCACTGTTTTTTTTCCAATCCGCAAAAACCGGGTAATGCCGGAGGGGGAATCAGGATT
GGCTATTACCGTAATGATATAGGCCGTTGTCTGGTAGACTCTAACCTGTTTATGCGTCAG
GATTCGGAAGCAGAGATCATCACCAGCAAATCGCAGGAAAATGTTTATTATGGTAATACT
TACCTGAATTGCCAGGGCACCATGAACTTTCGTCACGGTGATCATCAGGTGGCCATTAAC
AATTTTTATATAGGCAATGACCAGCGATTTGGATACGGGGGAATGTTTGTTTGGGGAAGC
AGGCATGTCATAGCCTGTAATTATTTTGAGCTGTCCGAAACCATAAAGTCGAGGGGGAAC
GCCGCATTGTATTTAAACCCCGGTGCTATGGCTTCGGAGCATGCTCTTGCTTTCGATATG
TTGATAGCCAACAACGCTTTCATCAATGTAAATGGGTATGCCATCCATTTTAATCCATTG
GATGAGCGCAGAAAAGAATATTGTGCAGCCAATAGGCTTAAGTTCGAAACCCCGCACCAG
CTAATGTTAAAAGGCAATCTTTTCTTTAAGGATAAACCTTATGTTTACCCATTTTTTAAA
GATGATTATTTTATAGCAGGGAAAAATAGCTGGACTGGTAATGTAGCCTTAGGTGTGGAA
AAGGGAATCCCTGTTAACATTTCGGCCAATAGGTCTGCCTATAAGCCGGTAAAAATTAAA
GATATCCAGCCCATAGAAGGAATCGCTCTTGATCTCAATGCGCTGATCAGCAAAGGCATT
ACAGGAAAGCCCCTTAGCTGGGATGAAGTAAGGCCCTACTGGTTAAAAGAAATGCCCGGG
ACGTATGCTTTAACGGCCAGGCTTTCTGCAGATAGGGCTGCAAAGTTTAAAGCCGTAATT
AAAAGAAATAAAGAGCACTGA

# Drug_Target_11_General_Function:
Not Available

# Drug_Target_11_General_References:
10600383	Huang W, Matte A, Li Y, Kim YS, Linhardt RJ, Su H, Cygler M: Crystal structure of chondroitinase B from Flavobacterium heparinum and its complex with a disaccharide product at 1.7 A resolution. J Mol Biol. 1999 Dec 17;294(5):1257-69.
10618199	Tkalec AL, Fink D, Blain F, Zhang-Sun G, Laliberte M, Bennett DC, Gu K, Zimmermann JJ, Su H: Isolation and expression in Escherichia coli of cslA and cslB, genes coding for the chondroitin sulfate-degrading enzymes chondroitinase AC and chondroitinase B, respectively, from Flavobacterium heparinum. Appl Environ Microbiol. 2000 Jan;66(1):29-35.
11327856	Huang W, Boju L, Tkalec L, Su H, Yang HO, Gunay NS, Linhardt RJ, Kim YS, Matte A, Cygler M: Active site of chondroitin AC lyase revealed by the structure of enzyme-oligosaccharide complexes and mutagenesis. Biochemistry. 2001 Feb 27;40(8):2359-72.
12063249	Pojasek K, Raman R, Kiley P, Venkataraman G, Sasisekharan R: Biochemical characterization of the chondroitinase B active site. J Biol Chem. 2002 Aug 23;277(34):31179-86. Epub 2002 Jun 12.

# Drug_Target_11_HGNC_ID:
Not Available

# Drug_Target_11_HPRD_ID:
Not Available

# Drug_Target_11_ID:
2430

# Drug_Target_11_Locus:
Not Available

# Drug_Target_11_Molecular_Weight:
56323

# Drug_Target_11_Name:
Chondroitinase B

# Drug_Target_11_Number_of_Residues:
506

# Drug_Target_11_PDB_ID:
1DBO

# Drug_Target_11_Pathway:
Not Available

# Drug_Target_11_Pfam_Domain_Function:
Not Available

# Drug_Target_11_Protein_Sequence:
>Chondroitinase B precursor
MKMLNKLAGYLLPIMVLLNVAPCLGQVVASNETLYQVVKEVKPGGLVQIADGTYKDVQLI
VSNSGKSGLPITIKALNPGKVFFTGDAKVELRGEHLILEGIWFKDGNRAIQAWKSHGPGL
VAIYGSYNRITACVFDCFDEANSAYITTSLTEDGKVPQHCRIDHCSFTDKITFDQVINLN
NTARAIKDGSVGGPGMYHRVDHCFFSNPQKPGNAGGGIRIGYYRNDIGRCLVDSNLFMRQ
DSEAEIITSKSQENVYYGNTYLNCQGTMNFRHGDHQVAINNFYIGNDQRFGYGGMFVWGS
RHVIACNYFELSETIKSRGNAALYLNPGAMASEHALAFDMLIANNAFINVNGYAIHFNPL
DERRKEYCAANRLKFETPHQLMLKGNLFFKDKPYVYPFFKDDYFIAGKNSWTGNVALGVE
KGIPVNISANRSAYKPVKIKDIQPIEGIALDLNALISKGITGKPLSWDEVRPYWLKEMPG
TYALTARLSADRAAKFKAVIKRNKEH

# Drug_Target_11_Reaction:
Eliminative cleavage of dermatan sulfate containing 1,4-beta-D-hexosaminyl and 1,3-beta-D-glucurosonyl or 1,3-alpha-L-iduronosyl linkages to disaccharides containing 4-deoxy-beta-D-gluc-4-enuronosyl groups to yield a 4,5-unsaturated dermatan-sulfate disaccharide (deltaUA-GalNAc-4S).

# Drug_Target_11_Signals:
1-25

# Drug_Target_11_Specific_Function:
Cleaves the glycosaminoglycan, dermatan sulfate

# Drug_Target_11_SwissProt_ID:
Q46079

# Drug_Target_11_SwissProt_Name:
CSLB_PEDHD

# Drug_Target_11_Synonyms:
Chondroitin B eliminase
Chondroitin B lyase
Chondroitin sulfate B lyase
Chondroitinase B precursor
EC 4.2.2.19

# Drug_Target_11_Theoretical_pI:
8.94

# Drug_Target_11_Transmembrane_Regions:
None

# Drug_Target_12_Cellular_Location:
Secreted protein

# Drug_Target_12_Chromosome_Location:
Not Available

# Drug_Target_12_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_12_Essentiality:
Non-Essential

# Drug_Target_12_GenAtlas_ID:
LCN2

# Drug_Target_12_GenBank_ID_Gene:
X83006

# Drug_Target_12_GenBank_ID_Protein:
929657

# Drug_Target_12_GeneCard_ID:
LCN2

# Drug_Target_12_Gene_Name:
LCN2

# Drug_Target_12_Gene_Sequence:
>597 bp
ATGCCCCTAGGTCTCCTGTGGCTGGGCCTAGCCCTGTTGGGGGCTCTGCATGCCCAGGCC
CAGGACTCCACCTCAGACCTGATCCCAGCCCCACCTCTGAGCAAGGTCCCTCTGCAGCAG
AACTTCCAGGACAACCAATTCCAGGGGAAGTGGTATGTGGTAGGCCTGGCAGGGAATGCA
ATTCTCAGAGAAGACAAAGACCCGCAAAAGATGTATGCCACCATCTATGAGCTGAAAGAA
GACAAGAGCTACAATGTCACCTCCGTCCTGTTTAGGAAAAAGAAGTGTGACTACTGGATC
AGGACTTTTGTTCCAGGTTGCCAGCCCGGCGAGTTCACGCTGGGCAACATTAAGAGTTAC
CCTGGATTAACGAGTTACCTCGTCCGAGTGGTGAGCACCAACTACAACCAGCATGCTATG
GTGTTCTTTAAGAAAGTTTCTCAAAACAGGGAGTACTTCAAGATCACCCTCTACGGGAGA
ACCAAGGAGCTGACTTCGGAACTAAAGGAGAACTTCATCCGCTTCTCCAAATCTCTGGGC
CTCCCTGAAAACCACATCGTCTTCCCTGTCCCAATCGACCAGTGTATCGACGGCTGA

# Drug_Target_12_General_Function:
Involved in lipophilic molecule transport

# Drug_Target_12_General_References:
10339412	Coles M, Diercks T, Muehlenweg B, Bartsch S, Zolzer V, Tschesche H, Kessler H: The solution structure and dynamics of human neutrophil gelatinase-associated lipocalin. J Mol Biol. 1999 May 28;289(1):139-57.
10684642	Goetz DH, Willie ST, Armen RS, Bratt T, Borregaard N, Strong RK: Ligand preference inferred from the structure of neutrophil gelatinase associated lipocalin. Biochemistry. 2000 Feb 29;39(8):1935-41.
1281792	Triebel S, Blaser J, Reinke H, Tschesche H: A 25 kDa alpha 2-microglobulin-related protein is a component of the 125 kDa form of human gelatinase. FEBS Lett. 1992 Dec 21;314(3):386-8.
7683678	Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N: Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem. 1993 May 15;268(14):10425-32.
7835423	Bartsch S, Tschesche H: Cloning and expression of human neutrophil lipocalin cDNA derived from bone marrow and ovarian cancer cells. FEBS Lett. 1995 Jan 9;357(3):255-9.
8060329	Bundgaard JR, Sengelov H, Borregaard N, Kjeldsen L: Molecular cloning and expression of a cDNA encoding NGAL: a lipocalin expressed in human neutrophils. Biochem Biophys Res Commun. 1994 Aug 15;202(3):1468-75.

# Drug_Target_12_HGNC_ID:
HGNC:6526

# Drug_Target_12_HPRD_ID:
02551

# Drug_Target_12_ID:
1782

# Drug_Target_12_Locus:
9q34

# Drug_Target_12_Molecular_Weight:
22588

# Drug_Target_12_Name:
Neutrophil gelatinase-associated lipocalin

# Drug_Target_12_Number_of_Residues:
198

# Drug_Target_12_PDB_ID:
1NGL

# Drug_Target_12_Pathway:
Not Available

# Drug_Target_12_Pfam_Domain_Function:
PF00061	Lipocalin

# Drug_Target_12_Protein_Sequence:
>Neutrophil gelatinase-associated lipocalin precursor
MPLGLLWLGLALLGALHAQAQDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNA
ILREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIKSY
PGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSELKENFIRFSKSLG
LPENHIVFPVPIDQCIDG

# Drug_Target_12_Reaction:
Not Available

# Drug_Target_12_Signals:
1-20

# Drug_Target_12_Specific_Function:
Transport of small lipophilic substances (Potential)

# Drug_Target_12_SwissProt_ID:
P80188

# Drug_Target_12_SwissProt_Name:
NGAL_HUMAN

# Drug_Target_12_Synonyms:
25 kDa alpha-2-microglobulin-related subunit of MMP-9
Lipocalin-2
NGAL
Neutrophil gelatinase-associated lipocalin precursor
Oncogene 24p3
p25

# Drug_Target_12_Theoretical_pI:
9.24

# Drug_Target_12_Transmembrane_Regions:
None

# Drug_Target_13_Cellular_Location:
Not Available

# Drug_Target_13_Chromosome_Location:
Not Available

# Drug_Target_13_Drug_References:
Not Available

# Drug_Target_13_Essentiality:
Non-Essential

# Drug_Target_13_GenAtlas_ID:
IGHG1

# Drug_Target_13_GenBank_ID_Gene:
Not Available

# Drug_Target_13_GenBank_ID_Protein:
Not Available

# Drug_Target_13_GeneCard_ID:
Not Available

# Drug_Target_13_Gene_Name:
IGHG1

# Drug_Target_13_Gene_Sequence:
Not Available

# Drug_Target_13_General_Function:
Not Available

# Drug_Target_13_General_References:
1002129	Dreker L, Schwarz J, Reichel W, Hilschmann N: [Rule of antibody structure. the primary structure of a monoclonal IgG1 immunoglobulin (myeloma protein Nie), I: Purification and characterization of the protein, the L- and H-chains, the cyanogenbromide cleavage products, and the disulfide bridges (author's transl)] Hoppe Seylers Z Physiol Chem. 1976 Nov;357(11):1515-40.
4923144	Gall WE, Edelman GM: The covalent structure of a human gamma G-immunoglobulin. X. Intrachain disulfide bonds. Biochemistry. 1970 Aug 4;9(16):3188-96.
5489771	Cunningham BA, Rutishauser U, Gall WE, Gottlieb PD, Waxdal MJ, Edelman GM: The covalent structure of a human gamma G-immunoglobulin. VII. Amino acid sequence of heavy-chain cyanogen bromide fragments H1-H4. Biochemistry. 1970 Aug 4;9(16):3161-70.
5530842	Rutishauser U, Cunningham BA, Bennett C, Konigsberg WH, Edelman GM: The covalent structure of a human gamma G-immunoglobulin. 8. Amino acid sequence of heavy-chain cyanogen bromide fragments H5-H7. Biochemistry. 1970 Aug 4;9(16):3171-81.
6287432	Ellison JW, Berson BJ, Hood LE: The nucleotide sequence of a human immunoglobulin C gamma1 gene. Nucleic Acids Res. 1982 Jul 10;10(13):4071-9.
6884994	Schmidt WE, Jung HD, Palm W, Hilschmann N: [Three-dimensional structure determination of antibodies. Primary structure of crystallized monoclonal immunoglobulin IgG1 KOL, I] Hoppe Seylers Z Physiol Chem. 1983 Jun;364(6):713-47.
7236608	Deisenhofer J: Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. Biochemistry. 1981 Apr 28;20(9):2361-70.
826475	Ponstingl H, Hilschmann N: [The rule of antibody structure. The primary structure of a monoclonal IgG1 immunoglobulin (myeloma protein Nie). III. The chymotryptic peptides of the H-chain, alignment of the tryptic peptides and discussion of the complete structure] Hoppe Seylers Z Physiol Chem. 1976 Nov;357(11):1571-604.

# Drug_Target_13_HGNC_ID:
HGNC:5525

# Drug_Target_13_HPRD_ID:
Not Available

# Drug_Target_13_ID:
4785

# Drug_Target_13_Locus:
14q32.33

# Drug_Target_13_Molecular_Weight:
36106

# Drug_Target_13_Name:
Ig gamma-1 chain C region

# Drug_Target_13_Number_of_Residues:
330

# Drug_Target_13_PDB_ID:
1HZH

# Drug_Target_13_Pathway:
Not Available

# Drug_Target_13_Pfam_Domain_Function:
PF07654	C1-set

# Drug_Target_13_Protein_Sequence:
>Ig gamma-1 chain C region
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG
PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN
STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE
LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW
QQGNVFSCSVMHEALHNHYTQKSLSLSPGK

# Drug_Target_13_Reaction:
Not Available

# Drug_Target_13_Signals:
None

# Drug_Target_13_Specific_Function:
Not Available

# Drug_Target_13_SwissProt_ID:
P01857

# Drug_Target_13_SwissProt_Name:
IGHG1_HUMAN

# Drug_Target_13_Synonyms:
Not Available

# Drug_Target_13_Theoretical_pI:
8.31

# Drug_Target_13_Transmembrane_Regions:
None

# Drug_Target_14_Cellular_Location:
Cytoplasmic

# Drug_Target_14_Chromosome_Location:
Not Available

# Drug_Target_14_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_14_Essentiality:
Non-Essential

# Drug_Target_14_GenAtlas_ID:
ACPP

# Drug_Target_14_GenBank_ID_Gene:
M97589

# Drug_Target_14_GenBank_ID_Protein:
189613

# Drug_Target_14_GeneCard_ID:
ACPP

# Drug_Target_14_Gene_Name:
ACPP

# Drug_Target_14_Gene_Sequence:
>1161 bp
ATGAGAGCTGCACCCCTCCTCCTGGCCAGGGCAGCAAGCCTTAGCCTTGGCTTCTTGTTT
CTGCTTTTTTTCTGGCTAGACCGAAGTGTACTAGCCAAGGAGTTGAAGTTTGTGACTTTG
GTGTTTCGGCATGGAGACCGAAGTCCCATTGACACCTTTCCCACTGACCCCATAAAGGAA
TCCTCATGGCCACAAGGATTTGGCCAACTCACCCAGCTGGGCATGGAGCAGCATTATGAA
CTTGGAGAGTATATAAGAAAGAGATATAGAAAATTCTTGAATGAGTCCTATAAACATGAA
CAGGTTTATATTCGAAGCACAGACGTTGACCGGACTTTGATGAGTGCTATGACAAACCTG
GCAGCCCTGTTTCCCCCAGAAGGTGTCAGCATCTGGAATCCTATCCTACTCTGGCAGCCC
ATCCCGGTGCACACAGTTCCTCTTTCTGAAGATCAGTTGCTATACCTGCCTTTCAGGAAC
TGCCCTCGTTTTCAAGAACTTGAGAGTGAGACTTTGAAATCAGAGGAATTCCAGAAGAGG
CTGCACCCTTATAAGGATTTTATAGCTACCTTGGGAAAACTTTCAGGATTACATGGCCAG
GACCTTTTTGGAATTTGGAGTAAAGTCTACGACCCTTTATATTGTGAGAGTGTTCACAAT
TTCACTTTACCCTCCTGGGCCACTGAGGACACCATGACTAAGTTGAGAGAATTGTCAGAA
TTGTCCCTCCTGTCCCTCTATGGAATTCACAAGCAGAAAGAGAAATCTAGGCTCCAAGGG
GGTGTCCTGGTCAATGAAATCCTCAATCACATGAAGAGAGCAACTCAGATACCAAGCTAC
AAAAAACTTATCATGTATTCTGCGCATGACACTACTGTGAGTGGCCTACAGATGGCGCTA
GATGTTTACAACGGACTCCTTCCTCCCTATGCTTCTTGCCACTTGACGGAATTGTACTTT
GAGAAGGGGGAGTACTTTGTGGAGATGTACTACCGGAATGAGACGCAGCACGAGCCGTAT
CCCCTCATGCTACCTGGCTGCAGCCCCAGCTGTCCTCTGGAGAGGTTTGCTGAGCTGGTT
GGCCCTGTGATCCCTCAAGACTGGTCCACGGAGTGTATGACCACAAACAGCCATCAAGGT
ACTGAGGACAGTACAGATTAG

# Drug_Target_14_General_Function:
Involved in acid phosphatase activity

# Drug_Target_14_General_References:
1375464	Sharief FS, Li SS: Structure of human prostatic acid phosphatase gene. Biochem Biophys Res Commun. 1992 May 15;184(3):1468-76.
1989985	Van Etten RL, Davidson R, Stevis PE, MacArthur H, Moore DL: Covalent structure, disulfide bonding, and identification of reactive surface and active site residues of human prostatic acid phosphatase. J Biol Chem. 1991 Feb 5;266(4):2313-9.
2395659	Tailor PG, Govindan MV, Patel PC: Nucleotide sequence of human prostatic acid phosphatase determined from a full-length cDNA clone. Nucleic Acids Res. 1990 Aug 25;18(16):4928.
2712834	Sharief FS, Lee H, Leuderman MM, Lundwall A, Deaven LL, Lee CL, Li SS: Human prostatic acid phosphatase: cDNA cloning, gene mapping and protein sequence homology with lysosomal acid phosphatase. Biochem Biophys Res Commun. 1989 Apr 14;160(1):79-86.
2842184	Vihko P, Virkkunen P, Henttu P, Roiko K, Solin T, Huhtala ML: Molecular cloning and sequence analysis of cDNA encoding human prostatic acid phosphatase. FEBS Lett. 1988 Aug 29;236(2):275-81.
7951074	Sharief FS, Li SS: Nucleotide sequence of human prostatic acid phosphatase ACPP gene, including seven Alu repeats. Biochem Mol Biol Int. 1994 Jun;33(3):561-5.
9804805	LaCount MW, Handy G, Lebioda L: Structural origins of L(+)-tartrate inhibition of human prostatic acid phosphatase. J Biol Chem. 1998 Nov 13;273(46):30406-9.

# Drug_Target_14_HGNC_ID:
HGNC:125

# Drug_Target_14_HPRD_ID:
01378

# Drug_Target_14_ID:
1859

# Drug_Target_14_Locus:
3q21-q23

# Drug_Target_14_Molecular_Weight:
44567

# Drug_Target_14_Name:
Prostatic acid phosphatase

# Drug_Target_14_Number_of_Residues:
386

# Drug_Target_14_PDB_ID:
1ND6

# Drug_Target_14_Pathway:
Not Available

# Drug_Target_14_Pfam_Domain_Function:
PF00328	Acid_phosphat_A

# Drug_Target_14_Protein_Sequence:
>Prostatic acid phosphatase precursor
MRAAPLLLARAASLSLGFLFLLFFWLDRSVLAKELKFVTLVFRHGDRSPIDTFPTDPIKE
SSWPQGFGQLTQLGMEQHYELGEYIRKRYRKFLNESYKHEQVYIRSTDVDRTLMSAMTNL
AALFPPEGVSIWNPILLWQPIPVHTVPLSEDQLLYLPFRNCPRFQELESETLKSEEFQKR
LHPYKDFIATLGKLSGLHGQDLFGIWSKVYDPLYCESVHNFTLPSWATEDTMTKLRELSE
LSLLSLYGIHKQKEKSRLQGGVLVNEILNHMKRATQIPSYKKLIMYSAHDTTVSGLQMAL
DVYNGLLPPYASCHLTELYFEKGEYFVEMYYRNETQHEPYPLMLPGCSPSCPLERFAELV
GPVIPQDWSTECMTTNSHQGTEDSTD

# Drug_Target_14_Reaction:
a phosphate monoester + H2O = an alcohol + phosphate

# Drug_Target_14_Signals:
1-32

# Drug_Target_14_Specific_Function:
A phosphate monoester + H(2)O = an alcohol + phosphate

# Drug_Target_14_SwissProt_ID:
P15309

# Drug_Target_14_SwissProt_Name:
PPAP_HUMAN

# Drug_Target_14_Synonyms:
EC 3.1.3.2
Prostatic acid phosphatase precursor

# Drug_Target_14_Theoretical_pI:
6.19

# Drug_Target_14_Transmembrane_Regions:
None

# Drug_Target_15_Cellular_Location:
Cell membrane

# Drug_Target_15_Chromosome_Location:
Not Available

# Drug_Target_15_Drug_References:
Not Available

# Drug_Target_15_Essentiality:
Non-Essential

# Drug_Target_15_GenAtlas_ID:
RTN4R

# Drug_Target_15_GenBank_ID_Gene:
AL834449

# Drug_Target_15_GenBank_ID_Protein:
Not Available

# Drug_Target_15_GeneCard_ID:
Not Available

# Drug_Target_15_Gene_Name:
RTN4R

# Drug_Target_15_Gene_Sequence:
>1422 bp
ATGAAGAGGGCGTCCGCTGGAGGGAGCCGGCTGCTGGCATGGGTGCTGTGGCTGCAGGCC
TGGCAGGTGGCAGCCCCATGCCCAGGTGCCTGCGTATGCTACAATGAGCCCAAGGTGACG
ACAAGCTGCCCCCAGCAGGGCCTGCAGGCTGTGCCCGTGGGCATCCCTGCTGCCAGCCAG
CGCATCTTCCTGCACGGCAACCGCATCTCGCATGTGCCAGCTGCCAGCTTCCGTGCCTGC
CGCAACCTCACCATCCTGTGGCTGCACTCGAATGTGCTGGCCCGAATTGATGCGGCTGCC
TTCACTGGCCTGGCCCTCCTGGAGCAGCTGGACCTCAGCGATAATGCACAGCTCCGGTCT
GTGGACCCTGCCACATTCCACGGCCTGGGCCGCCTACACACGCTGCACCTGGACCGCTGC
GGCCTGCAGGAGCTGGGCCCGGGGCTGTTCCGCGGCCTGGCTGCCCTGCAGTACCTCTAC
CTGCAGGACAACGCGCTGCAGGCACTGCCTGATGACACCTTCCGCGACCTGGGCAACCTC
ACACACCTCTTCCTGCACGGCAACCGCATCTCCAGCGTGCCCGAGCGCGCCTTCCGTGGG
CTGCACAGCCTCGACCGTCTCCTACTGCACCAGAACCGCGTGGCCCATGTGCACCCGCAT
GCCTTCCGTGACCTTGGCCGCCTCATGACACTCTATCTGTTTGCCAACAATCTATCAGCG
CTGCCCACTGAGGCCCTGGCCCCCCTGCGTGCCCTGCAGTACCTGAGGCTCAACGACAAC
CCCTGGGTGTGTGACTGCCGGGCACGCCCACTCTGGGCCTGGCTGCAGAAGTTCCGCGGC
TCCTCCTCCGAGGTGCCCTGCAGCCTCCCGCAACGCCTGGCTGGCCGTGACCTCAAACGC
CTAGCTGCCAATGACCTGCAGGGCTGCGCTGTGGCCACCGGCCCTTACCATCCCATCTGG
ACCGGCAGGGCCACCGATGAGGAGCCGCTGGGGCTTCCCAAGTGCTGCCAGCCAGATGCC
GCTGACAAGGCCTCAGTACTGGAGCCTGGAAGACCAGCTTCGGCAGGCAATGCGCTGAAG
GGACGCGTGCCGCCCGGTGACAGCCCGCCGGGCAACGGCTCTGGCCCACGGCACATCAAT
GACTCACCCTTTGGGACTCTGCCTGGCTCTGCTGAGCCCCCGCTCACTGCAGTGCGGCCC
GAGGGCTCCGAGCCACCAGGGTTCCCCACCTCGGGCCCTCGCCGGAGGCCAGGCTGTTCA
CGCAAGAACCGCACCCGCAGCCACTGCCGTCTGGGCCAGGCAGGCAGCGGGGGTGGCGGG
ACTGGTGACTCAGAAGGCTCAGGTGCCCTACCCAGCCTCACCTGCAGCCTCACCCCCCTG
GGCCTGGCGCTGGTGCTGTGGACAGTGCTTGGGCCCTGCTGA

# Drug_Target_15_General_Function:
Involved in protein binding

# Drug_Target_15_General_References:
10591208	Dunham I, Shimizu N, Roe BA, Chissoe S, Hunt AR, Collins JE, Bruskiewich R, Beare DM, Clamp M, Smink LJ, Ainscough R, Almeida JP, Babbage A, Bagguley C, Bailey J, Barlow K, Bates KN, Beasley O, Bird CP, Blakey S, Bridgeman AM, Buck D, Burgess J, Burrill WD, O'Brien KP, et al.: The DNA sequence of human chromosome 22. Nature. 1999 Dec 2;402(6761):489-95.
11201742	Fournier AE, GrandPre T, Strittmatter SM: Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration. Nature. 2001 Jan 18;409(6818):341-6.
12037567	GrandPre T, Li S, Strittmatter SM: Nogo-66 receptor antagonist peptide promotes axonal regeneration. Nature. 2002 May 30;417(6888):547-51.
12068310	Wang KC, Koprivica V, Kim JA, Sivasankaran R, Guo Y, Neve RL, He Z: Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth. Nature. 2002 Jun 27;417(6892):941-4. Epub 2002 Jun 16.
12089450	Liu BP, Fournier A, GrandPre T, Strittmatter SM: Myelin-associated glycoprotein as a functional ligand for the Nogo-66 receptor. Science. 2002 Aug 16;297(5584):1190-3. Epub 2002 Jun 27.
12975309	Clark HF, Gurney AL, Abaya E, Baker K, Baldwin D, Brush J, Chen J, Chow B, Chui C, Crowley C, Currell B, Deuel B, Dowd P, Eaton D, Foster J, Grimaldi C, Gu Q, Hass PE, Heldens S, Huang A, Kim HS, Klimowski L, Jin Y, Johnson S, Lee J, Lewis L, Liao D, Mark M, Robbie E, Sanchez C, Schoenfeld J, Seshagiri S, Simmons L, Singh J, Smith V, Stinson J, Vagts A, Vandlen R, Watanabe C, Wieand D, Woods K, Xie MH, Yansura D, Yi S, Yu G, Yuan J, Zhang M, Zhang Z, Goddard A, Wood WI, Godowski P, Gray A: The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res. 2003 Oct;13(10):2265-70. Epub 2003 Sep 15.

# Drug_Target_15_HGNC_ID:
HGNC:18601

# Drug_Target_15_HPRD_ID:
Not Available

# Drug_Target_15_ID:
4852

# Drug_Target_15_Locus:
22q11.21

# Drug_Target_15_Molecular_Weight:
50709

# Drug_Target_15_Name:
Reticulon-4 receptor

# Drug_Target_15_Number_of_Residues:
473

# Drug_Target_15_PDB_ID:
1OZN

# Drug_Target_15_Pathway:
Not Available

# Drug_Target_15_Pfam_Domain_Function:
PF00560	LRR_1

# Drug_Target_15_Protein_Sequence:
>Reticulon-4 receptor
MKRASAGGSRLLAWVLWLQAWQVAAPCPGACVCYNEPKVTTSCPQQGLQAVPVGIPAASQ
RIFLHGNRISHVPAASFRACRNLTILWLHSNVLARIDAAAFTGLALLEQLDLSDNAQLRS
VDPATFHGLGRLHTLHLDRCGLQELGPGLFRGLAALQYLYLQDNALQALPDDTFRDLGNL
THLFLHGNRISSVPERAFRGLHSLDRLLLHQNRVAHVHPHAFRDLGRLMTLYLFANNLSA
LPTEALAPLRALQYLRLNDNPWVCDCRARPLWAWLQKFRGSSSEVPCSLPQRLAGRDLKR
LAANDLQGCAVATGPYHPIWTGRATDEEPLGLPKCCQPDAADKASVLEPGRPASAGNALK
GRVPPGDSPPGNGSGPRHINDSPFGTLPGSAEPPLTAVRPEGSEPPGFPTSGPRRRPGCS
RKNRTRSHCRLGQAGSGGGGTGDSEGSGALPSLTCSLTPLGLALVLWTVLGPC

# Drug_Target_15_Reaction:
Not Available

# Drug_Target_15_Signals:
1-26

# Drug_Target_15_Specific_Function:
Receptor for RTN4, OMG and MAG. Mediates axonal growth inhibition and may play a role in regulating axonal regeneration and plasticity in the adult central nervous system

# Drug_Target_15_SwissProt_ID:
Q9BZR6

# Drug_Target_15_SwissProt_Name:
RTN4R_HUMAN

# Drug_Target_15_Synonyms:
NgR
Nogo receptor
Nogo-66 receptor
Reticulon-4 receptor precursor

# Drug_Target_15_Theoretical_pI:
8.95

# Drug_Target_15_Transmembrane_Regions:
None

# Drug_Target_16_Cellular_Location:
Sarcolemma
peripheral membrane protein. In skeletal muscle, it is localized b
sarcolemmal membrane

# Drug_Target_16_Chromosome_Location:
Not Available

# Drug_Target_16_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_16_Essentiality:
Non-Essential

# Drug_Target_16_GenAtlas_ID:
NOS1

# Drug_Target_16_GenBank_ID_Gene:
U17327

# Drug_Target_16_GenBank_ID_Protein:
642526

# Drug_Target_16_GeneCard_ID:
NOS1

# Drug_Target_16_Gene_Name:
NOS1

# Drug_Target_16_Gene_Sequence:
>4305 bp
ATGGAGGATCACATGTTCGGTGTTCAGCAAATCCAGCCCAATGTCATTTCTGTTCGTCTC
TTCAAGCGCAAAGTTGGGGGCCTGGGATTTCTGGTGAAGGAGCGGGTCAGTAAGCCGCCC
GTGATCATCTCTGACCTGATTCGTGGGGGCGCCGCAGAGCAGAGTGGCCTCATCCAGGCC
GGAGACATCATTCTTGCGGTCAACGGCCGGCCCTTGGTGGACCTGAGCTATGACAGCGCC
CTGGAGGTACTCAGAGGCATTGCCTCTGAGACCCACGTGGTCCTCATTCTGAGGGGCCCT
GAAGGTTTCACCACGCACCTGGAGACCACCTTTACAGGTGATGGGACCCCCAAGACCATC
CGGGTGACACAGCCCCTGGGTCCCCCCACCAAAGCCGTGGATCTGTCCCACCAGCCACCG
GCCGGCAAAGAACAGCCCCTGGCAGTGGATGGGGCCTCGGGTCCCGGGAATGGGCCTCAG
CATGCCTACGATGATGGGCAGGAGGCTGGCTCACTCCCCCATGCCAACGGCCTGGCCCCC
AGGCCCCCAGGCCAGGACCCCGCGAAGAAAGCAACCAGAGTCAGCCTCCAAGGCAGAGGG
GAGAACAATGAACTGCTCAAGGAGATAGAGCCTGTGCTGAGCCTTCTCACCAGTGGGAGC
AGAGGGGTCAAGGGAGGGGCACCTGCCAAGGCAGAGATGAAAGATATGGGAATCCAGGTG
GACAGAGATTTGGACGGCAAGTCACACAAACCTCTGCCCCTCGGCGTGGAGAACGACCGA
GTCTTCAATGACCTATGGGGGAAGGGCAATGTGCCTGTCGTCCTCAACAACCCATATTCA
GAGAAGGAGCAGCCCCCCACCTCAGGAAAACAGTCCCCCACAAAGAATGGCAGCCCCTCC
AAGTGTCCACGCTTCCTCAAGGTCAAGAACTGGGAGACTGAGGTGGTTCTCACTGACACC
CTCCACCTTAAGAGCACATTGGAAACGGGATGCACTGAGTACATCTGCATGGGCTCCATC
ATGCATCCTTCTCAGCATGCAAGGAGGCCTGAAGACGTCCGCACAAAAGGACAGCTCTTC
CCTCTCGCCAAAGAGTTTATTGATCAATACTATTCATCAATTAAAAGATTTGGCTCCAAA
GCCCACATGGAAAGGCTGGAAGAGGTGAACAAAGAGATCGACACCACTAGCACTTACCAG
CTCAAGGACACAGAGCTCATCTATGGGGCCAAGCACGCCTGGCGGAATGCCTCGCGCTGT
GTGGGCAGGATCCAGTGGTCCAAGCTGCAGGTATTCGATGCCCGTGACTGCACCACGGCC
CACGGGATGTTCAACTACATCTGTAACCATGTCAAGTATGCCACCAACAAAGGGAACCTC
AGGTCTGCCATCACCATATTCCCCCAGAGGACAGACGGCAAGCACGACTTCCGAGTCTGG
AACTCCCAGCTCATCCGCTACGCTGGCTACAAGCAGCCTGACGGCTCCACCCTGGGGGAC
CCAGCCAATGTGCAGTTCACAGAGATATGCATACAGCAGGGCTGGAAACCGCCTAGAGGC
CGCTTCGATGTCCTGCCGCTCCTGCTTCAGGCCAACGGCAATGACCCTGAGCTCTTCCAG
ATTCCTCCAGAGCTGGTGTTGGAAGTTCCCATCAGGCACCCCAAGTTTGAGTGGTTCAAG
GACCTGGGGCTGAAGTGGTACGGCCTCCCCGCCGTGTCCAACATGCTCCTAGAGATTGGC
GGCCTGGAGTTCAGCGCCTGTCCCTTCAGTGGCTGGTACATGGGCACAGAGATTGGTGTC
CGCGACTACTGTGACAACTCCCGCTACAATATCCTGGAGGAAGTGGCCAAGAAGATGAAC
TTAGACATGAGGAAGACGTCCTCCCTGTGGAAGGACCAGGCGCTGGTGGAGATCAATATC
GCGGTTCTCTATAGCTTCCAGAGTGACAAAGTGACCATTGTTGACCATCACTCCGCCACC
GAGTCCTTCATTAAGCACATGGAGAATGAGTACCGCTGCCGGGGGGGCTGCCCTGCCGAC
TGGGTGTGGATCGTGCCCCCCATGTCCGGAAGCATCACCCCTGTGTTCCACCAGGAGATG
CTCAACTACCGGCTCACCCCCTCCTTCGAATACCAGCCTGATCCCTGGAACACGCATGTC
TGGAAAGGCACCAACGGGACCCCCACAAAGCGGCGAGCCATCGGCTTCAAGAAGCTAGCA
GAAGCTGTCAAGTTCTCGGCCAAGCTGATGGGGCAGGCTATGGCCAAGAGGGTGAAAGCG
ACCATCCTCTATGCCACAGAGACAGGCAAATCGCAAGCTTATGCCAAGACCTTGTGTGAG
ATCTTCAAACACGCCTTTGATGCCAAGGTGATGTCCATGGAAGAATATGACATTGTGCAC
CTGGAACATGAAACTCTGGTCCTTGTGGTCACCAGCACCTTTGGCAATGGAGATCCCCCT
GAGAATGGGGAGAAATTCGGCTGTGCTTTGATGGAAATGAGGCACCCCAACTCTGTGCAG
GAAGAAAGGAAGAGCTACAAGGTCCGATTCAACAGCGTCTCCTCCTACTCTGACTCCCAA
AAATCATCAGGCGATGGGCCCGACCTCAGAGACAACTTTGAGAGTGCTGGACCCCTGGCC
AATGTGAGGTTCTCAGTTTTTGGCCTCGGCTCACGAGCATACCCTCACTTTTGCGCCTTC
GGACACGCTGTGGACACCCTCCTGGAAGAACTGGGAGGGGAGAGGATCCTGAAGATGAGG
GAAGGGGATGAGCTCTGTGGGCAGGAAGAGGCTTTCAGGACCTGGGCCAAGAAGGTCTTC
AAGGCAGCCTGTGATGTCTTCTGTGTGGGAGATGATGTCAACATTGAAAAGGCCAACAAT
TCCCTCATCAGCAATGATCGCAGCTGGAAGAGAAACAAGTTCCGCCTCACCTTTGTGGCC
GAAGCTCCAGAACTCACACAAGGTCTATCCAATGTCCACAAAAAGCGAGTCTCAGCTGCC
CGGCTCCTTAGCCGTCAAAACCTCCAGAGCCCTAAATCCAGTCGGTCAACTATCTTCGTG
CGTCTCCACACCAACGGGAGCCAGGAGCTGCAGTACCAGCCTGGGGACCACCTGGGTGTC
TTCCCTGGCAACCACGAGGACCTCGTGAATGCCCTGATCGAGCGGCTGGAGGACGCGCCG
CCTGTCAACCAGATGGTGAAAGTGGAACTGCTGGAGGAGCGGAACACGGCTTTAGGTGTC
ATCAGTAACTGGACAGACGAGCTCCGCCTCCCGCCCTGCACCATCTTCCAGGCCTTCAAG
TACTACCTGGACATCACCACGCCACCAACGCCTCTGCAGCTGCAGCAGTTTGCCTCCCTA
GCTACCAGCGAGAAGGAGAAGCAGCGTCTGCTGGTCCTCAGCAAGGGTTTGCAGGAGTAC
GAGGAATGGAAATGGGGCAAGAACCCCACCATCGTGGAGGTGCTGGAGGAGTTCCCATCT
ATCCAGATGCCGGCCACCCTGCTCCTGACCCAGCTGTCCCTGCTGCAGCCCCGCTACTAT
TCCATCAGCTCCTCCCCAGACATGTACCCTGATGAAGTGCACCTCACTGTGGCCATCGTT
TCCTACCGCACTCGAGATGGAGAAGGACCAATTCACCACGGCGTATGCTCCTCCTGGCTC
AACCGGATACAGGCTGACGAACTGGTCCCCTGTTTCGTGAGAGGAGCACCCAGCTTCCAC
CTGCCCCGGAACCCCCAAGTCCCCTGCATCCTCGTTGGACCAGGCACCGGCATTGCCCCT
TTCCGAAGCTTCTGGCAACAGCGGCAATTTGATATCCAACACAAAGGAATGAACCCCTGC
CCCATGGTCCTGGTCTTCGGGTGCCGGCAATCCAAGATAGATCATATCTACAGGGAAGAG
ACCCTGCAGGCCAAGAACAAGGGGGTCTTCAGAGAGCTGTACACGGCTTACTCCCGGGAG
CCAGACAAACCAAAGAAGTACGTGCAGGACATCCTGCAGGAGCAGCTGGCGGAGTCTGTG
TACCGAGCCCTGAAGGAGCAAGGGGGCCACATATACGTCTGTGGGGACGTCACCATGGCT
GCTGATGTCCTCAAAGCCATCCAGCGCATCATGACCCAGCAGGGGAAGCTCTCGGCAGAG
GACGCCGGCGTATTCATCAGCCGGATGAGGGATGACAACCGATACCATGAGGATATTTTT
GGAGTCACCCTGCGAACGTACGAAGTGACCAACCGCCTTAGATCTGAGTCCATTGCCTTC
ATTGAAGAGAGCAAAAAAGACACCGATGAGGTTTTCAGCTCCTAA

# Drug_Target_16_General_Function:
Inorganic ion transport and metabolism

# Drug_Target_16_General_References:
7515942	Fujisawa H, Ogura T, Kurashima Y, Yokoyama T, Yamashita J, Esumi H: Expression of two types of nitric oxide synthase mRNA in human neuroblastoma cell lines. J Neurochem. 1994 Jul;63(1):140-5.
7528745	Hall AV, Antoniou H, Wang Y, Cheung AH, Arbus AM, Olson SL, Lu WC, Kau CL, Marsden PA: Structural organization of the human neuronal nitric oxide synthase gene (NOS1). J Biol Chem. 1994 Dec 30;269(52):33082-90.
7678401	Nakane M, Schmidt HH, Pollock JS, Forstermann U, Murad F: Cloned human brain nitric oxide synthase is highly expressed in skeletal muscle. FEBS Lett. 1993 Jan 25;316(2):175-80.
8879752	Park CS, Gianotti C, Park R, Krishna G: Neuronal isoform of nitric oxide synthase is expressed at low levels in human retina. Cell Mol Neurobiol. 1996 Aug;16(4):499-515.
9111048	Wang Y, Goligorsky MS, Lin M, Wilcox JN, Marsden PA: A novel, testis-specific mRNA transcript encoding an NH2-terminal truncated nitric-oxide synthase. J Biol Chem. 1997 Apr 25;272(17):11392-401.

# Drug_Target_16_HGNC_ID:
HGNC:7872

# Drug_Target_16_HPRD_ID:
01226

# Drug_Target_16_ID:
76

# Drug_Target_16_Locus:
12q24.2-q24.31

# Drug_Target_16_Molecular_Weight:
160972

# Drug_Target_16_Name:
Nitric-oxide synthase, brain

# Drug_Target_16_Number_of_Residues:
1434

# Drug_Target_16_PDB_ID:
1TLL

# Drug_Target_16_Pathway:
Not Available

# Drug_Target_16_Pfam_Domain_Function:
PF00175	NAD_binding_1
PF00258	Flavodoxin_1
PF00595	PDZ
PF00667	FAD_binding_1
PF02898	NO_synthase

# Drug_Target_16_Protein_Sequence:
>Nitric-oxide synthase, brain
MEDHMFGVQQIQPNVISVRLFKRKVGGLGFLVKERVSKPPVIISDLIRGGAAEQSGLIQA
GDIILAVNGRPLVDLSYDSALEVLRGIASETHVVLILRGPEGFTTHLETTFTGDGTPKTI
RVTQPLGPPTKAVDLSHQPPAGKEQPLAVDGASGPGNGPQHAYDDGQEAGSLPHANGLAP
RPPGQDPAKKATRVSLQGRGENNELLKEIEPVLSLLTSGSRGVKGGAPAKAEMKDMGIQV
DRDLDGKSHKPLPLGVENDRVFNDLWGKGNVPVVLNNPYSEKEQPPTSGKQSPTKNGSPS
KCPRFLKVKNWETEVVLTDTLHLKSTLETGCTEYICMGSIMHPSQHARRPEDVRTKGQLF
PLAKEFIDQYYSSIKRFGSKAHMERLEEVNKEIDTTSTYQLKDTELIYGAKHAWRNASRC
VGRIQWSKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFPQRTDGKHDFRVW
NSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRFDVLPLLLQANGNDPELFQ
IPPELVLEVPIRHPKFEWFKDLGLKWYGLPAVSNMLLEIGGLEFSACPFSGWYMGTEIGV
RDYCDNSRYNILEEVAKKMNLDMRKTSSLWKDQALVEINIAVLYSFQSDKVTIVDHHSAT
ESFIKHMENEYRCRGGCPADWVWIVPPMSGSITPVFHQEMLNYRLTPSFEYQPDPWNTHV
WKGTNGTPTKRRAIGFKKLAEAVKFSAKLMGQAMAKRVKATILYATETGKSQAYAKTLCE
IFKHAFDAKVMSMEEYDIVHLEHETLVLVVTSTFGNGDPPENGEKFGCALMEMRHPNSVQ
EERKSYKVRFNSVSSYSDSQKSSGDGPDLRDNFESAGPLANVRFSVFGLGSRAYPHFCAF
GHAVDTLLEELGGERILKMREGDELCGQEEAFRTWAKKVFKAACDVFCVGDDVNIEKANN
SLISNDRSWKRNKFRLTFVAEAPELTQGLSNVHKKRVSAARLLSRQNLQSPKSSRSTIFV
RLHTNGSQELQYQPGDHLGVFPGNHEDLVNALIERLEDAPPVNQMVKVELLEERNTALGV
ISNWTDELRLPPCTIFQAFKYYLDITTPPTPLQLQQFASLATSEKEKQRLLVLSKGLQEY
EEWKWGKNPTIVEVLEEFPSIQMPATLLLTQLSLLQPRYYSISSSPDMYPDEVHLTVAIV
SYRTRDGEGPIHHGVCSSWLNRIQADELVPCFVRGAPSFHLPRNPQVPCILVGPGTGIAP
FRSFWQQRQFDIQHKGMNPCPMVLVFGCRQSKIDHIYREETLQAKNKGVFRELYTAYSRE
PDKPKKYVQDILQEQLAESVYRALKEQGGHIYVCGDVTMAADVLKAIQRIMTQQGKLSAE
DAGVFISRMRDDNRYHEDIFGVTLRTYEVTNRLRSESIAFIEESKKDTDEVFSS

# Drug_Target_16_Reaction:
L-arginine + n NADPH + n H+ + m O2 = citrulline + nitric oxide + n NADP+

# Drug_Target_16_Signals:
None

# Drug_Target_16_Specific_Function:
Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In the brain and peripheral nervous system, NO displays many properties of a neurotransmitter

# Drug_Target_16_SwissProt_ID:
P29475

# Drug_Target_16_SwissProt_Name:
NOS1_HUMAN

# Drug_Target_16_Synonyms:
Constitutive NOS
EC 1.14.13.39
N-NOS
NC-NOS
NOS type I
Neuronal NOS
bNOS
nNOS

# Drug_Target_16_Theoretical_pI:
7.44

# Drug_Target_16_Transmembrane_Regions:
None

# Drug_Target_17_Cellular_Location:
Cytoplasmic granule. Note=Cytoplasmic granules of cytolytic T-lymphocytes and natural killer cells

# Drug_Target_17_Chromosome_Location:
Not Available

# Drug_Target_17_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_17_Essentiality:
Non-Essential

# Drug_Target_17_GenAtlas_ID:
GZMB

# Drug_Target_17_GenBank_ID_Gene:
M17016

# Drug_Target_17_GenBank_ID_Protein:
338296

# Drug_Target_17_GeneCard_ID:
GZMB

# Drug_Target_17_Gene_Name:
GZMB

# Drug_Target_17_Gene_Sequence:
>744 bp
ATGCAACCAATCCTGCTTCTGCTGGCCTTCCTCCTGCTGCCCAGGGCAGATGCAGGGGAG
ATCATCGGGGGACATGAGGCCAAGCCCCACTCCCGCCCCTACATGGCTTATCTTATGATC
TGGGATCAGAAGTCTCTGAAGAGGTGCGGTGGCTTCCTGATACAAGACGACTTCGTGCTG
ACAGCTGCTCACTGTTGGGGAAGCTCCATAAATGTCACCTTGGGGGCCCACAATATCAAA
GAACAGGAGCCGACCCAGCAGTTTATCCCTGTGAAAAGACCCATCCCCCATCCAGCCTAT
AATCCTAAGAACTTCTCCAACGACATCATGCTACTGCAGCTGGAGAGAAAGGCCAAGCGG
ACCAGAGCTGTGCAGCCCCTCAGGCTACCTAGCAACAAGGCCCAGGTGAAGCCAGGGCAG
ACATGCAGTGTGGCCGGCTGGGGGCAGACGGCCCCCCTGGGAAAACACTCACACACACTA
CAAGAGGTGAAGATGACAGTGCAGGAAGATCGAAAGTGCGAATCTGACTTACGCCATTAT
TACGACAGTACCATTGAGTTGTGCGTGGGGGACCCAGAGATTAAAAAGACTTCCTTTAAG
GGGGACTCTGGAGGCCCTCTTGTGTGTAACAAGGTGGCCCAGGGCATTGTCTCCTATGGA
CGAAACAATGGCATGCCTCCACGAGCCTGCACCAAAGTCTCAAGCTTTGTACACTGGATA
AAGAAAACCATGAAACGCTACTAA

# Drug_Target_17_General_Function:
Involved in granzyme B activity

# Drug_Target_17_General_References:
11209755	Estebanez-Perpina E, Fuentes-Prior P, Belorgey D, Braun M, Kiefersauer R, Maskos K, Huber R, Rubin H, Bode W: Crystal structure of the caspase activator human granzyme B, a proteinase highly specific for an Asp-P1 residue. Biol Chem. 2000 Dec;381(12):1203-14.
12721789	Saito S, Iida A, Sekine A, Kawauchi S, Higuchi S, Ogawa C, Nakamura Y: Catalog of 680 variations among eight cytochrome p450 ( CYP) genes, nine esterase genes, and two other genes in the Japanese population. J Hum Genet. 2003;48(5):249-70. Epub 2003 Apr 29.
1985927	Poe M, Blake JT, Boulton DA, Gammon M, Sigal NH, Wu JK, Zweerink HJ: Human cytotoxic lymphocyte granzyme B. Its purification from granules and the characterization of substrate and inhibitor specificity. J Biol Chem. 1991 Jan 5;266(1):98-103.
2323780	Dahl CA, Bach FH, Chan W, Huebner K, Russo G, Croce CM, Herfurth T, Cairns JS: Isolation of a cDNA clone encoding a novel form of granzyme B from human NK cells and mapping to chromosome 14. Hum Genet. 1990 Apr;84(5):465-70.
2332171	Haddad P, Clement MV, Bernard O, Larsen CJ, Degos L, Sasportes M, Mathieu-Mahul D: Structural organization of the hCTLA-1 gene encoding human granzyme B. Gene. 1990 Mar 15;87(2):265-71.
2365998	Caputo A, Sauer DE, Rowe PB: Nucleotide sequence and genomic organization of a human T lymphocyte serine protease gene. J Immunol. 1990 Jul 15;145(2):737-44.
2788607	Klein JL, Shows TB, Dupont B, Trapani JA: Genomic organization and chromosomal assignment for a serine protease gene (CSPB) expressed by human cytotoxic lymphocytes. Genomics. 1989 Jul;5(1):110-7.
2953813	Schmid J, Weissmann C: Induction of mRNA for a serine protease and a beta-thromboglobulin-like protein in mitogen-stimulated human leukocytes. J Immunol. 1987 Jul 1;139(1):250-6.
3258865	Caputo A, Fahey D, Lloyd C, Vozab R, McCairns E, Rowe PB: Structure and differential mechanisms of regulation of expression of a serine esterase gene in activated human T lymphocytes. J Biol Chem. 1988 May 5;263(13):6363-9.
3261871	Trapani JA, Klein JL, White PC, Dupont B: Molecular cloning of an inducible serine esterase gene from human cytotoxic lymphocytes. Proc Natl Acad Sci U S A. 1988 Sep;85(18):6924-8.
3262682	Hameed A, Lowrey DM, Lichtenheld M, Podack ER: Characterization of three serine esterases isolated from human IL-2 activated killer cells. J Immunol. 1988 Nov 1;141(9):3142-7.
3263427	Krahenbuhl O, Rey C, Jenne D, Lanzavecchia A, Groscurth P, Carrel S, Tschopp J: Characterization of granzymes A and B isolated from granules of cloned human cytotoxic T lymphocytes. J Immunol. 1988 Nov 15;141(10):3471-7.

# Drug_Target_17_HGNC_ID:
HGNC:4709

# Drug_Target_17_HPRD_ID:
00476

# Drug_Target_17_ID:
1072

# Drug_Target_17_Locus:
14q11.2

# Drug_Target_17_Molecular_Weight:
27688

# Drug_Target_17_Name:
Granzyme B

# Drug_Target_17_Number_of_Residues:
247

# Drug_Target_17_PDB_ID:
1FQ3

# Drug_Target_17_Pathway:
Not Available

# Drug_Target_17_Pfam_Domain_Function:
PF00089	Trypsin

# Drug_Target_17_Protein_Sequence:
>Granzyme B precursor
MQPILLLLAFLLLPRADAGEIIGGHEAKPHSRPYMAYLMIWDQKSLKRCGGFLIQDDFVL
TAAHCWGSSINVTLGAHNIKEQEPTQQFIPVKRPIPHPAYNPKNFSNDIMLLQLERKAKR
TRAVQPLRLPSNKAQVKPGQTCSVAGWGQTAPLGKHSHTLQEVKMTVQEDRKCESDLRHY
YDSTIELCVGDPEIKKTSFKGDSGGPLVCNKVAQGIVSYGRNNGMPPRACTKVSSFVHWI
KKTMKRY

# Drug_Target_17_Reaction:
Preferential cleavage: -Asp! > > -Asn! > -Met!, -Ser!

# Drug_Target_17_Signals:
1-18

# Drug_Target_17_Specific_Function:
This enzyme is necessary for target cell lysis in cell- mediated immune responses. It cleaves after Asp. Seems to be linked to an activation cascade of caspases (aspartate-specific cysteine proteases) responsible for apoptosis execution. Cleaves caspase-3, -7, -9 and 10 to give rise to active enzymes mediating apoptosis

# Drug_Target_17_SwissProt_ID:
P10144

# Drug_Target_17_SwissProt_Name:
GRAB_HUMAN

# Drug_Target_17_Synonyms:
C11
CTLA-1
CTSGL1
Cathepsin G-like 1
Cytotoxic T-lymphocyte proteinase 2
EC 3.4.21.79
Fragmentin-2
Granzyme B precursor
Granzyme-2
HLP
Human lymphocyte protein
Lymphocyte protease
SECT
T-cell serine protease 1-3E

# Drug_Target_17_Theoretical_pI:
10.02

# Drug_Target_17_Transmembrane_Regions:
None

# Drug_Target_18_Cellular_Location:
Secreted protein

# Drug_Target_18_Chromosome_Location:
Not Available

# Drug_Target_18_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_18_Essentiality:
Non-Essential

# Drug_Target_18_GenAtlas_ID:
LTF

# Drug_Target_18_GenBank_ID_Gene:
X53961

# Drug_Target_18_GenBank_ID_Protein:
34416

# Drug_Target_18_GeneCard_ID:
LTF

# Drug_Target_18_Gene_Name:
LTF

# Drug_Target_18_Gene_Sequence:
>2136 bp
ATGAAACTTGTCTTCCTCGTCCTGCTGTTCCTCGGGGCCCTCGGACTGTGTCTGGCTGGC
CGTAGGAGAAGGAGTGTTCAGTGGTGCGCCGTATCCCAACCCGAGGCCACAAAATGCTTC
CAATGGCAAAGGAATATGAGAAAAGTGCGTGGCCCTCCTGTCAGCTGCATAAAGAGAGAC
TCCCCCATCCAGTGTATCCAGGCCATTGCGGAAAACAGGGCCGATGCTGTGACCCTTGAT
GGTGGTTTCATATACGAGGCAGGCCTGGCCCCCTACAAACTGCGACCTGTAGCGGCGGAA
GTCTACGGGACCGAAAGACAGCCACGAACTCACTATTATGCCGTGGCTGTGGTGAAGAAG
GGCGGCAGCTTTCAGCTGAACGAACTGCAAGGTCTGAAGTCCTGCCACACAGGCCTTCGC
AGGACCGCTGGATGGAATGTCCCTACAGGGACACTTCGTCCATTCTTGAATTGGACGGGT
CCACCTGAGCCCATTGAGGCAGCTGTGGCCAGGTTCTTCTCAGCCAGCTGTGTTCCCGGT
GCAGATAAAGGACAGTTCCCCAACCTGTGTCGCCTGTGTGCGGGGACAGGGGAAAACAAA
TGTGCCTTCTCCTCCCAGGAACCGTACTTCAGCTACTCTGGTGCCTTCAAGTGTCTGAGA
GACGGGGCTGGAGACGTGGCTTTTATCAGAGAGAGCACAGTGTTTGAGGACCTGTCAGAC
GAGGCTGAAAGGGACGAGTATGAGTTACTCTGCCCAGACAACACTCGGAAGCCAGTGGAC
AAGTTCAAAGACTGCCATCTGGCCCGGGTCCCTTCTCATGCCGTTGTGGCACGAAGTGTG
AATGGCAAGGAGGATGCCATCTGGAATCTTCTCCGCCAGGCACAGGAAAAGTTTGGAAAG
GACAAGTCACCGAAATTCCAGCTCTTTGGCTCCCCTAGTGGGCAGAAAGATCTGCTGTTC
AAGGACTCTGCCATTGGGTTTTCGAGGGTGCCCCCGAGGATAGATTCTGGGCTGTACCTT
GGCTCCGGCTACTTCACTGCCATCCAGAACTTGAGGAAAAGTGAGGAGGAAGTGGCTGCC
CGGCGTGCGCGGGTCGTGTGGTGTGCGGTGGGCGAGCAGGAGCTGCGCAAGTGTAACCAG
TGGAGTGGCTTGAGCGAAGGCAGCGTGACCTGCTCCTCGGCCTCCACCACAGAGGACTGC
ATCGCCCTGGTGCTGAAAGGAGAAGCTGATGCCATGAGTTTGGATGGAGGATATGTGTAC
ACTGCATGCAAATGTGGTTTGGTGCCTGTCCTGGCAGAGAACTACAAATCCCAACAAAGC
AGTGACCCTGATCCTAACTGTGTGGATAGACCTGTGGAAGGATATCTTGCTGTGGCGGTG
GTTAGGAGATCAGACACTAGCCTTACCTGGAACTCTGTGAAAGGCAAGAAGTCCTGCCAC
ACCGCCGTGGACAGGACTGCAGGCTGGAATATCCCCATGGGCCTGCTCTTCAACCAGACG
GGCTCCTGCAAATTTGATGAATATTTCAGTCAAAGCTGTGCCCCTGGGTCTGACCCGAGA
TCTAATCTCTGTGCTCTGTGTATTGGCGACGAGCAGGGTGAGAATAAGTGCGTGCCCAAC
AGCAACGAGAGATACTACGGCTACACTGGGGCTTTCCGGTGCCTGGCTGAGAATGCTGGA
GACGTTGCATTTGTGAAAGATGTCACTGTCTTGCAGAACACTGATGGAAATAACAATGAG
GCATGGGCTAAGGATTTGAAGCTGGCAGACTTTGCGCTGCTGTGCCTCGATGGCAAACGG
AAGCCTGTGACTGAGGCTAGAAGCTGCCATCTTGCCATGGCCCCGAATCATGCCGTGGTG
TCTCGGATGGATAAGGTGGAACGCCTGAAACAGGTGCTGCTCCACCAACAGGCTAAATTT
GGGAGAAATGGATCTGACTGCCCGGACAAGTTTTGCTTATTCCAGTCTGAAACCAAAAAC
CTTCTGTTCAATGACAACACTGAGTGTCTGGCCAGACTCCATGGCAAAACAACATATGAA
AAATATTTGGGACCACAGTATGTCGCAGGCATTACTAATCTGAAAAAGTGCTCAACCTCC
CCCCTCCTGGAAGCCTGTGAATTCCTCAGGAAGTAA

# Drug_Target_18_General_Function:
Involved in ferric iron binding

# Drug_Target_18_General_References:
10089347	Sun XL, Baker HM, Shewry SC, Jameson GB, Baker EN: Structure of recombinant human lactoferrin expressed in Aspergillus awamori. Acta Crystallogr D Biol Crystallogr. 1999 Feb;55(Pt 2):403-7.
10089508	Jameson GB, Anderson BF, Norris GE, Thomas DH, Baker EN: Structure of human apolactoferrin at 2.0 A resolution. Refinement and analysis of ligand-induced conformational change. Acta Crystallogr D Biol Crystallogr. 1998 Nov 1;54(Pt 6 Pt 2):1319-35.
12693969	Viejo-Diaz M, Andres MT, Perez-Gil J, Sanchez M, Fierro JF: Potassium efflux induced by a new lactoferrin-derived peptide mimicking the effect of native human lactoferrin on the bacterial cytoplasmic membrane. Biochemistry (Mosc). 2003 Feb;68(2):217-27.
1369293	Tani F, Iio K, Chiba H, Yoshikawa M: Isolation and characterization of opioid antagonist peptides derived from human lactoferrin. Agric Biol Chem. 1990 Jul;54(7):1803-10.
1480183	Teng CT, Liu Y, Yang N, Walmer D, Panella T: Differential molecular mechanism of the estrogen action that regulates lactoferrin gene in human and mouse. Mol Endocrinol. 1992 Nov;6(11):1969-81.
2374734	Powell MJ, Ogden JE: Nucleotide sequence of human lactoferrin cDNA. Nucleic Acids Res. 1990 Jul 11;18(13):4013.
2402455	Rey MW, Woloshuk SL, deBoer HA, Pieper FR: Complete nucleotide sequence of human mammary gland lactoferrin. Nucleic Acids Res. 1990 Sep 11;18(17):5288.
2585506	Anderson BF, Baker HM, Norris GE, Rice DW, Baker EN: Structure of human lactoferrin: crystallographic structure analysis and refinement at 2.8 A resolution. J Mol Biol. 1989 Oct 20;209(4):711-34.
3477300	Rado TA, Wei XP, Benz EJ Jr: Isolation of lactoferrin cDNA from a human myeloid library and expression of mRNA during normal and leukemic myelopoiesis. Blood. 1987 Oct;70(4):989-93.
6510420	Metz-Boutigue MH, Jolles J, Mazurier J, Schoentgen F, Legrand D, Spik G, Montreuil J, Jolles P: Human lactotransferrin: amino acid sequence and structural comparisons with other transferrins. Eur J Biochem. 1984 Dec 17;145(3):659-76.
6794640	Metz-Boutigue MH, Mazurier J, Jolles J, Spik G, Montreuil J, Jolles P: The present state of the human lactotransferrin sequence. Study and alignment of the cyanogen bromide fragments and characterization of N- and C-terminal domains. Biochim Biophys Acta. 1981 Sep 29;670(2):243-54.
7049727	Metz-Boutigue MH, Jolles J, Mazurier J, Spik G, Montreuil J, Jolles P: An 88 amino acid long C-terminal sequence of human lactotransferrin. FEBS Lett. 1982 Jun 1;142(1):107-10.
9003186	Nicholson H, Anderson BF, Bland T, Shewry SC, Tweedie JW, Baker EN: Mutagenesis of the histidine ligand in human lactoferrin: iron binding properties and crystal structure of the histidine-253-->methionine mutant. Biochemistry. 1997 Jan 14;36(2):341-6.
9873069	Klintworth GK, Sommer JR, Obrian G, Han L, Ahmed MN, Qumsiyeh MB, Lin PY, Basti S, Reddy MK, Kanai A, Hotta Y, Sugar J, Kumaramanickavel G, Munier F, Schorderet DF, El Matri L, Iwata F, Kaiser-Kupfer M, Nagata M, Nakayasu K, Hejtmancik JF, Teng CT: Familial subepithelial corneal amyloidosis (gelatinous drop-like corneal dystrophy): exclusion of linkage to lactoferrin gene. Mol Vis. 1998 Dec 31;4:31.

# Drug_Target_18_HGNC_ID:
HGNC:6720

# Drug_Target_18_HPRD_ID:
01028

# Drug_Target_18_ID:
1439

# Drug_Target_18_Locus:
3q21-q23

# Drug_Target_18_Molecular_Weight:
78182

# Drug_Target_18_Name:
Lactotransferrin

# Drug_Target_18_Number_of_Residues:
710

# Drug_Target_18_PDB_ID:
1CB6

# Drug_Target_18_Pathway:
Not Available

# Drug_Target_18_Pfam_Domain_Function:
PF00405	Transferrin

# Drug_Target_18_Protein_Sequence:
>Lactotransferrin precursor
MKLVFLVLLFLGALGLCLAGRRRSVQWCAVSQPEATKCFQWQRNMRKVRGPPVSCIKRDS
PIQCIQAIAENRADAVTLDGGFIYEAGLAPYKLRPVAAEVYGTERQPRTHYYAVAVVKKG
GSFQLNELQGLKSCHTGLRRTAGWNVPIGTLRPFLNWTGPPEPIEAAVARFFSASCVPGA
DKGQFPNLCRLCAGTGENKCAFSSQEPYFSYSGAFKCLRDGAGDVAFIRESTVFEDLSDE
AERDEYELLCPDNTRKPVDKFKDCHLARVPSHAVVARSVNGKEDAIWNLLRQAQEKFGKD
KSPKFQLFGSPSGQKDLLFKDSAIGFSRVPPRIDSGLYLGSGYFTAIQNLRKSEEEVAAR
RARVVWCAVGEQELRKCNQWSGLSEGSVTCSSASTTEDCIALVLKGEADAMSLDGGYVYT
AGKCGLVPVLAENYKSQQSSDPDPNCVDRPVEGYLAVAVVRRSDTSLTWNSVKGKKSCHT
AVDRTAGWNIPMGLLFNQTGSCKFDEYFSQSCAPGSDPRSNLCALCIGDEQGENKCVPNS
NERYYGYTGAFRCLAENAGDVAFVKDVTVLQNTDGNNNEAWAKDLKLADFALLCLDGKRK
PVTEARSCHLAMAPNHAVVSRMDKVERLKQVLLHQQAKFGRNGSDCPDKFCLFQSETKNL
LFNDNTECLARLHGKTTYEKYLGPQYVAGITNLKKCSTSPLLEACEFLRK

# Drug_Target_18_Reaction:
Not Available

# Drug_Target_18_Signals:
1-19

# Drug_Target_18_Specific_Function:
The lactotransferrin peptidase S60 domain 1 functions as a serine protease that cuts arginine rich regions. This function contributes to the antimicrobial activity

# Drug_Target_18_SwissProt_ID:
P02788

# Drug_Target_18_SwissProt_Name:
TRFL_HUMAN

# Drug_Target_18_Synonyms:
EC 3.4.21.-
Lactoferrin
Lactotransferrin precursor
Talalactoferrin alfa

# Drug_Target_18_Theoretical_pI:
8.17

# Drug_Target_18_Transmembrane_Regions:
None

# Drug_Target_19_Cellular_Location:
Membrane
single-pass type I membrane protein

# Drug_Target_19_Chromosome_Location:
Not Available

# Drug_Target_19_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_19_Essentiality:
Non-Essential

# Drug_Target_19_GenAtlas_ID:
CTLA4

# Drug_Target_19_GenBank_ID_Gene:
AF411058

# Drug_Target_19_GenBank_ID_Protein:
17646228

# Drug_Target_19_GeneCard_ID:
CTLA4

# Drug_Target_19_Gene_Name:
CTLA4

# Drug_Target_19_Gene_Sequence:
>672 bp
ATGGCTTGCCTTGGATTTCAGCGGCACAAGGCTCAGCTGAACCTGGCTGCCAGGACCTGG
CCCTGCACTCTCCTGTTTTTTCTTCTCTTCATCCCTGTCTTCTGCAAAGCAATGCACGTG
GCCCAGCCTGCTGTGGTACTGGCCAGCAGCCGAGGCATCGCCAGCTTTGTGTGTGAGTAT
GCATCTCCAGGCAAAGCCACTGAGGTCCGGGTGACAGTGCTTCGGCAGGCTGACAGCCAG
GTGACTGAAGTCTGTGCGGCAACCTACATGATGGGGAATGAGTTGACCTTCCTAGATGAT
TCCATCTGCACGGGCACCTCCAGTGGAAATCAAGTGAACCTCACTATCCAAGGACTGAGG
GCCATGGACACGGGACTCTACATCTGCAAGGTGGAGCTCATGTACCCACCGCCATACTAC
CTGGGCATAGGCAACGGAACCCAGATTTATGTAATTGATCCAGAACCGTGCCCAGATTCT
GACTTCCTCCTCTGGATCCTTGCAGCAGTTAGTTCGGGGTTGTTTTTTTATAGCTTTCTC
CTCACAGCTGTTTCTTTGAGCAAAATGCTAAAGAAAAGAAGCCCTCTTACAACAGGGGTC
TATGTGAAAATGCCCCCAACAGAGCCAGAATGTGAAAAGCAATTTCAGCCTTATTTTATT
CCCATCAATTGA

# Drug_Target_19_General_Function:
Not Available

# Drug_Target_19_General_References:
10189842	Djilali-Saiah I, Schmitz J, Harfouch-Hammoud E, Mougenot JF, Bach JF, Caillat-Zucman S: CTLA-4 gene polymorphism is associated with predisposition to coeliac disease. Gut. 1998 Aug;43(2):187-9.
10475192	Vaidya B, Imrie H, Perros P, Dickinson J, McCarthy MI, Kendall-Taylor P, Pearce SH: Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism confers susceptibility to thyroid associated orbitopathy. Lancet. 1999 Aug 28;354(9180):743-4.
10493833	Ling V, Wu PW, Finnerty HF, Sharpe AH, Gray GS, Collins M: Complete sequence determination of the mouse and human CTLA4 gene loci: cross-species DNA sequence similarity beyond exon borders. Genomics. 1999 Sep 15;60(3):341-55.
10903931	Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, Kalachikov S, Cayanis E, Fischer SG, Barst RJ, Hodge SE, Knowles JA: Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet. 2000 Sep;67(3):737-44. Epub 2000 Jul 20.
10924276	Chistyakov DA, Savost'anov KV, Turakulov RI, Petunina NA, Trukhina LV, Kudinova AV, Balabolkin MI, Nosikov VV: Complex association analysis of graves disease using a set of polymorphic markers. Mol Genet Metab. 2000 Jul;70(3):214-8.
11735222	Ling V, Wu PW, Finnerty HF, Agostino MJ, Graham JR, Chen S, Jussiff JM, Fisk GJ, Miller CP, Collins M: Assembly and annotation of human chromosome 2q33 sequence containing the CD28, CTLA4, and ICOS gene cluster: analysis by computational, comparative, and microarray approaches. Genomics. 2001 Dec;78(3):155-68.
1713603	Harper K, Balzano C, Rouvier E, Mattei MG, Luciani MF, Golstein P: CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. J Immunol. 1991 Aug 1;147(3):1037-44.
1714933	Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA: CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med. 1991 Sep 1;174(3):561-9.
3220103	Dariavach P, Mattei MG, Golstein P, Lefranc MP: Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains. Eur J Immunol. 1988 Dec;18(12):1901-5.
9228944	Metzler WJ, Bajorath J, Fenderson W, Shaw SY, Constantine KL, Naemura J, Leytze G, Peach RJ, Lavoie TB, Mueller L, Linsley PS: Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28. Nat Struct Biol. 1997 Jul;4(7):527-31.
9259273	Marron MP, Raffel LJ, Garchon HJ, Jacob CO, Serrano-Rios M, Martinez Larrad MT, Teng WP, Park Y, Zhang ZX, Goldstein DR, Tao YW, Beaurain G, Bach JF, Huang HS, Luo DF, Zeidler A, Rotter JI, Yang MC, Modilevsky T, Maclaren NK, She JX: Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA4 polymorphisms in multiple ethnic groups. Hum Mol Genet. 1997 Aug;6(8):1275-82.

# Drug_Target_19_HGNC_ID:
HGNC:2505

# Drug_Target_19_HPRD_ID:
00474

# Drug_Target_19_ID:
1052

# Drug_Target_19_Locus:
2q33

# Drug_Target_19_Molecular_Weight:
24656

# Drug_Target_19_Name:
Cytotoxic T-lymphocyte protein 4

# Drug_Target_19_Number_of_Residues:
223

# Drug_Target_19_PDB_ID:
1I85

# Drug_Target_19_Pathway:
Not Available

# Drug_Target_19_Pfam_Domain_Function:
PF07686	V-set

# Drug_Target_19_Protein_Sequence:
>Cytotoxic T-lymphocyte protein 4 precursor
MACLGFQRHKAQLNLATRTWPCTLLFFLLFIPVFCKAMHVAQPAVVLASSRGIASFVCEY
ASPGKATEVRVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLR
AMDTGLYICKVELMYPPPYYLGIGNGTQIYVIDPEPCPDSDFLLWILAAVSSGLFFYSFL
LTAVSLSKMLKKRSPLTTGVYVKMPPTEPECEKQFQPYFIPIN

# Drug_Target_19_Reaction:
Not Available

# Drug_Target_19_Signals:
1-35

# Drug_Target_19_Specific_Function:
Possibly involved in T-cell activation. Binds to B7-1 (CD80) and B7-2 (CD86)

# Drug_Target_19_SwissProt_ID:
P16410

# Drug_Target_19_SwissProt_Name:
CTLA4_HUMAN

# Drug_Target_19_Synonyms:
CD152 antigen
CTLA-4
Cytotoxic T-lymphocyte protein 4 precursor
Cytotoxic T-lymphocyte- associated antigen 4

# Drug_Target_19_Theoretical_pI:
7.12

# Drug_Target_19_Transmembrane_Regions:
162-182

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
Not Available

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
MBL2

# Drug_Target_1_Gene_Sequence:
Not Available

# Drug_Target_1_General_Function:
Not Available

# Drug_Target_1_General_References:
Not Available

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
6992

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
Not Available

# Drug_Target_1_Name:
Mannose-binding protein C

# Drug_Target_1_Number_of_Residues:
0

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
Not Available

# Drug_Target_1_Protein_Sequence:
Not Available

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
Not Available

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
P11226

# Drug_Target_1_SwissProt_Name:
MBL2_HUMAN

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
Not Available

# Drug_Target_1_Transmembrane_Regions:
Not Available

# Drug_Target_20_Cellular_Location:
Membrane
single-pass type I membrane protein

# Drug_Target_20_Chromosome_Location:
Not Available

# Drug_Target_20_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_20_Essentiality:
Non-Essential

# Drug_Target_20_GenAtlas_ID:
LDLR

# Drug_Target_20_GenBank_ID_Gene:
L00352

# Drug_Target_20_GenBank_ID_Protein:
307121

# Drug_Target_20_GeneCard_ID:
LDLR

# Drug_Target_20_Gene_Name:
LDLR

# Drug_Target_20_Gene_Sequence:
>2583 bp
ATGGGGCCCTGGGGCTGGAAATTGCGCTGGACCGTCGCCTTGCTCCTCGCCGCGGCGGGG
ACTGCAGTGGGCGACAGATGTGAAAGAAACGAGTTCCAGTGCCAAGACGGGAAATGCATC
TCCTACAAGTGGGTCTGCGATGGCAGCGCTGAGTGCCAGGATGGCTCTGATGAGTCCCAG
GAGACGTGCTTGTCTGTCACCTGCAAATCCGGGGACTTCAGCTGTGGGGGCCGTGTCAAC
CGCTGCATTCCTCAGTTCTGGAGGTGCGATGGCCAAGTGGACTGCGACAACGGCTCAGAC
GAGCAAGGCTGTCCCCCCAAGACGTGCTCCCAGGACGAGTTTCGCTGCCACGATGGGAAG
TGCATCTCTCGGCAGTTCGTCTGTGACTCAGACCGGGACTGCTTGGACGGCTCAGACGAG
GCCTCCTGCCCGGTGCTCACCTGTGGTCCCGCCAGCTTCCAGTGCAACAGCTCCACCTGC
ATCCCCCAGCTGTGGGCCTGCGACAACGACCCCGACTGCGAAGATGGCTCGGATGAGTGG
CCGCAGCGCTGTAGGGGTCTTTACGTGTTCCAAGGGGACAGTAGCCCCTGCTCGGCCTTC
GAGTTCCACTGCCTAAGTGGCGAGTGCATCCACTCCAGCTGGCGCTGTGATGGTGGCCCC
GACTGCAAGGACAAATCTGACGAGGAAAACTGCGCTGTGGCCACCTGTCGCCCTGACGAA
TTCCAGTGCTCTGATGGAAACTGCATCCATGGCAGCCGGCAGTGTGACCGGGAATATGAC
TGCAAGGACATGAGCGATGAAGTTGGCTGCGTTAATGTGACACTCTGCGAGGGACCCAAC
AAGTTCAAGTGTCACAGCGGCGAATGCATCACCCTGGACAAAGTCTGCAACATGGCTAGA
GACTGCCGGGACTGGTCAGATGAACCCATCAAAGAGTGCGGGACCAACGAATGCTTGGAC
AACAACGGCGGCTGTTCCCACGTCTGCAATGACCTTAAGATCGGCTACGAGTGCCTGTGC
CCCGACGGCTTCCAGCTGGTGGCCCAGCGAAGATGCGAAGATATCGATGAGTGTCAGGAT
CCCGACACCTGCAGCCAGCTCTGCGTGAACCTGGAGGGTGGCTACAAGTGCCAGTGTGAG
GAAGGCTTCCAGCTGGACCCCCACACGAAGGCCTGCAAGGCTGTGGGCTCCATCGCCTAC
CTCTTCTTCACCAACCGGCACGAGGTCAGGAAGATGACGCTGGACCGGAGCGAGTACACC
AGCCTCATCCCCAACCTGAGGAACGTGGTCGCTCTGGACACGGAGGTGGCCAGCAATAGA
ATCTACTGGTCTGACCTGTCCCAGAGAATGATCTGCAGCACCCAGCTTGACAGAGCCCAC
GGCGTCTCTTCCTATGACACCGTCATCAGCAGGGACATCCAGGCCCCCGACGGGCTGGCT
GTGGACTGGATCCACAGCAACATCTACTGGACCGACTCTGTCCTGGGCACTGTCTCTGTT
GCGGATACCAAGGGCGTGAAGAGGAAAACGTTATTCAGGGAGAACGGCTCCAAGCCAAGG
GCCATCGTGGTGGATCCTGTTCATGGCTTCATGTACTGGACTGACTGGGGAACTCCCGCC
AAGATCAAGAAAGGGGGCCTGAATGGTGTGGACATCTACTCGCTGGTGACTGAAAACATT
CAGTGGCCCAATGGCATCACCCTAGATCTCCTCAGTGGCCGCCTCTACTGGGTTGACTCC
AAACTTCACTCCATCTCAAGCATCGATGTCAATGGGGGCAACCGGAAGACCATCTTGGAG
GATGAAAAGAGGCTGGCCCACCCCTTCTCCTTGGCCGTCTTTGAGGACAAAGTATTTTGG
ACAGATATCATCAACGAAGCCATTTTCAGTGCCAACCGCCTCACAGGTTCCGATGTCAAC
TTGTTGGCTGAAAACCTACTGTCCCCAGAGGATATGGTCCTCTTCCACAACCTCACCCAG
CCAAGAGGAGTGAACTGGTGTGAGAGGACCACCCTGAGCAATGGCGGCTGCCAGTATCTG
TGCCTCCCTGCCCCGCAGATCAACCCCCACTCGCCCAAGTTTACCTGCGCCTGCCCGGAC
GGCATGCTGCTGGCCAGGGACATGAGGAGCTGCCTCACAGAGGCTGAGGCTGCAGTGGCC
ACCCAGGAGACATCCACCGTCAGGCTAAAGGTCAGCTCCACAGCCGTAAGGACACAGCAC
ACAACCACCCGGCCTGTTCCCGACACCTCCCGGCTGCCTGGGGCCACCCCTGGGCTCACC
ACGGTGGAGATAGTGACAATGTCTCACCAAGCTCTGGGCGACGTTGCTGGCAGAGGAAAT
GAGAAGAAGCCCAGTAGCGTGAGGGCTCTGTCCATTGTCCTCCCCATCGTGCTCCTCGTC
TTCCTTTGCCTGGGGGTCTTCCTTCTATGGAAGAACTGGCGGCTTAAGAACATCAACAGC
ATCAACTTTGACAACCCCGTCTATCAGAAGACCACAGAGGATGAGGTCCACATTTGCCAC
AACCAGGACGGCTACAGCTACCCCTCGAGACAGATGGTCAGTCTGGAGGATGACGTGGCG
TGA

# Drug_Target_20_General_Function:
Involved in calcium ion binding

# Drug_Target_20_General_References:
10090484	Ebhardt M, Schmidt H, Doerk T, Tietge U, Haas R, Manns MP, Schmidtke J, Stuhrmann M: Mutation analysis in 46 German families with familial hypercholesterolemia: identification of 8 new mutations. Mutations in brief no. 226. Online. Hum Mutat. 1999;13(3):257.
10391209	Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Shaw N, Lane CR, Lim EP, Kalyanaraman N, Nemesh J, Ziaugra L, Friedland L, Rolfe A, Warrington J, Lipshutz R, Daley GQ, Lander ES: Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet. 1999 Jul;22(3):231-8.
10422803	Ekstrom U, Abrahamson M, Floren CH, Tollig H, Wettrell G, Nilsson G, Sun XM, Soutar AK, Nilsson-Ehle P: An individual with a healthy phenotype in spite of a pathogenic LDL receptor mutation (C240F). Clin Genet. 1999 May;55(5):332-9.
10447263	Hattori H, Nagano M, Iwata F, Homma Y, Egashira T, Okada T: Identification of recurrent and novel mutations in the LDL receptor gene in Japanese familial hypercholesterolemia. Mutation in brief no. 248. Online. Hum Mutat. 1999;14(1):87.
10882754	Thiart R, Scholtz CL, Vergotine J, Hoogendijk CF, de Villiers JN, Nissen H, Brusgaard K, Gaffney D, Hoffs MS, Vermaak WJ, Kotze MJ: Predominance of a 6 bp deletion in exon 2 of the LDL receptor gene in Africans with familial hypercholesterolaemia. J Med Genet. 2000 Jul;37(7):514-9.
11298688	Takahashi M, Ikeda U, Takahashi S, Hattori H, Iwasaki T, Ishihara M, Egashira T, Honma S, Asano Y, Shimada K: A novel mutation in exon 2 of the low-density lipoprotein-receptor gene in a patient with homozygous familial hypercholesterolemia. Clin Genet. 2001 Apr;59(4):290-2.
12615904	Bartosch B, Dubuisson J, Cosset FL: Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med. 2003 Mar 3;197(5):633-42.
12754519	Zhang H, Li XJ, Martin DB, Aebersold R: Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol. 2003 Jun;21(6):660-6. Epub 2003 May 18.
1301956	Hobbs HH, Brown MS, Goldstein JL: Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat. 1992;1(6):445-66.
1446662	Miyake Y, Tajima S, Funahashi T, Yamamura T, Yamamoto A: A point mutation of low-density-lipoprotein receptor causing rapid degradation of the receptor. Eur J Biochem. 1992 Nov 15;210(1):1-7.
1464748	Rubinsztein DC, Coetzee GA, Marais AD, Leitersdorf E, Seftel HC, van der Westhuyzen DR: Identification and properties of the proline664-leucine mutant LDL receptor in South Africans of Indian origin. J Lipid Res. 1992 Nov;33(11):1647-55.
1867200	Meiner V, Landsberger D, Berkman N, Reshef A, Segal P, Seftel HC, van der Westhuyzen DR, Jeenah MS, Coetzee GA, Leitersdorf E: A common Lithuanian mutation causing familial hypercholesterolemia in Ashkenazi Jews. Am J Hum Genet. 1991 Aug;49(2):443-9.
2318961	Leitersdorf E, Tobin EJ, Davignon J, Hobbs HH: Common low-density lipoprotein receptor mutations in the French Canadian population. J Clin Invest. 1990 Apr;85(4):1014-23.
2569482	Leitersdorf E, Van der Westhuyzen DR, Coetzee GA, Hobbs HH: Two common low density lipoprotein receptor gene mutations cause familial hypercholesterolemia in Afrikaners. J Clin Invest. 1989 Sep;84(3):954-61.
2726768	Soutar AK, Knight BL, Patel DD: Identification of a point mutation in growth factor repeat C of the low density lipoprotein-receptor gene in a patient with homozygous familial hypercholesterolemia that affects ligand binding and intracellular movement of receptors. Proc Natl Acad Sci U S A. 1989 Jun;86(11):4166-70.
2988123	Sudhof TC, Goldstein JL, Brown MS, Russell DW: The LDL receptor gene: a mosaic of exons shared with different proteins. Science. 1985 May 17;228(4701):815-22.
3005267	Davis CG, Elhammer A, Russell DW, Schneider WJ, Kornfeld S, Brown MS, Goldstein JL: Deletion of clustered O-linked carbohydrates does not impair function of low density lipoprotein receptor in transfected fibroblasts. J Biol Chem. 1986 Feb 25;261(6):2828-38.
3104336	Davis CG, van Driel IR, Russell DW, Brown MS, Goldstein JL: The low density lipoprotein receptor. Identification of amino acids in cytoplasmic domain required for rapid endocytosis. J Biol Chem. 1987 Mar 25;262(9):4075-82.
3263645	Leitersdorf E, Hobbs HH, Fourie AM, Jacobs M, van der Westhuyzen DR, Coetzee GA: Deletion in the first cysteine-rich repeat of low density lipoprotein receptor impairs its transport but not lipoprotein binding in fibroblasts from a subject with familial hypercholesterolemia. Proc Natl Acad Sci U S A. 1988 Nov;85(21):7912-6.
3955657	Davis CG, Lehrman MA, Russell DW, Anderson RG, Brown MS, Goldstein JL: The J.D. mutation in familial hypercholesterolemia: amino acid substitution in cytoplasmic domain impedes internalization of LDL receptors. Cell. 1986 Apr 11;45(1):15-24.
6091915	Yamamoto T, Davis CG, Brown MS, Schneider WJ, Casey ML, Goldstein JL, Russell DW: The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA. Cell. 1984 Nov;39(1):27-38.
7550239	Tricot-Guerber F, Saint-Jore B, Valenti K, Foulon T, Bost M, Hadjian AJ: Identification of a mutation, N543H, in exon 11 of the low-density lipoprotein receptor gene in a French family with familial hypercholesterolemia. Hum Mutat. 1995;6(1):87-8.
7573037	Koivisto UM, Viikari JS, Kontula K: Molecular characterization of minor gene rearrangements in Finnish patients with heterozygous familial hypercholesterolemia: identification of two common missense mutations (Gly823-->Asp and Leu380-->His) and eight rare mutations of the LDL receptor gene. Am J Hum Genet. 1995 Oct;57(4):789-97.
7578052	Daly NL, Djordjevic JT, Kroon PA, Smith R: Three-dimensional structure of the second cysteine-rich repeat from the human low-density lipoprotein receptor. Biochemistry. 1995 Nov 7;34(44):14474-81.
7583548	Maruyama T, Miyake Y, Tajima S, Harada-Shiba M, Yamamura T, Tsushima M, Kishino B, Horiguchi Y, Funahashi T, Matsuzawa Y, et al.: Common mutations in the low-density-lipoprotein-receptor gene causing familial hypercholesterolemia in the Japanese population. Arterioscler Thromb Vasc Biol. 1995 Oct;15(10):1713-8.
7603991	Daly NL, Scanlon MJ, Djordjevic JT, Kroon PA, Smith R: Three-dimensional structure of a cysteine-rich repeat from the low-density lipoprotein receptor. Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6334-8.
7635461	Ekstrom U, Abrahamson M, Sveger T, Lombardi P, Nilsson-Ehle P: An efficient screening procedure detecting six novel mutations in the LDL receptor gene in Swedish children with hypercholesterolemia. Hum Genet. 1995 Aug;96(2):147-50.
7635482	Leren TP, Solberg K, Rodningen OK, Tonstad S, Ose L: Two novel point mutations in the EGF precursor homology domain of the LDL receptor gene causing familial hypercholesterolemia. Hum Genet. 1995 Aug;96(2):241-2.
7649546	Giesel J, Holzem G, Oette K: Screening for mutations in exon 4 of the LDL receptor gene in a German population with severe hypercholesterolemia. Hum Genet. 1995 Sep;96(3):301-4.
7649549	Pereira E, Ferreira R, Hermelin B, Thomas G, Bernard C, Bertrand V, Nassiff H, Mendez del Castillo D, Bereziat G, Benlian P: Recurrent and novel LDL receptor gene mutations causing heterozygous familial hypercholesterolemia in La Habana. Hum Genet. 1995 Sep;96(3):319-22.
8168830	Lelli N, Garuti R, Pedrazzi P, Ghisellini M, Simone ML, Tiozzo R, Cattin L, Valenti M, Rolleri M, Bertolini S, et al.: A new missense mutation (Cys297-->Phe) of the low density lipoprotein receptor in Italian patients with familial hypercholesterolemia (FHTrieste). Hum Genet. 1994 May;93(5):538-40.
8347689	Rubinsztein DC, Jialal I, Leitersdorf E, Coetzee GA, van der Westhuyzen DR: Identification of two new LDL-receptor mutations causing homozygous familial hypercholesterolemia in a South African of Indian origin. Biochim Biophys Acta. 1993 Aug 4;1182(1):75-82.
8462973	Leitersdorf E, Reshef A, Meiner V, Dann EJ, Beigel Y, van Roggen FG, van der Westhuyzen DR, Coetzee GA: A missense mutation in the low density lipoprotein receptor gene causes familial hypercholesterolemia in Sephardic Jews. Hum Genet. 1993 Mar;91(2):141-7.
8664907	Sundvold H, Solberg K, Tonstad S, Rodningen OK, Ose L, Berg K, Leren TP: A common missense mutation (C210G) in the LDL receptor gene among Norwegian familial hypercholesterolemia subjects. Hum Mutat. 1996;7(1):70-1.
8740918	Gundersen KE, Solberg K, Rodningen OK, Tonstad S, Ose L, Berg K, Leren TP: Two novel missense mutations in the LDL receptor gene causing familial hypercholesterolemia. Clin Genet. 1996 Feb;49(2):85-7.
9016531	Varret M, Rabes JP, Collod-Beroud G, Junien C, Boileau C, Beroud C: Software and database for the analysis of mutations in the human LDL receptor gene. Nucleic Acids Res. 1997 Jan 1;25(1):172-80.
9026534	Webb JC, Sun XM, McCarthy SN, Neuwirth C, Thompson GR, Knight BL, Soutar AK: Characterization of mutations in the low density lipoprotein (LDL)-receptor gene in patients with homozygous familial hypercholesterolemia, and frequency of these mutations in FH patients in the United Kingdom. J Lipid Res. 1996 Feb;37(2):368-81.
9104431	Leren TP, Tonstad S, Gundersen KE, Bakken KS, Rodningen OK, Sundvold H, Ose L, Berg K: Molecular genetics of familial hypercholesterolaemia in Norway. J Intern Med. 1997 Mar;241(3):185-94.
9143924	Jensen HK, Jensen TG, Faergeman O, Jensen LG, Andresen BS, Corydon MJ, Andreasen PH, Hansen PS, Heath F, Bolund L, Gregersen N: Two mutations in the same low-density lipoprotein receptor allele act in synergy to reduce receptor function in heterozygous familial hypercholesterolemia. Hum Mutat. 1997;9(5):437-44.
9254862	Peeters AV, Van Gaal LF, du Plessis L, Lombardi MP, Havekes LM, Kotze MJ: Mutational and genetic origin of LDL receptor gene mutations detected in both Belgian and Dutch familial hypercholesterolemics. Hum Genet. 1997 Aug;100(2):266-70.
9259195	Day IN, Whittall RA, O'Dell SD, Haddad L, Bolla MK, Gudnason V, Humphries SE: Spectrum of LDL receptor gene mutations in heterozygous familial hypercholesterolemia. Hum Mutat. 1997;10(2):116-27.
9262405	Fass D, Blacklow S, Kim PS, Berger JM: Molecular basis of familial hypercholesterolaemia from structure of LDL receptor module. Nature. 1997 Aug 14;388(6643):691-3.
9452094	Couture P, Vohl MC, Gagne C, Gaudet D, Torres AL, Lupien PJ, Despres JP, Labrie F, Simard J, Moorjani S: Identification of three mutations in the low-density lipoprotein receptor gene causing familial hypercholesterolemia among French Canadians. Hum Mutat. 1998;Suppl 1:S226-31.
9452095	Thiart R, Loubser O, de Villiers JN, Marx MP, Zaire R, Raal FJ, Kotze MJ: Two novel and two known low-density lipoprotein receptor gene mutations in German patients with familial hypercholesterolemia. Hum Mutat. 1998;Suppl 1:S232-3.
9452118	Mak YT, Zhang J, Chan YS, Mak TW, Tomlinson B, Masarei JR, Pang CP: Possible common mutations in the low density lipoprotein receptor gene in Chinese. Hum Mutat. 1998;Suppl 1:S310-3.
9654205	Gorski B, Kubalska J, Naruszewicz M, Lubinski J: LDL-R and Apo-B-100 gene mutations in Polish familial hypercholesterolemias. Hum Genet. 1998 May;102(5):562-5.
9678702	Lee WK, Haddad L, Macleod MJ, Dorrance AM, Wilson DJ, Gaffney D, Dominiczak MH, Packard CJ, Day IN, Humphries SE, Dominiczak AF: Identification of a common low density lipoprotein receptor mutation (C163Y) in the west of Scotland. J Med Genet. 1998 Jul;35(7):573-8.
9852677	Hirayama T, Yamaki E, Hata A, Tsuji M, Hashimoto K, Yamamoto M, Emi M: Five familial hypercholesterolemic kindreds in Japan with novel mutations of the LDL receptor gene. J Hum Genet. 1998;43(4):250-4.

# Drug_Target_20_HGNC_ID:
HGNC:6547

# Drug_Target_20_HPRD_ID:
06091

# Drug_Target_20_ID:
554

# Drug_Target_20_Locus:
19p13.3

# Drug_Target_20_Molecular_Weight:
95376

# Drug_Target_20_Name:
Low-density lipoprotein receptor

# Drug_Target_20_Number_of_Residues:
860

# Drug_Target_20_PDB_ID:
1N7D

# Drug_Target_20_Pathway:
Not Available

# Drug_Target_20_Pfam_Domain_Function:
PF00008	EGF
PF00057	Ldl_recept_a
PF00058	Ldl_recept_b
PF07645	EGF_CA

# Drug_Target_20_Protein_Sequence:
>Low-density lipoprotein receptor precursor
MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQ
ETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGK
CISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEW
PQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDE
FQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMAR
DCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQD
PDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYT
SLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLA
VDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPA
KIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILE
DEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQ
PRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVA
TQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGN
EKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICH
NQDGYSYPSRQMVSLEDDVA

# Drug_Target_20_Reaction:
Not Available

# Drug_Target_20_Signals:
1-21

# Drug_Target_20_Specific_Function:
Binds LDL, the major cholesterol-carrying lipoprotein of plasma, and transports it into cells by endocytosis. In order to be internalized, the receptor-ligand complexes must first cluster into clathrin-coated pits

# Drug_Target_20_SwissProt_ID:
P01130

# Drug_Target_20_SwissProt_Name:
LDLR_HUMAN

# Drug_Target_20_Synonyms:
LDL receptor
Low-density lipoprotein receptor precursor

# Drug_Target_20_Theoretical_pI:
4.64

# Drug_Target_20_Transmembrane_Regions:
789-810

# Drug_Target_21_Cellular_Location:
Isoform 1:Cell membrane

# Drug_Target_21_Chromosome_Location:
Not Available

# Drug_Target_21_Drug_References:
Not Available

# Drug_Target_21_Essentiality:
Non-Essential

# Drug_Target_21_GenAtlas_ID:
CD209

# Drug_Target_21_GenBank_ID_Gene:
M98457

# Drug_Target_21_GenBank_ID_Protein:
Not Available

# Drug_Target_21_GeneCard_ID:
Not Available

# Drug_Target_21_Gene_Name:
CD209

# Drug_Target_21_Gene_Sequence:
>1215 bp
ATGAGTGACTCCAAGGAACCAAGACTGCAGCAGCTGGGCCTCCTGGAGGAGGAACAGCTG
AGAGGCCTTGGATTCCGACAGACTCGAGGATACAAGAGCTTAGCAGGGTGTCTTGGCCAT
GGTCCCCTGGTGCTGCAACTCCTCTCCTTCACGCTCTTGGCTGGGCTCCTTGTCCAAGTG
TCCAAGGTCCCCAGCTCCATAAGTCAGGAACAATCCAGGCAAGACGCGATCTACCAGAAC
CTGACCCAGCTTAAAGCTGCAGTGGGTGAGCTCTCAGAGAAATCCAAGCTGCAGGAGATC
TACCAGGAGCTGACCCAGCTGAAGGCTGCAGTGGGTGAGCTTCCAGAGAAATCTAAGCTG
CAGGAGATCTACCAGGAGCTGACCCGGCTGAAGGCTGCAGTGGGTGAGCTTCCAGAGAAA
TCTAAGCTGCAGGAGATCTACCAGGAGCTGACCTGGCTGAAGGCTGCAGTGGGTGAGCTT
CCAGAGAAATCTAAGATGCAGGAGATCTACCAGGAGCTGACTCGGCTGAAGGCTGCAGTG
GGTGAGCTTCCAGAGAAATCTAAGCAGCAGGAGATCTACCAGGAGCTGACCCGGCTGAAG
GCTGCAGTGGGTGAGCTTCCAGAGAAATCTAAGCAGCAGGAGATCTACCAGGAGCTGACC
CGGCTGAAGGCTGCAGTGGGTGAGCTTCCAGAGAAATCTAAGCAGCAGGAGATCTACCAG
GAGCTGACCCAGCTGAAGGCTGCAGTGGAACGCCTGTGCCACCCCTGTCCCTGGGAATGG
ACATTCTTCCAAGGAAACTGTTACTTCATGTCTAACTCCCAGCGGAACTGGCACGACTCC
ATCACCGCCTGCAAAGAAGTGGGGGCCCAGCTCGTCGTAATCAAAAGTGCTGAGGAGCAG
AACTTCCTACAGCTGCAGTCTTCCAGAAGTAACCGCTTCACCTGGATGGGACTTTCAGAT
CTAAATCAGGAAGGCACGTGGCAATGGGTGGACGGCTCACCTCTGTTGCCCAGCTTCAAG
CAGTATTGGAACAGAGGAGAGCCCAACAACGTTGGGGAGGAAGACTGCGCGGAATTTAGT
GGCAATGGCTGGAACGACGACAAATGTAATCTTGCCAAATTCTGGATCTGCAAAAAGTCC
GCAGCCTCCTGCTCCAGGGATGAAGAACAGTTTCTTTCTCCAGCCCCTGCCACCCCAAAC
CCCCCTCCTGCGTAG

# Drug_Target_21_General_Function:
Involved in sugar binding

# Drug_Target_21_General_References:
10975799	Soilleux EJ, Barten R, Trowsdale J: DC-SIGN; a related gene, DC-SIGNR; and CD23 form a cluster on 19p13. J Immunol. 2000 Sep 15;165(6):2937-42.
11257134	Bashirova AA, Geijtenbeek TB, van Duijnhoven GC, van Vliet SJ, Eilering JB, Martin MP, Wu L, Martin TD, Viebig N, Knolle PA, KewalRamani VN, van Kooyk Y, Carrington M: A dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN)-related protein is highly expressed on human liver sinusoidal endothelial cells and promotes HIV-1 infection. J Exp Med. 2001 Mar 19;193(6):671-8.
1518869	Curtis BM, Scharnowske S, Watson AJ: Sequence and expression of a membrane-associated C-type lectin that exhibits CD4-independent binding of human immunodeficiency virus envelope glycoprotein gp120. Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):8356-60.

# Drug_Target_21_HGNC_ID:
HGNC:1641

# Drug_Target_21_HPRD_ID:
Not Available

# Drug_Target_21_ID:
4856

# Drug_Target_21_Locus:
19p13

# Drug_Target_21_Molecular_Weight:
45775

# Drug_Target_21_Name:
CD209 antigen

# Drug_Target_21_Number_of_Residues:
404

# Drug_Target_21_PDB_ID:
1K9I

# Drug_Target_21_Pathway:
Not Available

# Drug_Target_21_Pfam_Domain_Function:
PF00059	Lectin_C

# Drug_Target_21_Protein_Sequence:
>CD209 antigen
MSDSKEPRLQQLGLLEEEQLRGLGFRQTRGYKSLAGCLGHGPLVLQLLSFTLLAGLLVQV
SKVPSSISQEQSRQDAIYQNLTQLKAAVGELSEKSKLQEIYQELTQLKAAVGELPEKSKL
QEIYQELTRLKAAVGELPEKSKLQEIYQELTWLKAAVGELPEKSKMQEIYQELTRLKAAV
GELPEKSKQQEIYQELTRLKAAVGELPEKSKQQEIYQELTRLKAAVGELPEKSKQQEIYQ
ELTQLKAAVERLCHPCPWEWTFFQGNCYFMSNSQRNWHDSITACKEVGAQLVVIKSAEEQ
NFLQLQSSRSNRFTWMGLSDLNQEGTWQWVDGSPLLPSFKQYWNRGEPNNVGEEDCAEFS
GNGWNDDKCNLAKFWICKKSAASCSRDEEQFLSPAPATPNPPPA

# Drug_Target_21_Reaction:
Not Available

# Drug_Target_21_Signals:
None

# Drug_Target_21_Specific_Function:
On DCs it is a high affinity receptor for ICAM2 and ICAM3 by binding to mannose-like carbohydrates. May act as a DC rolling receptor that mediates transendothelial migration of DC presursors from blood to tissues by binding endothelial ICAM2. Seems to regulate DC-induced T-cell proliferation by binding to ICAM3 on T-cells in the immunological synapse formed between DC and T-cells

# Drug_Target_21_SwissProt_ID:
Q9NNX6

# Drug_Target_21_SwissProt_Name:
CD209_HUMAN

# Drug_Target_21_Synonyms:
C-type lectin domain family 4 member L
DC-SIGN
DC-SIGN1
Dendritic cell-specific ICAM-3-grabbing nonintegrin 1

# Drug_Target_21_Theoretical_pI:
5.16

# Drug_Target_21_Transmembrane_Regions:
38-58

# Drug_Target_22_Cellular_Location:
Membrane
single-pass type I membrane protein

# Drug_Target_22_Chromosome_Location:
Not Available

# Drug_Target_22_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_22_Essentiality:
Non-Essential

# Drug_Target_22_GenAtlas_ID:
FCER1A

# Drug_Target_22_GenBank_ID_Gene:
X06948

# Drug_Target_22_GenBank_ID_Protein:
31318

# Drug_Target_22_GeneCard_ID:
FCER1A

# Drug_Target_22_Gene_Name:
FCER1A

# Drug_Target_22_Gene_Sequence:
>774 bp
ATGGCTCCTGCCATGGAATCCCCTACTCTACTGTGTGTAGCCTTACTGTTCTTCGCTCCA
GATGGCGTGTTAGCAGTCCCTCAGAAACCTAAGGTCTCCTTGAACCCTCCATGGAATAGA
ATATTTAAAGGAGAGAATGTGACTCTTACATGTAATGGGAACAATTTCTTTGAAGTCAGT
TCCACCAAATGGTTCCACAATGGCAGCCTTTCAGAAGAGACAAATTCAAGTTTGAATATT
GTGAATGCCAAATTTGAAGACAGTGGAGAATACAAATGTCAGCACCAACAAGTTAATGAG
AGTGAACCTGTGTACCTGGAAGTCTTCAGTGACTGGCTGCTCCTTCAGGCCTCTGCTGAG
GTGGTGATGGAGGGCCAGCCCCTCTTCCTCAGGTGCCATGGTTGGAGGAACTGGGATGTG
TACAAGGTGATCTATTATAAGGATGGTGAAGCTCTCAAGTACTGGTATGAGAACCACAAC
ATCTCCATTACAAATGCCACAGTTGAAGACAGTGGAACCTACTACTGTACGGGCAAAGTG
TGGCAGCTGGACTATGAGTCTGAGCCCCTCAACATTACTGTAATAAAAGCTCCGCGTGAG
AAGTACTGGCTACAATTTTTTATCCCATTGTTGGTGGTGATTCTGTTTGCTGTGGACACA
GGATTATTTATCTCAACTCAGCAGCAGGTCACATTTCTCTTGAAGATTAAGAGAACCAGG
AAAGGCTTCAGACTTCTGAACCCACATCCTAAGCCAAACCCCAAAAACAACTGA

# Drug_Target_22_General_Function:
Not Available

# Drug_Target_22_General_References:
1472946	Padlan EA, Helm BA: A modeling study of the alpha-subunit of human high-affinity receptor for immunoglobulin-E. Receptor. 1992 Summer;2(2):129-44.
2964640	Shimizu A, Tepler I, Benfey PN, Berenstein EH, Siraganian RP, Leder P: Human and rat mast cell high-affinity immunoglobulin E receptors: characterization of putative alpha-chain gene products. Proc Natl Acad Sci U S A. 1988 Mar;85(6):1907-11.
2967464	Kochan J, Pettine LF, Hakimi J, Kishi K, Kinet JP: Isolation of the gene coding for the alpha subunit of the human high affinity IgE receptor. Nucleic Acids Res. 1988 Apr 25;16(8):3584.
8125119	Yagi S, Yanagida M, Tanida I, Hasegawa A, Okumura K, Ra C: High-level expression of the truncated alpha chain of human high-affinity receptor for IgE as a soluble form by baculovirus-infected insect cells. Biochemical characterization of the recombinant product. Eur J Biochem. 1994 Mar 1;220(2):593-8.

# Drug_Target_22_HGNC_ID:
HGNC:3609

# Drug_Target_22_HPRD_ID:
00917

# Drug_Target_22_ID:
18

# Drug_Target_22_Locus:
1q23

# Drug_Target_22_Molecular_Weight:
29596

# Drug_Target_22_Name:
High affinity immunoglobulin epsilon receptor subunit alpha

# Drug_Target_22_Number_of_Residues:
257

# Drug_Target_22_PDB_ID:
1RPQ

# Drug_Target_22_Pathway:
Not Available

# Drug_Target_22_Pfam_Domain_Function:
PF00047	ig

# Drug_Target_22_Protein_Sequence:
>High affinity immunoglobulin epsilon receptor alpha-subunit precursor
MAPAMESPTLLCVALLFFAPDGVLAVPQKPKVSLNPPWNRIFKGENVTLTCNGNNFFEVS
STKWFHNGSLSEETNSSLNIVNAKFEDSGEYKCQHQQVNESEPVYLEVFSDWLLLQASAE
VVMEGQPLFLRCHGWRNWDVYKVIYYKDGEALKYWYENHNISITNATVEDSGTYYCTGKV
WQLDYESEPLNITVIKAPREKYWLQFFIPLLVVILFAVDTGLFISTQQQVTFLLKIKRTR
KGFRLLNPHPKPNPKNN

# Drug_Target_22_Reaction:
Not Available

# Drug_Target_22_Signals:
1-25

# Drug_Target_22_Specific_Function:
Binds to the Fc region of immunoglobulins epsilon. High affinity receptor. Responsible for initiating the allergic response. Binding of allergen to receptor-bound IgE leads to cell activation and the release of mediators (such as histamine) responsible for the manifestations of allergy. The same receptor also induces the secretion of important lymphokines

# Drug_Target_22_SwissProt_ID:
P12319

# Drug_Target_22_SwissProt_Name:
FCERA_HUMAN

# Drug_Target_22_Synonyms:
Fc-epsilon RI-alpha
FcERI
High affinity immunoglobulin epsilon receptor subunit alpha precursor
IgE Fc receptor, alpha-subunit

# Drug_Target_22_Theoretical_pI:
6.67

# Drug_Target_22_Transmembrane_Regions:
206-224

# Drug_Target_23_Cellular_Location:
Secreted protein

# Drug_Target_23_Chromosome_Location:
Not Available

# Drug_Target_23_Drug_References:
Not Available

# Drug_Target_23_Essentiality:
Non-Essential

# Drug_Target_23_GenAtlas_ID:
AZGP1

# Drug_Target_23_GenBank_ID_Gene:
D90427

# Drug_Target_23_GenBank_ID_Protein:
Not Available

# Drug_Target_23_GeneCard_ID:
Not Available

# Drug_Target_23_Gene_Name:
AZGP1

# Drug_Target_23_Gene_Sequence:
>888 bp
ATGGTGCCTGTCCTGCTGTCTCTGCTGCTGCTTCTGGGTCCTGCTGTCCCCCAGGAGAAC
CAAGATGGTCGTTACTCTCTGACCTATATCTACACTGGGCTGTCCAAGCATGTTGAAGAC
GTCCCCGCGTTTCAGGCCCTTGGCTCACTCAATGACCTCCAGTTCTTTAGATACAACAGT
AAAGACAGGAAGTCTCAGCCCATGGGACTCTGGAGACAGGTGGAAGGAATGGAGGATTGG
AAGCAGGACAGCCAACTTCAGAAGGCCAGGGAGGACATCTTTATGGAGACCCTGAAAGAC
ATTGTGGAGTATTACAACGACAGTAACGGGTCTCACGTATTGCAGGGAAGGTTTGGTTGT
GAGATCGAGAATAACAGAAGCAGCGGAGCATTCTGGAAATATTACTATGATGGAAAGGAC
TACATTGAATTCAACAAAGAAATCCCAGCCTGGGTCCCCTTCGACCCAGCAGCCCAGATA
ACCAAGCAGAAGTGGGAGGCAGAACCAGTCTACGTGCAGCGGGCCAAGGCTTACCTGGAG
GAGGAGTGCCCTGCGACTCTGCGGAAATACCTGAAATACAGCAAAAATATCCTGGACCGG
CAAGATCCTCCCTCTGTGGTGGTCACCAGCCACCAGGCCCCAGGAGAAAAGAAGAAACTG
AAGTGCCTGGCCTACGACTTCTACCCAGGGAAAATTGATGTGCACTGGACTCGGGCCGGC
GAGGTGCAGGAGCCTGAGTTACGGGGAGATGTTCTTCACAATGGAAATGGCACTTACCAG
TCCTGGGTGGTGGTGGCAGTGCCCCCGCAGGACACAGCCCCCTACTCCTGCCACGTGCAG
CACAGCAGCCTGGCCCAGCCCCTCGTGGTGCCCTGGGAGGCCAGCTAG

# Drug_Target_23_General_Function:
Not Available

# Drug_Target_23_General_References:
11425849	Kennedy MW, Heikema AP, Cooper A, Bjorkman PJ, Sanchez LM: Hydrophobic ligand binding by Zn-alpha 2-glycoprotein, a soluble fat-depleting factor related to major histocompatibility complex proteins. J Biol Chem. 2001 Sep 14;276(37):35008-13. Epub 2001 Jun 25.
12853948	Hillier LW, Fulton RS, Fulton LA, Graves TA, Pepin KH, Wagner-McPherson C, Layman D, Maas J, Jaeger S, Walker R, Wylie K, Sekhon M, Becker MC, O'Laughlin MD, Schaller ME, Fewell GA, Delehaunty KD, Miner TL, Nash WE, Cordes M, Du H, Sun H, Edwards J, Bradshaw-Cordum H, Ali J, Andrews S, Isak A, Vanbrunt A, Nguyen C, Du F, Lamar B, Courtney L, Kalicki J, Ozersky P, Bielicki L, Scott K, Holmes A, Harkins R, Harris A, Strong CM, Hou S, Tomlinson C, Dauphin-Kohlberg S, Kozlowicz-Reilly A, Leonard S, Rohlfing T, Rock SM, Tin-Wollam AM, Abbott A, Minx P, Maupin R, Strowmatt C, Latreille P, Miller N, Johnson D, Murray J, Woessner JP, Wendl MC, Yang SP, Schultz BR, Wallis JW, Spieth J, Bieri TA, Nelson JO, Berkowicz N, Wohldmann PE, Cook LL, Hickenbotham MT, Eldred J, Williams D, Bedell JA, Mardis ER, Clifton SW, Chissoe SL, Marra MA, Raymond C, Haugen E, Gillett W, Zhou Y, James R, Phelps K, Iadanoto S, Bubb K, Simms E, Levy R, Clendenning J, Kaul R, Kent WJ, Furey TS, Baertsch RA, Brent MR, Keibler E, Flicek P, Bork P, Suyama M, Bailey JA, Portnoy ME, Torrents D, Chinwalla AT, Gish WR, Eddy SR, McPherson JD, Olson MV, Eichler EE, Green ED, Waterston RH, Wilson RK: The DNA sequence of human chromosome 7. Nature. 2003 Jul 10;424(6945):157-64.
1915885	Freije JP, Fueyo A, Uria J, Lopez-Otin C: Human Zn-alpha 2-glycoprotein cDNA cloning and expression analysis in benign and malignant breast tissues. FEBS Lett. 1991 Sep 23;290(1-2):247-9.
2049092	Ueyama H, Niwa M, Tada T, Sasaki M, Ohkubo I: Cloning and nucleotide sequence of a human Zn-alpha 2-glycoprotein cDNA and chromosomal assignment of its gene. Biochem Biophys Res Commun. 1991 Jun 14;177(2):696-703.
3422450	Araki T, Gejyo F, Takagaki K, Haupt H, Schwick HG, Burgi W, Marti T, Schaller J, Rickli E, Brossmer R, et al.: Complete amino acid sequence of human plasma Zn-alpha 2-glycoprotein and its homology to histocompatibility antigens. Proc Natl Acad Sci U S A. 1988 Feb;85(3):679-83.
8241150	Ueyama H, Deng HX, Ohkubo I: Molecular cloning and chromosomal assignment of the gene for human Zn-alpha 2-glycoprotein. Biochemistry. 1993 Dec 7;32(48):12968-76.
8307568	Freije JP, Fueyo A, Uria JA, Velasco G, Sanchez LM, Lopez-Boado YS, Lopez-Otin C: Human Zn-alpha 2-glycoprotein: complete genomic sequence, identification of a related pseudogene and relationship to class I major histocompatibility complex genes. Genomics. 1993 Dec;18(3):575-87.
9114041	Sanchez LM, Lopez-Otin C, Bjorkman PJ: Biochemical characterization and crystalization of human Zn-alpha2-glycoprotein, a soluble class I major histocompatibility complex homolog. Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4626-30.

# Drug_Target_23_HGNC_ID:
HGNC:910

# Drug_Target_23_HPRD_ID:
Not Available

# Drug_Target_23_ID:
4857

# Drug_Target_23_Locus:
7q22.1

# Drug_Target_23_Molecular_Weight:
33872

# Drug_Target_23_Name:
Zinc-alpha-2-glycoprotein

# Drug_Target_23_Number_of_Residues:
295

# Drug_Target_23_PDB_ID:
1T80

# Drug_Target_23_Pathway:
Not Available

# Drug_Target_23_Pfam_Domain_Function:
PF00129	MHC_I
PF07654	C1-set

# Drug_Target_23_Protein_Sequence:
>Zinc-alpha-2-glycoprotein
MVPVLLSLLLLLGPAVPQENQDGRYSLTYIYTGLSKHVEDVPAFQALGSLNDLQFFRYNS
KDRKSQPMGLWRQVEGMEDWKQDSQLQKAREDIFMETLKDIVEYYNDSNGSHVLQGRFGC
EIENNRSSGAFWKYYYDGKDYIEFNKEIPAWVPFDPAAQITKQKWEAEPVYVQRAKAYLE
EECPATLRKYLKYSKNILDRQDPPSVVVTSHQAPGEKKKLKCLAYDFYPGKIDVHWTRAG
EVQEPELRGDVLHNGNGTYQSWVVVAVPPQDTAPYSCHVQHSSLAQPLVVPWEAS

# Drug_Target_23_Reaction:
Not Available

# Drug_Target_23_Signals:
1-17

# Drug_Target_23_Specific_Function:
Stimulates lipid degradation in adipocytes and causes the extensive fat losses associated with some advanced cancers. May bind polyunsaturated fatty acids

# Drug_Target_23_SwissProt_ID:
P25311

# Drug_Target_23_SwissProt_Name:
ZA2G_HUMAN

# Drug_Target_23_Synonyms:
Zinc-alpha-2-glycoprotein precursor
Zn- alpha-2-GP
Zn-alpha-2-glycoprotein

# Drug_Target_23_Theoretical_pI:
5.66

# Drug_Target_23_Transmembrane_Regions:
None

# Drug_Target_24_Cellular_Location:
Membrane
single-pass type I membrane protein

# Drug_Target_24_Chromosome_Location:
Not Available

# Drug_Target_24_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_24_Essentiality:
Non-Essential

# Drug_Target_24_GenAtlas_ID:
GP1BA

# Drug_Target_24_GenBank_ID_Gene:
J02940

# Drug_Target_24_GenBank_ID_Protein:
306793

# Drug_Target_24_GeneCard_ID:
GP1BA

# Drug_Target_24_Gene_Name:
GP1BA

# Drug_Target_24_Gene_Sequence:
>1881 bp
ATGCCTCTCCTCCTCTTGCTGCTCCTGCTGCCAAGCCCCTTACACCCCCACCCCATCTGT
GAGGTCTCCAAAGTGGCCAGCCACCTAGAAGTGAACTGTGACAAGAGGAATCTGACAGCG
CTGCCTCCAGACCTGCCGAAAGACACAACCATCCTCCACCTGAGTGAGAACCTCCTGTAC
ACCTTCTCCCTGGCAACCCTGATGCCTTACACTCGCCTCACTCAGCTGAACCTAGATAGG
TGCGAGCTCACCAAGCTCCAGGTCGATGGGACGCTGCCAGTGCTGGGGACCCTGGATCTA
TCCCACAATCAGCTGCAAAGCCTGCCCTTGCTAGGGCAGACACTGCCTGCTCTCACCGTC
CTGGACGTCTCCTTCAACCGGCTGACCTCGCTGCCTCTTGGTGCCCTGCGTGGTCTTGGC
GAACTCCAAGAGCTCTACCTGAAAGGCAATGAGCTGAAGACCCTGCCCCCAGGGCTCCTG
ACGCCCACACCCAAGCTGGAGAAGCTCAGTCTGGCTAACAACAACTTGACTGAGCTCCCC
GCTGGGCTCCTGAATGGGCTGGAGAATCTCGACACCCTTCTCCTCCAAGAGAACTCGCTG
TATACAATACCAAAGGGCTTTTTTGGGTCCCACCTCCTGCCTTTTGCTTTTCTCCACGGG
AACCCCTGGTTATGCAACTGTGAGATCCTCTATTTTCGTCGCTGGCTGCAGGACAATGCT
GAAAATGTCTACGTATGGAAGCAAGGTGTGGACGTCAAGGCCATGACCTCTAACGTGGCC
AGTGTGCAGTGTGACAATTCAGACAAGTTTCCCGTCTACAAATACCCAGGAAAGGGGTGC
CCCACCCTTGGTGATGAAGGTGACACAGACCTATATGATTACTACCCAGAAGAGGACACT
GAGGGCGATAAGGTGCGTGCCACAAGGACTGTGGTCAAGTTCCCCACCAAAGCCCATACA
ACCCCCTGGGGTCTATTCTACTCATGGTCCACTGCTTCTCTAGACAGCCAAATGCCCTCC
TCCTTGCATCCAACACAAGAATCCACTAAGGAGCAGACCACATTCCCACCTAGATGGACC
CCAAATTTCACACTTCACATGGAATCCATCACATTCTCCAAAACTCCAAAATCCACTACT
GAACCAACCCCAAGCCCGACCACCTCAGAGCCCGTCCCGGAGCCCGCCCCAAACATGACC
ACCCTGGAGCCCACTCCAAGCCCGACCACCCCAGAGCCCACCTCAGAGCCCGCCCCCAGC
CCGACCACCCCGGAGCCCACCCCAATCCCGACCATCGCCACAAGCCCGACCATCCTGGTG
TCTGCCACAAGCCTGATCACTCCAAAAAGCACATTTTTAACTACCACAAAACCCGTATCA
CTCTTAGAATCCACCAAAAAAACCATCCCTGAACTTGATCAGCCACCAAAGCTCCGTGGG
GTGCTCCAAGGGCATTTGGAGAGCTCCAGAAATGACCCTTTTCTCCACCCCGACTTTTGC
TGCCTCCTCCCCCTGGGCTTCTATGTCTTGGGTCTCTTCTGGCTGCTCTTTGCCTCTGTG
GTCCTCATCCTGCTGCTGAGCTGGGTTGGGCATGTGAAACCACAGGCCCTGGACTCTGGC
CAAGGTGCTGCTCTGACCACAGCCACACAAACCACACACCTGGAGCTGCAGAGGGGACGG
CAAGTGACAGTGCCCCGGGCCTGGCTGCTCTTCCTTCGAGGTTCGCTTCCCACTTTCCGC
TCCAGCCTCTTCCTGTGGGTACGGCCTAATGGCCGTGTGGGGCCTCTAGTGGCAGGAAGG
AGGCCCTCAGCTCTGAGTCAGGGTCGTGGTCAGGACCTGCTGAGCACAGTGAGCATTAGG
TACTCTGGCCACAGCCTCTGA

# Drug_Target_24_General_Function:
Involved in protein binding

# Drug_Target_24_General_References:
10089893	Koskela S, Partanen J, Salmi TT, Kekomaki R: Molecular characterization of two mutations in platelet glycoprotein (GP) Ib alpha in two Finnish Bernard-Soulier syndrome families. Eur J Haematol. 1999 Mar;62(3):160-8.
10391209	Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Shaw N, Lane CR, Lim EP, Kalyanaraman N, Nemesh J, Ziaugra L, Friedland L, Rolfe A, Warrington J, Lipshutz R, Daley GQ, Lander ES: Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet. 1999 Jul;22(3):231-8.
11222377	Savoia A, Balduini CL, Savino M, Noris P, Del Vecchio M, Perrotta S, Belletti S, Poggi, Iolascon A: Autosomal dominant macrothrombocytopenia in Italy is most frequently a type of heterozygous Bernard-Soulier syndrome. Blood. 2001 Mar 1;97(5):1330-5.
11858495	Whisstock JC, Shen Y, Lopez JA, Andrews RK, Berndt MC: Molecular modeling of the seven tandem leucine-rich repeats within the ligand-binding region of platelet glycoprotein Ib alpha. Thromb Haemost. 2002 Feb;87(2):329-33.
12038791	Matsubara Y, Murata M, Moriki T, Yokoyama K, Watanabe N, Nakajima H, Handa M, Kawano K, Aoki N, Yoshino H, Ikeda Y: A novel polymorphism, 70Leu/Phe, disrupts a consensus Leu residue within the leucine-rich repeat sequence of platelet glycoprotein Ibalpha. Thromb Haemost. 2002 May;87(5):867-72.
12087105	Uff S, Clemetson JM, Harrison T, Clemetson KJ, Emsley J: Crystal structure of the platelet glycoprotein Ib(alpha) N-terminal domain reveals an unmasking mechanism for receptor activation. J Biol Chem. 2002 Sep 20;277(38):35657-63. Epub 2002 Jun 26.
12183630	Huizinga EG, Tsuji S, Romijn RA, Schiphorst ME, de Groot PG, Sixma JJ, Gros P: Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain. Science. 2002 Aug 16;297(5584):1176-9.
12665801	Gevaert K, Goethals M, Martens L, Van Damme J, Staes A, Thomas GR, Vandekerckhove J: Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat Biotechnol. 2003 May;21(5):566-9. Epub 2003 Mar 31.
14521605	Matsubara Y, Murata M, Sugita K, Ikeda Y: Identification of a novel point mutation in platelet glycoprotein Ibalpha, Gly to Ser at residue 233, in a Japanese family with platelet-type von Willebrand disease. J Thromb Haemost. 2003 Oct;1(10):2198-205.
1577776	Lopez JA, Ludwig EH, McCarthy BJ: Polymorphism of human glycoprotein Ib alpha results from a variable number of tandem repeats of a 13-amino acid sequence in the mucin-like macroglycopeptide region. Structure/function implications. J Biol Chem. 1992 May 15;267(14):10055-61.
1586750	Murata M, Furihata K, Ishida F, Russell SR, Ware J, Ruggeri ZM: Genetic and structural characterization of an amino acid dimorphism in glycoprotein Ib alpha involved in platelet transfusion refractoriness. Blood. 1992 Jun 1;79(11):3086-90.
1730088	Miller JL, Lyle VA, Cunningham D: Mutation of leucine-57 to phenylalanine in a platelet glycoprotein Ib alpha leucine tandem repeat occurring in patients with an autosomal dominant variant of Bernard-Soulier disease. Blood. 1992 Jan 15;79(2):439-46.
2052556	Miller JL, Cunningham D, Lyle VA, Finch CN: Mutation in the gene encoding the alpha chain of platelet glycoprotein Ib in platelet-type von Willebrand disease. Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4761-5.
2070794	Hess D, Schaller J, Rickli EE, Clemetson KJ: Identification of the disulphide bonds in human platelet glycocalicin. Eur J Biochem. 1991 Jul 15;199(2):389-93.
2845978	Wenger RH, Kieffer N, Wicki AN, Clemetson KJ: Structure of the human blood platelet membrane glycoprotein Ib alpha gene. Biochem Biophys Res Commun. 1988 Oct 14;156(1):389-95.
3303030	Lopez JA, Chung DW, Fujikawa K, Hagen FS, Papayannopoulou T, Roth GJ: Cloning of the alpha chain of human platelet glycoprotein Ib: a transmembrane protein with homology to leucine-rich alpha 2-glycoprotein. Proc Natl Acad Sci U S A. 1987 Aug;84(16):5615-9.
3497398	Titani K, Takio K, Handa M, Ruggeri ZM: Amino acid sequence of the von Willebrand factor-binding domain of platelet membrane glycoprotein Ib. Proc Natl Acad Sci U S A. 1987 Aug;84(16):5610-4.
7632942	Ishida F, Furihata K, Ishida K, Yan J, Kitano K, Kiyosawa K, Furuta S: The largest variant of platelet glycoprotein Ib alpha has four tandem repeats of 13 amino acids in the macroglycopeptide region and a genetic linkage with methionine145. Blood. 1995 Aug 15;86(4):1357-60.
7690774	Ware J, Russell SR, Marchese P, Murata M, Mazzucato M, De Marco L, Ruggeri ZM: Point mutation in a leucine-rich repeat of platelet glycoprotein Ib alpha resulting in the Bernard-Soulier syndrome. J Clin Invest. 1993 Sep;92(3):1213-20.
7819107	Simsek S, Noris P, Lozano M, Pico M, von dem Borne AE, Ribera A, Gallardo D: Cys209 Ser mutation in the platelet membrane glycoprotein Ib alpha gene is associated with Bernard-Soulier syndrome. Br J Haematol. 1994 Dec;88(4):839-44.
7873390	de la Salle C, Baas MJ, Lanza F, Schwartz A, Hanau D, Chevalier J, Gachet C, Briquel ME, Cazenave JP: A three-base deletion removing a leucine residue in a leucine-rich repeat of platelet glycoprotein Ib alpha associated with a variant of Bernard-Soulier syndrome (Nancy I). Br J Haematol. 1995 Feb;89(2):386-96.
8384898	Russell SD, Roth GJ: Pseudo-von Willebrand disease: a mutation in the platelet glycoprotein Ib alpha gene associated with a hyperactive surface receptor. Blood. 1993 Apr 1;81(7):1787-91.
8486780	Murata M, Russell SR, Ruggeri ZM, Ware J: Expression of the phenotypic abnormality of platelet-type von Willebrand disease in a recombinant glycoprotein Ib alpha fragment. J Clin Invest. 1993 May;91(5):2133-7.
9088113	Suzuki K, Hayashi T, Akiba J, Yahagi A, Tajima K, Satoh S, Sasaki H: StyI polymorphism at nucleotide 1610 in the human platelet glycoprotein Ib alpha gene. Jpn J Hum Genet. 1996 Dec;41(4):419-21.
9639514	Kenny D, Jonsson OG, Morateck PA, Montgomery RR: Naturally occurring mutations in glycoprotein Ibalpha that result in defective ligand binding and synthesis of a truncated protein. Blood. 1998 Jul 1;92(1):175-83.
9651345	Takafuta T, Wu G, Murphy GF, Shapiro SS: Human beta-filamin is a new protein that interacts with the cytoplasmic tail of glycoprotein Ibalpha. J Biol Chem. 1998 Jul 10;273(28):17531-8.

# Drug_Target_24_HGNC_ID:
HGNC:4439

# Drug_Target_24_HPRD_ID:
01976

# Drug_Target_24_ID:
1563

# Drug_Target_24_Locus:
17pter-p12

# Drug_Target_24_Molecular_Weight:
68956

# Drug_Target_24_Name:
Platelet glycoprotein Ib alpha chain

# Drug_Target_24_Number_of_Residues:
626

# Drug_Target_24_PDB_ID:
1QYY

# Drug_Target_24_Pathway:
Not Available

# Drug_Target_24_Pfam_Domain_Function:
PF00560	LRR_1
PF01462	LRRNT

# Drug_Target_24_Protein_Sequence:
>Platelet glycoprotein Ib alpha chain precursor
MPLLLLLLLLPSPLHPHPICEVSKVASHLEVNCDKRNLTALPPDLPKDTTILHLSENLLY
TFSLATLMPYTRLTQLNLDRCELTKLQVDGTLPVLGTLDLSHNQLQSLPLLGQTLPALTV
LDVSFNRLTSLPLGALRGLGELQELYLKGNELKTLPPGLLTPTPKLEKLSLANNNLTELP
AGLLNGLENLDTLLLQENSLYTIPKGFFGSHLLPFAFLHGNPWLCNCEILYFRRWLQDNA
ENVYVWKQGVDVKAMTSNVASVQCDNSDKFPVYKYPGKGCPTLGDEGDTDLYDYYPEEDT
EGDKVRATRTVVKFPTKAHTTPWGLFYSWSTASLDSQMPSSLHPTQESTKEQTTFPPRWT
PNFTLHMESITFSKTPKSTTEPTPSPTTSEPVPEPAPNMTTLEPTPSPTTPEPTSEPAPS
PTTPEPTPIPTIATSPTILVSATSLITPKSTFLTTTKPVSLLESTKKTIPELDQPPKLRG
VLQGHLESSRNDPFLHPDFCCLLPLGFYVLGLFWLLFASVVLILLLSWVGHVKPQALDSG
QGAALTTATQTTHLELQRGRQVTVPRAWLLFLRGSLPTFRSSLFLWVRPNGRVGPLVAGR
RPSALSQGRGQDLLSTVSIRYSGHSL

# Drug_Target_24_Reaction:
Not Available

# Drug_Target_24_Signals:
1-16

# Drug_Target_24_Specific_Function:
GP-Ib, a surface membrane protein of platelets, participates in the formation of platelet plugs by binding to the A1 domain of von Willebrand factor, which is already bound to the subendothelium

# Drug_Target_24_SwissProt_ID:
P07359

# Drug_Target_24_SwissProt_Name:
GP1BA_HUMAN

# Drug_Target_24_Synonyms:
Antigen CD42b-alpha
CD42b antigen
GP-Ib alpha
GPIb-alpha
GPIbA
Glycoprotein Ibalpha
Platelet glycoprotein Ib alpha chain precursor

# Drug_Target_24_Theoretical_pI:
6.67

# Drug_Target_24_Transmembrane_Regions:
506-526

# Drug_Target_25_Cellular_Location:
Secreted protein

# Drug_Target_25_Chromosome_Location:
Not Available

# Drug_Target_25_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_25_Essentiality:
Non-Essential

# Drug_Target_25_GenAtlas_ID:
IFNB1

# Drug_Target_25_GenBank_ID_Gene:
V00534

# Drug_Target_25_GenBank_ID_Protein:
32638

# Drug_Target_25_GeneCard_ID:
IFNB1

# Drug_Target_25_Gene_Name:
IFNB1

# Drug_Target_25_Gene_Sequence:
>564 bp
ATGACCAACAAGTGTCTCCTCCAAATTGCTCTCCTGTTGTGCTTCTCCACTACAGCTCTT
TCCATGAGCTACAACTTGCTTGGATTCCTACAAAGAAGCAGCAATTTTCAGTGTCAGAAG
CTCCTGTGGCAATTGAATGGGAGGCTTGAATACTGCCTCAAGGACAGGATGAACTTTGAC
ATCCCTGAGGAGATTAAGCAGCTGCAGCAGTTCCAGAAGGAGGACGCCGCATTGACCATC
TATGAGATGCTCCAGAACATCTTTGCTATTTTCAGACAAGATTCATCTAGCACTGGCTGG
AATGAGACTATTGTTGAGAACCTCCTGGCTAATGTCTATCATCAGATAAACCATCTGAAG
ACAGTCCTGGAAGAAAAACTGGAGAAAGAAGATTTCACCAGGGGAAAACTCATGAGCAGT
CTGCACCTGAAAAGATATTATGGGAGGATTCTGCATTACCTGAAGGCCAAGGAGTACAGT
CACTGTGCCTGGACCATAGTCAGAGTGGAAATCCTAAGGAACTTTTACTTCATTAACAGA
CTTACAGGTTACCTCCGAAACTGA

# Drug_Target_25_General_Function:
Involved in hematopoietin/interferon-class (D200-domain) cytokine receptor binding

# Drug_Target_25_General_References:
2414376	May LT, Sehgal PB: On the relationship between human interferon alpha 1 and beta 1 genes. J Interferon Res. 1985 Summer;5(3):521-6.
6157094	Derynck R, Content J, DeClercq E, Volckaert G, Tavernier J, Devos R, Fiers W: Isolation and structure of a human fibroblast interferon gene. Nature. 1980 Jun 19;285(5766):542-7.
6157601	Taniguchi T, Ohno S, Fujii-Kuriyama Y, Muramatsu M: The nucleotide sequence of human fibroblast interferon cDNA. Gene. 1980 Jun;10(1):11-5.
6159580	Houghton M, Easton MA, Stewart AG, Smith JC, Doel SM, Catlin GH, Lewis HM, Patel TP, Emtage JS, Carey NH, Porter AG: The complete amino acid sequence of human fibroblast interferon as deduced using synthetic oligodeoxyribonucleotide primers of reverse transcriptase. Nucleic Acids Res. 1980 Jul 11;8(13):2885-94.
6159584	Goeddel DV, Shepard HM, Yelverton E, Leung D, Crea R, Sloma A, Pestka S: Synthesis of human fibroblast interferon by E. coli. Nucleic Acids Res. 1980 Sep 25;8(18):4057-74.
6159597	Houghton M, Stewart AG, Doel SM, Emtage JS, Eaton MA, Smith JC, Patel TP, Lewis HM, Porter AG, Birch JR, Cartwright T, Carey NH: The amino-terminal sequence of human fibroblast interferon as deduced from reverse transcripts obtained using synthetic oligonucleotide primers. Nucleic Acids Res. 1980 May 10;8(9):1913-31.
6162107	Wetzel R: Assignment of the disulphide bonds of leukocyte interferon. Nature. 1981 Feb 12;289(5798):606-7.
6164984	Lawn RM, Adelman J, Franke AE, Houck CM, Gross M, Najarian R, Goeddel DV: Human fibroblast interferon gene lacks introns. Nucleic Acids Res. 1981 Mar 11;9(5):1045-52.
6171735	Shepard HM, Leung D, Stebbing N, Goeddel DV: A single amino acid change in IFN-beta1 abolishes its antiviral activity. Nature. 1981 Dec 10;294(5841):563-5.
9342320	Karpusas M, Nolte M, Benton CB, Meier W, Lipscomb WN, Goelz S: The crystal structure of human interferon beta at 2.2-A resolution. Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):11813-8.

# Drug_Target_25_HGNC_ID:
HGNC:5434

# Drug_Target_25_HPRD_ID:
00972

# Drug_Target_25_ID:
1184

# Drug_Target_25_Locus:
9p21

# Drug_Target_25_Molecular_Weight:
22294

# Drug_Target_25_Name:
Interferon beta

# Drug_Target_25_Number_of_Residues:
187

# Drug_Target_25_PDB_ID:
1AU1

# Drug_Target_25_Pathway:
Not Available

# Drug_Target_25_Pfam_Domain_Function:
PF00143	Interferon

# Drug_Target_25_Protein_Sequence:
>Interferon beta precursor
MTNKCLLQIALLLCFSTTALSMSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFD
IPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLK
TVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINR
LTGYLRN

# Drug_Target_25_Reaction:
Not Available

# Drug_Target_25_Signals:
1-21

# Drug_Target_25_Specific_Function:
Has antiviral, antibacterial and anticancer activities

# Drug_Target_25_SwissProt_ID:
P01574

# Drug_Target_25_SwissProt_Name:
IFNB_HUMAN

# Drug_Target_25_Synonyms:
Fibroblast interferon
IFN-beta
Interferon beta precursor

# Drug_Target_25_Theoretical_pI:
8.91

# Drug_Target_25_Transmembrane_Regions:
None

# Drug_Target_26_Cellular_Location:
TM:Virion

# Drug_Target_26_Chromosome_Location:
Not Available

# Drug_Target_26_Drug_References:
Not Available

# Drug_Target_26_Essentiality:
Non-Essential

# Drug_Target_26_GenAtlas_ID:
Not Available

# Drug_Target_26_GenBank_ID_Gene:
K01209

# Drug_Target_26_GenBank_ID_Protein:
Not Available

# Drug_Target_26_GeneCard_ID:
Not Available

# Drug_Target_26_Gene_Name:
env

# Drug_Target_26_Gene_Sequence:
>1989 bp
ATGGAAAGTCCAACGCACCCAAAACCCTCTAAAGATAAGACTCTCTCGTGGAACTTAGTG
TTTCTGGTGGGGATCTTATTCACAATAGACATAGGAATGGCCAATCCTAGTCCGCACCAA
GTGTATAATGTAACTTGGACAATAACCAACCTTGTAACTGGAACAAAGGCTAATGCCACC
TCCATGTTGGGAACCCTGACAGACGCCTTCCCTACCATGTATTTTGACTTATGTGATATA
ATAGGAAATACATGGAACCCTTCAGATCAGGAACCATTCCCAGGGTATGGATGTGATCAG
CCTATGAGGAGGTGGCAACAGAGAAACACACCCTTTTATGTCTGTCCAGGACATGCCAAC
CGGAAGCAATGTGGGGGGCCACAAGATGGGTTCTGCGCTGTATGGGGTTGCGAGACCACC
GGGGAAACCTATTGGAGACCCACCTCCTCATGGGACTACATCACAGTAAAAAAAGGGGTT
ACTCAGGGAATATATCAATGTAGTGGAGGTGGTTGGTGTGGGCCCTGTTACGATAAAGCT
GTTCACTCCTCGACAACGGGAGCTAGTGAAGGGGGCCGGTGCAACCCCTTGATCTTGCAA
TTTACCCAAAAGGGAAGACAAACATCTTGGGATGGACCTAAGTCATGGGGGCTACGACTA
TACCGTTCAGGATATGACCCTATAGCCCTGTTCTCGGTATCCCGGCAAGTAATGACCATT
ACGCCGCCTCAGGCCATGGGACCAAATCTAGTCCTGCCTGATCAAAAACCCCCATCCAGG
CAATCTCAAATAGAGTCCCGAGTAACACCTCACCATTCCCAAGGCAACGGAGGCACCCCA
GGTATAACTCTTGTTAATGCCTCCATTGCCCCTCTAAGTACCCCTGTCACCCCCGCAAGT
CCCAAACGGATTGGGACCGGAGATAGGTTAATAAATTTAGTACAAGGGACATACCTAGCC
TTAAATGCCACCGACCCCAACAGAACTAAAGACTGTTGGCTCTGCCTGGTTTCTCGACCA
CCCTATTACGAAGGGATTGCAATCTTAGGTAACTACAGCAACCAAACAAACCCCCCCCCA
TCCTGCCTATCTATTCCGCAACACAAACTAACCATATCTGAAGTATCAGGGCAAGGACTG
TGCATAGGGACTGTTCCTAAGACCCACCAGGCTTTGTGCAATGAGACACAACAGGGACAT
ACAGGGGCGCACTATCTAGCCGCCCCCAATGGCACCTATTGGGCCTGTAACACTGGACTC
ACCCCATGTATTTCCATGGCGGTGCTCAATTGGACCTCTGATTTTTGTGTCTTAATCGAA
TTATGGCCCAGAGTGACTTACCATCAACCCGAATATGTGTACACACATTTTGCCAAAGCT
GCCAGGTTCCGAAGAGAACCAATATCACTAACTGTTGCCCTCATGTTGGGAGGACTCACT
GTAGGGGGCATAGCCGCGGGGGTCGGAACAGGGACTAAAGCCCTCATTGAAACAGCCCAG
TTCAGACAACTACAAATGGCCATGCACACAGACATCCAGGCCCTAGAAGAGTCAATTAGT
GCCTTAGAAAAGTCCCTGACCTCCCTTTCTGAAGTAGTCTTACAAAACAGACGGGGCCTG
GATATTCTATTCTTACAAGAGGGAGGGCTCTGTGCCGCATTAAAAGAAGAATGTTGCTTC
TATGCGGATCACACCGGACTTGTCCGAGACAATATGGCTAAATTAAGAGAAAGACTAAAA
CAGCGGCAACAACTGTTTGACTCCCAACAGGGATGGTTTGAAGGATGGTTCAACAAGTCC
CCCTGGTTTACAACCCTAATTTCCTCCATTATGGGCCCCTTACTAATCCTACTCCTAATT
CTCCTCTTCGGCCCATGCATCCTTAACAGATTAGTACAATTCGTAAAAGACAGAATATCT
GTGGTACAAGCCTTAATTTTAACCCAACAGTACCAACAGATAAAGCAATACGATCCGGAC
CGACCATAA

# Drug_Target_26_General_Function:
Involved in structural molecule activity

# Drug_Target_26_General_References:
2823466	Guilhot S, Hampe A, D'Auriol L, Galibert F: Nucleotide sequence analysis of the LTRs and env genes of SM-FeSV and GA-FeSV. Virology. 1987 Nov;161(1):252-8.
6304347	Elder JH, Mullins JI: Nucleotide sequence of the envelope gene of Gardner-Arnstein feline leukemia virus B reveals unique sequence homologies with a murine mink cell focus-forming virus. J Virol. 1983 Jun;46(3):871-80.
6319767	Nunberg JH, Williams ME, Innis MA: Nucleotide sequences of the envelope genes of two isolates of feline leukemia virus subgroup B. J Virol. 1984 Feb;49(2):629-32.
6321156	Wunsch M, Schulz AS, Koch W, Friedrich R, Hunsmann G: Sequence analysis of Gardner-Arnstein feline leukaemia virus envelope gene reveals common structural properties of mammalian retroviral envelope genes. EMBO J. 1983;2(12):2239-46.

# Drug_Target_26_HGNC_ID:
Not Available

# Drug_Target_26_HPRD_ID:
Not Available

# Drug_Target_26_ID:
4859

# Drug_Target_26_Locus:
Not Available

# Drug_Target_26_Molecular_Weight:
73150

# Drug_Target_26_Name:
Envelope glycoprotein

# Drug_Target_26_Number_of_Residues:
662

# Drug_Target_26_PDB_ID:
1LCS

# Drug_Target_26_Pathway:
Not Available

# Drug_Target_26_Pfam_Domain_Function:
PF00429	TLV_coat

# Drug_Target_26_Protein_Sequence:
>Envelope glycoprotein
MESPTHPKPSKDKTLSWNLVFLVGILFTIDIGMANPSPHQVYNVTWTITNLVTGTKANAT
SMLGTLTDAFPTMYFDLCDIIGNTWNPSDQEPFPGYGCDQPMRRWQQRNTPFYVCPGHAN
RKQCGGPQDGFCAVWGCETTGETYWRPTSSWDYITVKKGVTQGIYQCSGGGWCGPCYDKA
VHSSTTGASEGGRCNPLILQFTQKGRQTSWDGPKSWGLRLYRSGYDPIALFSVSRQVMTI
TPPQAMGPNLVLPDQKPPSRQSQIESRVTPHHSQGNGGTPGITLVNASIAPLSTPVTPAS
PKRIGTGDRLINLVQGTYLALNATDPNRTKDCWLCLVSRPPYYEGIAILGNYSNQTNPPP
SCLSIPQHKLTISEVSGQGLCIGTVPKTHQALCNETQQGHTGAHYLAAPNGTYWACNTGL
TPCISMAVLNWTSDFCVLIELWPRVTYHQPEYVYTHFAKAARFRREPISLTVALMLGGLT
VGGIAAGVGTGTKALIETAQFRQLQMAMHTDIQALEESISALEKSLTSLSEVVLQNRRGL
DILFLQEGGLCAALKEECCFYADHTGLVRDNMAKLRERLKQRQQLFDSQQGWFEGWFNKS
PWFTTLISSIMGPLLILLLILLFGPCILNRLVQFVKDRISVVQALILTQQYQQIKQYDPD
RP

# Drug_Target_26_Reaction:
Not Available

# Drug_Target_26_Signals:
1-34

# Drug_Target_26_Specific_Function:
The transmembrane protein (TM) acts as a class I viral fusion protein. Under the current model, the protein has at least 3 conformational states:pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During viral and target cell membrane fusion, the coiled coil regions (heptad repeats) assume a trimer-of-hairpins structure, positioning the fusion peptide in close proximity to the C-terminal region of the ectodomain. The formation of this structure appears to drive apposition and subsequent fusion of viral and target cell membranes. Membranes fusion leads to delivery of the nucleocapsid into the cytoplasm (By similarity)

# Drug_Target_26_SwissProt_ID:
P03391

# Drug_Target_26_SwissProt_Name:
ENV_FSVGA

# Drug_Target_26_Synonyms:
Env polyprotein
Envelope glycoprotein precursor

# Drug_Target_26_Theoretical_pI:
8.15

# Drug_Target_26_Transmembrane_Regions:
607-627

# Drug_Target_27_Cellular_Location:
Not Available

# Drug_Target_27_Chromosome_Location:
Not Available

# Drug_Target_27_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_27_Essentiality:
Non-Essential

# Drug_Target_27_GenAtlas_ID:
Not Available

# Drug_Target_27_GenBank_ID_Gene:
Not Available

# Drug_Target_27_GenBank_ID_Protein:
Not Available

# Drug_Target_27_GeneCard_ID:
Not Available

# Drug_Target_27_Gene_Name:
MAN1A1

# Drug_Target_27_Gene_Sequence:
Not Available

# Drug_Target_27_General_Function:
Not Available

# Drug_Target_27_General_References:
Not Available

# Drug_Target_27_HGNC_ID:
Not Available

# Drug_Target_27_HPRD_ID:
Not Available

# Drug_Target_27_ID:
7049

# Drug_Target_27_Locus:
Not Available

# Drug_Target_27_Molecular_Weight:
Not Available

# Drug_Target_27_Name:
Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA

# Drug_Target_27_Number_of_Residues:
0

# Drug_Target_27_PDB_ID:
Not Available

# Drug_Target_27_Pathway:
Not Available

# Drug_Target_27_Pfam_Domain_Function:
Not Available

# Drug_Target_27_Protein_Sequence:
Not Available

# Drug_Target_27_Reaction:
Not Available

# Drug_Target_27_Signals:
Not Available

# Drug_Target_27_Specific_Function:
Not Available

# Drug_Target_27_SwissProt_ID:
P33908

# Drug_Target_27_SwissProt_Name:
MA1A1_HUMAN

# Drug_Target_27_Synonyms:
Not Available

# Drug_Target_27_Theoretical_pI:
Not Available

# Drug_Target_27_Transmembrane_Regions:
Not Available

# Drug_Target_28_Cellular_Location:
Not Available

# Drug_Target_28_Chromosome_Location:
Not Available

# Drug_Target_28_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_28_Essentiality:
Non-Essential

# Drug_Target_28_GenAtlas_ID:
Not Available

# Drug_Target_28_GenBank_ID_Gene:
J02473

# Drug_Target_28_GenBank_ID_Protein:
Not Available

# Drug_Target_28_GeneCard_ID:
Not Available

# Drug_Target_28_Gene_Name:
9

# Drug_Target_28_Gene_Sequence:
Not Available

# Drug_Target_28_General_Function:
Not Available

# Drug_Target_28_General_References:
11053393	Vander Byl C, Kropinski AM: Sequence of the genome of Salmonella bacteriophage P22. J Bacteriol. 2000 Nov;182(22):6472-81.
12562822	Pedulla ML, Ford ME, Karthikeyan T, Houtz JM, Hendrix RW, Hatfull GF, Poteete AR, Gilcrease EB, Winn-Stapley DA, Casjens SR: Corrected sequence of the bacteriophage p22 genome. J Bacteriol. 2003 Feb;185(4):1475-7.
6295443	Sauer RT, Krovatin W, Poteete AR, Berget PB: Phage P22 tail protein: gene and amino acid sequence. Biochemistry. 1982 Nov 9;21(23):5811-5.
8023158	Steinbacher S, Seckler R, Miller S, Steipe B, Huber R, Reinemer P: Crystal structure of P22 tailspike protein: interdigitated subunits in a thermostable trimer. Science. 1994 Jul 15;265(5170):383-6.
8855221	Steinbacher S, Baxa U, Miller S, Weintraub A, Seckler R, Huber R: Crystal structure of phage P22 tailspike protein complexed with Salmonella sp. O-antigen receptors. Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10584-8.
9135118	Steinbacher S, Miller S, Baxa U, Budisa N, Weintraub A, Seckler R, Huber R: Phage P22 tailspike protein: crystal structure of the head-binding domain at 2.3 A, fully refined structure of the endorhamnosidase at 1.56 A resolution, and the molecular basis of O-antigen recognition and cleavage. J Mol Biol. 1997 Apr 11;267(4):865-80.

# Drug_Target_28_HGNC_ID:
Not Available

# Drug_Target_28_HPRD_ID:
Not Available

# Drug_Target_28_ID:
2372

# Drug_Target_28_Locus:
Not Available

# Drug_Target_28_Molecular_Weight:
71858

# Drug_Target_28_Name:
Bifunctional tail protein

# Drug_Target_28_Number_of_Residues:
667

# Drug_Target_28_PDB_ID:
1TSP

# Drug_Target_28_Pathway:
Not Available

# Drug_Target_28_Pfam_Domain_Function:
PF09008	Head_binding
PF09251	PhageP22-tail

# Drug_Target_28_Protein_Sequence:
>Bifunctional tail protein
MTDITANVVVSNPRPIFTESRSFKAVANGKIYIGQIDTDPVNPANQIPVYIENEDGSHVQ
ITQPLIINAAGKIVYNGQLVKIVTVQGHSMAIYDANGSQVDYIANVLKYDPDQYSIEADK
KFKYSVKLSDYPTLQDAASAAVDGLLIDRDYNFYGGETVDFGGKVLTIECKAKFIGDGNL
IFTKLGKGSRIAGVFMESTTTPWVIKPWTDDNQWLTDAAAVVATLKQSKTDGYQPTVSDY
VKFPGIETLLPPNAKGQNITSTLEIRECIGVEVHRASGLMAGFLFRGCHFCKMVDANNPS
GGKDGIITFENLSGDWGKGNYVIGGRTSYGSVSSAQFLRNNGGFERDGGVIGFTSYRAGE
SGVKTWQGTVGSTTSRNYNLQFRDSVVIYPVWDGFDLGADTDMNPELDRPGDYPITQYPL
HQLPLNHLIDNLLVRGALGVGFGMDGKGMYVSNITVEDCAGSGAYLLTHESVFTNIAIID
TNTKDFQANQIYISGACRVNGLRLIGIRSTDGQGLTIDAPNSTVSGITGMVDPSRINVAN
LAEEGLGNIRANSFGYDSAAIKLRIHKLSKTLDSGALYSHINGGAGSGSAYTQLTAISGS
TPDAVSLKVNHKDCRGAEIPFVPDIASDDFIKDSSCFLPYWENNSTSLKALVKKPNGELV
RLTLATL

# Drug_Target_28_Reaction:
Not Available

# Drug_Target_28_Signals:
None

# Drug_Target_28_Specific_Function:
Non-covalently bound to the neck of the phage capsid and essential for phage adsorption to the bacterial host. It displays endorhamnosidase enzymatic activity, hydrolyzing the alpha-1,3-O- glycosidic linkage between rhamnose and galactose of the O-antigen polysaccharide

# Drug_Target_28_SwissProt_ID:
P12528

# Drug_Target_28_SwissProt_Name:
TSPE_BPP22

# Drug_Target_28_Synonyms:
EC 3.2.1.-
Endorhamnosidase
Late protein gp9
TSP

# Drug_Target_28_Theoretical_pI:
5.25

# Drug_Target_28_Transmembrane_Regions:
None

# Drug_Target_29_Cellular_Location:
Isoform 1:Cell membrane

# Drug_Target_29_Chromosome_Location:
Not Available

# Drug_Target_29_Drug_References:
Not Available

# Drug_Target_29_Essentiality:
Non-Essential

# Drug_Target_29_GenAtlas_ID:
IL6R

# Drug_Target_29_GenBank_ID_Gene:
X12830

# Drug_Target_29_GenBank_ID_Protein:
Not Available

# Drug_Target_29_GeneCard_ID:
Not Available

# Drug_Target_29_Gene_Name:
IL6R

# Drug_Target_29_Gene_Sequence:
>1407 bp
ATGCTGGCCGTCGGCTGCGCGCTGCTGGCTGCCCTGCTGGCCGCGCCGGGAGCGGCGCTG
GCCCCAAGGCGCTGCCCTGCGCAGGAGGTGGCAAGAGGCGTGCTGACCAGTCTGCCAGGA
GACAGCGTGACTCTGACCTGCCCGGGGGTAGAGCCGGAAGACAATGCCACTGTTCACTGG
GTGCTCAGGAAGCCGGCTGCAGGCTCCCACCCCAGCAGATGGGCTGGCATGGGAAGGAGG
CTGCTGCTGAGGTCGGTGCAGCTCCACGACTCTGGAAACTATTCATGCTACCGGGCCGGC
CGCCCAGCTGGGACTGTGCACTTGCTGGTGGATGTTCCCCCCGAGGAGCCCCAGCTCTCC
TGCTTCCGGAAGAGCCCCCTCAGCAATGTTGTTTGTGAGTGGGGTCCTCGGAGCACCCCA
TCCCTGACGACAAAGGCTGTGCTCTTGGTGAGGAAGTTTCAGAACAGTCCGGCCGAAGAC
TTCCAGGAGCCGTGCCAGTATTCCCAGGAGTCCCAGAAGTTCTCCTGCCAGTTAGCAGTC
CCGGAGGGAGACAGCTCTTTCTACATAGTGTCCATGTGCGTCGCCAGTAGTGTCGGGAGC
AAGTTCAGCAAAACTCAAACCTTTCAGGGTTGTGGAATCTTGCAGCCTGATCCGCCTGCC
AACATCACAGTCACTGCCGTGGCCAGAAACCCCCGCTGGCTCAGTGTCACCTGGCAAGAC
CCCCACTCCTGGAACTCATCTTTCTACAGACTACGGTTTGAGCTCAGATATCGGGCTGAA
CGGTCAAAGACATTCACAACATGGATGGTCAAGGACCTCCAGCATCACTGTGTCATCCAC
GACGCCTGGAGCGGCCTGAGGCACGTGGTGCAGCTTCGTGCCCAGGAGGAGTTCGGGCAA
GGCGAGTGGAGCGAGTGGAGCCCGGAGGCCATGGGCACGCCTTGGACAGAATCCAGGAGT
CCTCCAGCTGAGAACGAGGTGTCCACCCCCATGCAGGCACTTACTACTAATAAAGACGAT
GATAATATTCTCTTCAGAGATTCTGCAAATGCGACAAGCCTCCCAGTGCAAGATTCTTCT
TCAGTACCACTGCCCACATTCCTGGTTGCTGGAGGGAGCCTGGCCTTCGGAACGCTCCTC
TGCATTGCCATTGTTCTGAGGTTCAAGAAGACGTGGAAGCTGCGGGCTCTGAAGGAAGGC
AAGACAAGCATGCATCCGCCGTACTCTTTGGGGCAGCTGGTCCCGGAGAGGCCTCGACCC
ACCCCAGTGCTTGTTCCTCTCATCTCCCCACCGGTGTCCCCCAGCAGCCTGGGGTCTGAC
AATACCTCGAGCCACAACCGACCAGATGCCAGGGACCCACGGAGCCCTTATGACATCAGC
AATACAGACTACTTCTTCCCCAGATAG

# Drug_Target_29_General_Function:
Involved in hematopoietin/interferon-class (D200-domain) cytokine receptor activity

# Drug_Target_29_General_References:
10066782	Cole AR, Hall NE, Treutlein HR, Eddes JS, Reid GE, Moritz RL, Simpson RJ: Disulfide bond structure and N-glycosylation sites of the extracellular domain of the human interleukin-6 receptor. J Biol Chem. 1999 Mar 12;274(11):7207-15.
1872801	Schooltink H, Stoyan T, Lenz D, Schmitz H, Hirano T, Kishimoto T, Heinrich PC, Rose-John S: Structural and functional studies on the human hepatic interleukin-6 receptor. Molecular cloning and overexpression in HepG2 cells. Biochem J. 1991 Aug 1;277 ( Pt 3):659-64.
2529343	Novick D, Engelmann H, Wallach D, Rubinstein M: Soluble cytokine receptors are present in normal human urine. J Exp Med. 1989 Oct 1;170(4):1409-14.
3136546	Yamasaki K, Taga T, Hirata Y, Yawata H, Kawanishi Y, Seed B, Taniguchi T, Hirano T, Kishimoto T: Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science. 1988 Aug 12;241(4867):825-8.
8056053	Horiuchi S, Koyanagi Y, Zhou Y, Miyamoto H, Tanaka Y, Waki M, Matsumoto A, Yamamoto M, Yamamoto N: Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism. Eur J Immunol. 1994 Aug;24(8):1945-8.
8467812	Yawata H, Yasukawa K, Natsuka S, Murakami M, Yamasaki K, Hibi M, Taga T, Kishimoto T: Structure-function analysis of human IL-6 receptor: dissociation of amino acid residues required for IL-6-binding and for IL-6 signal transduction through gp130. EMBO J. 1993 Apr;12(4):1705-12.

# Drug_Target_29_HGNC_ID:
HGNC:6019

# Drug_Target_29_HPRD_ID:
Not Available

# Drug_Target_29_ID:
4861

# Drug_Target_29_Locus:
1q21

# Drug_Target_29_Molecular_Weight:
51548

# Drug_Target_29_Name:
Interleukin-6 receptor alpha chain

# Drug_Target_29_Number_of_Residues:
468

# Drug_Target_29_PDB_ID:
1N26

# Drug_Target_29_Pathway:
Not Available

# Drug_Target_29_Pfam_Domain_Function:
PF00041	fn3
PF00047	ig
PF09240	IL6Ra-bind

# Drug_Target_29_Protein_Sequence:
>Interleukin-6 receptor alpha chain
MLAVGCALLAALLAAPGAALAPRRCPAQEVARGVLTSLPGDSVTLTCPGVEPEDNATVHW
VLRKPAAGSHPSRWAGMGRRLLLRSVQLHDSGNYSCYRAGRPAGTVHLLVDVPPEEPQLS
CFRKSPLSNVVCEWGPRSTPSLTTKAVLLVRKFQNSPAEDFQEPCQYSQESQKFSCQLAV
PEGDSSFYIVSMCVASSVGSKFSKTQTFQGCGILQPDPPANITVTAVARNPRWLSVTWQD
PHSWNSSFYRLRFELRYRAERSKTFTTWMVKDLQHHCVIHDAWSGLRHVVQLRAQEEFGQ
GEWSEWSPEAMGTPWTESRSPPAENEVSTPMQALTTNKDDDNILFRDSANATSLPVQDSS
SVPLPTFLVAGGSLAFGTLLCIAIVLRFKKTWKLRALKEGKTSMHPPYSLGQLVPERPRP
TPVLVPLISPPVSPSSLGSDNTSSHNRPDARDPRSPYDISNTDYFFPR

# Drug_Target_29_Reaction:
Not Available

# Drug_Target_29_Signals:
1-19

# Drug_Target_29_Specific_Function:
Low concentration of a soluble form of IL6 receptor acts as an agonist of IL6 activity

# Drug_Target_29_SwissProt_ID:
P08887

# Drug_Target_29_SwissProt_Name:
IL6RA_HUMAN

# Drug_Target_29_Synonyms:
CD126 antigen
IL-6R 1
IL-6R-alpha
Interleukin-6 receptor alpha chain precursor
Membrane glycoprotein 80
gp80

# Drug_Target_29_Theoretical_pI:
8.30

# Drug_Target_29_Transmembrane_Regions:
366-386

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
Not Available

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
EFNB2

# Drug_Target_2_Gene_Sequence:
Not Available

# Drug_Target_2_General_Function:
Not Available

# Drug_Target_2_General_References:
Not Available

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
7056

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
Not Available

# Drug_Target_2_Name:
Ephrin-B2

# Drug_Target_2_Number_of_Residues:
0

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
Not Available

# Drug_Target_2_Protein_Sequence:
Not Available

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
Not Available

# Drug_Target_2_Specific_Function:
Not Available

# Drug_Target_2_SwissProt_ID:
P52799

# Drug_Target_2_SwissProt_Name:
EFNB2_HUMAN

# Drug_Target_2_Synonyms:
Not Available

# Drug_Target_2_Theoretical_pI:
Not Available

# Drug_Target_2_Transmembrane_Regions:
Not Available

# Drug_Target_30_Cellular_Location:
Lysosome. Melanosome. Note=Identified by mass spectrometry in melanosome fractions from stage I to s

# Drug_Target_30_Chromosome_Location:
Not Available

# Drug_Target_30_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_30_Essentiality:
Non-Essential

# Drug_Target_30_GenAtlas_ID:
CTSD

# Drug_Target_30_GenBank_ID_Gene:
M11233

# Drug_Target_30_GenBank_ID_Protein:
181180

# Drug_Target_30_GeneCard_ID:
CTSD

# Drug_Target_30_Gene_Name:
CTSD

# Drug_Target_30_Gene_Sequence:
>1239 bp
ATGCAGCCCTCCAGCCTTCTGCCGCTCGCCCTCTGCCTGCTGGCTGCACCCGCCTCCGCG
CTCGTCAGGATCCCGCTGCACAAGTTCACGTCCATCCGCCGGACCATGTCGGAGGTTGGG
GGCTCTGTGGAGGACCTGATTGCCAAAGGCCCCGTCTCAAAGTACTCCCAGGCGGTGCCA
GCCGTGACCGAGGGGCCCATTCCCGAGGTGCTCAAGAACTACATGGACGCCCAGTACTAC
GGGGAGATTGGCATCGGGACGCCCCCCCAGTGCTTCACAGTCGTCTTCGACACGGGCTCC
TCCAACCTGTGGGTCCCCTCCATCCACTGCAAACTGCTGGACATCGCTTGCTGGATCCAC
CACAAGTACAACAGCGACAAGTCCAGCACCTACGTGAAGAATGGTACCTCGTTTGACATC
CACTATGGCTCGGGCAGCCTCTCCGGGTACCTGAGCCAGGACACTGTGTCGGTGCCCTGC
CAGTCAGCGTCGTCAGCCTCTGCCCTGGGCGGTGTCAAAGTGGAGAGGCAGGTCTTTGGG
GAGGCCACCAAGCAGCCAGGCATCACCTTCATCGCAGCCAAGTTCGATGGCATCCTGGGC
ATGGCCTACCCCCGCATCTCCGTCAACAACGTGCTGCCCGTCTTCGACAACCTGATGCAG
CAGAAGCTGGTGGACCAGAACATCTTCTCCTTCTACCTGAGCAGGGACCCAGATGCGCAG
CCTGGGGGTGAGCTGATGCTGGGTGGCACAGACTCCAAGTATTACAAGGGTTCTCTGTCC
TACCTGAATGTCACCCGCAAGGCCTACTGGCAGGTCCACCTGGACCAGGTGGAGGTGGCC
AGCGGGCTGACCCTGTGCAAGGAGGGCTGTGAGGCCATTGTGGACACAGGCACTTCCCTC
ATGGTGGGCCCGGTGGATGAGGTGCGCGAGCTGCAGAAGGCCATCGGGGCCGTGCCGCTG
ATTCAGGGCGAGTACATGATCCCCTGTGAGAAGGTGTCCACCCTGCCCGCGATCACACTG
AAGCTGGGAGGCAAAGGCTACAAGCTGTCCCCAGAGGACTACACGCTCAAGGTGTCGCAG
GCCGGGAAGACCCTCTGCCTGAGCGGCTTCATGGGCATGGACATCCCGCCACCCAGCGGG
CCACTCTGGATCCTGGGCGACGTCTTCATCGGCCGCTACTACACTGTGTTTGACCGTGAC
AACAACAGGGTGGGCTTCGCCGAGGCTGCCCGCCTCTAG

# Drug_Target_30_General_Function:
Involved in aspartic-type endopeptidase activity

# Drug_Target_30_General_References:
10716266	Papassotiropoulos A, Bagli M, Kurz A, Kornhuber J, Forstl H, Maier W, Pauls J, Lautenschlager N, Heun R: A genetic variation of cathepsin D is a major risk factor for Alzheimer's disease. Ann Neurol. 2000 Mar;47(3):399-403.
12754519	Zhang H, Li XJ, Martin DB, Aebersold R: Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol. 2003 Jun;21(6):660-6. Epub 2003 May 18.
2069717	Redecker B, Heckendorf B, Grosch HW, Mersmann G, Hasilik A: Molecular organization of the human cathepsin D gene. DNA Cell Biol. 1991 Jul-Aug;10(6):423-31.
3588310	Westley BR, May FE: Oestrogen regulates cathepsin D mRNA levels in oestrogen responsive human breast cancer cells. Nucleic Acids Res. 1987 May 11;15(9):3773-86.
3927292	Faust PL, Kornfeld S, Chirgwin JM: Cloning and sequence analysis of cDNA for human cathepsin D. Proc Natl Acad Sci U S A. 1985 Aug;82(15):4910-4.
7935485	Augereau P, Miralles F, Cavailles V, Gaudelet C, Parker M, Rochefort H: Characterization of the proximal estrogen-responsive element of human cathepsin D gene. Mol Endocrinol. 1994 Jun;8(6):693-703.
8262386	May FE, Smith DJ, Westley BR: The human cathepsin D-encoding gene is transcribed from an estrogen-regulated and a constitutive start point. Gene. 1993 Dec 8;134(2):277-82.
8393577	Baldwin ET, Bhat TN, Gulnik S, Hosur MV, Sowder RC 2nd, Cachau RE, Collins J, Silva AM, Erickson JW: Crystal structures of native and inhibited forms of human cathepsin D: implications for lysosomal targeting and drug design. Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6796-800.
8467789	Metcalf P, Fusek M: Two crystal structures for cathepsin D: the lysosomal targeting signal and active site. EMBO J. 1993 Apr;12(4):1293-302.

# Drug_Target_30_HGNC_ID:
HGNC:2529

# Drug_Target_30_HPRD_ID:
00291

# Drug_Target_30_ID:
1243

# Drug_Target_30_Locus:
11p15.5

# Drug_Target_30_Molecular_Weight:
44553

# Drug_Target_30_Name:
Cathepsin D

# Drug_Target_30_Number_of_Residues:
412

# Drug_Target_30_PDB_ID:
1LYW

# Drug_Target_30_Pathway:
Not Available

# Drug_Target_30_Pfam_Domain_Function:
PF00026	Asp
PF07966	A1_Propeptide

# Drug_Target_30_Protein_Sequence:
>Cathepsin D precursor
MQPSSLLPLALCLLAAPASALVRIPLHKFTSIRRTMSEVGGSVEDLIAKGPVSKYSQAVP
AVTEGPIPEVLKNYMDAQYYGEIGIGTPPQCFTVVFDTGSSNLWVPSIHCKLLDIACWIH
HKYNSDKSSTYVKNGTSFDIHYGSGSLSGYLSQDTVSVPCQSASSASALGGVKVERQVFG
EATKQPGITFIAAKFDGILGMAYPRISVNNVLPVFDNLMQQKLVDQNIFSFYLSRDPDAQ
PGGELMLGGTDSKYYKGSLSYLNVTRKAYWQVHLDQVEVASGLTLCKEGCEAIVDTGTSL
MVGPVDEVRELQKAIGAVPLIQGEYMIPCEKVSTLPAITLKLGGKGYKLSPEDYTLKVSQ
AGKTLCLSGFMGMDIPPPSGPLWILGDVFIGRYYTVFDRDNNRVGFAEAARL

# Drug_Target_30_Reaction:
Specificity similar to, but narrower than, that of pepsin A. Does not cleave the Gln4-His bond in B chain of insulin INHIBITOR Methyl 2-diazoacetamidohexonate

# Drug_Target_30_Signals:
1-18

# Drug_Target_30_Specific_Function:
Acid protease active in intracellular protein breakdown. Involved in the pathogenesis of several diseases such as breast cancer and possibly Alzheimer disease

# Drug_Target_30_SwissProt_ID:
P07339

# Drug_Target_30_SwissProt_Name:
CATD_HUMAN

# Drug_Target_30_Synonyms:
Cathepsin D precursor
EC 3.4.23.5

# Drug_Target_30_Theoretical_pI:
6.50

# Drug_Target_30_Transmembrane_Regions:
None

# Drug_Target_31_Cellular_Location:
Membrane
single-pass type I membrane protein

# Drug_Target_31_Chromosome_Location:
Not Available

# Drug_Target_31_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_31_Essentiality:
Non-Essential

# Drug_Target_31_GenAtlas_ID:
IGF1R

# Drug_Target_31_GenBank_ID_Gene:
X04434

# Drug_Target_31_GenBank_ID_Protein:
804990

# Drug_Target_31_GeneCard_ID:
IGF1R

# Drug_Target_31_Gene_Name:
IGF1R

# Drug_Target_31_Gene_Sequence:
>4104 bp
ATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCC
GCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGC
AACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCAC
ATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTC
ATTACCGAGTACTTGCTGCTGTTCCGAGTGGCTGGCCTCGAGAGCCTCGGAGACCTCTTC
CCCAACCTCACGGTCATCCGCGGCTGGAAACTCTTCTACAACTACGCCCTGGTCATCTTC
GAGATGACCAATCTCAAGGATATTGGGCTTTACAACCTGAGGAACATTACTCGGGGGGCC
ATCAGGATTGAGAAAAATGCTGACCTCTGTTACCTCTCCACTGTGGACTGGTCCCTGATC
CTGGATGCGGTGTCCAATAACTACATTGTGGGGAATAAGCCCCCAAAGGAATGTGGGGAC
CTGTGTCCAGGGACCATGGAGGAGAAGCCGATGTGTGAGAAGACCACCATCAACAATGAG
TACAACTACCGCTGCTGGACCACAAACCGCTGCCAGAAAATGTGCCCAAGCACGTGTGGG
AAGCGGGCGTGCACCGAGAACAATGAGTGCTGCCACCCCGAGTGCCTGGGCAGCTGCAGC
GCGCCTGACAACGACACGGCCTGTGTAGCTTGCCGCCACTACTACTATGCCGGTGTCTGT
GTGCCTGCCTGCCCGCCCAACACCTACAGGTTTGAGGGCTGGCGCTGTGTGGACCGTGAC
TTCTGCGCCAACATCCTCAGCGCCGAGAGCAGCGACTCCGAGGGGTTTGTGATCCACGAC
GGCGAGTGCATGCAGGAGTGCCCCTCGGGCTTCATCCGCAACGGCAGCCAGAGCATGTAC
TGCATCCCTTGTGAAGGTCCTTGCCCGAAGGTCTGTGAGGAAGAAAAGAAAACAAAGACC
ATTGATTCTGTTACTTCTGCTCAGATGCTCCAAGGATGCACCATCTTCAAGGGCAATTTG
CTCATTAACATCCGACGGGGGAATAACATTGCTTCAGAGCTGGAGAACTTCATGGGGCTC
ATCGAGGTGGTGACGGGCTACGTGAAGATCCGCCATTCTCATGCCTTGGTCTCCTTGTCC
TTCCTAAAAAACCTTCGCCTCATCCTAGGAGAGGAGCAGCTAGAAGGGAATTACTCCTTC
TACGTCCTCGACAACCAGAACTTGCAGCAACTGTGGGACTGGGACCACCGCAACCTGACC
ATCAAAGCAGGGAAAATGTACTTTGCTTTCAATCCCAAATTATGTGTTTCCGAAATTTAC
CGCATGGAGGAAGTGACGGGGACTAAAGGGCGCCAAAGCAAAGGGGACATAAACACCAGG
AACAACGGGGAGAGAGCCTCCTGTGAAAGTGACGTCCTGCATTTCACCTCCACCACCACG
TCGAAGAATCGCATCATCATAACCTGGCACCGGTACCGGCCCCCTGACTACAGGGATCTC
ATCAGCTTCACCGTTTACTACAAGGAAGCACCCTTTAAGAATGTCACAGAGTATGATGGG
CAGGATGCCTGCGGCTCCAACAGCTGGAACATGGTGGACGTGGACCTCCCGCCCAACAAG
GACGTGGAGCCCGGCATCTTACTACATGGGCTGAAGCCCTGGACTCAGTACGCCGTTTAC
GTCAAGGCTGTGACCCTCACCATGGTGGAGAACGACCATATCCGTGGGGCCAAGAGTGAG
ATCTTGTACATTCGCACCAATGCTTCAGTTCCTTCCATTCCCTTGGACGTTCTTTCAGCA
TCGAACTCCTCTTCTCAGTTAATCGTGAAGTGGAACCCTCCCTCTCTGCCCAACGGCAAC
CTGAGTTACTACATTGTGCGCTGGCAGCGGCAGCCTCAGGACGGCTACCTTTACCGGCAC
AATTACTGCTCCAAAGACAAAATCCCCATCAGGAAGTATGCCGACGGCACCATCGACATT
GAGGAGGTCACAGAGAACCCCAAGACTGAGGTGTGTGGTGGGGAGAAAGGGCCTTGCTGC
GCCTGCCCCAAAACTGAAGCCGAGAAGCAGGCCGAGAAGGAGGAGGCTGAATACCGCAAA
GTCTTTGAGAATTTCCTGCACAACTCCATCTTCGTGCCCAGACCTGAAAGGAAGCGGAGA
GATGTCATGCAAGTGGCCAACACCACCATGTCCAGCCGAAGCAGGAACACCACGGCCGCA
GACACCTACAACATCACCGACCCGGAAGAGCTGGAGACAGAGTACCCTTTCTTTGAGAGC
AGAGTGGATAACAAGGAGAGAACTGTCATTTCTAACCTTCGGCCTTTCACATTGTACCGC
ATCGATATCCACAGCTGCAACCACGAGGCTGAGAAGCTGGGCTGCAGCGCCTCCAACTTC
GTCTTTGCAAGGACTATGCCCGCAGAAGGAGCAGATGACATTCCTGGGCCAGTGACCTGG
GAGCCAAGGCCTGAAAACTCCATCTTTTTAAAGTGGCCGGAACCTGAGAATCCCAATGGA
TTGATTCTAATGTATGAAATAAAATACGGATCACAAGTTGAGGATCAGCGAGAATGTGTG
TCCAGACAGGAATACAGGAAGTATGGAGGGGCCAAGCTAAACCGGCTAAACCCGGGGAAC
TACACAGCCCGGATTCAGGCCACATCTCTCTCTGGGAATGGGTCGTGGACAGATCCTGTG
TTCTTCTATGTCCAGGCCAAAACAGGATATGAAAACTTCATCCATCTGATCATCGCTCTG
CCCGTCGCTGTCCTGTTGATCGTGGGAGGGTTGGTGATTATGCTGTACGTCTTCCATAGA
AAGAGAAATAACAGCAGGCTGGGGAATGGAGTGCTGTATGCCTCTGTGAACCCGGAGTAC
TTCAGCGCTGCTGATGTGTACGTTCCTGATGAGTGGGAGGTGGCTCGGGAGAAGATCACC
ATGAGCCGGGAACTTGGGCAGGGGTCGTTTGGGATGGTCTATGAAGGAGTTGCCAAGGGT
GTGGTGAAAGATGAACCTGAAACCAGAGTGGCCATTAAAACAGTGAACGAGGCCGCAAGC
ATGCGTGAGAGGATTGAGTTTCTCAACGAAGCTTCTGTGATGAAGGAGTTCAATTGTCAC
CATGTGGTGCGATTGCTGGGTGTGGTGTCCCAAGGCCAGCCAACACTGGTCATCATGGAA
CTGATGACACGGGGCGATCTCAAAAGTTATCTCCGGTCTCTGAGGCCAGAAATGGAGAAT
AATCCAGTCCTAGCACCTCCAAGCCTGAGCAAGATGATTCAGATGGCCGGAGAGATTGCA
GACGGCATGGCATACCTCAACGCCAATAAGTTCGTCCACAGAGACCTTGCTGCCCGGAAT
TGCATGGTAGCCGAAGATTTCACAGTCAAAATCGGAGATTTTGGTATGACGCGAGATATC
TATGAGACAGACTATTACCGGAAAGGAGGCAAAGGGCTGCTGCCCGTGCGCTGGATGTCT
CCTGAGTCCCTCAAGGATGGAGTCTTCACCACTTACTCGGACGTCTGGTCCTTCGGGGTC
GTCCTCTGGGAGATCGCCACACTGGCCGAGCAGCCCTACCAGGGCTTGTCCAACGAGCAA
GTCCTTCGCTTCGTCATGGAGGGCGGCCTTCTGGACAAGCCAGACAACTGTCCTGACATG
CTGTTTGAACTGATGCGCATGTGCTGGCAGTATAACCCCAAGATGAGGCCTTCCTTCCTG
GAGATCATCAGCAGCATCAAAGAGGAGATGGAGCCTGGCTTCCGGGAGGTCTCCTTCTAC
TACAGCGAGGAGAACAAGCTGCCCGAGCCGGAGGAGCTGGACCTGGAGCCAGAGAACATG
GAGAGCGTCCCCCTGGACCCCTCGGCCTCCTCGTCCTCCCTGCCACTGCCCGACAGACAC
TCAGGACACAAGGCCGAGAACGGCCCCGGCCCTGGGGTGCTGGTCCTCCGCGCCAGCTTC
GACGAGAGACAGCCTTACGCCCACATGAACGGGGGCCGCAAGAACGAGCGGGCCTTGCCG
CTGCCCCAGTCTTCGACCTGCTGA

# Drug_Target_31_General_Function:
Involved in transmembrane receptor protein tyrosine kinase activity

# Drug_Target_31_General_References:
1316909	Abbott AM, Bueno R, Pedrini MT, Murray JM, Smith RJ: Insulin-like growth factor I receptor gene structure. J Biol Chem. 1992 May 25;267(15):10759-63.
1711844	Cooke DW, Bankert LA, Roberts CT Jr, LeRoith D, Casella SJ: Analysis of the human type I insulin-like growth factor receptor promoter region. Biochem Biophys Res Commun. 1991 Jun 28;177(3):1113-20.
2877871	Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, Collins C, Henzel W, Le Bon T, Kathuria S, Chen E, et al.: Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J. 1986 Oct;5(10):2503-12.
7541045	Craparo A, O'Neill TJ, Gustafson TA: Non-SH2 domains within insulin receptor substrate-1 and SHC mediate their phosphotyrosine-dependent interaction with the NPEY motif of the insulin-like growth factor I receptor. J Biol Chem. 1995 Jun 30;270(26):15639-43.
8247543	Lee ST, Strunk KM, Spritz RA: A survey of protein tyrosine kinase mRNAs expressed in normal human melanocytes. Oncogene. 1993 Dec;8(12):3403-10.

# Drug_Target_31_HGNC_ID:
HGNC:5465

# Drug_Target_31_HPRD_ID:
00932

# Drug_Target_31_ID:
958

# Drug_Target_31_Locus:
15q26.3

# Drug_Target_31_Molecular_Weight:
154795

# Drug_Target_31_Name:
Insulin-like growth factor 1 receptor

# Drug_Target_31_Number_of_Residues:
1367

# Drug_Target_31_PDB_ID:
1IGR

# Drug_Target_31_Pathway:
Not Available

# Drug_Target_31_Pfam_Domain_Function:
PF00041	fn3
PF00757	Furin-like
PF01030	Recep_L_domain
PF07714	Pkinase_Tyr

# Drug_Target_31_Protein_Sequence:
>Insulin-like growth factor 1 receptor precursor
MKSGSGGGSPTSLWGLLFLSAALSLWPTSGEICGPGIDIRNDYQQLKRLENCTVIEGYLH
ILLISKAEDYRSYRFPKLTVITEYLLLFRVAGLESLGDLFPNLTVIRGWKLFYNYALVIF
EMTNLKDIGLYNLRNITRGAIRIEKNADLCYLSTVDWSLILDAVSNNYIVGNKPPKECGD
LCPGTMEEKPMCEKTTINNEYNYRCWTTNRCQKMCPSTCGKRACTENNECCHPECLGSCS
APDNDTACVACRHYYYAGVCVPACPPNTYRFEGWRCVDRDFCANILSAESSDSEGFVIHD
GECMQECPSGFIRNGSQSMYCIPCEGPCPKVCEEEKKTKTIDSVTSAQMLQGCTIFKGNL
LINIRRGNNIASELENFMGLIEVVTGYVKIRHSHALVSLSFLKNLRLILGEEQLEGNYSF
YVLDNQNLQQLWDWDHRNLTIKAGKMYFAFNPKLCVSEIYRMEEVTGTKGRQSKGDINTR
NNGERASCESDVLHFTSTTTSKNRIIITWHRYRPPDYRDLISFTVYYKEAPFKNVTEYDG
QDACGSNSWNMVDVDLPPNKDVEPGILLHGLKPWTQYAVYVKAVTLTMVENDHIRGAKSE
ILYIRTNASVPSIPLDVLSASNSSSQLIVKWNPPSLPNGNLSYYIVRWQRQPQDGYLYRH
NYCSKDKIPIRKYADGTIDIEEVTENPKTEVCGGEKGPCCACPKTEAEKQAEKEEAEYRK
VFENFLHNSIFVPRPERKRRDVMQVANTTMSSRSRNTTAADTYNITDPEELETEYPFFES
RVDNKERTVISNLRPFTLYRIDIHSCNHEAEKLGCSASNFVFARTMPAEGADDIPGPVTW
EPRPENSIFLKWPEPENPNGLILMYEIKYGSQVEDQRECVSRQEYRKYGGAKLNRLNPGN
YTARIQATSLSGNGSWTDPVFFYVQAKTGYENFIHLIIALPVAVLLIVGGLVIMLYVFHR
KRNNSRLGNGVLYASVNPEYFSAADVYVPDEWEVAREKITMSRELGQGSFGMVYEGVAKG
VVKDEPETRVAIKTVNEAASMRERIEFLNEASVMKEFNCHHVVRLLGVVSQGQPTLVIME
LMTRGDLKSYLRSLRPEMENNPVLAPPSLSKMIQMAGEIADGMAYLNANKFVHRDLAARN
CMVAEDFTVKIGDFGMTRDIYETDYYRKGGKGLLPVRWMSPESLKDGVFTTYSDVWSFGV
VLWEIATLAEQPYQGLSNEQVLRFVMEGGLLDKPDNCPDMLFELMRMCWQYNPKMRPSFL
EIISSIKEEMEPGFREVSFYYSEENKLPEPEELDLEPENMESVPLDPSASSSSLPLPDRH
SGHKAENGPGPGVLVLRASFDERQPYAHMNGGRKNERALPLPQSSTC

# Drug_Target_31_Reaction:
ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate

# Drug_Target_31_Signals:
1-30

# Drug_Target_31_Specific_Function:
This receptor binds insulin-like growth factor 1 (IGF1) with a high affinity and IGF2 with a lower affinity. It has a tyrosine-protein kinase activity, which is necessary for the activation of the IGF1-stimulated downstream signaling cascade

# Drug_Target_31_SwissProt_ID:
P08069

# Drug_Target_31_SwissProt_Name:
IGF1R_HUMAN

# Drug_Target_31_Synonyms:
CD221 antigen
EC 2.7.10.1
IGF-I receptor
Insulin-like growth factor 1 receptor precursor
Insulin-like growth factor I receptor

# Drug_Target_31_Theoretical_pI:
5.54

# Drug_Target_31_Transmembrane_Regions:
936-959

# Drug_Target_32_Cellular_Location:
Cytoplasmic

# Drug_Target_32_Chromosome_Location:
Not Available

# Drug_Target_32_Drug_References:
Not Available

# Drug_Target_32_Essentiality:
Non-Essential

# Drug_Target_32_GenAtlas_ID:
Not Available

# Drug_Target_32_GenBank_ID_Gene:
U39812

# Drug_Target_32_GenBank_ID_Protein:
Not Available

# Drug_Target_32_GeneCard_ID:
Not Available

# Drug_Target_32_Gene_Name:
manA

# Drug_Target_32_Gene_Sequence:
>2736 bp
ATGGGGGTATGTTTAGATATGTGGAGAAATTGGAGAGTGCTTTTTGTTCTTGTTACAATC
ATATTTTTATTTAGTCTCATTCCCACTGGGATATTTGGTGCTGTTGAGTCGTCTGTAAAT
CCAGTAGTGCTGGACTTTGAAGATGGCACTGTAATGAGCTTTGGTGAAGCTTGGGGGGAT
TCATTAAAGTGCATAAAAAAGGTTTCTGTTTCGCAGGACCTTCAAAGACCAGGGAACAAA
TATGCATTAAGGCTTGATGTTGAGTTTAACCCAAACAATGGCTGGGACCAAGGCGACCTT
GGTACCTGGTTTGGCGGTGTTGTAGAAGGTCAGTTTGACTTTACAGGCTACAAATCTGTT
GAGTTTGAGATGTTCATTCCATACGATGAGTTTTCTAAATCCCAAGGCGGTTTTCCTTAC
AAAGTTGTCATAAATGACGGGTGGAAAGAGCTTGGAAGTGAGTTTAACATAACTGCAAAT
GCAGGCAAAAAGGTTAAGATAAATGGCAAAGATTACACAGTCATTCACAAGGCATTTGCA
ATCCCAGAAGATTTTAGAACCAAAAAACGTGCACAGCTTGTCTTCCAGTTTGCAGGGCAA
AATTCAAACTACAAAGGACCTATCTATCTTGACAATGTAAGAATAAGACCTGAGGATGCT
TCAAATCTGTCAAAAGAGGACTATGGAGAACAGGCTGAAGAAGGAGTAGCAGTTGAAGAT
TTCTTCACAGGTGTGAAACTCGTATATCCTGAACAGGGTAAGTCTTTTGTTTACAACTTT
GAAATTGACACAATGGGATTTTATAAGTACAGCGGCGATGGTTTCAACAAAAAGACAAAA
TCCTTAGAATATTCACAGGATTTAAAGAGAAGTGGGAATAACGGCGCGCTGAAAGTCAAC
GCAAGCCTTGCTGGTACTGCCTTTGATGAGATGAACATTGCTATAAAGCTCACAGACAAA
GACGATAAAAAATTTGATTTTAGCAAGTATTCTACTTTGGAGTACACTCTCTATATTCCA
AACCCTGATAAGATTTCTGGCAAGCTTATGGTTGCAAGTGCAATAGATAATCCATGGCAG
ATTATTAAAGACTTCACAGCTATTAATTACAAGGATAAGAACGCCATTCAAAAGATAAAT
GGAAAAGACTATGCGGTAATTAAATGTTCAGACAATCTTTACAATGTAAATACAAAGGCA
AATGTTTTGGTTTTAAGAATTGCAGGGTCATATGTCAAATATACAGGACCTATTTACATT
GACAATGTAAAACTTGTGGCAGGAAAGAAGGTTGCTCCAAAAGTGAAAACAACAAGCAGT
ATTCCAAATATCAAGAACTATTACAGGGTAAAAATTGAAGCGGAAACAGCTAAGGATGGG
TGGGCATACAGTATTGAAAAAGAAAATGCAAAGTATTCTGGAAAAGGATATATTCTTTTG
TTTGGGAACAATATGGGCAATACTCTCTATGATTTAAAGATACCGAAAACAGGATACTAT
ATATTCACAATCAGCAGCTCTACGCTTGGTATGGTAAACTATGGTAGTGTTGATATATGG
ATAGATGGTGAATTAAAGGGAGCAGCAAAGGTTCCAAATGTTAAAGGTAAATTCCAGGAA
GTTGTGGTAATGAAAAAGATATATCTTACACAAGGTGAACATACTCTGTCACTTCAAAAA
TCCGGTGGATATACGATTGCAATAGACTACTTTACAATTGAAGAGCTTGTTTTGGCAAAC
AAGAATAAAATAAGTGTTGATACAAAGCTTGTAACACCAAATCCACATCCTAATGCGCAA
AAGCTTATGAAATACCTGGCAAGCATATATGGTGAAAAGATTCTCTCTGGGCAACAGAGC
AGTGGTGATGGAAAAGAAATTCAAATGATATTTGATGTTACAAAAAGATATCCTGCTGTC
AGGGGCTTTGACTTTATGGACTACTCACCAAGCAGGGTAGAGCATGGCACAAAAGGTACT
GATGTAGAAGAGGCAATAAAATGGTGGAAGAGCGGTGGAATTGTTGCTTTCTGCTGGCAT
TGGAATGCACCAACAGGGCTTATTGACCAGCCGGGCAAAGAATGGTGGAGAGGATTTTAC
ACAGAAGCAACAACATTTGATATAAAGAAGGCTATGGACAATCCTAATTCAACTGAGTAT
AAGCTCATTTTGAGAGATATAGACGCAATTGCTGAGCAGCTCAAGAGGCTTCAGAAAGAA
GGAGTCCCAGTTCTTTTCAGACCGCTGCACGAAGCTTCAGGTGGCTGGTTCTGGTGGGGG
GCAAAAGGACCCGAGCCCTATATCAAACTCTGGAAACTTATGTTTGATAGGCTTGTAAAT
TATCACAAGTTAAACAACCTCATCTGGGTATGGAACGGTCAGGATGCAGCATGGTATCCG
GGGGACAACTATGTTGATATAATTGGCGAAGACATTTATGAGGAAAAAGCTCAATATTCC
CCCTATGCAGACAGGTTTGCAAAGGCATTGAAGTACACAAATGCAAGAAAGATGATAGCA
CTTACTGAGTGTGGAACAATTCCAGACCCAGCAGTATTAAAACAGGAAGGTATTTCATGG
AGCTGGTTCTCTGTCTGGGCAGGAAACTTTGTCATGACAGGCAGCAAGTATAATGATGAG
TGGAATGACAATCATATGCTAAGAAAGATTTACAATAGCGACTATGTAATAACAAAAGAC
GAACTTCCTGATATTAAGAACATACCATTAAAGTAA

# Drug_Target_32_General_Function:
Involved in carbohydrate binding

# Drug_Target_32_General_References:
8764509	Gibbs MD, Elinder AU, Reeves RA, Bergquist PL: Sequencing, cloning and expression of a beta-1,4-mannanase gene, manA, from the extremely thermophilic anaerobic bacterium, Caldicellulosiruptor Rt8B.4. FEMS Microbiol Lett. 1996 Jul 15;141(1):37-43.

# Drug_Target_32_HGNC_ID:
Not Available

# Drug_Target_32_HPRD_ID:
Not Available

# Drug_Target_32_ID:
4721

# Drug_Target_32_Locus:
Not Available

# Drug_Target_32_Molecular_Weight:
103326

# Drug_Target_32_Name:
Beta-1,4-mannanase

# Drug_Target_32_Number_of_Residues:
911

# Drug_Target_32_PDB_ID:
1PMJ

# Drug_Target_32_Pathway:
Not Available

# Drug_Target_32_Pfam_Domain_Function:
PF02156	Glyco_hydro_26
PF03422	CBM_6
PF03424	CBM_17_28

# Drug_Target_32_Protein_Sequence:
>Beta-1,4-mannanase
MGVCLDMWRNWRVLFVLVTIIFLFSLIPTGIFGAVESSVNPVVLDFEDGTVMSFGEAWGD
SLKCIKKVSVSQDLQRPGNKYALRLDVEFNPNNGWDQGDLGTWFGGVVEGQFDFTGYKSV
EFEMFIPYDEFSKSQGGFPYKVVINDGWKELGSEFNITANAGKKVKINGKDYTVIHKAFA
IPEDFRTKKRAQLVFQFAGQNSNYKGPIYLDNVRIRPEDASNLSKEDYGEQAEEGVAVED
FFTGVKLVYPEQGKSFVYNFEIDTMGFYKYSGDGFNKKTKSLEYSQDLKRSGNNGALKVN
ASLAGTAFDEMNIAIKLTDKDDKKFDFSKYSTLEYTLYIPNPDKISGKLMVASAIDNPWQ
IIKDFTAINYKDKNAIQKINGKDYAVIKCSDNLYNVNTKANVLVLRIAGSYVKYTGPIYI
DNVKLVAGKKVAPKVKTTSSIPNIKNYYRVKIEAETAKDGWAYSIEKENAKYSGKGYILL
FGNNMGNTLYDLKIPKTGYYIFTISSSTLGMVNYGSVDIWIDGELKGAAKVPNVKGKFQE
VVVMKKIYLTQGEHTLSLQKSGGYTIAIDYFTIEELVLANKNKISVDTKLVTPNPHPNAQ
KLMKYLASIYGEKILSGQQSSGDGKEIQMIFDVTKRYPAVRGFDFMDYSPSRVEHGTKGT
DVEEAIKWWKSGGIVAFCWHWNAPTGLIDQPGKEWWRGFYTEATTFDIKKAMDNPNSTEY
KLILRDIDAIAEQLKRLQKEGVPVLFRPLHEASGGWFWWGAKGPEPYIKLWKLMFDRLVN
YHKLNNLIWVWNGQDAAWYPGDNYVDIIGEDIYEEKAQYSPYADRFAKALKYTNARKMIA
LTECGTIPDPAVLKQEGISWSWFSVWAGNFVMTGSKYNDEWNDNHMLRKIYNSDYVITKD
ELPDIKNIPLK

# Drug_Target_32_Reaction:
Not Available

# Drug_Target_32_Signals:
None

# Drug_Target_32_Specific_Function:
Not Available

# Drug_Target_32_SwissProt_ID:
P77847

# Drug_Target_32_SwissProt_Name:
P77847_CALSA

# Drug_Target_32_Synonyms:
EC 3.2.1.78

# Drug_Target_32_Theoretical_pI:
8.26

# Drug_Target_32_Transmembrane_Regions:
None

# Drug_Target_33_Cellular_Location:
Not Available

# Drug_Target_33_Chromosome_Location:
Not Available

# Drug_Target_33_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_33_Essentiality:
Non-Essential

# Drug_Target_33_GenAtlas_ID:
Not Available

# Drug_Target_33_GenBank_ID_Gene:
Not Available

# Drug_Target_33_GenBank_ID_Protein:
Not Available

# Drug_Target_33_GeneCard_ID:
Not Available

# Drug_Target_33_Gene_Name:
AMY2B

# Drug_Target_33_Gene_Sequence:
Not Available

# Drug_Target_33_General_Function:
Not Available

# Drug_Target_33_General_References:
Not Available

# Drug_Target_33_HGNC_ID:
Not Available

# Drug_Target_33_HPRD_ID:
Not Available

# Drug_Target_33_ID:
6967

# Drug_Target_33_Locus:
Not Available

# Drug_Target_33_Molecular_Weight:
Not Available

# Drug_Target_33_Name:
Alpha-amylase 2B

# Drug_Target_33_Number_of_Residues:
0

# Drug_Target_33_PDB_ID:
Not Available

# Drug_Target_33_Pathway:
Not Available

# Drug_Target_33_Pfam_Domain_Function:
Not Available

# Drug_Target_33_Protein_Sequence:
Not Available

# Drug_Target_33_Reaction:
Not Available

# Drug_Target_33_Signals:
Not Available

# Drug_Target_33_Specific_Function:
Not Available

# Drug_Target_33_SwissProt_ID:
P19961

# Drug_Target_33_SwissProt_Name:
AMY2B_HUMAN

# Drug_Target_33_Synonyms:
Not Available

# Drug_Target_33_Theoretical_pI:
Not Available

# Drug_Target_33_Transmembrane_Regions:
Not Available

# Drug_Target_34_Cellular_Location:
Not Available

# Drug_Target_34_Chromosome_Location:
Not Available

# Drug_Target_34_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_34_Essentiality:
Non-Essential

# Drug_Target_34_GenAtlas_ID:
Not Available

# Drug_Target_34_GenBank_ID_Gene:
Not Available

# Drug_Target_34_GenBank_ID_Protein:
Not Available

# Drug_Target_34_GeneCard_ID:
Not Available

# Drug_Target_34_Gene_Name:
GALNT1

# Drug_Target_34_Gene_Sequence:
Not Available

# Drug_Target_34_General_Function:
Not Available

# Drug_Target_34_General_References:
Not Available

# Drug_Target_34_HGNC_ID:
Not Available

# Drug_Target_34_HPRD_ID:
Not Available

# Drug_Target_34_ID:
6942

# Drug_Target_34_Locus:
Not Available

# Drug_Target_34_Molecular_Weight:
Not Available

# Drug_Target_34_Name:
Polypeptide N-acetylgalactosaminyltransferase 1

# Drug_Target_34_Number_of_Residues:
0

# Drug_Target_34_PDB_ID:
Not Available

# Drug_Target_34_Pathway:
Not Available

# Drug_Target_34_Pfam_Domain_Function:
Not Available

# Drug_Target_34_Protein_Sequence:
Not Available

# Drug_Target_34_Reaction:
Not Available

# Drug_Target_34_Signals:
Not Available

# Drug_Target_34_Specific_Function:
Not Available

# Drug_Target_34_SwissProt_ID:
Q10472

# Drug_Target_34_SwissProt_Name:
GALT1_HUMAN

# Drug_Target_34_Synonyms:
Not Available

# Drug_Target_34_Theoretical_pI:
Not Available

# Drug_Target_34_Transmembrane_Regions:
Not Available

# Drug_Target_35_Cellular_Location:
Secreted protein

# Drug_Target_35_Chromosome_Location:
Not Available

# Drug_Target_35_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_35_Essentiality:
Non-Essential

# Drug_Target_35_GenAtlas_ID:
FGA

# Drug_Target_35_GenBank_ID_Gene:
AF361104

# Drug_Target_35_GenBank_ID_Protein:
13591824

# Drug_Target_35_GeneCard_ID:
FGA

# Drug_Target_35_Gene_Name:
FGA

# Drug_Target_35_Gene_Sequence:
>2601 bp
ATGTTTTCCATGAGGATCGTCTGCCTAGTTCTAAGTGTGGTGGGCACAGCATGGACTGCA
GATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTG
GAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGG
AACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGAT
TTTACAAACAGAATAAATAAGCTCAAAAATTCACTATTTGAATATCAGAAGAACAATAAG
GATTCTCATTCGTTGACCACTAATATAATGGAAATTTTGAGAGGCGATTTTTCCTCAGCC
AATAACCGTGATAATACCTACAACCGAGTGTCAGAGGATCTGAGAAGCAGAATTGAAGTC
CTGAAGCGCAAAGTCATAGAAAAAGTACAGCATATCCAGCTTCTGCAGAAAAATGTTAGA
GCTCAGTTGGTTGATATGAAACGACTGGAGGTGGACATTGATATTAAGATCCGATCTTGT
CGAGGGTCATGCAGTAGGGCTTTAGCTCGTGAAGTAGATCTGAAGGACTATGAAGATCAG
CAGAAGCAACTTGAACAGGTCATTGCCAAAGACTTACTTCCCTCTAGAGATAGGCAACAC
TTACCACTGATAAAAATGAAACCAGTTCCAGACTTGGTTCCCGGAAATTTTAAGAGCCAG
CTTCAGAAGGTACCCCCAGAGTGGAAGGCATTAACAGACATGCCGCAGATGAGAATGGAG
TTAGAGAGACCTGGTGGAAATGAGATTACTCGAGGAGGCTCCACCTCTTATGGAACCGGA
TCAGAGACGGAAAGCCCCAGGAACCCTAGCAGTGCTGGAAGCTGGAACTCTGGGAGCTCT
GGACCTGGAAGTACTGGAAACCGAAACCCTGGGAGCTCTGGGACTGGAGGGACTGCAACC
TGGAAACCTGGGAGCTCTGGACCTGGAAGTACTGGAAGCTGGAACTCTGGGAGCTCTGGA
ACTGGAAGTACTGGAAACCAAAACCCTGGGAGCCCTAGACCTGGTAGTACCGGAACCTGG
AATCCTGGCAGCTCTGAACGCGGAAGTGCTGGGCACTGGACCTCTGAGAGCTCTGTATCT
GGTAGTACTGGACAATGGCACTCTGAATCTGGAAGTTTTAGGCCAGATAGCCCAGGCTCT
GGGAACGCGAGGCCTAACAACCCAGACTGGGGCACATTTGAAGAGGTGTCAGGAAATGTA
AGTCCAGGGACAAGGAGAGAGTACCACACAGAAAAACTGGTCACTTCTAAAGGAGATAAA
GAGCTCAGGACTGGTAAAGAGAAGGTCACCTCTGGTAGCACAACCACCACGCGTCGTTCA
TGCTCTAAAACCGTTACTAAGACTGTTATTGGTCCTGATGGTCACAAAGAAGTTACCAAA
GAAGTGGTGACCTCCGAAGATGGTTCTGACTGTCCCGAGGCAATGGATTTAGGCACATTG
TCTGGCATAGGTACTCTGGATGGGTTCCGCCATAGGCACCCTGATGAAGCTGCCTTCTTC
GACACTGCCTCAACTGGAAAAACATTCCCAGGTTTCTTCTCACCTATGTTAGGAGAGTTT
GTCAGTGAGACTGAGTCTAGGGGCTCAGAATCTGGCATCTTCACAAATACAAAGGAATCC
AGTTCTCATCACCCTGGGATAGCTGAATTCCCTTCCCGTGGTAAATCTTCAAGTTACAGC
AAACAATTTACTAGTAGCACGAGTTACAACAGAGGAGACTCCACATTTGAAAGCAAGAGC
TATAAAATGGCAGATGAGGCCGGAAGTGAAGCCGATCATGAAGGAACACATAGCACCAAG
AGAGGCCATGCTAAATCTCGCCCTGTCAGAGACTGTGATGATGTCCTCCAAACACATCCT
TCAGGTACCCAAAGTGGCATTTTCAATATCAAGCTACCGGGATCCAGTAAGATTTTTTCT
GTTTATTGCGATCAAGAGACCAGTTTGGGAGGATGGCTTTTGATCCAGCAAAGAATGGAT
GGATCACTGAATTTTAACCGGACCTGGCAAGACTACAAGAGAGGTTTCGGCAGCCTGAAT
GACGAGGGGGAAGGAGAATTCTGGCTAGGCAATGACTACCTCCACTTACTAACCCAAAGG
GGCTCTGTTCTTAGGGTTGAATTAGAGGACTGGGCTGGGAATGAAGCTTATGCAGAATAT
CACTTCCGGGTAGGCTCTGAGGCTGAAGGCTATGCCCTCCAAGTCTCCTCCTATGAAGGC
ACTGCGGGTGATGCTCTGATTGAGGGTTCCGTAGAGGAAGGGGCAGAGTACACCTCTCAC
AACAACATGCAGTTCAGCACCTTTGACAGGGATGCAGACCAGTGGGAAGAGAACTGTGCA
GAAGTCTATGGGGGAGGCTGGTGGTATAATAACTGCCAAGCAGCCAATCTCAATGGAATC
TACTACCCTGGGGGCTCCTATGACCCAAGGAATAACAGTCCTTATGAGATTGAGAATGGA
GTGGTCTGGGTTTCCTTTAGAGGGGCAGATTATTCCCTCAGGGCTGTTCGCATGAAAATT
AGGCCCCTTGTGACCCAATAG

# Drug_Target_35_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_35_General_References:
10074346	Everse SJ, Spraggon G, Veerapandian L, Doolittle RF: Conformational changes in fragments D and double-D from human fibrin(ogen) upon binding the peptide ligand Gly-His-Arg-Pro-amide. Biochemistry. 1999 Mar 9;38(10):2941-6.
10391209	Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Shaw N, Lane CR, Lim EP, Kalyanaraman N, Nemesh J, Ziaugra L, Friedland L, Rolfe A, Warrington J, Lipshutz R, Daley GQ, Lander ES: Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet. 1999 Jul;22(3):231-8.
1457396	Fu Y, Weissbach L, Plant PW, Oddoux C, Cao Y, Liang TJ, Roy SN, Redman CM, Grieninger G: Carboxy-terminal-extended variant of the human fibrinogen alpha subunit: a novel exon conferring marked homology to beta and gamma subunits. Biochemistry. 1992 Dec 8;31(48):11968-72.
1560020	Martin PD, Robertson W, Turk D, Huber R, Bode W, Edwards BF: The structure of residues 7-16 of the A alpha-chain of human fibrinogen bound to bovine thrombin at 2.3-A resolution. J Biol Chem. 1992 Apr 15;267(11):7911-20.
1634621	Maekawa H, Yamazumi K, Muramatsu S, Kaneko M, Hirata H, Takahashi N, Arocha-Pinango CL, Rodriguez S, Nagy H, Perez-Requejo JL, et al.: Fibrinogen Lima: a homozygous dysfibrinogen with an A alpha-arginine-141 to serine substitution associated with extra N-glycosylation at A alpha-asparagine-139. Impaired fibrin gel formation but normal fibrin-facilitated plasminogen activation catalyzed by tissue-type plasminogen activator. J Clin Invest. 1992 Jul;90(1):67-76.
1675636	Maekawa H, Yamazumi K, Muramatsu S, Kaneko M, Hirata H, Takahashi N, de Bosch NB, Carvajal Z, Ojeda A, Arocha-Pinango CL, et al.: An A alpha Ser-434 to N-glycosylated Asn substitution in a dysfibrinogen, fibrinogen Caracas II, characterized by impaired fibrin gel formation. J Biol Chem. 1991 Jun 25;266(18):11575-81.
2070049	Yoshida N, Okuma M, Hirata H, Matsuda M, Yamazumi K, Asakura S: Fibrinogen Kyoto II, a new congenitally abnormal molecule, characterized by the replacement of A alpha proline-18 by leucine. Blood. 1991 Jul 1;78(1):149-53.
2102623	Chung DW, Harris JE, Davie EW: Nucleotide sequences of the three genes coding for human fibrinogen. Adv Exp Med Biol. 1990;281:39-48.
2877981	Kimura S, Aoki N: Cross-linking site in fibrinogen for alpha 2-plasmin inhibitor. J Biol Chem. 1986 Nov 25;261(33):15591-5.
518845	Cottrell BA, Strong DD, Watt KW, Doolittle RF: Amino acid sequence studies on the alpha chain of human fibrinogen. Exact location of cross-linking acceptor sites. Biochemistry. 1979 Nov 27;18(24):5405-10.
518846	Watt KW, Cottrell BA, Strong DD, Doolittle RF: Amino acid sequence studies on the alpha chain of human fibrinogen. Overlapping sequences providing the complete sequence. Biochemistry. 1979 Nov 27;18(24):5410-6.
6318767	Itarte E, Plana M, Guasch MD, Martos C: Phosphorylation of fibrinogen by casein kinase 1. Biochem Biophys Res Commun. 1983 Dec 16;117(2):631-6.
632262	Fretto LJ, Ferguson EW, Steinman HM, McKee PA: Localization of the alpha-chain cross-link acceptor sites of human fibrin. J Biol Chem. 1978 Apr 10;253(7):2184-95.
6383194	Doolittle RF: Fibrinogen and fibrin. Annu Rev Biochem. 1984;53:195-229.
6575389	Kant JA, Lord ST, Crabtree GR: Partial mRNA sequences for human A alpha, B beta, and gamma fibrinogen chains: evolutionary and functional implications. Proc Natl Acad Sci U S A. 1983 Jul;80(13):3953-7.
6575700	Chung DW, Rixon MW, Que BG, Davie EW: Cloning of fibrinogen genes and their cDNA. Ann N Y Acad Sci. 1983 Jun 27;408:449-56.
6688355	Rixon MW, Chan WY, Davie EW, Chung DW: Characterization of a complementary deoxyribonucleic acid coding for the alpha chain of human fibrinogen. Biochemistry. 1983 Jun 21;22(13):3237-44.
6689067	Imam AM, Eaton MA, Williamson R, Humphries S: Isolation and characterisation of cDNA clones for the A alpha- and gamma-chains of human fibrinogen. Nucleic Acids Res. 1983 Nov 11;11(21):7427-34.
8097946	Benson MD, Liepnieks J, Uemichi T, Wheeler G, Correa R: Hereditary renal amyloidosis associated with a mutant fibrinogen alpha-chain. Nat Genet. 1993 Mar;3(3):252-5.
8461606	Yamazumi K, Terukina S, Matsuda M, Kanbayashi J, Sakon M, Tsujinaka T: Fibrinogen Osaka IV: a congenital dysfibrinogenemia found in a patient originally reported in relation to surgery, now defined to have an A alpha arginine-16 to histidine substitution. Surg Today. 1993;23(1):45-50.
8473507	Koopman J, Haverkate F, Grimbergen J, Lord ST, Mosesson MW, DiOrio JP, Siebenlist KS, Legrand C, Soria J, Soria C, et al.: Molecular basis for fibrinogen Dusart (A alpha 554 Arg-->Cys) and its association with abnormal fibrin polymerization and thrombophilia. J Clin Invest. 1993 Apr;91(4):1637-43.
8675656	Brennan SO, Hammonds B, George PM: Aberrant hepatic processing causes removal of activation peptide and primary polymerisation site from fibrinogen Canterbury (A alpha 20 Val --> Asp). J Clin Invest. 1995 Dec;96(6):2854-8.
9333233	Spraggon G, Everse SJ, Doolittle RF: Crystal structures of fragment D from human fibrinogen and its crosslinked counterpart from fibrin. Nature. 1997 Oct 2;389(6650):455-62.
936108	Blomback B, Hessel B, Hogg D: Disulfide bridges in nh2 -terminal part of human fibrinogen. Thromb Res. 1976 May;8(5):639-58.
9628725	Everse SJ, Spraggon G, Veerapandian L, Riley M, Doolittle RF: Crystal structure of fragment double-D from human fibrin with two different bound ligands. Biochemistry. 1998 Jun 16;37(24):8637-42.
9689040	Spraggon G, Applegate D, Everse SJ, Zhang JZ, Veerapandian L, Redman C, Doolittle RF, Grieninger G: Crystal structure of a recombinant alphaEC domain from human fibrinogen-420. Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9099-104.

# Drug_Target_35_HGNC_ID:
HGNC:3661

# Drug_Target_35_HPRD_ID:
00619

# Drug_Target_35_ID:
595

# Drug_Target_35_Locus:
4q28

# Drug_Target_35_Molecular_Weight:
94974

# Drug_Target_35_Name:
Fibrinogen alpha chain

# Drug_Target_35_Number_of_Residues:
866

# Drug_Target_35_PDB_ID:
Not Available

# Drug_Target_35_Pathway:
Acenocoumarol Pathway	SMP00269
Alteplase Pathway	SMP00280
Aminocaproic Acid Pathway	SMP00286
Anistreplase Pathway	SMP00281
Aprotinin Pathway	SMP00288
Ardeparin Pathway	SMP00275
Argatroban Pathway	SMP00276
Bivalirudin Pathway	SMP00277
Dicumarol Pathway	SMP00270
Enoxaparin Pathway	SMP00272
Fondaparinux Pathway	SMP00273
Heparin Pathway	SMP00274
Lepirudin Pathway	SMP00278
Phenprocoumon Pathway	SMP00271
Reteplase Pathway	SMP00285
Streptokinase Pathway	SMP00282
Tenecteplase Pathway	SMP00283
Tranexamic Acid Pathway	SMP00287
Urokinase Pathway	SMP00284
Warfarin Pathway	SMP00268
Ximelagatran Pathway	SMP00279

# Drug_Target_35_Pfam_Domain_Function:
PF00147	Fibrinogen_C

# Drug_Target_35_Protein_Sequence:
>Fibrinogen alpha chain precursor [Contains: Fibrinopeptide A]
MFSMRIVCLVLSVVGTAWTADSGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW
NYKCPSGCRMKGLIDEVNQDFTNRINKLKNSLFEYQKNNKDSHSLTTNIMEILRGDFSSA
NNRDNTYNRVSEDLRSRIEVLKRKVIEKVQHIQLLQKNVRAQLVDMKRLEVDIDIKIRSC
RGSCSRALAREVDLKDYEDQQKQLEQVIAKDLLPSRDRQHLPLIKMKPVPDLVPGNFKSQ
LQKVPPEWKALTDMPQMRMELERPGGNEITRGGSTSYGTGSETESPRNPSSAGSWNSGSS
GPGSTGNRNPGSSGTGGTATWKPGSSGPGSTGSWNSGSSGTGSTGNQNPGSPRPGSTGTW
NPGSSERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEVSGNV
SPGTRREYHTEKLVTSKGDKELRTGKEKVTSGSTTTTRRSCSKTVTKTVIGPDGHKEVTK
EVVTSEDGSDCPEAMDLGTLSGIGTLDGFRHRHPDEAAFFDTASTGKTFPGFFSPMLGEF
VSETESRGSESGIFTNTKESSSHHPGIAEFPSRGKSSSYSKQFTSSTSYNRGDSTFESKS
YKMADEAGSEADHEGTHSTKRGHAKSRPVRDCDDVLQTHPSGTQSGIFNIKLPGSSKIFS
VYCDQETSLGGWLLIQQRMDGSLNFNRTWQDYKRGFGSLNDEGEGEFWLGNDYLHLLTQR
GSVLRVELEDWAGNEAYAEYHFRVGSEAEGYALQVSSYEGTAGDALIEGSVEEGAEYTSH
NNMQFSTFDRDADQWEENCAEVYGGGWWYNNCQAANLNGIYYPGGSYDPRNNSPYEIENG
VVWVSFRGADYSLRAVRMKIRPLVTQ

# Drug_Target_35_Reaction:
Not Available

# Drug_Target_35_Signals:
1-19

# Drug_Target_35_Specific_Function:
Fibrinogen has a double function:yielding monomers that polymerize into fibrin and acting as a cofactor in platelet aggregation

# Drug_Target_35_SwissProt_ID:
P02671

# Drug_Target_35_SwissProt_Name:
FIBA_HUMAN

# Drug_Target_35_Synonyms:
Fibrinogen alpha chain precursor

# Drug_Target_35_Theoretical_pI:
5.87

# Drug_Target_35_Transmembrane_Regions:
None

# Drug_Target_36_Cellular_Location:
Cytoplasmic

# Drug_Target_36_Chromosome_Location:
Not Available

# Drug_Target_36_Drug_References:
Not Available

# Drug_Target_36_Essentiality:
Non-Essential

# Drug_Target_36_GenAtlas_ID:
Not Available

# Drug_Target_36_GenBank_ID_Gene:
M93130

# Drug_Target_36_GenBank_ID_Protein:
Not Available

# Drug_Target_36_GeneCard_ID:
Not Available

# Drug_Target_36_Gene_Name:
Not Available

# Drug_Target_36_Gene_Sequence:
>10173 bp
ATGAACAACCAACGGAAAAAGACGGGAAAACCGTCTATCAATATGCTGAAACGCGTGAGA
AACCGTGTGTCAACTGGATCACAGTTGGCGAAGAGATTCTCAAGAGGATTGCTGAACGGC
CAAGGACCAATGAAATTGGTTATGGCGTTTATAGCTTTCCTCAGATTTCTAGCCATTCCA
CCGACAGCAGGAGTCTTGGCTAGATGGGGTACCTTTAAGAAGTCGGGGGCTATTAAGGTC
TTAAAAGGCTTCAAGAAGGAGATCTCAAACATGCTGAGCATTATCAACAAACGGAAAAAG
ACATCGCTCTGTCTCATGATGATGTTACCAGCAACACTTGCTTTCCACTTAACTTCACGA
GATGGAGAGCCGCGCATGATTGTGGGGAAGAATGAAAGAGGAAAATCCCTACTTTTTAAG
ACAGCCTCTGGAATCAACATGTGCACACTCATAGCCATGGATTTGGGAGAGATGTGTGAT
GACACGGTCACTTACAAATGCCCCCACATTACCGAAGTGGAGCCTGAAGACATTGACTGT
TGGTGCAACCTTACATCGACATGGGTGACTTATGGAACATGCAATCAAGCTGGAGAGCAT
AGACGCGATAAGAGATCAGTGGCGTTAGCTCCCCATGTCGGCATGGGACTGGACACACGC
ACTCAAACCTGGATGTCGGCTGAAGGAGCTTGGAGACAAGTCGAGAAGGTAGAGACATGG
GCCCTTAGGCACCCAGGGTTTACCATACTAGCCCTATTTCTTGCCCATTACATAGGCACT
TCCTTGACCCAGAAAGTGGTTATTTTTATACTATTAATGCTGGTTACCCCATCCATGACA
ATGAGATGTGTGGGAGTAGGAAACAGAGATTTTGTGGAAGGCCTATCGGGAGCTACGTGG
GTTGACGTGGTGCTCGAGCACGGTGGGTGTGTGACTACCATGGCTAAGAACAAGCCCACG
CTGGACATAGAGCTTCAGAAGACTGAGGCCACTCAGCTGGCGACCCTAAGGAAGCTATGC
ATTGAGGGAAAAATTACCAACATAACAACCGACTCAAGATGTCCCACCCAAGGGGAAGCG
ATTTTACCTGAGGAGCAGGACCAGAACTACGTGTGTAAGCATACATACGTGGACAGAGGC
TGGGGAAACGGTTGTGGTTTGTTTGGCAAGGGAAGCTTGGTGACATGCGCGAAATTTCAA
TGTTTAGAATCAATAGAGGGAAAAGTGGTGCAACATGAGAACCTCAAATACACCGTCATC
ATCACAGTGCACACAGGAGACCAACACCAGGTGGGAAATGAAACGCAGGGAGTTACGGCT
GAGATAACATCCCAGGCATCAACCGCTGAAGCCATTTTACCTGAATATGGAACCCTCGGG
CTAGAATGCTCACCACGGACAGGTTTGGATTTCAATGAAATGATTTTATTGACAATGAAG
AACAAAGCATGGATGGTACATAGACAATGGTTCTTTGACTTACCCCTACCATGGACATCA
GGAGCTACAACAAAAACACCAACTTGGAACAGGAAAGAGCTTCTTGTGACATTTAAAAAT
GCACATGCAAAAAAGCAAGAAGTAGTTGTCCTTGGATCACAAGAGGGAGCAATGCATACA
GCACTGACAGGAGCTACAGAGATCCAAACCTCAGGAGGCACAAGTATTTTTGCGGGGCAC
TTAAAATGTAGACTCAAGATGGACAAATTGAAACTCAAGGGGATGAGCTATGCAATGTGC
TTGAATACCTTTGTGTTGAAGAAAGAAGTCTCCGAAACGCAGCATGGGACAATACTCATT
AAGGTTGAGTACAAAGGGGAAGATGCACCCTGCAAGATTCCTTTCTCCACGGAGGATGGA
CAAGGGAAAGCTCACAATGGCAGACTGATCACAGCCAATCCAGTGGTGACCAAGAAGGAG
GAGCCTGTCAACATTGAGGCTGAACCTCCTTTTGGGGAAAGTAATATAGTAATTGGAATT
GGAGACAAAGCCCTGAAAATCAACTGGTACAGGAAGGGAAGCTCGATTGGGAAGATGTTC
GAGGCCACTGCCAGAGGTGCAAGGCGCATGGCCATCTTGGGAGACACAGCCTGGGACTTT
GGATCAGTGGGTGGTGTTTTGAATTCATTAGGGAAAATGGTCCACCAAATATTTGGGAGT
GCTTACACAGCCCTATTTAGTGGAGTCTCCTGGATAATGAAAATTGGAATAGGTGTCCTC
TTAACCTGGATAGGGTTGAATTCAAAAAACACTTCTATGTCATTTTCATGCATTGCGATA
GGAATCATTACACTCTATCTGGGGGTCGTGGTGCAAGCTGACATGGGGTGTGTCATAAAC
TGGAAAGGCAAAGAACTCAAATGTGGAAGTGGAATTTTCGTCACTAATGAGGTCCACACC
TGGACAGAGCAATACAAATTTCAAGCAGACTCCCCCAAAAGAGTGGCAACAGCCATTGCA
GGCGCTTGGGAGAATGGAGTGTGCGGAATTAGGTCAACAACCAGAATGGAGAACCTCTTG
TGGAAGCAAATAGCCAATGAACTGAACTACATATTATGGGAAAACGACATTAAATTAACG
GTAGTTGTAGGCGACATAACTGGGGTCTTAGAGCAAGGGAAAAGAACACTAACACCACAA
CCCATGGAGCTAAAATATTCTTGGAAAACATGGGGTTTGGCAAAAATAGTGACAGCTGAA
ACACAAAATTCCTCTTTCATAATAGATGGGCCAAGCACACCGGAGTGTCCAAGTGCCTCA
AGAGCATGGAATGTGTGGGAGGTGGAAGATTACGGGTTCGGAGTTTTCACAACCAACATA
TGGCTGAAACTCCGAGAGGTGTACACCCAACTATGTGACCATAGGCTAATGTCGGCAGCC
GTCAAGGATGAGAGGGCCGTACACGCCGACATGGGCTATTGGATAGAAAGCCAAAAGAAT
GGAAGTTGGAAGCTAGAAAAAGCATCCCTCATAGAGGTGAAAACCTGCACATGGCCAAAA
TCACACACTCTTTGGAGCAATGGTGTGCTAGAGAGTGACATGATTATCCCAAAGAGTCTA
GCTGGTCCCATTTCGCAACACAACCACAGGCCCGGGTACCACACCCAAACGGCAGGACCC
TGGCACTTAGGAAAATTGGAGCTGGACTTCAACTATTGTGAAGGAACAACAGTTGTCATC
TCAGAAAACTGTGGGACAAGAGGCCCATCATTGAGAACAACAACAGTGTCAGGGAAGTTG
ATACACGAATGGTGTTGCCGCTCGTGCACACTTCCTCCCCTGCGATACATGGGAGAAGAC
GGCTGCTGGTATGGCATGGAAATCAGACCCATTAATGAGAAAGAAGAGAACATGGTAAAG
TCTCTAGCCTCAGCAGGGAGTGGAAAGGTGGACAACTTCACAATGGGTGTCTTGTGTTTG
GCAATCCTCTTTGAAGAGGTGATGAGAGGAAAATTTGGGAAAAAACACATGATTGCAGGG
GTTCTCTTCACGTTTGTGCTCCTCCTCTCAGGGCAAATAACATGGAGAGGCATGGCGCAC
ACACTCATAATGATTGGGTCCAACGCCTCTGACAGAATGGGGATGGGCGTCACTTACCTA
GCTCTAATTGCAACATTTAAAATTCAGCCATTCTTGGCTTTGGGATTCTTCCTGAGGAAA
CTGACATCTAGAGAAAATTTATTGCTGGGAGTTGGGTTGGCCATGGCAGCAACGTTACGA
CTGCCAGAGGACATTGAACAAATGGCGAATGGAATTGCTTTGGGGCTCATGGCTCTTAAA
CTGATAACACAATTTGAAACATACCAACTATGGACGGCATTAGTTTCCCTAACGTGTTCA
AATACAATTTTCACGTTGACTGTTGCCTGGAGAACAGCCACTCTGATTTTAGCCGGAATT
TCGCTTTTGCCAGTGTGCCAGTCTTCGAGCATGAGGAAAACAGATTGGCTCCCAATGACT
GTGGCAGCTATGGGAGTTCCACCCCTACCACTTTTTATTTTCAGTCTGAAAGATACACTC
AAAAGGAGAAGCTGGCCACTGAATGAGGGGGTGATGGCAGTTGGACTTGTGAGCATTCTA
GCTAGTTCTCTCCTTAGGAATGATGTGCCCATGGCTGGACCATTAGTGGCTGGGGGCTTG
CTGATAGCGTGCTACGTCATAACTGGCACGTCAGCAGACCTCACTGTAGAAAAAGCAGCA
GATGTAACATGGGAGGAAGAGGCCGAGCAAACAGGAGTGTCCCACAATTTAATGATCACA
GTTGATGATGATGGAACAATGAGAATAAAAGATGACGAGACTGAGAACATCTTAACAGTG
CTTTTAAAAACAGCACTACTAATAGTATCAGGCATCTTTCCATACTCCATACCCGCAACA
ATGTTGGTCTGGCATACTTGGCAAAAGCAAACCCAAAGATCCGGCGTCCTATGGGACGTA
CCCAGCCCCCCAGAGACACAGAAAGCGGAACTGGAAGAAGGGGTCTATAGGATCAAACAG
CAAGGAATTTTTGGGAAAACCCAAGTGGGGGTTGGAGTACAGAAAGAAGGAGTTTTCCAC
ACCATGTGGCACGTCACAAGAGGGGCAGTGTTGACACACAATGGGAAAAGACTGGAACCA
AACTGGGCTAGCGTGAAAAAAGATCTGATTTCATACGGAGGAGGATGGAGATTGAGTGCA
CAATGGCAAAAGGGGGAGGAGGTGCAGGTTATTGCCGTAGAGCCTGGGAAGAACCCAAAG
AACTTTCAAACCATGCCAGGCATTTTTCAGACAACAACAGGGGAAATAGGAGCAATTGCA
CTGGATTTCAAGCCTGGAACTTCAGGATCTCCCATCATAAACAGAGAGGGAAAGGTAGTG
GGACTGTATGGCAATGGAGTGGTTACAAAGAATGGAGGCTATGTTAGTGGAATAGCGCAA
ACAAATGCAGAACCAGATGGACCGACACCAGAGTTGGAAGAAGAGATGTTCAAAAAGCGA
AATCTAACCATAATGGATCTTCATCCTGGGTCAGGAAAGACGCGGAAATATCTTCCAGCT
ATTGTTAGAGAGGCAATCAAGAGACGCTTAAGGACTCTAATTTTGGCACCAACAAGGGTA
GTTGCAGCTGAGATGGAAGAAGCAATGAAAGGGCTCCCAATAAGGTATCAAACAACTGCA
ACAAAATCTGAACACACAGGAAGAGAGATTGTTGATCTAATGTGTCACGCAACGTTCACA
ATGCGCTTGCTGTCACCAGTCAGGGTTCCAAACTACAACTTGATAATAATGGATGAGGCT
CATTTCACAGACCCAGCCAGTATAGCGGCTAGAGGGTACATATCAACTCGTGTAGGAATG
GGAGAGGCAGCCGCAATTTTCATGACAGCAACACCCCCTGGAACAGCTGATGCCTTTCCT
CAGAGCAACGCTCCAATTCAAGATGAAGAGAGAGACATACCGGAACGCTCATGGAATTCA
GGCAATGAATGGATTACTGACTTTGTTGGGAAGACAGTGTGGTTTGTCCCTAGCATCAAA
GCCGGAAATGTCATAGCAAACTGTTTGCGGAAAAATGGAAAAAAGGTCATTCAACTCAGC
AGGAAGACCTTTGACACAGAATATCAAAAGACCAAACTGAATGATTGGGACTTTGTGGTG
ACAACAGACATTTCAGAAATGGGAGCCAATTTCATAGCAGATAGAGTGATCGACCCAAGA
AGATGTCTCAAGCCGGTGATTTTGACAGATGGACCCGAGCGGGTGATCCTGGCTGGACCA
ATGCCAGTCACCGTAGCGAGCGCTGCGCAAAGGAGAGGGAGAGTTGGCAGGAACCCACAA
AAAGAAAATGACCAGTACATATTCATGGGCCAGCCTCTCAACAAAGATGAAGACCATGCT
CACTGGACAGAAGCAAAAATGCTGCTGGACAACATCAACACACCAGAAGGGATTATACCA
GCTCTCTTTGAACCAGAAAGGGAGAAGTCAGCCGCCATAGACGGCGAATACCGCCTGAAG
GGTGAGTCCAGGAAGACTTTCGTGGAACTCATGAGGAGGGGTGACCTCCCAGTTTGGCTA
GCCCATAAAGTAGCATCAGAAGGGATCAAATATACAGATAGAAAATGGTGCTTTGATGGA
GAACGTAATAATCAAATTTTAGAGGAGAATATGGATGTGGAAATCTGGACAAAGGAAGGA
GAAAAGAAAAAACTGAGACCTAGGTGGCTCGATGCCCGCACTTATTCAGATCCTTTAGCA
CTCAAGGAATTCAAGGATTTTGCAGCTGGCAGAAAGTCAATCGCCCTTGATCTTGTGACA
GAAATAGGAAGAGTGCCTTCACACTTAGCCCACAGAACGAGAAACGCCCTGGACAATTTG
GTGATGCTGCACACGTCAGAACATGGCGGTAGGGCCTACAGGCATGCAGTGGAGGAACTA
CCAGAAACGATGGAAACACTCTTACTCCTGGGACTGATGATCTTGTTAACAGGTGGAGCA
ATGCTCTTCTTGATATCAGGTAAAGGGATTGGAAAGACTTCAATAGGACTCATTTGTGTA
ATTGCTTCCAGCGGCATGTTATGGATGGCTGATGTCCCACTCCAATGGATCGCGTCGGCT
ATAGTCCTGGAGTTTTTTATGATGGTGTTGCTCATACCAGAACCAGAAAAGCAGAGAACT
CCCCAAGACAACCAACTCGCATATGTCGTGATAGGCATACTTACATTGGCTGCAATAGTA
GCGGCCAATGAAATGGGACTGTTGGAAACTACAAAGAGAGATTTAGGAATGTCTAAAGAA
CCAGGTGTTGTTTCTCCAACCAGCTATTTGGATGTGGACTTGCACCCAGCATCAGCCTGG
ACATTGTACGCCGTGGCCACAACAGTAATAACACCAATGTTGAGACACACCATAGAGAAT
TCCACAGCAAATGTGTCCCTGGCAGCCATAGCTAACCAGGCAGTGGTCCTGATGGGTTTA
GACAAAGGATGGCCGATATCGAAAATGGACTTGGGCGTACCACTATTGGCACTGGGTTGC
TATTCACAAGTGAACCCACTAACTCTTATAGCGGCAGTACTTTTGCTAGTCACACATTAT
GCAATTATAGGTCCAGGATTGCAGGCAAAAGCCACTCGTGAAGCTCAGAAAAGGACAGCT
GCTGGAATAATGAAGAATCCAACGGTGGATGGAATAATGACAATAGACCTAGATCCTGTA
ATATATGATTCAAAATTTGAAAAGCAACTAGGACAGGTTATGCTCCTGGTTCTGTGTGCA
GTTCAACTTTTGTTAATGAGAACATCATGGGCCTTGTGTGAAGTTCTAACCCTAGCCACA
GGACCAATAACAACACTCTGGGAAGGATCACCTGGGAAGTTCTGGAACACCACGATAGCT
GTTTCCATGGCGAACATCTTTAGAGGGAGCTATTTAGCAGGAGCTGGGCTTGCTCTTTCT
ATCATGAAATCAGTTGGAACAGGAAAGAGAGGAACAGGGTCACAAGGTGAAACCTTAGGA
GAAAAGTGGAAAAAGAAATTAAATCAGTTATCCCGGAAAGAGTTTGACCTTTACAAGAAA
TCCGGAATCACCGAAGTGGATAGAACAGAAGCCAAAGAAGGGTTAAAAAGAGGAGAAATA
ACACACCATGCCGTGTCCAGAGGCAGCGCAAAACTTCAATGGTTCGTGGAGAGAAACATG
GTCATTCCCGAAGGAAGAGTCATAGACTTAGGCTGTGGAAGAGGAGGCTGGTCATATTAC
TGTGCAGGACTGAAAAAAGTTACAGAAGTGCGAGGATACACAAAAGGCGGCCCAGGACAC
GAAGAACCAGTACCTATGTCTACATACGGATGGAACATAGTCAAGTTAATGAGTGGAAAG
GATGTTTTTTATCTGCCACCTGAAAAGTGTGATACCCTATTGTGTGACATTGGAGAATCT
TCACCAAGCCCAACAGTGGAAGAAAGCAGAACCATAAGAGTCTTGAAGATGGTTGAACCA
TGGCTAAAAAACAACCAGTTTTGCATTAAAGTATTGAACCCATACATGCCAACTGTGATT
GAGCACTTAGAAAGACTACAAAGGAAACATGGAGGAATGCTTGTGAGAAATCCACTCTCA
CGAAACTCCACGCACGAAATGTATTGGATATCCAATGGTACAGGCAACATCGTCTCTTCA
GTCAACATGGTATCCAGATTGCTACTGAACAGATTCACAATGACACACAGGAGACCCACC
ATAGAGAAAGATGTGGATTTAGGAGCAGGAACCCGACATGTCAATGCGGAACCAGAAACA
CCCAACATGGATGTCATTGGGGAAAGAATAAAAAGGATCAAAGAGGAGCATAGTTCAACA
TGGCACTATGATGATGAAAATCCTTACAAAACGTGGGCTTACCATGGATCCTATGAAGTA
AAAGCCACAGGCTCAGCCTCCTCCATGATAAATGGAGTCGTGAAACTCCTCACAAAACCA
TGGGATGTGGTGCCCATGGTGACACAGATGGCAATGACAGATACAACTCCATTTGGCCAG
CAAAGAGTTTTTAAAGAGAAAGTGGACACCAGGACACCTAGGCCCATGCCAGGAACAAGA
AAGGTTATGGAGATCACAGCGGAGTGGCTTTGGAGGACCCTGGGAAGGAACAAAAGACCC
AGATTATGCACAAGGGAGGAGTTCACAAAGAAGGTCAGAACCAACGCAGCTATGGGCGCT
GTCTTCACAGAAGAGAACCAATGGGACAGTGCGAGAGCTGCTGTTGAGGACGAAGAATTT
TGGAAACTTGTGGACAGAGAACGTGAACTCCACAAACTGGGCAAGTGTGGAAGCTGCGTT
TACAACATGATGGGCAAGAGAGAGAAAAAACTTGGAGAGTTTGGTAAAGCAAAAGGCAGT
AGGGCTATATGGTACATGTGGTTGGGAGCCAGGTACCTTGAGTTCGAGGCGCTCGGATTC
CTCAATGAAGACCACTGGTTCTCGCGTGAAAACTCTTACAGTGGAGTAGAAGGAGAAGGA
CTGCACAAGCTGGGATACATCTTGAGAGATATTTCCAAGATACCCGGAGGAGCCATGTAT
GCTGATGACACAGCCGGTTGGGACACAAGAATAACAGAAGATGACCTGCACAATGAGGAA
AAAATCACACAGCAGATGGACCCTGAACACAGGCAGCTAGCGAACGCTATATTCAAGCTC
ACATACCAAAACAAAGTGGTCAAAGTCCAACGACCAACTCCAAAGGGCACGGTAATGGAC
ATCATATCTAGGAAAGACCAAAGAGGCAGTGGACAGGTGGGAACTTATGGTCTGAACACA
TTCACCAACATGGAAGCCCAGCTAATCAGACAAATGGAAGGAGAAGGCGTGTTGTCAAAG
GCAGACCTCGAGAACCCCCATCCGCTAGAGAAGAAAATTACACAATGGTTGGAAACTAAA
GGAGTGGAGAGGTTAAAAAGAATGGCCATCAGCGGGGATGATTGCGTAGTGAAACCAATC
GACGACAGATTCGCCAATGCCCTGCTTGCCCTGAACGATATGGGAAAGGTTAGGAAGGAC
ATACCTCAATGGCAGCCATCAAAGGGATGGCATGATTGGCAACAGGTCCCTTTCTGCTCC
CACCACTTTCATGAATTGATCATGAAAGATGGAAGAAAGTTGGTAGTTCCCTGCAGACCC
CAGGACGAACTAATAGGAAGAGCGAGAATCTCTCAAGGAGCAGGATGGAGCCTTAGAGAA
ACTGCATGTCTAGGGAAAGCCTACGCTCAAATGTGGACTCTCATGTATTTTCACAGAAGA
GATCTTAGACTAGCATCCAACGCCATATGTTCAGCAGTACCAGTCCATTGGGTCCCCACG
AGCAGAACGACATGGTCTATTCATGCTCACCATCAGTGGATGACTACAGAAGACATGCTT
ACTGTCTGGAACAGGGTGTGGATAGAGGACAATCCATGGATGGAAGACAAAACTCCAGTC
ACAACGTGGGAAGATGTTCCATATCTAGGAAAGAGAGAAGACCAATGGTGCGGATCACTC
ATAGGTCTCACTTCCAGAGCAACCTGGGCCCAGAACATACTCACAGCAATCCAACAGGTG
AGAAGCCTCATAGGCAATGAAGAGTTTCTGGACTACATGCCTTCGATGAAGAGATTCAGG
AAGGAGGAGGAGTCAGAGGGAGCCATTTGGTAA

# Drug_Target_36_General_Function:
Involved in nucleic acid binding

# Drug_Target_36_General_References:
2345967	Osatomi K, Sumiyoshi H: Complete nucleotide sequence of dengue type 3 virus genome RNA. Virology. 1990 Jun;176(2):643-7.

# Drug_Target_36_HGNC_ID:
Not Available

# Drug_Target_36_HPRD_ID:
Not Available

# Drug_Target_36_ID:
4783

# Drug_Target_36_Locus:
Not Available

# Drug_Target_36_Molecular_Weight:
378068

# Drug_Target_36_Name:
Genome polyprotein

# Drug_Target_36_Number_of_Residues:
3390

# Drug_Target_36_PDB_ID:
1UZG

# Drug_Target_36_Pathway:
Not Available

# Drug_Target_36_Pfam_Domain_Function:
PF00271	Helicase_C
PF00869	Flavi_glycoprot
PF00948	Flavi_NS1
PF00949	Peptidase_S7
PF00972	Flavi_NS5
PF01002	Flavi_NS2B
PF01003	Flavi_capsid
PF01004	Flavi_M
PF01005	Flavi_NS2A
PF01349	Flavi_NS4B
PF01350	Flavi_NS4A
PF01570	Flavi_propep
PF01728	FtsJ
PF02832	Flavi_glycop_C
PF07652	Flavi_DEAD

# Drug_Target_36_Protein_Sequence:
>Genome polyprotein
MNNQRKKTGKPSINMLKRVRNRVSTGSQLAKRFSRGLLNGQGPMKLVMAFIAFLRFLAIP
PTAGVLARWGTFKKSGAIKVLKGFKKEISNMLSIINKRKKTSLCLMMMLPATLAFHLTSR
DGEPRMIVGKNERGKSLLFKTASGINMCTLIAMDLGEMCDDTVTYKCPHITEVEPEDIDC
WCNLTSTWVTYGTCNQAGEHRRDKRSVALAPHVGMGLDTRTQTWMSAEGAWRQVEKVETW
ALRHPGFTILALFLAHYIGTSLTQKVVIFILLMLVTPSMTMRCVGVGNRDFVEGLSGATW
VDVVLEHGGCVTTMAKNKPTLDIELQKTEATQLATLRKLCIEGKITNITTDSRCPTQGEA
ILPEEQDQNYVCKHTYVDRGWGNGCGLFGKGSLVTCAKFQCLESIEGKVVQHENLKYTVI
ITVHTGDQHQVGNETQGVTAEITSQASTAEAILPEYGTLGLECSPRTGLDFNEMILLTMK
NKAWMVHRQWFFDLPLPWTSGATTKTPTWNRKELLVTFKNAHAKKQEVVVLGSQEGAMHT
ALTGATEIQTSGGTSIFAGHLKCRLKMDKLKLKGMSYAMCLNTFVLKKEVSETQHGTILI
KVEYKGEDAPCKIPFSTEDGQGKAHNGRLITANPVVTKKEEPVNIEAEPPFGESNIVIGI
GDKALKINWYRKGSSIGKMFEATARGARRMAILGDTAWDFGSVGGVLNSLGKMVHQIFGS
AYTALFSGVSWIMKIGIGVLLTWIGLNSKNTSMSFSCIAIGIITLYLGVVVQADMGCVIN
WKGKELKCGSGIFVTNEVHTWTEQYKFQADSPKRVATAIAGAWENGVCGIRSTTRMENLL
WKQIANELNYILWENDIKLTVVVGDITGVLEQGKRTLTPQPMELKYSWKTWGLAKIVTAE
TQNSSFIIDGPSTPECPSASRAWNVWEVEDYGFGVFTTNIWLKLREVYTQLCDHRLMSAA
VKDERAVHADMGYWIESQKNGSWKLEKASLIEVKTCTWPKSHTLWSNGVLESDMIIPKSL
AGPISQHNHRPGYHTQTAGPWHLGKLELDFNYCEGTTVVISENCGTRGPSLRTTTVSGKL
IHEWCCRSCTLPPLRYMGEDGCWYGMEIRPINEKEENMVKSLASAGSGKVDNFTMGVLCL
AILFEEVMRGKFGKKHMIAGVLFTFVLLLSGQITWRGMAHTLIMIGSNASDRMGMGVTYL
ALIATFKIQPFLALGFFLRKLTSRENLLLGVGLAMAATLRLPEDIEQMANGIALGLMALK
LITQFETYQLWTALVSLTCSNTIFTLTVAWRTATLILAGISLLPVCQSSSMRKTDWLPMT
VAAMGVPPLPLFIFSLKDTLKRRSWPLNEGVMAVGLVSILASSLLRNDVPMAGPLVAGGL
LIACYVITGTSADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILTV
LLKTALLIVSGIFPYSIPATMLVWHTWQKQTQRSGVLWDVPSPPETQKAELEEGVYRIKQ
QGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSA
QWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVV
GLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEMFKKRNLTIMDLHPGSGKTRKYLPA
IVREAIKRRLRTLILAPTRVVAAEMEEAMKGLPIRYQTTATKSEHTGREIVDLMCHATFT
MRLLSPVRVPNYNLIIMDEAHFTDPASIAARGYISTRVGMGEAAAIFMTATPPGTADAFP
QSNAPIQDEERDIPERSWNSGNEWITDFVGKTVWFVPSIKAGNVIANCLRKNGKKVIQLS
RKTFDTEYQKTKLNDWDFVVTTDISEMGANFIADRVIDPRRCLKPVILTDGPERVILAGP
MPVTVASAAQRRGRVGRNPQKENDQYIFMGQPLNKDEDHAHWTEAKMLLDNINTPEGIIP
ALFEPEREKSAAIDGEYRLKGESRKTFVELMRRGDLPVWLAHKVASEGIKYTDRKWCFDG
ERNNQILEENMDVEIWTKEGEKKKLRPRWLDARTYSDPLALKEFKDFAAGRKSIALDLVT
EIGRVPSHLAHRTRNALDNLVMLHTSEHGGRAYRHAVEELPETMETLLLLGLMILLTGGA
MLFLISGKGIGKTSIGLICVIASSGMLWMADVPLQWIASAIVLEFFMMVLLIPEPEKQRT
PQDNQLAYVVIGILTLAAIVAANEMGLLETTKRDLGMSKEPGVVSPTSYLDVDLHPASAW
TLYAVATTVITPMLRHTIENSTANVSLAAIANQAVVLMGLDKGWPISKMDLGVPLLALGC
YSQVNPLTLIAAVLLLVTHYAIIGPGLQAKATREAQKRTAAGIMKNPTVDGIMTIDLDPV
IYDSKFEKQLGQVMLLVLCAVQLLLMRTSWALCEVLTLATGPITTLWEGSPGKFWNTTIA
VSMANIFRGSYLAGAGLALSIMKSVGTGKRGTGSQGETLGEKWKKKLNQLSRKEFDLYKK
SGITEVDRTEAKEGLKRGEITHHAVSRGSAKLQWFVERNMVIPEGRVIDLGCGRGGWSYY
CAGLKKVTEVRGYTKGGPGHEEPVPMSTYGWNIVKLMSGKDVFYLPPEKCDTLLCDIGES
SPSPTVEESRTIRVLKMVEPWLKNNQFCIKVLNPYMPTVIEHLERLQRKHGGMLVRNPLS
RNSTHEMYWISNGTGNIVSSVNMVSRLLLNRFTMTHRRPTIEKDVDLGAGTRHVNAEPET
PNMDVIGERIKRIKEEHSSTWHYDDENPYKTWAYHGSYEVKATGSASSMINGVVKLLTKP
WDVVPMVTQMAMTDTTPFGQQRVFKEKVDTRTPRPMPGTRKVMEITAEWLWRTLGRNKRP
RLCTREEFTKKVRTNAAMGAVFTEENQWDSARAAVEDEEFWKLVDRERELHKLGKCGSCV
YNMMGKREKKLGEFGKAKGSRAIWYMWLGARYLEFEALGFLNEDHWFSRENSYSGVEGEG
LHKLGYILRDISKIPGGAMYADDTAGWDTRITEDDLHNEEKITQQMDPEHRQLANAIFKL
TYQNKVVKVQRPTPKGTVMDIISRKDQRGSGQVGTYGLNTFTNMEAQLIRQMEGEGVLSK
ADLENPHPLEKKITQWLETKGVERLKRMAISGDDCVVKPIDDRFANALLALNDMGKVRKD
IPQWQPSKGWHDWQQVPFCSHHFHELIMKDGRKLVVPCRPQDELIGRARISQGAGWSLRE
TACLGKAYAQMWTLMYFHRRDLRLASNAICSAVPVHWVPTSRTTWSIHAHHQWMTTEDML
TVWNRVWIEDNPWMEDKTPVTTWEDVPYLGKREDQWCGSLIGLTSRATWAQNILTAIQQV
RSLIGNEEFLDYMPSMKRFRKEEESEGAIW

# Drug_Target_36_Reaction:
Not Available

# Drug_Target_36_Signals:
None

# Drug_Target_36_Specific_Function:
The small proteins NS2A, NS4A and NS4B are hydrophobic, suggesting a possible membrane-related function. NS5 may play a role in the viral RNA replication. The NS2B/NS3 protease complex processes the viral polyprotein

# Drug_Target_36_SwissProt_ID:
P27915

# Drug_Target_36_SwissProt_Name:
POLG_DEN3P

# Drug_Target_36_Synonyms:
Not Available

# Drug_Target_36_Theoretical_pI:
8.65

# Drug_Target_36_Transmembrane_Regions:
46-67
266-280
724-746
753-771
1156-1175

# Drug_Target_37_Cellular_Location:
Not Available

# Drug_Target_37_Chromosome_Location:
Not Available

# Drug_Target_37_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_37_Essentiality:
Non-Essential

# Drug_Target_37_GenAtlas_ID:
SERPIND1

# Drug_Target_37_GenBank_ID_Gene:
M12849

# Drug_Target_37_GenBank_ID_Protein:
183910

# Drug_Target_37_GeneCard_ID:
SERPIND1

# Drug_Target_37_Gene_Name:
SERPIND1

# Drug_Target_37_Gene_Sequence:
>1500 bp
ATGAAACACTCATTAAACGCACTTCTCATTTTCCTCATCATAACATCTGCGTGGGGTGGG
AGCAAAGGCCCGCTGGATCAGCTAGAGAAAGGAGGGGAAACTGCTCAGTCTGCAGATCCC
CAGTGGGAGCAGTTAAATAACAAAAACCTGAGCATGCCTCTTCTCCCTGCCGACTTCCAC
AAGGAAAACACCGTCACCAACGACTGGATTCCAGAGGGGGAGGAGGACGACGACTATCTG
GACCTGGAGAAGATATTCAGTGAAGACGACGACTACATCGACATCGTCGACAGTCTGTCA
GTTTCCCCGACAGACTCTGATGTGAGTGCTGGGAACATCCTCCAGCTTTTTCATGGCAAG
AGCCGGATCCAGCGTCTTAACATCCTCAACGCCAAGTTCGCTTTCAACCTCTACCGAGTG
CTGAAAGACCAGGTCAACACTTTCGATAACATCTTCATAGCACCCGTTGGCATTTCTACT
GCGATGGGTATGATTTCCTTAGGTCTGAAGGGAGAGACCCATGAACAAGTGCACTCGATT
TTGCATTTTAAAGACTTTGTTAATGCCAGCAGCAAGTATGAAATCACGACCATTCATAAT
CTCTTCCGTAAGCTGACTCATCGCCTCTTCAGGAGGAATTTTGGGTACACACTGCGGTCA
GTCAATGACCTTTATATCCAGAAGCAGTTTCCAATCCTGCTTGACTTCAGAACTAAAGTA
AGAGAGTATTACTTTGCTGAGGCCCAGATAGCTGACTTCTCAGACCCTGCCTTCATATCA
AAAACCAACAACCACATCATGAAGCTCACCAAGGGCCTCATAAAAGATGCTCTGGAGAAT
ATAGACCCTGCTACCCAGATGATGATTCTCAACTGCATCTACTTCAAAGGATCCTGGGTG
AATAAATTCCCAGTGGAAATGACACACAACCACAACTTCCGGCTGAATGAGAGAGAGGTA
GTTAAGGTTTCCATGATGCAGACCAAGGGGAACTTCCTCGCAGCAAATGACCAGGAGCTG
GACTGCGACATCCTCCAGCTGGAATACGTGGGGGGCATCAGCATGCTAATTGTGGTCCCA
CACAAGATGTCTGGGATGAAGACCCTCGAAGCGCAACTGACACCCCGGGTGGTGGAGAGA
TGGCAAAAAAGCATGACAAACAGAACTCGAGAAGTGCTTCTGCCGAAATTCAAGCTGGAG
AAGAACTACAATCTAGTGGAGTCCCTGAAGTTGATGGGGATCAGGATGCTGTTTGACAAA
AATGGCAACATGGCAGGCATCTCAGACCAAAGGATCGCCATCGACCTGTTCAAGCACCAA
GGCACGATCACAGTGAACGAGGAAGGCACCCAAGCCACCACTGTGACCACGGTGGGGTTC
ATGCCGCTGTCCACCCAAGTCCGCTTCACTGTCGACCGCCCCTTTCTTTTCCTCATCTAC
GAGCACCGCACCAGCTGCCTGCTCTTCATGGGAAGAGTGGCCAACCCCAGCAGGTCCTAG

# Drug_Target_37_General_Function:
Involved in serine-type endopeptidase inhibitor activity

# Drug_Target_37_General_References:
10391209	Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Shaw N, Lane CR, Lim EP, Kalyanaraman N, Nemesh J, Ziaugra L, Friedland L, Rolfe A, Warrington J, Lipshutz R, Daley GQ, Lander ES: Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet. 1999 Jul;22(3):231-8.
1671335	Herzog R, Lutz S, Blin N, Marasa JC, Blinder MA, Tollefsen DM: Complete nucleotide sequence of the gene for human heparin cofactor II and mapping to chromosomal band 22q11. Biochemistry. 1991 Feb 5;30(5):1350-7.
1939083	Van Deerlin VM, Tollefsen DM: The N-terminal acidic domain of heparin cofactor II mediates the inhibition of alpha-thrombin in the presence of glycosaminoglycans. J Biol Chem. 1991 Oct 25;266(30):20223-31.
1985958	Church FC, Pratt CW, Hoffman M: Leukocyte chemoattractant peptides from the serpin heparin cofactor II. J Biol Chem. 1991 Jan 15;266(2):704-9.
2104620	Blinder MA, Tollefsen DM: Site-directed mutagenesis of arginine 103 and lysine 185 in the proposed glycosaminoglycan-binding site of heparin cofactor II. J Biol Chem. 1990 Jan 5;265(1):286-91.
2647747	Blinder MA, Andersson TR, Abildgaard U, Tollefsen DM: Heparin cofactor IIOslo. Mutation of Arg-189 to His decreases the affinity for dermatan sulfate. J Biol Chem. 1989 Mar 25;264(9):5128-33.
2841345	Ragg H, Preibisch G: Structure and expression of the gene coding for the human serpin hLS2. J Biol Chem. 1988 Aug 25;263(24):12129-34.
2894851	Blinder MA, Marasa JC, Reynolds CH, Deaven LL, Tollefsen DM: Heparin cofactor II: cDNA sequence, chromosome localization, restriction fragment length polymorphism, and expression in Escherichia coli. Biochemistry. 1988 Jan 26;27(2):752-9.
3003690	Ragg H: A new member of the plasma protease inhibitor gene family. Nucleic Acids Res. 1986 Jan 24;14(2):1073-88.
3755044	Inhorn RC, Tollefsen DM: Isolation and characterization of a partial cDNA clone for heparin cofactor II1. Biochem Biophys Res Commun. 1986 May 29;137(1):431-6.
3907702	Griffith MJ, Noyes CM, Tyndall JA, Church FC: Structural evidence for leucine at the reactive site of heparin cofactor II. Biochemistry. 1985 Nov 19;24(24):6777-82.

# Drug_Target_37_HGNC_ID:
HGNC:4838

# Drug_Target_37_HPRD_ID:
00795

# Drug_Target_37_ID:
852

# Drug_Target_37_Locus:
22q11.2|22q11.21

# Drug_Target_37_Molecular_Weight:
57071

# Drug_Target_37_Name:
Heparin cofactor 2

# Drug_Target_37_Number_of_Residues:
499

# Drug_Target_37_PDB_ID:
1JMJ

# Drug_Target_37_Pathway:
Not Available

# Drug_Target_37_Pfam_Domain_Function:
PF00079	Serpin

# Drug_Target_37_Protein_Sequence:
>Heparin cofactor 2 precursor
MKHSLNALLIFLIITSAWGGSKGPLDQLEKGGETAQSADPQWEQLNNKNLSMPLLPADFH
KENTVTNDWIPEGEEDDDYLDLEKIFSEDDDYIDIVDSLSVSPTDSDVSAGNILQLFHGK
SRIQRLNILNAKFAFNLYRVLKDQVNTFDNIFIAPVGISTAMGMISLGLKGETHEQVHSI
LHFKDFVNASSKYEITTIHNLFRKLTHRLFRRNFGYTLRSVNDLYIQKQFPILLDFKTKV
REYYFAEAQIADFSDPAFISKTNNHIMKLTKGLIKDALENIDPATQMMILNCIYFKGSWV
NKFPVEMTHNHNFRLNEREVVKVSMMQTKGNFLAANDQELDCDILQLEYVGGISMLIVVP
HKMSGMKTLEAQLTPRVVERWQKSMTNRTREVLLPKFKLEKNYNLVESLKLMGIRMLFDK
NGNMAGISDQRIAIDLFKHQGTITVNEEGTQATTVTTVGFMPLSTQVRFTVDRPFLFLIY
EHRTSCLLFMGRVANPSRS

# Drug_Target_37_Reaction:
Not Available

# Drug_Target_37_Signals:
1-19

# Drug_Target_37_Specific_Function:
Peptides at the N-terminal of HC-II have chemotactic activity for both monocytes and neutrophils

# Drug_Target_37_SwissProt_ID:
P05546

# Drug_Target_37_SwissProt_Name:
HEP2_HUMAN

# Drug_Target_37_Synonyms:
HC-II
HLS2
Heparin cofactor 2 precursor
Heparin cofactor II
Protease inhibitor leuserpin 2

# Drug_Target_37_Theoretical_pI:
6.89

# Drug_Target_37_Transmembrane_Regions:
None

# Drug_Target_38_Cellular_Location:
Membrane

# Drug_Target_38_Chromosome_Location:
Not Available

# Drug_Target_38_Drug_References:
Not Available

# Drug_Target_38_Essentiality:
Non-Essential

# Drug_Target_38_GenAtlas_ID:
NPR3

# Drug_Target_38_GenBank_ID_Gene:
X52282

# Drug_Target_38_GenBank_ID_Protein:
Not Available

# Drug_Target_38_GeneCard_ID:
Not Available

# Drug_Target_38_Gene_Name:
NPR3

# Drug_Target_38_Gene_Sequence:
>1623 bp
ATGCCGTCTCTGCTGGTGCTCACTTTCTCCCCGTGCGTACTACTCGGCTGGGCGTTGCTG
GCCGGCGGCACCGGTGGCGGTGGCGTTGGCGGCGGCGGCGGTGGCGCGGGCATAGGCGGC
GGACGCCAGGAGAGAGAGGCGCTGCCGCCACAGAAGATCGAGGTGCTGGTGTTACTGCCC
CAGGATGACTCGTACTTGTTTTCACTCACCCGGGTGCGGCCGGCCATCGAGTATGCTCTG
CGCAGCGTGGAGGGCAACGGGACTGGGAGGCGGCTTCTGCCGCCGGGCACTCGCTTCCAG
GTGGCTTACGAGGATTCAGACTGTGGGAACCGTGCGCTCTTCAGCTTGGTGGACCGCGTG
GCGGCGGCGCGGGGCGCCAAGCCAGACCTTATCCTGGGGCCAGTGTGCGAGTATGCAGCA
GCGCCAGTGGCCCGGCTTGCATCGCACTGGGACCTGCCCATGCTGTCGGCTGGGGCGCTG
GCCGCTGGCTTCCAGCACAAGGACTCTGAGTACTCGCACCTCACGCGCGTGGCGCCCGCC
TACGCCAAGATGGGCGAGATGATGCTCGCCCTGTTCCGCCACCACCACTGGAGCCGCGCT
GCACTGGTCTACAGCGACGACAAGCTGGAGCGGAACTGCTACTTCACCCTCGAGGGGGTC
CACGAGGTCTTCCAGGAGGAGGGTTTGCACACGTCCATCTACAGTTTCGACGAGACCAAA
GACTTGGATCTGGAAGACATCGTGCGCAATATCCAGGCCAGTGAGAGAGTGGTGATCATG
TGTGCGAGCAGTGACACCATCCGGAGCATCATGCTGGTGGCGCACAGGCATGGCATGACC
AGTGGAGACTACGCCTTCTTCAACATTGAGCTCTTCAACAGCTCTTCCTATGGAGATGGC
TCATGGAAGAGAGGAGACAAACACGACTTTGAAGCTAAGCAAGCATACTCGTCCCTCCAG
ACAGTCACTCTACTGAGGACAGTGAAACCTGAGTTTGAGAAGTTTTCCATGGAGGTGAAA
AGTTCAGTTGAGAAACAAGGGCTCAATATGGAGGATTACGTTAACATGTTTGTTGAAGGA
TTCCACGATGCCATCCTCCTCTACGTCTTGGCTCTACATGAAGTACTCAGAGCTGGTTAC
AGCAAAAAGGATGGAGGGAAAATTATACAGCAGACTTGGAACAGAACATTTGAAGGTATC
GCCGGGCAGGTGTCCATAGATGCCAACGGAGACCGATATGGGGATTTCTCTGTGATTGCC
ATGACTGATGTGGAGGCGGGCACCCAGGAGGTTATTGGTGATTATTTTGGAAAAGAAGGT
CGTTTTGAAATGCGGCCGAATGTCAAATATCCTTGGGGCCCTTTAAAACTGAGAATAGAT
GAAAACCGAATTGTAGAGCATACAAACAGCTCTCCCTGCAAATCATGTGGCCTAGAAGAA
TCGGCAGTGACAGGAATTGTCGTGGGGGCTTTACTAGGAGCTGGCTTGCTAATGGCCTTC
TACTTTTTCAGGAAGAAATACAGAATAACCATTGAGAGGCGAACCCAGCAAGAAGAAAGT
AACCTTGGAAAACATCGGGAATTACGGGAAGATTCCATCAGATCCCATTTTTCAGTAGCT
TAA

# Drug_Target_38_General_Function:
Involved in peptide receptor activity, G-protein coupled

# Drug_Target_38_General_References:
2162522	Lowe DG, Camerato TR, Goeddel DV: cDNA sequence of the human atrial natriuretic peptide clearance receptor. Nucleic Acids Res. 1990 Jun 11;18(11):3412.
2169733	Porter JG, Arfsten A, Fuller F, Miller JA, Gregory LC, Lewicki JA: Isolation and functional expression of the human atrial natriuretic peptide clearance receptor cDNA. Biochem Biophys Res Commun. 1990 Sep 14;171(2):796-803.
7727388	Stults JT, O'Connell KL, Garcia C, Wong S, Engel AM, Garbers DL, Lowe DG: The disulfide linkages and glycosylation sites of the human natriuretic peptide receptor-C homodimer. Biochemistry. 1994 Sep 20;33(37):11372-81.

# Drug_Target_38_HGNC_ID:
HGNC:7945

# Drug_Target_38_HPRD_ID:
Not Available

# Drug_Target_38_ID:
4193

# Drug_Target_38_Locus:
5p14-p13

# Drug_Target_38_Molecular_Weight:
59809

# Drug_Target_38_Name:
Atrial natriuretic peptide clearance receptor

# Drug_Target_38_Number_of_Residues:
541

# Drug_Target_38_PDB_ID:
1JDP

# Drug_Target_38_Pathway:
Not Available

# Drug_Target_38_Pfam_Domain_Function:
PF01094	ANF_receptor

# Drug_Target_38_Protein_Sequence:
>Atrial natriuretic peptide clearance receptor
MPSLLVLTFSPCVLLGWALLAGGTGGGGVGGGGGGAGIGGGRQEREALPPQKIEVLVLLP
QDDSYLFSLTRVRPAIEYALRSVEGNGTGRRLLPPGTRFQVAYEDSDCGNRALFSLVDRV
AAARGAKPDLILGPVCEYAAAPVARLASHWDLPMLSAGALAAGFQHKDSEYSHLTRVAPA
YAKMGEMMLALFRHHHWSRAALVYSDDKLERNCYFTLEGVHEVFQEEGLHTSIYSFDETK
DLDLEDIVRNIQASERVVIMCASSDTIRSIMLVAHRHGMTSGDYAFFNIELFNSSSYGDG
SWKRGDKHDFEAKQAYSSLQTVTLLRTVKPEFEKFSMEVKSSVEKQGLNMEDYVNMFVEG
FHDAILLYVLALHEVLRAGYSKKDGGKIIQQTWNRTFEGIAGQVSIDANGDRYGDFSVIA
MTDVEAGTQEVIGDYFGKEGRFEMRPNVKYPWGPLKLRIDENRIVEHTNSSPCKSSGGLE
ESAVTGIVVGALLGAGLLMAFYFFRKKYRITIERRTQQEESNLGKHRELREDSIRSHFSV
A

# Drug_Target_38_Reaction:
Not Available

# Drug_Target_38_Signals:
1-26

# Drug_Target_38_Specific_Function:
Receptor for natriuretic peptide hormones. Has broad specificity and can bind several distinct natriuretic peptides, including atrial natriuretic peptide (NPPA) and brain natriuretic peptide (NPPB). Does not have guanylate cyclase activity

# Drug_Target_38_SwissProt_ID:
P17342

# Drug_Target_38_SwissProt_Name:
ANPRC_HUMAN

# Drug_Target_38_Synonyms:
ANP-C
ANPRC
Atrial natriuretic peptide C-type receptor
Atrial natriuretic peptide clearance receptor precursor
NPR-C

# Drug_Target_38_Theoretical_pI:
6.31

# Drug_Target_38_Transmembrane_Regions:
482-504

# Drug_Target_39_Cellular_Location:
Isoform A, isoform B, isoform C:Cell membrane
single-pass type I membrane protein. Isoform G, isofo

# Drug_Target_39_Chromosome_Location:
Not Available

# Drug_Target_39_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_39_Essentiality:
Non-Essential

# Drug_Target_39_GenAtlas_ID:
CEACAM1

# Drug_Target_39_GenBank_ID_Gene:
J03858

# Drug_Target_39_GenBank_ID_Protein:
179440

# Drug_Target_39_GeneCard_ID:
CEACAM1

# Drug_Target_39_Gene_Name:
CEACAM1

# Drug_Target_39_Gene_Sequence:
>1581 bp
ATGGGGCACCTCTCAGCCCCACTTCACAGAGTGCGTGTACCCTGGCAGGGGCTTCTGCTC
ACAGCCTCACTTCTAACCTTCTGGAACCCGCCCACCACTGCCCAGCTCACTACTGAATCC
ATGCCATTCAATGTTGCAGAGGGGAAGGAGGTTCTTCTCCTTGTCCACAATCTGCCCCAG
CAACTTTTTGGCTACAGCTGGTACAAAGGGGAAAGAGTGGATGGCAACCGTCAAATTGTA
GGATATGCAATAGGAACTCAACAAGCTACCCCAGGGCCCGCAAACAGCGGTCGAGAGACA
ATATACCCCAATGCATCCCTGCTGATCCAGAACGTCACCCAGAATGACACAGGATTCTAC
ACCCTACAAGTCATAAAGTCAGATCTTGTGAATGAAGAAGCAACTGGACAGTTCCATGTA
TACCCGGAGCTGCCCAAGCCCTCCATCTCCAGCAACAACTCCAACCCTGTGGAGGACAAG
GATGCTGTGGCCTTCACCTGTGAACCTGAGACTCAGGACACAACCTACCTGTGGTGGATA
AACAATCAGAGCCTCCCGGTCAGTCCCAGGCTGCAGCTGTCCAATGGCAACAGGACCCTC
ACTCTACTCAGTGTCACAAGGAATGACACAGGACCCTATGAGTGTGAAATACAGAACCCA
GTGAGTGCGAACCGCAGTGACCCAGTCACCTTGAATGTCACCTATGGCCCGGACACCCCC
ACCATTTCCCCTTCAGACACCTATTACCGTCCAGGGGCAAACCTCAGCCTCTCCTGCTAT
GCAGCCTCTAACCCACCTGCACAGTACTCCTGGCTTATCAATGGAACATTCCAGCAAAGC
ACACAAGAGCTCTTTATCCCTAACATCACTGTGAATAATAGTGGATCCTATACCTGCCAC
GCCAATAACTCAGTCACTGGCTGCAACAGGACCACAGTCAAGACGATCATAGTCACTGAG
CTAAGTCCAGTAGTAGCAAAGCCCCAAATCAAAGCCAGCAAGACCACAGTCACAGGAGAT
AAGGACTCTGTGAACCTGACCTGCTCCACAAATGACACTGGAATCTCCATCCGTTGGTTC
TTCAAAAACCAGAGTCTCCCGTCCTCGGAGAGGATGAAGCTGTCCCAGGGCAACACCACC
CTCAGCATAAACCCTGTCAAGAGGGAGGATGCTGGGACGTATTGGTGTGAGGTCTTCAAC
CCAATCAGTAAGAACCAAAGCGACCCCATCATGCTGAACGTAAACTATAATGCTCTACCA
CAAGAAAATGGCCTCTCACCTGGGGCCATTGCTGGCATTGTGATTGGAGTAGTGGCCCTG
GTTGCTCTGATAGCAGTAGCCCTGGCATGTTTTCTGCATTTCGGGAAGACCGGCAGGGCA
AGCGACCAGCGTGATCTCACAGAGCACAAACCCTCAGTCTCCAACCACACTCAGGACCAC
TCCAATGACCCACCTAACAAGATGAATGAAGTTACTTATTCTACCCTGAACTTTGAAGCC
CAGCAACCCACACAACCAACTTCAGCCTCCCCATCCCTAACAGCCACAGAAATAATTTAT
TCAGAAGTAAAAAAGCAGTAA

# Drug_Target_39_General_Function:
Not Available

# Drug_Target_39_General_References:
2025273	Kuroki M, Arakawa F, Matsuo Y, Oikawa S, Nakazato H, Matsuoka Y: Three novel molecular forms of biliary glycoprotein deduced from cDNA clones from a human leukocyte library. Biochem Biophys Res Commun. 1991 Apr 30;176(2):578-85.
2457922	Hinoda Y, Neumaier M, Hefta SA, Drzeniek Z, Wagener C, Shively L, Hefta LJ, Shively JE, Paxton RJ: Molecular cloning of a cDNA coding biliary glycoprotein I: primary structure of a glycoprotein immunologically crossreactive with carcinoembryonic antigen. Proc Natl Acad Sci U S A. 1988 Sep;85(18):6959-63.
2537311	Barnett TR, Kretschmer A, Austen DA, Goebel SJ, Hart JT, Elting JJ, Kamarck ME: Carcinoembryonic antigens: alternative splicing accounts for the multiple mRNAs that code for novel members of the carcinoembryonic antigen family. J Cell Biol. 1989 Feb;108(2):267-76.
7628460	Nedellec P, Turbide C, Beauchemin N: Characterization and transcriptional activity of the mouse biliary glycoprotein 1 gene, a carcinoembryonic antigen-related gene. Eur J Biochem. 1995 Jul 1;231(1):104-14.
8055923	Hauck W, Nedellec P, Turbide C, Stanners CP, Barnett TR, Beauchemin N: Transcriptional control of the human biliary glycoprotein gene, a CEA gene family member down-regulated in colorectal carcinomas. Eur J Biochem. 1994 Jul 15;223(2):529-41.
8423792	Barnett TR, Drake L, Pickle W 2nd: Human biliary glycoprotein gene: characterization of a family of novel alternatively spliced RNAs and their expressed proteins. Mol Cell Biol. 1993 Feb;13(2):1273-82.

# Drug_Target_39_HGNC_ID:
HGNC:1814

# Drug_Target_39_HPRD_ID:
00191

# Drug_Target_39_ID:
119

# Drug_Target_39_Locus:
19q13.2

# Drug_Target_39_Molecular_Weight:
57561

# Drug_Target_39_Name:
Carcinoembryonic antigen-related cell adhesion molecule 1

# Drug_Target_39_Number_of_Residues:
526

# Drug_Target_39_PDB_ID:
Not Available

# Drug_Target_39_Pathway:
Not Available

# Drug_Target_39_Pfam_Domain_Function:
PF00047	ig
PF07686	V-set

# Drug_Target_39_Protein_Sequence:
>Carcinoembryonic antigen-related cell adhesion molecule 1 precursor
MGHLSAPLHRVRVPWQGLLLTASLLTFWNPPTTAQLTTESMPFNVAEGKEVLLLVHNLPQ
QLFGYSWYKGERVDGNRQIVGYAIGTQQATPGPANSGRETIYPNASLLIQNVTQNDTGFY
TLQVIKSDLVNEEATGQFHVYPELPKPSISSNNSNPVEDKDAVAFTCEPETQDTTYLWWI
NNQSLPVSPRLQLSNGNRTLTLLSVTRNDTGPYECEIQNPVSANRSDPVTLNVTYGPDTP
TISPSDTYYRPGANLSLSCYAASNPPAQYSWLINGTFQQSTQELFIPNITVNNSGSYTCH
ANNSVTGCNRTTVKTIIVTELSPVVAKPQIKASKTTVTGDKDSVNLTCSTNDTGISIRWF
FKNQSLPSSERMKLSQGNTTLSINPVKREDAGTYWCEVFNPISKNQSDPIMLNVNYNALP
QENGLSPGAIAGIVIGVVALVALIAVALACFLHFGKTGRASDQRDLTEHKPSVSNHTQDH
SNDPPNKMNEVTYSTLNFEAQQPTQPTSASPSLTATEIIYSEVKKQ

# Drug_Target_39_Reaction:
Not Available

# Drug_Target_39_Signals:
1-34

# Drug_Target_39_Specific_Function:
Not Available

# Drug_Target_39_SwissProt_ID:
P13688

# Drug_Target_39_SwissProt_Name:
CEAM1_HUMAN

# Drug_Target_39_Synonyms:
BGP-1
Biliary glycoprotein 1
CD66 antigen
CD66a antigen
Carcinoembryonic antigen-related cell adhesion molecule 1 precursor

# Drug_Target_39_Theoretical_pI:
5.84

# Drug_Target_39_Transmembrane_Regions:
429-452

# Drug_Target_3_Cellular_Location:
Virion
apical cell membrane
single-pass type II membrane protein (
virion membrane. Cell membrane

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
K01393

# Drug_Target_3_GenBank_ID_Protein:
1480200

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
NA

# Drug_Target_3_Gene_Sequence:
>1410 bp
ATGAATCCAAATCAAAAGATAATAACAATTGGCTCTGTCTCTCTCACCATTGCAACAGTA
TGCTTTCTCATGCAGATTGCCATCTTGGTAACTACTGTAACATTGCACTTTAAGCAACAT
GAGTGCGACTCCCCCGCGAGCAACCAAGTAATGCCGTGTGAACCAATAATAATAGAAAGG
AACATAACAGAGATAGTGTATTTGAATAACACCACCATAGAGAAAGAGATATGCCCCAAA
GTAGTGGAATACAGAAATTGGTCAAAGCCGCAATGTCAAATTACAGGATTTGCACCTTTT
TCTAAGGACAATTCAATCCGGCTTTCTGCTGGTGGGGACATTTGGGTGACGAGAGAACCT
TATGTGTCATGCGATCCTGTCAAGTGTTATCAATTTGCACTCGGGCAGGGGACCACACTA
GACAACAAACATTCAAATGACACAGTACATGATAGAATCCCTCATCGAACCCTATTAATG
AATGAGTTGGGTGTTCCATTTCACTTAGGAACCAGGCAAGTGTGTATAGCATGGTCCAGC
TCAAGTTGTCACGATGGAAAAGCATGGCTGCATGTTTGTATCACTGGGGATGATAAAAAT
GCAACTGCTAGCTTCATTTATGACGGGAGGCTTGTGGACAGTATTGGTTCATGGTCTCAA
AATATCCTCAGAACCCAGGAGTCGGAATGCGTTTGTATCAATGGGACTTGCACAGTAGTA
ATGACTGATGGAAGTGCTTCAGGAAGAGCCGATACTAGAATACTATTCATTGAAGAGGGG
AAAATTGTCCATATTAGCCCATTGGCAGGAAGTGCTCAGCATGTAGAGGAGTGTTCCTGT
TATCCTCGATATCCTGGCGTCAGATGTATCTGCAGAGACAACTGGAAAGGCTCTAATAGG
CCCGTCGTAGACATAAATATGGAAGATTATAGCATTGATTCCAGTTATGTGTGCTCAGGG
CTTGTTGGCGACACACCTAGAAACGATGACAGATCTAGCAATAGCAATTGCAGGAATCCT
AACAATGAGAGAGGGACTCAAGGAGTGAAAGGCTGGGCCTTTGACAATGGAAATGACTTG
TGGATGGGAAGAACAATCAGCAAGGATTTACGCTCAGGTTATGAAACTTTCAAAGTCATT
GGTGGTTGGTCCACACCTAATTCCAAATCGCAGATCAATAGACAAGTCATAGTTGACAGT
GATAATCGGTCAGGTTACTCTGGTATTTTCTCTGTTGAGGGCAAAAGCTGCATCAATAGG
TGCTTTTATGTGGAGTTGATAAGGGGAAGGAAACAGGAGACTAGAGTATGGTGGACCTCA
AACAGTATTGTTGTGTTTTGTGGCACTTCAGGTACCTATGGAACAGGCTCATGGCCTGAT
GGGGCGAACATCAATTTCATGCCTATATAA

# Drug_Target_3_General_Function:
Not Available

# Drug_Target_3_General_References:
1920428	Varghese JN, Colman PM: Three-dimensional structure of the neuraminidase of influenza virus A/Tokyo/3/67 at 2.2 A resolution. J Mol Biol. 1991 Sep 20;221(2):473-86.
6203216	Lentz MR, Air GM, Laver WG, Webster RG: Sequence of the neuraminidase gene of influenza virus A/Tokyo/3/67 and previously uncharacterized monoclonal variants. Virology. 1984 May;135(1):257-65.
7844831	White CL, Janakiraman MN, Laver WG, Philippon C, Vasella A, Air GM, Luo M: A sialic acid-derived phosphonate analog inhibits different strains of influenza virus neuraminidase with different efficiencies. J Mol Biol. 1995 Feb 3;245(5):623-34.
7880809	Jedrzejas MJ, Singh S, Brouillette WJ, Laver WG, Air GM, Luo M: Structures of aromatic inhibitors of influenza virus neuraminidase. Biochemistry. 1995 Mar 14;34(10):3144-51.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
2676

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
52131

# Drug_Target_3_Name:
Neuraminidase

# Drug_Target_3_Number_of_Residues:
469

# Drug_Target_3_PDB_ID:
2BAT

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00064	Neur

# Drug_Target_3_Protein_Sequence:
>Neuraminidase
MNPNQKIITIGSVSLTIATVCFLMQIAILVTTVTLHFKQHECDSPASNQVMPCEPIIIER
NITEIVYLNNTTIEKEICPKVVEYRNWSKPQCQITGFAPFSKDNSIRLSAGGDIWVTREP
YVSCDPVKCYQFALGQGTTLDNKHSNDTVHDRIPHRTLLMNELGVPFHLGTRQVCIAWSS
SSCHDGKAWLHVCITGDDKNATASFIYDGRLVDSIGSWSQNILRTQESECVCINGTCTVV
MTDGSASGRADTRILFIEEGKIVHISPLAGSAQHVEECSCYPRYPGVRCICRDNWKGSNR
PVVDINMEDYSIDSSYVCSGLVGDTPRNDDRSSNSNCRNPNNERGTQGVKGWAFDNGNDL
WMGRTISKDLRSGYETFKVIGGWSTPNSKSQINRQVIVDSDNRSGYSGIFSVEGKSCINR
CFYVELIRGRKQETRVWWTSNSIVVFCGTSGTYGTGSWPDGANINFMPI

# Drug_Target_3_Reaction:
Hydrolysis of alpha-(2->3)-, alpha-(2->6)-, alpha-(2->8)- glycosidic linkages of terminal sialic acid residues in oligosaccharides, glycoproteins, glycolipids, colominic acid and synthetic substrates ALL_REAC (other) R03491 R04018 R04634 R04650 R05115 R05117 R05996(G) R05998(G) R05999(G) R06012(G) R06147(G) R06253(G) INHIBITOR 2-Deoxy-2,3-dehydro-N-acetylneuraminic acid

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Catalyzes the removal of terminal sialic acid residues from viral and cellular glycoconjugates. Cleaves off the terminal sialic acids on the glycosylated HA during virus budding to facilitate virus release. Additionally helps virus spread through the circulation by further removing sialic acids from the cell surface. These cleavages prevent self-aggregation and ensure the efficient spread of the progeny virus from cell to cell. Otherwise, infection would be limited to one round of replication. Described as a receptor-destroying enzyme because it cleaves a terminal sialic acid from the cellular receptors. May facilitate viral invasion of the upper airways by cleaving the sialic acid moities on the mucin of the airway epithelial cells. Likely to plays a role in the budding process through its association with lipid rafts during intracellular transport. May additionally display a raft-association independent effect on budding. Plays a role in the determination of host range restriction on replication and virulence. Sialidase activity in late endosome/lysosome traffic seems to enhance virus replication

# Drug_Target_3_SwissProt_ID:
P06820

# Drug_Target_3_SwissProt_Name:
NRAM_I67A0

# Drug_Target_3_Synonyms:
EC 3.2.1.18

# Drug_Target_3_Theoretical_pI:
6.79

# Drug_Target_3_Transmembrane_Regions:
7-35

# Drug_Target_40_Cellular_Location:
Membrane
single-pass type I membrane protein

# Drug_Target_40_Chromosome_Location:
Not Available

# Drug_Target_40_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_40_Essentiality:
Non-Essential

# Drug_Target_40_GenAtlas_ID:
CD2

# Drug_Target_40_GenBank_ID_Gene:
M19806

# Drug_Target_40_GenBank_ID_Protein:
180081

# Drug_Target_40_GeneCard_ID:
CD2

# Drug_Target_40_Gene_Name:
CD2

# Drug_Target_40_Gene_Sequence:
>1056 bp
ATGAGCTTTCCATGTAAATTTGTAGCCAGCTTCCTTCTGATTTTCAATGTTTCTTCCAAA
GGTGCAGTCTCCAAAGAGATTACGAATGCCTTGGAAACCTGGGGTGCCTTGGGTCAGGAC
ATCAACTTGGACATTCCTAGTTTTCAAATGAGTGATGATATTGACGATATAAAATGGGAA
AAAACTTCAGACAAGAAAAAGATTGCACAATTCAGAAAAGAGAAAGAGACTTTCAAGGAA
AAAGATACATATAAGCTATTTAAAAATGGAACTCTGAAAATTAAGCATCTGAAGACCGAT
GATCAGGATATCTACAAGGTATCAATATATGATACAAAAGGAAAAAATGTGTTGGAAAAA
ATATTTGATTTGAAGATTCAAGAGAGGGTCTCAAAACCAAAGATCTCCTGGACTTGTATC
AACACAACCCTGACCTGTGAGGTAATGAATGGAACTGACCCCGAATTAAACCTGTATCAA
GATGGGAAACATCTAAAACTTTCTCAGAGGGTCATCACACACAAGTGGACCACCAGCCTG
AGTGCAAAATTCAAGTGCACAGCAGGGAACAAAGTCAGCAAGGAATCCAGTGTCGAGCCT
GTCAGCTGTCCAGAGAAAGGTCTGGACATCTATCTCATCATTGGCATATGTGGAGGAGGC
AGCCTCTTGATGGTCTTTGTGGCACTGCTCGTTTTCTATATCACCAAAAGGAAAAAACAG
AGGAGTCGGAGAAATGATGAGGAGCTGGAGACAAGAGCCCACAGAGTAGCTACTGAAGAA
AGGGGCCGGAAGCCCCACCAAATTCCAGCTTCAACCCCTCAGAATCCAGCAACTTCCCAA
CATCCTCCTCCACCACCTGGTCATCGTTCCCAGGCACCTAGTCATCGTCCCCCGCCTCCT
GGACACCGTGTTCAGCACCAGCCTCAGAAGAGGCCTCCTGCTCCGTCGGGCACACAAGTT
CACCAGCAGAAAGGCCCGCCCCTCCCCAGACCTCGAGTTCAGCCAAAACCTCCCCATGGG
GCAGCAGAAAACTCATTGTCCCCTTCCTCTAATTAA

# Drug_Target_40_General_Function:
Involved in cell-cell adhesion

# Drug_Target_40_General_References:
1377404	Hahn WC, Menu E, Bothwell AL, Sims PJ, Bierer BE: Overlapping but nonidentical binding sites on CD2 for CD58 and a second ligand CD59. Science. 1992 Jun 26;256(5065):1805-7.
2437578	Seed B, Aruffo A: Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure. Proc Natl Acad Sci U S A. 1987 May;84(10):3365-9.
2444890	Peterson A, Seed B: Monoclonal antibody and ligand binding sites of the T cell erythrocyte receptor (CD2). Nature. 1987 Oct 29-Nov 4;329(6142):842-6.
2883656	Sayre PH, Chang HC, Hussey RE, Brown NR, Richardson NE, Spagnoli G, Clayton LK, Reinherz EL: Molecular cloning and expression of T11 cDNAs reveal a receptor-like structure on human T lymphocytes. Proc Natl Acad Sci U S A. 1987 May;84(9):2941-5.
2894031	Diamond DJ, Clayton LK, Sayre PH, Reinherz EL: Exon-intron organization and sequence comparison of human and murine T11 (CD2) genes. Proc Natl Acad Sci U S A. 1988 Mar;85(5):1615-9.
2901953	Lang G, Wotton D, Owen MJ, Sewell WA, Brown MH, Mason DY, Crumpton MJ, Kioussis D: The structure of the human CD2 gene and its expression in transgenic mice. EMBO J. 1988 Jun;7(6):1675-82.
3490670	Sewell WA, Brown MH, Dunne J, Owen MJ, Crumpton MJ: Molecular cloning of the human T-lymphocyte surface CD2 (T11) antigen. Proc Natl Acad Sci U S A. 1986 Nov;83(22):8718-22.
7544493	Wyss DF, Choi JS, Li J, Knoppers MH, Willis KJ, Arulanandam AR, Smolyar A, Reinherz EL, Wagner G: Conformation and function of the N-linked glycan in the adhesion domain of human CD2. Science. 1995 Sep 1;269(5228):1273-8.
7915183	Withka JM, Wyss DF, Wagner G, Arulanandam AR, Reinherz EL, Recny MA: Structure of the glycosylated adhesion domain of human T lymphocyte glycoprotein CD2. Structure. 1993 Sep 15;1(1):69-81.
7994575	Bodian DL, Jones EY, Harlos K, Stuart DI, Davis SJ: Crystal structure of the extracellular region of the human cell adhesion molecule CD2 at 2.5 A resolution. Structure. 1994 Aug 15;2(8):755-66.
9857189	Li J, Nishizawa K, An W, Hussey RE, Lialios FE, Salgia R, Sunder-Plassmann R, Reinherz EL: A cdc15-like adaptor protein (CD2BP1) interacts with the CD2 cytoplasmic domain and regulates CD2-triggered adhesion. EMBO J. 1998 Dec 15;17(24):7320-36.

# Drug_Target_40_HGNC_ID:
HGNC:1639

# Drug_Target_40_HPRD_ID:
01750

# Drug_Target_40_ID:
793

# Drug_Target_40_Locus:
1p13

# Drug_Target_40_Molecular_Weight:
39440

# Drug_Target_40_Name:
T-cell surface antigen CD2

# Drug_Target_40_Number_of_Residues:
351

# Drug_Target_40_PDB_ID:
1HNF

# Drug_Target_40_Pathway:
Not Available

# Drug_Target_40_Pfam_Domain_Function:
PF05790	C2-set
PF07686	V-set

# Drug_Target_40_Protein_Sequence:
>T-cell surface antigen CD2 precursor
MSFPCKFVASFLLIFNVSSKGAVSKEITNALETWGALGQDINLDIPSFQMSDDIDDIKWE
KTSDKKKIAQFRKEKETFKEKDTYKLFKNGTLKIKHLKTDDQDIYKVSIYDTKGKNVLEK
IFDLKIQERVSKPKISWTCINTTLTCEVMNGTDPELNLYQDGKHLKLSQRVITHKWTTSL
SAKFKCTAGNKVSKESSVEPVSCPEKGLDIYLIIGICGGGSLLMVFVALLVFYITKRKKQ
RSRRNDEELETRAHRVATEERGRKPQQIPASTPQNPATSQHPPPPPGHRSQAPSHRPPPP
GHRVQHQPQKRPPAPSGTQVHQQKGPPLPRPRVQPKPPHGAAENSLSPSSN

# Drug_Target_40_Reaction:
Not Available

# Drug_Target_40_Signals:
1-24

# Drug_Target_40_Specific_Function:
CD2 interacts with lymphocyte function-associated antigen (LFA-3) and CD48/BCM1 to mediate adhesion between T-cells and other cell types. CD2 is implicated in the triggering of T- cells, the cytoplasmic domain is implicated in the signaling function

# Drug_Target_40_SwissProt_ID:
P06729

# Drug_Target_40_SwissProt_Name:
CD2_HUMAN

# Drug_Target_40_Synonyms:
Erythrocyte receptor
LFA-2
LFA-3 receptor
Rosette receptor
T-cell surface antigen CD2 precursor
T-cell surface antigen T11/Leu- 5

# Drug_Target_40_Theoretical_pI:
10.30

# Drug_Target_40_Transmembrane_Regions:
210-235

# Drug_Target_41_Cellular_Location:
Not Available

# Drug_Target_41_Chromosome_Location:
Not Available

# Drug_Target_41_Drug_References:
Not Available

# Drug_Target_41_Essentiality:
Non-Essential

# Drug_Target_41_GenAtlas_ID:
Not Available

# Drug_Target_41_GenBank_ID_Gene:
M85052

# Drug_Target_41_GenBank_ID_Protein:
Not Available

# Drug_Target_41_GeneCard_ID:
Not Available

# Drug_Target_41_Gene_Name:
A430L

# Drug_Target_41_Gene_Sequence:
>1314 bp
ATGGCCGGAGGACTTTCACAGCTCGTCGCGTACGGTGCCCAGGACGTTTACCTGACCGGC
AACCCCCAGATTACCTTCTTCAAGACGGTTTACCGCCGTTACACCAACTTCGCCATTGAA
TCAATCCAACAAACGATCAATGGCTCGGTTGGATTTGGCAACAAAGTGAGCACCCAGATC
TCCCGTAACGGTGACTTGATCACCGACATTGTGGTTGAGTTCGTGCTGACCAAGGGTGGC
AACGGTGGTACCACCTACTACCCCGCTGAGGAGCTGCTACAGGATGTTGAGCTCGAAATC
GGTGGCCAGCGCATTGACAAGCACTACAACGACTGGTTCCGCACCTACGACGCTCTGTTC
CGCATGAACGACGACCGTTACAACTACCGTCGTATGACCGACTGGGTCAACAACGAACTT
GTCGGTGCCCAGAAGCGTTTCTATGTGCCCCTCATCTTCTTCTTCAACCAGACCCCTGGT
CTTGCCCTCCCCCTAATTGCCCTGCAATACCACGAAGTGAAGCTTTACTTCACCCTGGCA
AGCCAGGTGCAGGGTGTGAACTACAACGGCAGCAGTGCCATCGCCGGTGCCGCCCAGCCT
ACTATGTCCGTGTGGGTTGACTACATCTTCCTGGATACCCAAGAACGCACCCGTTTCGCC
CAGCTACCCCACGAGTACCTGATCGAACAGCTACAGTTCACTGGTTCCGAGACCGCCACC
CCCTCCGCCACCACCCAAGCCAGCCAGAACATCCGCCTCAACTTCAACCACCCCACCAAG
TACCTGGCATGGAACTTCAACAACCCCACCAACTATGGTCAATACACTGCTCTGGCTAAC
ATCCCCGGTGCTTGCTCCGGTGCCGGTACTGCCGCCGCTACCGTGACCACCCCCGACTAC
GGTAACACTGGCACCTACAACGAACAGCTTGCCGTGCTGGACTCTGCCAAGATCCAGCTG
AACGGTCAAGATCGTTTCGCCACCCGCAAGGGCTCTTACTTCAACAAGGTGCAGCCTTAC
CAGAGCATCGGTGGCGTCACCCCCGCCGGTGTCTACCTGTACTCCTTCGCCCTGAAGCCC
GCTGGTCGCCAACCCTCCGGTACCTGCAACTTCTCCCGCATTGATAACGCCACTCTGTCT
CTGACTTACAAGACTTGCAGCATCGATGCCACTTCCCCCGCCGCAGTACTCGGCAACACC
GAAACCGTGACTGCCAACACCGCCACTCTCCTGACTGCCCTCAACATCTATGCCAAAAAT
TACAACGTCCTTCGCATAATGAGTGGCATGGGAGGCTTAGCTTATGCCAACTGA

# Drug_Target_41_General_Function:
Involved in structural molecule activity

# Drug_Target_41_General_References:
1566573	Graves MV, Meints RH: Characterization of the major capsid protein and cloning of its gene from algal virus PBCV-1. Virology. 1992 May;188(1):198-207.
8806566	Kutish GF, Li Y, Lu Z, Furuta M, Rock DL, Van Etten JL: Analysis of 76 kb of the chlorella virus PBCV-1 330-kb genome: map positions 182 to 258. Virology. 1996 Sep 15;223(2):303-17.

# Drug_Target_41_HGNC_ID:
Not Available

# Drug_Target_41_HPRD_ID:
Not Available

# Drug_Target_41_ID:
4869

# Drug_Target_41_Locus:
Not Available

# Drug_Target_41_Molecular_Weight:
48165

# Drug_Target_41_Name:
Major capsid protein

# Drug_Target_41_Number_of_Residues:
437

# Drug_Target_41_PDB_ID:
1J5Q

# Drug_Target_41_Pathway:
Not Available

# Drug_Target_41_Pfam_Domain_Function:
PF04451	Capsid_Iridovir

# Drug_Target_41_Protein_Sequence:
>Major capsid protein
MAGGLSQLVAYGAQDVYLTGNPQITFFKTVYRRYTNFAIESIQQTINGSVGFGNKVSTQI
SRNGDLITDIVVEFVLTKGGNGGTTYYPAEELLQDVELEIGGQRIDKHYNDWFRTYDALF
RMNDDRYNYRRMTDWVNNELVGAQKRFYVPLIFFFNQTPGLALPLIALQYHEVKLYFTLA
SQVQGVNYNGSSAIAGAAQPTMSVWVDYIFLDTQERTRFAQLPHEYLIEQLQFTGSETAT
PSATTQASQNIRLNFNHPTKYLAWNFNNPTNYGQYTALANIPGACSGAGTAAATVTTPDY
GNTGTYNEQLAVLDSAKIQLNGQDRFATRKGSYFNKVQPYQSIGGVTPAGVYLYSFALKP
AGRQPSGTCNFSRIDNATLSLTYKTCSIDATSPAAVLGNTETVTANTATLLTALNIYAKN
YNVLRIMSGMGGLAYAN

# Drug_Target_41_Reaction:
Not Available

# Drug_Target_41_Signals:
None

# Drug_Target_41_Specific_Function:
Not Available

# Drug_Target_41_SwissProt_ID:
P30328

# Drug_Target_41_SwissProt_Name:
MCP_PBCV1

# Drug_Target_41_Synonyms:
VP54

# Drug_Target_41_Theoretical_pI:
7.47

# Drug_Target_41_Transmembrane_Regions:
None

# Drug_Target_42_Cellular_Location:
Cell membrane
single-pass type II membrane protein. Processed form:Secreted protein. Note=Also exis

# Drug_Target_42_Chromosome_Location:
Not Available

# Drug_Target_42_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_42_Essentiality:
Non-Essential

# Drug_Target_42_GenAtlas_ID:
DPP4

# Drug_Target_42_GenBank_ID_Gene:
U13735

# Drug_Target_42_GenBank_ID_Protein:
535388

# Drug_Target_42_GeneCard_ID:
DPP4

# Drug_Target_42_Gene_Name:
DPP4

# Drug_Target_42_Gene_Sequence:
>2301 bp
ATGAAGACACCGTGGAAGGTTCTTCTGGGACTGCTGGGTGCTGCTGCGCTTGTCACCATC
ATCACCGTGCCCGTGGTTCTGCTGAACAAAGGCACAGATGATGCTACAGCTGACAGTCGC
AAAACTTACACTCTAACTGATTACTTAAAAAATACTTATAGACTGAAGTTATACTCCTTA
AGATGGATTTCAGATCATGAATATCTCTACAAACAAGAAAATAATATCTTGGTATTCAAT
GCTGAATATGGAAACAGCTCAGTTTTCTTGGAGAACAGTACATTTGATGAGTTTGGACAT
TCTATCAATGATTATTCAATATCTCCTGATGGGCAGTTTATTCTCTTAGAATACAACTAC
GTGAAGCAATGGAGGCATTCCTACACAGCTTCATATGACATTTATGATTTAAATAAAAGG
CAGCTGATTACAGAAGAGAGGATTCCAAACAACACACAGTGGGTCACATGGTCACCAGTG
GGTCATAAATTGGCATATGTTTGGAACAATGACATTTATGTTAAAATTGAACCAAATTTA
CCAAGTTACAGAATCACATGGACGGGGAAAGAAGATATAATATATAATGGAATAACTGAC
TGGGTTTATGAAGAGGAAGTCTTCAGTGCCTACTCTGCTCTGTGGTGGTCTCCAAACGGC
ACTTTTTTAGCATATGCCCAATTTAACGACACAGAAGTCCCACTTATTGAATACTCCTTC
TACTCTGATGAGTCACTGCAGTACCCAAAGACTGTACGGGTTCCATATCCAAAGGCAGGA
GCTGTGAATCCAACTGTAAAGTTCTTTGTTGTAAATACAGACTCTCTCAGCTCAGTCACC
AATGCAACTTCCATACAAATCACTGCTCCTGCTTCTATGTTGATAGGGGATCACTACTTG
TGTGATGTGACATGGGCAACACAAGAAAGAATTTCTTTGCAGTGGCTCAGGAGGATTCAG
AACTATTCGGTCATGGATATTTGTGACTATGATGAATCCAGTGGAAGATGGAACTGCTTA
GTGGCACGGCAACACATTGAAATGAGTACTACTGGCTGGGTTGGAAGATTTAGGCCTTCA
GAACCTCATTTTACCCTTGATGGTAATAGCTTCTACAAGATCATCAGCAATGAAGAAGGT
TACAGACACATTTGCTATTTCCAAATAGATAAAAAAGACTGCACATTTATTACAAAAGGC
ACCTGGGAAGTCATCGGGATAGAAGCTCTAACCAGTGATTATCTATACTACATTAGTAAT
GAATATAAAGGAATGCCAGGAGGAAGGAATCTTTATAAAATCCAACTTAGTGACTATACA
AAAGTGACATGCCTCAGTTGTGAGCTGAATCCGGAAAGGTGTCAGTACTATTCTGTGTCA
TTCAGTAAAGAGGCGAAGTATTATCAGCTGAGATGTTCCGGTCCTGGTCTGCCCCTCTAT
ACTCTACACAGCAGCGTGAATGATAAAGGGCTGAGAGTCCTGGAAGACAATTCAGCTTTG
GATAAAATGCTGCAGAATGTCCAGATGCCCTCCAAAAAACTGGACTTCATTATTTTGAAT
GAAACAAAATTTTGGTATCAGATGATCTTGCCTCCTCATTTTGATAAATCCAAGAAATAT
CCTCTACTATTAGATGTGTATGCAGGCCCATGTAGTCAAAAAGCAGACACTGTCTTCAGA
CTGAACTGGGCCACTTACCTTGCAAGCACAGAAAACATTATAGTAGCTAGCTTTGATGGC
AGAGGAAGTGGTTACCAAGGAGATAAGATCATGCATGCAATCAACAGAAGACTGGGAACA
TTTGAAGTTGAAGATCAAATTGAAGCAGCCAGACAATTTTCAAAAATGGGATTTGTGGAC
AACAAACGAATTGCAATTTGGGGCTGGTCATATGGAGGGTACGTAACCTCAATGGTCCTG
GGATCGGGAAGTGGCGTGTTCAAGTGTGGAATAGCCGTGGCGCCTGTATCCCGGTGGGAG
TACTATGACTCAGTGTACACAGAACGTTACATGGGTCTCCCAACTCCAGAAGACAACCTT
GACCATTACAGAAATTCAACAGTCATGAGCAGAGCTGAAAATTTTAAACAAGTTGAGTAC
CTCCTTATTCATGGAACAGCAGATGATAACGTTCACTTTCAGCAGTCAGCTCAGATCTCC
AAAGCCCTGGTCGATGTTGGAGTGGATTTCCAGGCAATGTGGTATACTGATGAAGACCAT
GGAATAGCTAGCAGCACAGCACACCAACATATATATACCCACATGAGCCACTTCATAAAA
CAATGTTTCTCTTTACCTTAG

# Drug_Target_42_General_Function:
Amino acid transport and metabolism

# Drug_Target_42_General_References:
1347043	Darmoul D, Lacasa M, Baricault L, Marguet D, Sapin C, Trotot P, Barbat A, Trugnan G: Dipeptidyl peptidase IV (CD 26) gene expression in enterocyte-like colon cancer cell lines HT-29 and Caco-2. Cloning of the complete human coding sequence and changes of dipeptidyl peptidase IV mRNA levels during cell differentiation. J Biol Chem. 1992 Mar 5;267(7):4824-33.
1352530	Tanaka T, Camerini D, Seed B, Torimoto Y, Dang NH, Kameoka J, Dahlberg HN, Schlossman SF, Morimoto C: Cloning and functional expression of the T cell activation antigen CD26. J Immunol. 1992 Jul 15;149(2):481-6.
1352704	Misumi Y, Hayashi Y, Arakawa F, Ikehara Y: Molecular cloning and sequence analysis of human dipeptidyl peptidase IV, a serine proteinase on the cell surface. Biochim Biophys Acta. 1992 Jul 15;1131(3):333-6.
1677636	Gorvel JP, Ferrero A, Chambraud L, Rigal A, Bonicel J, Maroux S: Expression of sucrase-isomaltase and dipeptidylpeptidase IV in human small intestine and colon. Gastroenterology. 1991 Sep;101(3):618-25.
1977364	Darmoul D, Lacasa M, Chantret I, Swallow DM, Trugnan G: Isolation of a cDNA probe for the human intestinal dipeptidylpeptidase IV and assignment of the gene locus DPP4 to chromosome 2. Ann Hum Genet. 1990 Jul;54(Pt 3):191-7.
7487939	Bohm SK, Gum JR Jr, Erickson RH, Hicks JW, Kim YS: Human dipeptidyl peptidase IV gene promoter: tissue-specific regulation from a TATA-less GC-rich sequence characteristic of a housekeeping gene promoter. Biochem J. 1995 Nov 1;311 ( Pt 3):835-43.
7927537	Abbott CA, Baker E, Sutherland GR, McCaughan GW: Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene. Immunogenetics. 1994;40(5):331-8.
8094732	Tanaka T: Cloning and functional expression of the T cell activation antigen CD26. J Immunol. 1993 Mar 1;150(5):2090.
8096237	Morrison ME, Vijayasaradhi S, Engelstein D, Albino AP, Houghton AN: A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase. J Exp Med. 1993 Apr 1;177(4):1135-43.

# Drug_Target_42_HGNC_ID:
HGNC:3009

# Drug_Target_42_HPRD_ID:
02187

# Drug_Target_42_ID:
952

# Drug_Target_42_Locus:
2q24.3

# Drug_Target_42_Molecular_Weight:
88279

# Drug_Target_42_Name:
Dipeptidyl peptidase 4

# Drug_Target_42_Number_of_Residues:
766

# Drug_Target_42_PDB_ID:
2BGR

# Drug_Target_42_Pathway:
Not Available

# Drug_Target_42_Pfam_Domain_Function:
PF00326	Peptidase_S9
PF00930	DPPIV_N

# Drug_Target_42_Protein_Sequence:
>Dipeptidyl peptidase 4
MKTPWKVLLGLLGAAALVTIITVPVVLLNKGTDDATADSRKTYTLTDYLKNTYRLKLYSL
RWISDHEYLYKQENNILVFNAEYGNSSVFLENSTFDEFGHSINDYSISPDGQFILLEYNY
VKQWRHSYTASYDIYDLNKRQLITEERIPNNTQWVTWSPVGHKLAYVWNNDIYVKIEPNL
PSYRITWTGKEDIIYNGITDWVYEEEVFSAYSALWWSPNGTFLAYAQFNDTEVPLIEYSF
YSDESLQYPKTVRVPYPKAGAVNPTVKFFVVNTDSLSSVTNATSIQITAPASMLIGDHYL
CDVTWATQERISLQWLRRIQNYSVMDICDYDESSGRWNCLVARQHIEMSTTGWVGRFRPS
EPHFTLDGNSFYKIISNEEGYRHICYFQIDKKDCTFITKGTWEVIGIEALTSDYLYYISN
EYKGMPGGRNLYKIQLSDYTKVTCLSCELNPERCQYYSVSFSKEAKYYQLRCSGPGLPLY
TLHSSVNDKGLRVLEDNSALDKMLQNVQMPSKKLDFIILNETKFWYQMILPPHFDKSKKY
PLLLDVYAGPCSQKADTVFRLNWATYLASTENIIVASFDGRGSGYQGDKIMHAINRRLGT
FEVEDQIEAARQFSKMGFVDNKRIAIWGWSYGGYVTSMVLGSGSGVFKCGIAVAPVSRWE
YYDSVYTERYMGLPTPEDNLDHYRNSTVMSRAENFKQVEYLLIHGTADDNVHFQQSAQIS
KALVDVGVDFQAMWYTDEDHGIASSTAHQHIYTHMSHFIKQCFSLP

# Drug_Target_42_Reaction:
Release of an N-terminal dipeptide, Xaa-Yaa!Zaa-, from a polypeptide, preferentially when Yaa is Pro, provided Zaa is neither Pro nor hydroxyproline INHIBITOR L-Pro-L-boroPro

# Drug_Target_42_Signals:
None

# Drug_Target_42_Specific_Function:
Removes N-terminal dipeptides sequentially from polypeptides having unsubstituted N-termini provided that the penultimate residue is proline. Plays a role in T-cell activation

# Drug_Target_42_SwissProt_ID:
P27487

# Drug_Target_42_SwissProt_Name:
DPP4_HUMAN

# Drug_Target_42_Synonyms:
ADABP
Adenosine deaminase complexing protein 2
DPP IV
Dipeptidyl peptidase IV
EC 3.4.14.5
T-cell activation antigen CD26
TP103

# Drug_Target_42_Theoretical_pI:
5.92

# Drug_Target_42_Transmembrane_Regions:
7-28

# Drug_Target_43_Cellular_Location:
Microsome
microsomal membrane
peripheral membrane protein

# Drug_Target_43_Chromosome_Location:
Not Available

# Drug_Target_43_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_43_Essentiality:
Non-Essential

# Drug_Target_43_GenAtlas_ID:
PTGS1

# Drug_Target_43_GenBank_ID_Gene:
M31822

# Drug_Target_43_GenBank_ID_Protein:
387018

# Drug_Target_43_GeneCard_ID:
PTGS1

# Drug_Target_43_Gene_Name:
PTGS1

# Drug_Target_43_Gene_Sequence:
>1800 bp
ATGAGCCGGAGTCTCTTGCTCCGGTTCTTGCTGTTGCTGCTCCTGCTCCCGCCGCTCCCC
GTCCTGCTCGCGGACCCAGGGGCGCCCACGCCAGTGAATCCCTGTTGTTACTATCCATGC
CAGCACCAGGGCATCTGTGTCCGCTTCGGCCTTGACCGCTACCAGTGTGACTGCACCCGC
ACGGGCTATTCCGGCCCCAACTGCACCATCCCTGGCCTGTGGACCTGGCTCCGGAATTCA
CTGCGGCCCAGCCCCTCTTTCACCCACTTCCTGCTCACTCACGGGCGCTGGTTCTGGGAG
TTTGTCAATGCCACCTTCATCCGAGAGATGCTCATGCTCCTGGTACTCACAGTGCGCTCC
AACCTTATCCCCAGTCCCCCCACCTACAACTCTGCACATGACTACATCAGCTGGGAGTCT
TTCTCCAACGTGAGCTATTACACTCGTATTCTGCCCTCTGTGCCTAAAGATTGCCCCACA
CCCATGGGAACCAAAGGGAAGAAGCAGTTGCCAGATGCCCAGCTCCTGGCCCGCCGCTTC
CTGCTCAGGAGGAAGTTCATACCTGACCCCCAAGGCACCAACCTCATGTTTGCCTTCTTT
GCACAACACTTCACCCACCAGTTCTTCAAAACTTCTGGCAAGATGGGTCCTGGCTTCACC
AAGGCCTTGGGCCATGGGGTAGACCTCGGCCACATTTATGGAGACAATCTGGAGCGTCAG
TATCAACTGCGGCTCTTTAAGGATGGGAAACTCAAGTACCAGGTGCTGGATGGAGAAATG
TACCCGCCCTCGGTAGAAGAGGCGCCTGTGTTGATGCACTACCCCCGAGGCATCCCGCCC
CAGAGCCAGATGGCTGTGGGCCAGGAGGTGTTTGGGCTGCTTCCTGGGCTCATGCTGTAT
GCCACGCTCTGGCTACGTGAGCACAACCGTGTGTGTGACCTGCTGAAGGCTGAGCACCCC
ACCTGGGGCGATGAGCAGCTTTTCCAGACGACCCGCCTCATCCTCATAGGGGAGACCATC
AAGATTGTCATCGAGGAGTACGTGCAGCAGCTGAGTGGCTATTTCCTGCAGCTGAAATTT
GACCCAGAGCTGCTGTTCGGTGTCCAGTTCCAATACCGCAACCGCATTGCCACGGAGTTC
AACCATCTCTACCACTGGCACCCCCTCATGCCTGACTCCTTCAAGGTGGGCTCCCAGGAG
TACAGCTACGAGCAGTTCTTGTTCAACACCTCCATGTTGGTGGACTATGGGGTTGAGGCC
CTGGTGGATGCCTTCTCTCGCCAGATTGCTGGCCGGATCGGTGGGGGCAGGAACATGGAC
CACCACATCCTGCATGTGGCTGTGGATGTCATCAGGGAGTCTCGGGAGATGCGGCTGCAG
CCCTTCAATGAGTACCGCAAGAGGTTTGGCATGAAACCCTACACCTCCTTCCAGGAGCTC
GTAGGAGAGAAGGAGATGGCAGCAGAGTTGGAGGAATTGTATGGAGACATTGATGCGTTG
GAGTTCTACCCTGGACTGCTTCTTGAAAAGTGCCATCCAAACTCTATCTTTGGGGAGAGT
ATGATAGAGATTGGGGCTCCCTTTTCCCTCAAGGGTCTCCTAGGGAATCCCATCTGTTCT
CCGGAGTACTGGAAGCCGAGCACATTTGGCGGCGAGGTGGGCTTTAACATTGTCAAGACG
GCCACACTGAAGAAGCTGGTCTGCCTCAACACCAAGACCTGTCCCTACGTTTCCTTCCGT
GTGCCGGATGCCAGTCAGGATGATGGGCCTGCTGTGGAGCGACCATCCACAGAGCTCTGA

# Drug_Target_43_General_Function:
Involved in peroxidase activity

# Drug_Target_43_General_References:
1587858	Diaz A, Reginato AM, Jimenez SA: Alternative splicing of human prostaglandin G/H synthase mRNA and evidence of differential regulation of the resulting transcripts by transforming growth factor beta 1, interleukin 1 beta, and tumor necrosis factor alpha. J Biol Chem. 1992 May 25;267(15):10816-22.
1734857	Takahashi Y, Ueda N, Yoshimoto T, Yamamoto S, Yokoyama C, Miyata A, Tanabe T, Fuse I, Hattori A, Shibata A: Immunoaffinity purification and cDNA cloning of human platelet prostaglandin endoperoxide synthase (cyclooxygenase). Biochem Biophys Res Commun. 1992 Jan 31;182(2):433-8.
1907252	Funk CD, Funk LB, Kennedy ME, Pong AS, Fitzgerald GA: Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J. 1991 Jun;5(9):2304-12.
2512924	Yokoyama C, Tanabe T: Cloning of human gene encoding prostaglandin endoperoxide synthase and primary structure of the enzyme. Biochem Biophys Res Commun. 1989 Dec 15;165(2):888-94.

# Drug_Target_43_HGNC_ID:
HGNC:9604

# Drug_Target_43_HPRD_ID:
07518

# Drug_Target_43_ID:
20

# Drug_Target_43_Locus:
9q32-q33.3

# Drug_Target_43_Molecular_Weight:
68657

# Drug_Target_43_Name:
Prostaglandin G/H synthase 1

# Drug_Target_43_Number_of_Residues:
599

# Drug_Target_43_PDB_ID:
Not Available

# Drug_Target_43_Pathway:
Abciximab Pathway	SMP00265
Acetylsalicylic Acid Pathway	SMP00083
Bromfenac Pathway	SMP00102
Celecoxib Pathway	SMP00096
Cilostazol Pathway	SMP00263
Clopidogrel Pathway	SMP00260
Diclofenac Pathway	SMP00093
Diflunisal Pathway	SMP00289
Dipyridamole (Antiplatelet) Pathway	SMP00264
Eptifibatide Pathway	SMP00266
Etodolac Pathway	SMP00084
Ibuprofen Pathway	SMP00086
Indomethacin Pathway	SMP00104
Ketoprofen Pathway	SMP00085
Ketorolac Pathway	SMP00098
Mefanamic Acid Pathway	SMP00109
Meloxicam Pathway	SMP00106
Nabumetone Pathway	SMP00114
Naproxen Pathway	SMP00120
Oxaprozin Pathway	SMP00113
Piroxicam Pathway	SMP00077
Rofecoxib Pathway	SMP00087
Sulindac Pathway	SMP00094
Suprofen Pathway	SMP00101
Ticlopidine Pathway	SMP00261
Tirofiban Pathway	SMP00267
Valdecoxib Pathway	SMP00116

# Drug_Target_43_Pfam_Domain_Function:
PF00008	EGF
PF03098	An_peroxidase

# Drug_Target_43_Protein_Sequence:
>Prostaglandin G/H synthase 1 precursor
MSRSLLLRFLLFLLLLPPLPVLLADPGAPTPVNPCCYYPCQHQGICVRFGLDRYQCDCTR
TGYSGPNCTIPGLWTWLRNSLRPSPSFTHFLLTHGRWFWEFVNATFIREMLMRLVLTVRS
NLIPSPPTYNSAHDYISWESFSNVSYYTRILPSVPKDCPTPMGTKGKKQLPDAQLLARRF
LLRRKFIPDPQGTNLMFAFFAQHFTHQFFKTSGKMGPGFTKALGHGVDLGHIYGDNLERQ
YQLRLFKDGKLKYQVLDGEMYPPSVEEAPVLMHYPRGIPPQSQMAVGQEVFGLLPGLMLY
ATLWLREHNRVCDLLKAEHPTWGDEQLFQTTRLILIGETIKIVIEEYVQQLSGYFLQLKF
DPELLFGVQFQYRNRIAMEFNHLYHWHPLMPDSFKVGSQEYSYEQFLFNTSMLVDYGVEA
LVDAFSRQIAGRIGGGRNMDHHILHVAVDVIRESREMRLQPFNEYRKRFGMKPYTSFQEL
VGEKEMAAELEELYGDIDALEFYPGLLLEKCHPNSIFGESMIEIGAPFSLKGLLGNPICS
PEYWKPSTFGGEVGFNIVKTATLKKLVCLNTKTCPYVSFRVPDASQDDGPAVERPSTEL

# Drug_Target_43_Reaction:
arachidonate + AH2 + 2 O2 = prostaglandin H2 + A + H2O

# Drug_Target_43_Signals:
1-23

# Drug_Target_43_Specific_Function:
May play an important role in regulating or promoting cell proliferation in some normal and neoplastically transformed cells

# Drug_Target_43_SwissProt_ID:
P23219

# Drug_Target_43_SwissProt_Name:
PGH1_HUMAN

# Drug_Target_43_Synonyms:
COX-1
Cyclooxygenase- 1
EC 1.14.99.1
PGH synthase 1
PGHS-1
PHS 1
Prostaglandin G/H synthase 1 precursor
Prostaglandin H2 synthase 1
Prostaglandin-endoperoxide synthase 1

# Drug_Target_43_Theoretical_pI:
7.39

# Drug_Target_43_Transmembrane_Regions:
None

# Drug_Target_44_Cellular_Location:
Secreted protein

# Drug_Target_44_Chromosome_Location:
Not Available

# Drug_Target_44_Drug_References:
Not Available

# Drug_Target_44_Essentiality:
Non-Essential

# Drug_Target_44_GenAtlas_ID:
Not Available

# Drug_Target_44_GenBank_ID_Gene:
L06332

# Drug_Target_44_GenBank_ID_Protein:
Not Available

# Drug_Target_44_GeneCard_ID:
Not Available

# Drug_Target_44_Gene_Name:
endOF3

# Drug_Target_44_Gene_Sequence:
>987 bp
ATGAAAAAAATCTTTTTTGCCCAGTGTTCAATACTTTTATTGATGCTGGGATCATGTTCC
AAAATGACAGAGGATATGACACCTGAGTCAGTTAATAAAGAAGCTTCTGTTAAAAGTGCT
ACTGCTTTGGCGGGCTCTAATGGTGTATGTATTGCTTATTATATTACTGACGGAAGAAAT
CCGACATTCAAACTGAAAGATATACCGGATAAAGTAGATATGGTAATACTTTTTGGACTG
AAGTACTGGAGCCTGCAGGATACCACCAAATTACCGGGAGGTACTGGTATGATGGGAAGC
TTTAAATCTTATAAAGATCTGGATACTCAGATACGTTCTCTTCAAAGCAGAGGTATCAAG
GTACTACAAAATATAGATGATGATGTAAGCTGGCAATCTTCCAAACCGGGAGGTTTTGCT
TCCGCTGCTGCATATGGAGATGCCATAAAATCTATTGTTATCGACAAGTGGAAACTGGAC
GGGATAAGCCTGGATATAGAACATTCCGGAGCAAAGCCTAATCCTATACCTACATTCCCC
GGCTATGCAGCAACAGGATATAATGGTTGGTATTCCGGAAGTATGGCAGCAACACCAGCA
TTTCTGAATGTAATAAGCGAACTGACTAAGTATTTCGGTACTACTGCACCAAATAATAAA
CAATTACAAATCGCTTCAGGTATCGATGTATATGCATGGAATAAGATTATGGAAAATTTC
CGGAATAATTTTAATTACATTCAATTACAATCTTATGGAGCTAATGTAAGCAGAACACAG
CTTATGATGAATTATGCTACCGGGACCAATAAAATTCCGGCCAGTAAAATGGTCTTCGGC
GCCTATGCTGAAGGCGGAACTAACCAAGCCAATGATGTAGAGGTTGCCAAATGGACACCT
ACACAGGGAGCTAAGGGTGGAATGATGATTTATACATACAATTCTAATGTTAGTTATGCC
AATGCTGTAAGAGATGCAGTGAAGAAC

# Drug_Target_44_General_Function:
Involved in hydrolase activity, hydrolyzing O-glycosyl compounds

# Drug_Target_44_General_References:
7768917	Reinhold BB, Hauer CR, Plummer TH, Reinhold VN: Detailed structural analysis of a novel, specific O-linked glycan from the prokaryote Flavobacterium meningosepticum. J Biol Chem. 1995 Jun 2;270(22):13197-203.
8486657	Tarentino AL, Quinones G, Changchien LM, Plummer TH Jr: Multiple endoglycosidase F activities expressed by Flavobacterium meningosepticum endoglycosidases F2 and F3. Molecular cloning, primary sequence, and enzyme expression. J Biol Chem. 1993 May 5;268(13):9702-8.

# Drug_Target_44_HGNC_ID:
Not Available

# Drug_Target_44_HPRD_ID:
Not Available

# Drug_Target_44_ID:
4871

# Drug_Target_44_Locus:
Not Available

# Drug_Target_44_Molecular_Weight:
35844

# Drug_Target_44_Name:
Endo-beta-N-acetylglucosaminidase F3

# Drug_Target_44_Number_of_Residues:
329

# Drug_Target_44_PDB_ID:
1EOM

# Drug_Target_44_Pathway:
Not Available

# Drug_Target_44_Pfam_Domain_Function:
PF00704	Glyco_hydro_18

# Drug_Target_44_Protein_Sequence:
>Endo-beta-N-acetylglucosaminidase F3
MKKIFFAQCSILLLMLGSCSKMTEDMTPESVNKEASVKSATALAGSNGVCIAYYITDGRN
PTFKLKDIPDKVDMVILFGLKYWSLQDTTKLPGGTGMMGSFKSYKDLDTQIRSLQSRGIK
VLQNIDDDVSWQSSKPGGFASAAAYGDAIKSIVIDKWKLDGISLDIEHSGAKPNPIPTFP
GYAATGYNGWYSGSMAATPAFLNVISELTKYFGTTAPNNKQLQIASGIDVYAWNKIMENF
RNNFNYIQLQSYGANVSRTQLMMNYATGTNKIPASKMVFGAYAEGGTNQANDVEVAKWTP
TQGAKGGMMIYTYNSNVSYANAVRDAVKN

# Drug_Target_44_Reaction:
Not Available

# Drug_Target_44_Signals:
1-39

# Drug_Target_44_Specific_Function:
Endohydrolysis of the di-N-acetylchitobiosyl unit in high-mannose glycopeptides and glycoproteins. Hydrolyzes bi- and triantennary glycans. The presence of a core-bound fucose greatly augments endo F3 activity on biantennary and, presumably, triantennary oligosaccharides

# Drug_Target_44_SwissProt_ID:
P36913

# Drug_Target_44_SwissProt_Name:
EBA3_FLAME

# Drug_Target_44_Synonyms:
Di-N- acetylchitobiosyl beta-N-acetylglucosaminidase F3
EC 3.2.1.96
Endo-beta-N-acetylglucosaminidase F3 precursor
Endoglycosidase F3
Mannosyl-glycoprotein endo-beta-N-acetyl-glucosaminidase F3

# Drug_Target_44_Theoretical_pI:
9.22

# Drug_Target_44_Transmembrane_Regions:
None

# Drug_Target_45_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_45_Chromosome_Location:
Not Available

# Drug_Target_45_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_45_Essentiality:
Non-Essential

# Drug_Target_45_GenAtlas_ID:
RHO

# Drug_Target_45_GenBank_ID_Gene:
U49742

# Drug_Target_45_GenBank_ID_Protein:
1236137

# Drug_Target_45_GeneCard_ID:
RHO

# Drug_Target_45_Gene_Name:
RHO

# Drug_Target_45_Gene_Sequence:
>1047 bp
ATGAATGGCACAGAAGGCCCTAACTTCTACGTGCCCTTCTCCAATGCGACGGGTGTGGTA
CGCAGCCCCTTCGAGTACCCACAGTACTACCTGGCTGAGCCATGGCAGTTCTCCATGCTG
GCCGCCTACATGTTTCTGCTGATCGTGCTGGGCTTCCCCATCAACTTCCTCACGCTCTAC
GTCACCGTCCAGCACAAGAAGCTGCGCACGCCTCTCAACTACATCCTGCTCAACCTAGCC
GTGGCTGACCTCTTCATGGTCCTAGGTGGCTTCACCAGCACCCTCTACACCTCTCTGCAT
GGATACTTCGTCTTCGGGCCCACAGGATGCAATTTGGAGGGCTTCTTTGCCACCCTGGGC
GGTGAAATTGCCCTGTGGTCCTTGGTGGTCCTGGCCATCGAGCGGTACGTGGTGGTGTGT
AAGCCCATGAGCAACTTCCGCTTCGGGGAGAACCATGCCATCATGGGCGTTGCCTTCACC
TGGGTCATGGCGCTGGCCTGCGCCGCACCCCCACTCGCCGGCTGGTCCAGGTACATCCCC
GAGGGCCTGCAGTGCTCGTGTGGAATCGACTACTACACGCTCAAGCCGGAGGTCAACAAC
GAGTCTTTTGTCATCTACATGTTCGTGGTCCACTTCACCATCCCCATGATTATCATCTTT
TTCTGCTATGGGCAGCTCGTCTTCACCGTCAAGGAGGCCGCTGCCCAGCAGCAGGAGTCA
GCCACCACACAGAAGGCAGAGAAGGAGGTCACCCGCATGGTCATCATCATGGTCATCGCT
TTCCTGATCTGCTGGGTGCCCTACGCCAGCGTGGCATTCTACATCTTCACCCACCAGGGC
TCCAACTTCGGTCCCATCTTCATGACCATCCCAGCGTTCTTTGCCAAGAGCGCCGCCATC
TACAACCCTGTCATCTATATCATGATGAACAAGCAGTTCCGGAACTGCATGCTCACCACC
ATCTGCTGCGGCAAGAACCCACTGGGTGACGATGAGGCCTCTGCTACCGTGTCCAAGACG
GAGACGAGCCAGGTGGCCCCGGCCTAA

# Drug_Target_45_General_Function:
Involved in rhodopsin-like receptor activity

# Drug_Target_45_General_References:
1302614	Farrar GJ, Findlay JB, Kumar-Singh R, Kenna P, Humphries MM, Sharpe E, Humphries P: Autosomal dominant retinitis pigmentosa: a novel mutation in the rhodopsin gene in the original 3q linked family. Hum Mol Genet. 1992 Dec;1(9):769-71.
1391967	Fujiki K, Hotta Y, Hayakawa M, Sakuma H, Shiono T, Noro M, Sakuma T, Tamai M, Hikiji K, Kawaguchi R, et al.: Point mutations of rhodopsin gene found in Japanese families with autosomal dominant retinitis pigmentosa (ADRP). Jpn J Hum Genet. 1992 Jun;37(2):125-32.
1833777	Dryja TP, Hahn LB, Cowley GS, McGee TL, Berson EL: Mutation spectrum of the rhodopsin gene among patients with autosomal dominant retinitis pigmentosa. Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9370-4.
1840561	Gal A, Artlich A, Ludwig M, Niemeyer G, Olek K, Schwinger E, Schinzel A: Pro-347-Arg mutation of the rhodopsin gene in autosomal dominant retinitis pigmentosa. Genomics. 1991 Oct;11(2):468-70.
1862076	Sung CH, Davenport CM, Hennessey JC, Maumenee IH, Jacobson SG, Heckenlively JR, Nowakowski R, Fishman G, Gouras P, Nathans J: Rhodopsin mutations in autosomal dominant retinitis pigmentosa. Proc Natl Acad Sci U S A. 1991 Aug 1;88(15):6481-5.
1897520	Sheffield VC, Fishman GA, Beck JS, Kimura AE, Stone EM: Identification of novel rhodopsin mutations associated with retinitis pigmentosa by GC-clamped denaturing gradient gel electrophoresis. Am J Hum Genet. 1991 Oct;49(4):699-706.
1985460	Inglehearn CF, Bashir R, Lester DH, Jay M, Bird AC, Bhattacharya SS: A 3-bp deletion in the rhodopsin gene in a family with autosomal dominant retinitis pigmentosa. Am J Hum Genet. 1991 Jan;48(1):26-30.
2137202	Dryja TP, McGee TL, Reichel E, Hahn LB, Cowley GS, Yandell DW, Sandberg MA, Berson EL: A point mutation of the rhodopsin gene in one form of retinitis pigmentosa. Nature. 1990 Jan 25;343(6256):364-6.
2215617	Dryja TP, McGee TL, Hahn LB, Cowley GS, Olsson JE, Reichel E, Sandberg MA, Berson EL: Mutations within the rhodopsin gene in patients with autosomal dominant retinitis pigmentosa. N Engl J Med. 1990 Nov 8;323(19):1302-7.
2239971	Farrar GJ, Kenna P, Redmond R, McWilliam P, Bradley DG, Humphries MM, Sharp EM, Inglehearn CF, Bashir R, Jay M, et al.: Autosomal dominant retinitis pigmentosa: absence of the rhodopsin proline----histidine substitution (codon 23) in pedigrees from Europe. Am J Hum Genet. 1990 Dec;47(6):941-5.
6589631	Nathans J, Hogness DS: Isolation and nucleotide sequence of the gene encoding human rhodopsin. Proc Natl Acad Sci U S A. 1984 Aug;81(15):4851-5.
7633434	Macke JP, Hennessey JC, Nathans J: Rhodopsin mutation proline347-to-alanine in a family with autosomal dominant retinitis pigmentosa indicates an important role for proline at position 347. Hum Mol Genet. 1995 Apr;4(4):775-6.
7846071	Sieving PA, Richards JE, Naarendorp F, Bingham EL, Scott K, Alpern M: Dark-light: model for nightblindness from the human rhodopsin Gly-90-->Asp mutation. Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):880-4.
7981701	Fuchs S, Kranich H, Denton MJ, Zrenner E, Bhattacharya SS, Humphries P, Gal A: Three novel rhodopsin mutations (C110F, L131P, A164V) in patients with autosomal dominant retinitis pigmentosa. Hum Mol Genet. 1994 Jul;3(7):1203.
7987326	Antinolo G, Sanchez B, Borrego S, Rueda T, Chaparro P, Cabeza JC: Identification of a new mutation at codon 171 of rhodopsin gene causing autosomal dominant retinitis pigmentosa. Hum Mol Genet. 1994 Aug;3(8):1421.
7987331	Souied E, Gerber S, Rozet JM, Bonneau D, Dufier JL, Ghazi I, Philip N, Soubrane G, Coscas G, Munnich A, et al.: Five novel missense mutations of the rhodopsin gene in autosomal dominant retinitis pigmentosa. Hum Mol Genet. 1994 Aug;3(8):1433-4.
7987385	Kumaramanickavel G, Maw M, Denton MJ, John S, Srikumari CR, Orth U, Oehlmann R, Gal A: Missense rhodopsin mutation in a family with recessive RP. Nat Genet. 1994 Sep;8(1):10-1.
8045708	Rosas DJ, Roman AJ, Weissbrod P, Macke JP, Nathans J: Autosomal dominant retinitis pigmentosa in a large family: a clinical and molecular genetic study. Invest Ophthalmol Vis Sci. 1994 Jul;35(8):3134-44.
8076945	Reig C, Antich J, Gean E, Garcia-Sandoval B, Ramos C, Ayuso C, Carballo M: Identification of a novel rhodopsin mutation (Met-44-Thr) in a simplex case of retinitis pigmentosa. Hum Genet. 1994 Sep;94(3):283-6.
8081400	al-Maghtheh M, Inglehearn C, Lunt P, Jay M, Bird A, Bhattacharya S: Two new rhodopsin transversion mutations (L40R; M216K) in families with autosomal dominant retinitis pigmentosa. Hum Mutat. 1994;3(4):409-10.
8088850	Vaithinathan R, Berson EL, Dryja TP: Further screening of the rhodopsin gene in patients with autosomal dominant retinitis pigmentosa. Genomics. 1994 May 15;21(2):461-3.
8317502	Macke JP, Davenport CM, Jacobson SG, Hennessey JC, Gonzalez-Fernandez F, Conway BP, Heckenlively J, Palmer R, Maumenee IH, Sieving P, et al.: Identification of novel rhodopsin mutations responsible for retinitis pigmentosa: implications for the structure and function of rhodopsin. Am J Hum Genet. 1993 Jul;53(1):80-9.
8353500	Kranich H, Bartkowski S, Denton MJ, Krey S, Dickinson P, Duvigneau C, Gal A: Autosomal dominant 'sector' retinitis pigmentosa due to a point mutation predicting an Asn-15-Ser substitution of rhodopsin. Hum Mol Genet. 1993 Jun;2(6):813-4.
8358437	Dryja TP, Berson EL, Rao VR, Oprian DD: Heterozygous missense mutation in the rhodopsin gene as a cause of congenital stationary night blindness. Nat Genet. 1993 Jul;4(3):280-3.
8401533	al-Maghtheh M, Gregory C, Inglehearn C, Hardcastle A, Bhattacharya S: Rhodopsin mutations in autosomal dominant retinitis pigmentosa. Hum Mutat. 1993;2(4):249-55.
8554077	Souied E, Soubrane G, Benlian P, Coscas GJ, Gerber S, Munnich A, Kaplan J: Retinitis punctata albescens associated with the Arg135Trp mutation in the rhodopsin gene. Am J Ophthalmol. 1996 Jan;121(1):19-25.
9452035	Goliath R, Bardien S, September A, Martin R, Ramesar R, Greenberg J: Rhodopsin mutation G109R in a family with autosomal dominant retinitis pigmentosa. Hum Mutat. 1998;Suppl 1:S40-1.
9888392	al-Jandal N, Farrar GJ, Kiang AS, Humphries MM, Bannon N, Findlay JB, Humphries P, Kenna PF: A novel mutation within the rhodopsin gene (Thr-94-Ile) causing autosomal dominant congenital stationary night blindness. Hum Mutat. 1999;13(1):75-81.

# Drug_Target_45_HGNC_ID:
HGNC:10012

# Drug_Target_45_HPRD_ID:
01584

# Drug_Target_45_ID:
2207

# Drug_Target_45_Locus:
3q21-q24

# Drug_Target_45_Molecular_Weight:
38893

# Drug_Target_45_Name:
Rhodopsin

# Drug_Target_45_Number_of_Residues:
348

# Drug_Target_45_PDB_ID:
1LN6

# Drug_Target_45_Pathway:
Not Available

# Drug_Target_45_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_45_Protein_Sequence:
>Rhodopsin
MNGTEGPNFYVPFSNATGVVRSPFEYPQYYLAEPWQFSMLAAYMFLLIVLGFPINFLTLY
VTVQHKKLRTPLNYILLNLAVADLFMVLGGFTSTLYTSLHGYFVFGPTGCNLEGFFATLG
GEIALWSLVVLAIERYVVVCKPMSNFRFGENHAIMGVAFTWVMALACAAPPLAGWSRYIP
EGLQCSCGIDYYTLKPEVNNESFVIYMFVVHFTIPMIIIFFCYGQLVFTVKEAAAQQQES
ATTQKAEKEVTRMVIIMVIAFLICWVPYASVAFYIFTHQGSNFGPIFMTIPAFFAKSAAI
YNPVIYIMMNKQFRNCMLTTICCGKNPLGDDEASATVSKTETSQVAPA

# Drug_Target_45_Reaction:
Not Available

# Drug_Target_45_Signals:
None

# Drug_Target_45_Specific_Function:
Visual pigments are the light-absorbing molecules that mediate vision. They consist of an apoprotein, opsin, covalently linked to cis-retinal

# Drug_Target_45_SwissProt_ID:
P08100

# Drug_Target_45_SwissProt_Name:
OPSD_HUMAN

# Drug_Target_45_Synonyms:
Opsin-2

# Drug_Target_45_Theoretical_pI:
6.64

# Drug_Target_45_Transmembrane_Regions:
37-61
74-98
114-133
153-176
203-230
253-276
285-309

# Drug_Target_46_Cellular_Location:
Secreted (Potential)

# Drug_Target_46_Chromosome_Location:
1

# Drug_Target_46_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_46_Essentiality:
Non-Essential

# Drug_Target_46_GenAtlas_ID:
Not Available

# Drug_Target_46_GenBank_ID_Gene:
AF106005

# Drug_Target_46_GenBank_ID_Protein:
6492116

# Drug_Target_46_GeneCard_ID:
CES4

# Drug_Target_46_Gene_Name:
CES1P1

# Drug_Target_46_Gene_Sequence:
>867 bp
ATGTGGCTCCCTGCTCTTGTCCTGGCCACTCTCGCTGCTTCCGCGGCTTGGGCAGTGCAT
CCGTCCTCGCCACCTGTGGTGGACACCGTGCATGGCAAAGTGTTGGGGAAGTTCATCAGC
TTAGAAGGATTTGCACAGCCTGTGGCCGTTTTCCTGGGAATCCCTTTTGCCAAGCCCCCT
CTTGGACCCCTGAGGTTTACTCCACCGCAGCCTGCAGAGCCGTGGAGCTTTGTGAAGAAT
GCCACCTTGTACCCTCCTATGTTCACCCAAGATCCAAGGCGGGGGGGGCAGTTAATCTCA
GAGCTATTTACAAACCGAAAAGAGAACATTCCTCTCAAGCTTTCTGAAGACTGTCTTTAC
CTCAATATTTACACTCCTGCTGACTTGACCAAGAAAAACAGGCTGCCGGTGATGGTGTGG
ATCCACGGAGGGGGGCTGATGGTGGGTGCGGCATCAACCTATGATGGGCTGGCCCTTGCT
GCCCATGAAAACGTGGTGGTGGTGACCATTCAATATCGCCTGGGCATCTGGGGATTCTTC
AGCACAGGGGATGAACACAGCCCGGGGAACTGGGGTCACCTGGACCAGCTGGCTGCCCTG
CACTGGGTCCAGGACAACATTGCCAGCTTTGGAGGGAACCCAGGCTCTGTGACCATCTTT
GGAGGGTCAGCGGGAGGAGAAAGTGTCTCTGTTCTTGTTTTGTCTCCATTGGCCAAGAAC
CTCTTCCACCGGGCCATTTCTGAGAGTGGCGTGGCCCTCACTTCTGTTCTGGTGAAGAAA
GGTGATGTCAAGCCCTTGGCTGAGGTAGGTCTCCGGCTGGTACGTCTCTGGCTGGACACC
CACACCTCCTTGGCTCTATGCTCCTGA

# Drug_Target_46_General_Function:
Lipid transport and metabolism

# Drug_Target_46_General_References:
10452915	Yan B, Matoney L, Yang D: Human carboxylesterases in term placentae: enzymatic characterization, molecular cloning and evidence for the existence of multiple forms. Placenta. 1999 Sep;20(7):599-607.
15489334	Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.
15616553	Martin J, Han C, Gordon LA, Terry A, Prabhakar S, She X, Xie G, Hellsten U, Chan YM, Altherr M, Couronne O, Aerts A, Bajorek E, Black S, Blumer H, Branscomb E, Brown NC, Bruno WJ, Buckingham JM, Callen DF, Campbell CS, Campbell ML, Campbell EW, Caoile C, Challacombe JF, Chasteen LA, Chertkov O, Chi HC, Christensen M, Clark LM, Cohn JD, Denys M, Detter JC, Dickson M, Dimitrijevic-Bussod M, Escobar J, Fawcett JJ, Flowers D, Fotopulos D, Glavina T, Gomez M, Gonzales E, Goodstein D, Goodwin LA, Grady DL, Grigoriev I, Groza M, Hammon N, Hawkins T, Haydu L, Hildebrand CE, Huang W, Israni S, Jett J, Jewett PB, Kadner K, Kimball H, Kobayashi A, Krawczyk MC, Leyba T, Longmire JL, Lopez F, Lou Y, Lowry S, Ludeman T, Manohar CF, Mark GA, McMurray KL, Meincke LJ, Morgan J, Moyzis RK, Mundt MO, Munk AC, Nandkeshwar RD, Pitluck S, Pollard M, Predki P, Parson-Quintana B, Ramirez L, Rash S, Retterer J, Ricke DO, Robinson DL, Rodriguez A, Salamov A, Saunders EH, Scott D, Shough T, Stallings RL, Stalvey M, Sutherland RD, Tapia R, Tesmer JG, Thayer N, Thompson LS, Tice H, Torney DC, Tran-Gyamfi M, Tsai M, Ulanovsky LE, Ustaszewska A, Vo N, White PS, Williams AL, Wills PL, Wu JR, Wu K, Yang J, Dejong P, Bruce D, Doggett NA, Deaven L, Schmutz J, Grimwood J, Richardson P, Rokhsar DS, Eichler EE, Gilna P, Lucas SM, Myers RM, Rubin EM, Pennacchio LA: The sequence and analysis of duplication-rich human chromosome 16. Nature. 2004 Dec 23;432(7020):988-94.

# Drug_Target_46_HGNC_ID:
GNC:18546

# Drug_Target_46_HPRD_ID:
Not Available

# Drug_Target_46_ID:
6858

# Drug_Target_46_Locus:
16q12.2

# Drug_Target_46_Molecular_Weight:
30678.3

# Drug_Target_46_Name:
Inactive carboxylesterase 4

# Drug_Target_46_Number_of_Residues:
287

# Drug_Target_46_PDB_ID:
1MX1

# Drug_Target_46_Pathway:
Not Available

# Drug_Target_46_Pfam_Domain_Function:
Not Available

# Drug_Target_46_Protein_Sequence:
>Inactive carboxylesterase 4
MWLPALVLATLAASAAWAGHLSSPPLVDTLHGKVLGKFVSLEGFAQPVAVFLGIPFAKPP
LGPLRFTLPQPAEPWNFVKNATSYPPMFTQDPKAGQLISELFTNRKENIPLKLSEDCLYL
NIYTPADLTKKNRLPVMVWIHGGGLMVGAASTYDGLALAAHENVVVVTIQYRLGIWGFFS
TGDEHSPGNWGHLDQLAALHWVQDNIASFGGNPGSVTIFGGSVGGESVSVLVLSPLAKNL
FHRAISESGVALTSVLVKKGDVKPLAEVGLRLVRLRLDTPTSLALCS

# Drug_Target_46_Reaction:
Not Available

# Drug_Target_46_Signals:
1-18

# Drug_Target_46_Specific_Function:
Has no esterase activity (Probable)

# Drug_Target_46_SwissProt_ID:
Q9UKY3

# Drug_Target_46_SwissProt_Name:
CES1P_HUMAN

# Drug_Target_46_Synonyms:
PCE-3
Placental carboxylesterase 3

# Drug_Target_46_Theoretical_pI:
8.25

# Drug_Target_46_Transmembrane_Regions:
None

# Drug_Target_47_Cellular_Location:
Secreted protein
extracellular space

# Drug_Target_47_Chromosome_Location:
Not Available

# Drug_Target_47_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_47_Essentiality:
Non-Essential

# Drug_Target_47_GenAtlas_ID:
SERPINC1

# Drug_Target_47_GenBank_ID_Gene:
M21642

# Drug_Target_47_GenBank_ID_Protein:
179161

# Drug_Target_47_GeneCard_ID:
SERPINC1

# Drug_Target_47_Gene_Name:
SERPINC1

# Drug_Target_47_Gene_Sequence:
>1395 bp
ATGTATTCCAATGTGATAGGAACTGTAACCTCTGGAAAAAGGAAGGTTTATCTTTTGTCC
TTGCTGCTCATTGGCTTCTGGGACTGCGTGACCTGTCACGGGAGCCCTGTGGACATCTGC
ACAGCCAAGCCGCGGGACATTCCCATGAATCCCATGTGCATTTACCGCTCCCCGGAGAAG
AAGGCAACTGAGGATGAGGGCTCAGAACAGAAGATCCCGGAGGCCACCAACCGGCGTGTC
TGGGAACTGTCCAAGGCCAATTCCCGCTTTGCTACCACTTTCTATCAGCACCTGGCAGAT
TCCAAGAATGACAATGATAACATTTTCCTGTCACCCCTGAGTATCTCCACGGCTTTTGCT
ATGACCAAGCTGGGTGCCTGTAATGACACCCTCCAGCAACTGATGGAGGTATTTAAGTTT
GACACCATATCTGAGAAAACATCTGATCAGATCCACTTCTTCTTTGCCAAACTGAACTGC
CGACTCTATCGAAAAGCCAACAAATCCTCCAAGTTAGTATCAGCCAATCGCCTTTTTGGA
GACAAATCCCTTACCTTCAATGAGACCTACCAGGACATCAGTGAGTTGGTATATGGAGCC
AAGCTCCAGCCCCTGGACTTCAAGGAAAATGCAGAGCAATCCAGAGCGGCCATCAACAAA
TGGGTGTCCAATAAGACCGAAGGCCGAATCACCGATGTCATTCCCTCGGAAGCCATCAAT
GAGCTCACTGTTCTGGTGCTGGTTAACACCATTTACTTCAAGGGCCTGTGGAAGTCAAAG
TTCAGCCCTGAGAACACAAGGAAGGAACTGTTCTACAAGGCTGATGGAGAGTCGTGTTCA
GCATCTATGATGTACCAGGAAGGCAAGTTCCGTTATCGGCGCGTGGCTGAAGGCACCCAG
GTGCTTGAGTTGCCCTTCAAAGGTGATGACATCACCATGGTCCTCATCTTGCCCAAGCCT
GAGAAGAGCCTGGCCAAGGTGGAGAAGGAACTCACCCCAGAGGTGCTGCAGGAGTGGCTG
GATGAATTGGAGGAGATGATGCTGGTGGTCCACATGCCCCGCTTCCGCATTGAGGACGGC
TTCAGTTTGAAGGAGCAGCTGCAAGACATGGGCCTTGTCGATCTGTTCAGCCCTGAAAAG
TCCAAACTCCCAGGTATTGTTGCAGAAGGCCGAGATGACCTCTATGTCTCAGATGCATTC
CATAAGGCATTTCTTGAGGTAAATGAAGAAGGCAGTGAAGCAGCTGCAAGTACCGCTGTT
GTGATTGCTGGCCGTTCGCTAAACCCCAACAGGGTGACTTTCAAGGCCAACAGGCTTTTC
CTGGTTTTTATAAGAGAAGTTCCTCTGAACACTATTATCTTCATGGGCAGAGTAGCCAAC
CCTTGTGTTAAGTAA

# Drug_Target_47_General_Function:
Involved in serine-type endopeptidase inhibitor activity

# Drug_Target_47_General_References:
10361121	Bayston TA, Tripodi A, Mannucci PM, Thompson E, Ireland H, Fitches AC, Hananeia L, Olds RJ, Lane DA: Familial overexpression of beta antithrombin caused by an Asn135Thr substitution. Blood. 1999 Jun 15;93(12):4242-7.
11794707	Niiya K, Kiguchi T, Dansako H, Fujimura K, Fujimoto T, Iijima K, Tanimoto M, Harada M: Two novel gene mutations in type I antithrombin deficiency. Int J Hematol. 2001 Dec;74(4):469-72.
1547341	Blajchman MA, Fernandez-Rachubinski F, Sheffield WP, Austin RC, Schulman S: Antithrombin-III-Stockholm: a codon 392 (Gly----Asp) mutation with normal heparin binding and impaired serine protease reactivity. Blood. 1992 Mar 15;79(6):1428-34.
1555650	Olds RJ, Lane DA, Boisclair M, Sas G, Bock SC, Thein SL: Antithrombin Budapest 3. An antithrombin variant with reduced heparin affinity resulting from the substitution L99F. FEBS Lett. 1992 Apr 6;300(3):241-6.
1906811	Perry DJ, Daly M, Harper PL, Tait RC, Price J, Walker ID, Carrell RW: Antithrombin Cambridge II, 384 Ala to Ser. Further evidence of the role of the reactive centre loop in the inhibitory function of the serpins. FEBS Lett. 1991 Jul 22;285(2):248-50.
1977621	Daly M, Bruce D, Perry DJ, Price J, Harper PL, O'Meara A, Carrell RW: Antithrombin Dublin (-3 Val----Glu): an N-terminal variant which has an aberrant signal peptidase cleavage site. FEBS Lett. 1990 Oct 29;273(1-2):87-90.
2013320	Austin RC, Rachubinski RA, Blajchman MA: Site-directed mutagenesis of alanine-382 of human antithrombin III. FEBS Lett. 1991 Mar 25;280(2):254-8.
2126464	Mourey L, Samama JP, Delarue M, Choay J, Lormeau JC, Petitou M, Moras D: Antithrombin III: structural and functional aspects. Biochimie. 1990 Aug;72(8):599-608.
2229057	Gandrille S, Aiach M, Lane DA, Vidaud D, Molho-Sabatier P, Caso R, de Moerloose P, Fiessinger JN, Clauser E: Important role of arginine 129 in heparin-binding site of antithrombin III. Identification of a novel mutation arginine 129 to glutamine. J Biol Chem. 1990 Nov 5;265(31):18997-9001.
2365065	Borg JY, Brennan SO, Carrell RW, George P, Perry DJ, Shaw J: Antithrombin Rouen-IV 24 Arg----Cys. The amino-terminal contribution to heparin binding. FEBS Lett. 1990 Jun 18;266(1-2):163-6.
2781509	Erdjument H, Lane DA, Panico M, Di Marzo V, Morris HR, Bauer K, Rosenberg RD: Antithrombin Chicago, amino acid substitution of arginine 393 to histidine. Thromb Res. 1989 Jun 15;54(6):613-9.
3080419	Chang JY, Tran TH: Antithrombin III Basel. Identification of a Pro-Leu substitution in a hereditary abnormal antithrombin with impaired heparin cofactor activity. J Biol Chem. 1986 Jan 25;261(3):1174-6.
3162733	Erdjument H, Lane DA, Panico M, Di Marzo V, Morris HR: Single amino acid substitutions in the reactive site of antithrombin leading to thrombosis. Congenital substitution of arginine 393 to cysteine in antithrombin Northwick Park and to histidine in antithrombin Glasgow. J Biol Chem. 1988 Apr 25;263(12):5589-93.
3179438	Devraj-Kizuk R, Chui DH, Prochownik EV, Carter CJ, Ofosu FA, Blajchman MA: Antithrombin-III-Hamilton: a gene with a point mutation (guanine to adenine) in codon 382 causing impaired serine protease reactivity. Blood. 1988 Nov;72(5):1518-23.
3191114	Bock SC, Marrinan JA, Radziejewska E: Antithrombin III Utah: proline-407 to leucine mutation in a highly conserved region near the inhibitor reactive site. Biochemistry. 1988 Aug 9;27(16):6171-8.
3805013	Stephens AW, Thalley BS, Hirs CH: Antithrombin-III Denver, a reactive site variant. J Biol Chem. 1987 Jan 25;262(3):1044-8.
6298709	Bock SC, Wion KL, Vehar GA, Lawn RM: Cloning and expression of the cDNA for human antithrombin III. Nucleic Acids Res. 1982 Dec 20;10(24):8113-25.
6305982	Prochownik EV, Markham AF, Orkin SH: Isolation of a cDNA clone for human antithrombin III. J Biol Chem. 1983 Jul 10;258(13):8389-94.
6572945	Chandra T, Stackhouse R, Kidd VJ, Woo SL: Isolation and sequence characterization of a cDNA clone of human antithrombin III. Proc Natl Acad Sci U S A. 1983 Apr;80(7):1845-8.
6582486	Koide T, Odani S, Takahashi K, Ono T, Sakuragawa N: Antithrombin III Toyama: replacement of arginine-47 by cysteine in hereditary abnormal antithrombin III that lacks heparin-binding ability. Proc Natl Acad Sci U S A. 1984 Jan;81(2):289-93.
6693405	Blackburn MN, Smith RL, Carson J, Sibley CC: The heparin-binding site of antithrombin III. Identification of a critical tryptophan in the amino acid sequence. J Biol Chem. 1984 Jan 25;259(2):939-41.
7238875	Bjork I, Danielsson A, Fenton JW, Jornvall: The site in human antithrombin for functional proteolytic cleavage by human thrombin. FEBS Lett. 1981 Apr 20;126(2):257-60.
7656006	Schreuder HA, de Boer B, Dijkema R, Mulders J, Theunissen HJ, Grootenhuis PD, Hol WG: The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions. Nat Struct Biol. 1994 Jan;1(1):48-54.
7749926	Stein PE, Carrell RW: What do dysfunctional serpins tell us about molecular mobility and disease? Nat Struct Biol. 1995 Feb;2(2):96-113.
7832187	Okajima K, Abe H, Wagatsuma M, Okabe H, Takatsuki K: Antithrombin III Kumamoto II; a single mutation at Arg393-His increased the affinity of antithrombin III for heparin. Am J Hematol. 1995 Jan;48(1):12-8.
7878627	Emmerich J, Chadeuf G, Alhenc-Gelas M, Gouault-Heilman M, Toulon P, Fiessinger JN, Aiach M: Molecular basis of antithrombin type I deficiency: the first large in-frame deletion and two novel mutations in exon 6. Thromb Haemost. 1994 Oct;72(4):534-9.
7959685	Millar DS, Wacey AI, Ribando J, Melissari E, Laursen B, Woods P, Kakkar VV, Cooper DN: Three novel missense mutations in the antithrombin III (AT3) gene causing recurrent venous thrombosis. Hum Genet. 1994 Nov;94(5):509-12.
7989582	Bruce D, Perry DJ, Borg JY, Carrell RW, Wardell MR: Thromboembolic disease due to thermolabile conformational changes of antithrombin Rouen-VI (187 Asn-->Asp) J Clin Invest. 1994 Dec;94(6):2265-74.
7994035	van Boven HH, Olds RJ, Thein SL, Reitsma PH, Lane DA, Briet E, Vandenbroucke JP, Rosendaal FR: Hereditary antithrombin deficiency: heterogeneity of the molecular basis and mortality in Dutch families. Blood. 1994 Dec 15;84(12):4209-13.
8087553	Carrell RW, Stein PE, Fermi G, Wardell MR: Biological implications of a 3 A structure of dimeric antithrombin. Structure. 1994 Apr 15;2(4):257-70.
8236149	Lane DA, Olds RJ, Boisclair M, Chowdhury V, Thein SL, Cooper DN, Blajchman M, Perry D, Emmerich J, Aiach M: Antithrombin III mutation database: first update. For the Thrombin and its Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 1993 Aug 2;70(2):361-9.
8274732	Jochmans K, Lissens W, Vervoort R, Peeters S, De Waele M, Liebaers I: Antithrombin-Gly 424 Arg: a novel point mutation responsible for type 1 antithrombin deficiency and neonatal thrombosis. Blood. 1994 Jan 1;83(1):146-51.
8443391	Okajima K, Abe H, Maeda S, Motomura M, Tsujihata M, Nagataki S, Okabe H, Takatsuki K: Antithrombin III Nagasaki (Ser116-Pro): a heterozygous variant with defective heparin binding associated with thrombosis. Blood. 1993 Mar 1;81(5):1300-5.
8476848	Olds RJ, Lane DA, Chowdhury V, De Stefano V, Leone G, Thein SL: Complete nucleotide sequence of the antithrombin gene: evidence for homologous recombination causing thrombophilia. Biochemistry. 1993 Apr 27;32(16):4216-24.
8486379	Olds RJ, Lane DA, Beresford CH, Abildgaard U, Hughes PM, Thein SL: A recurrent deletion in the antithrombin gene, AT106-108(-6 bp), identified by DNA heteroduplex detection. Genomics. 1993 Apr;16(1):298-9.
8664906	Perry DJ, Carrell RW: Molecular genetics of human antithrombin deficiency. Hum Mutat. 1996;7(1):7-22.
9067613	Skinner R, Abrahams JP, Whisstock JC, Lesk AM, Carrell RW, Wardell MR: The 2.6 A structure of antithrombin indicates a conformational change at the heparin binding site. J Mol Biol. 1997 Feb 28;266(3):601-9.
9761669	Skinner R, Chang WS, Jin L, Pei X, Huntington JA, Abrahams JP, Carrell RW, Lomas DA: Implications for function and therapy of a 2.9 A structure of binary-complexed antithrombin. J Mol Biol. 1998;283(1):9-14.
9845533	Fitches AC, Appleby R, Lane DA, De Stefano V, Leone G, Olds RJ: Impaired cotranslational processing as a mechanism for type I antithrombin deficiency. Blood. 1998 Dec 15;92(12):4671-6.

# Drug_Target_47_HGNC_ID:
HGNC:775

# Drug_Target_47_HPRD_ID:
00122

# Drug_Target_47_ID:
309

# Drug_Target_47_Locus:
1q23-q25.1

# Drug_Target_47_Molecular_Weight:
52603

# Drug_Target_47_Name:
Antithrombin-III

# Drug_Target_47_Number_of_Residues:
464

# Drug_Target_47_PDB_ID:
1JVQ

# Drug_Target_47_Pathway:
Ardeparin Pathway	SMP00275
Enoxaparin Pathway	SMP00272
Fondaparinux Pathway	SMP00273
Heparin Pathway	SMP00274

# Drug_Target_47_Pfam_Domain_Function:
PF00079	Serpin

# Drug_Target_47_Protein_Sequence:
>Antithrombin-III precursor
MYSNVIGTVTSGKRKVYLLSLLLIGFWDCVTCHGSPVDICTAKPRDIPMNPMCIYRSPEK
KATEDEGSEQKIPEATNRRVWELSKANSRFATTFYQHLADSKNDNDNIFLSPLSISTAFA
MTKLGACNDTLQQLMEVFKFDTISEKTSDQIHFFFAKLNCRLYRKANKSSKLVSANRLFG
DKSLTFNETYQDISELVYGAKLQPLDFKENAEQSRAAINKWVSNKTEGRITDVIPSEAIN
ELTVLVLVNTIYFKGLWKSKFSPENTRKELFYKADGESCSASMMYQEGKFRYRRVAEGTQ
VLELPFKGDDITMVLILPKPEKSLAKVEKELTPEVLQEWLDELEEMMLVVHMPRFRIEDG
FSLKEQLQDMGLVDLFSPEKSKLPGIVAEGRDDLYVSDAFHKAFLEVNEEGSEAAASTAV
VIAGRSLNPNRVTFKANRPFLVFIREVPLNTIIFMGRVANPCVK

# Drug_Target_47_Reaction:
Not Available

# Drug_Target_47_Signals:
1-32

# Drug_Target_47_Specific_Function:
Most important serine protease inhibitor in plasma that regulates the blood coagulation cascade. AT-III inhibits thrombin as well as factors IXa, Xa and XIa. Its inhibitory activity is greatly enhanced in the presence of heparin

# Drug_Target_47_SwissProt_ID:
P01008

# Drug_Target_47_SwissProt_Name:
ANT3_HUMAN

# Drug_Target_47_Synonyms:
ATIII
Antithrombin-III precursor

# Drug_Target_47_Theoretical_pI:
6.68

# Drug_Target_47_Transmembrane_Regions:
None

# Drug_Target_48_Cellular_Location:
Lysosome

# Drug_Target_48_Chromosome_Location:
Not Available

# Drug_Target_48_Drug_References:
Not Available

# Drug_Target_48_Essentiality:
Non-Essential

# Drug_Target_48_GenAtlas_ID:
GLA

# Drug_Target_48_GenBank_ID_Gene:
X05790

# Drug_Target_48_GenBank_ID_Protein:
Not Available

# Drug_Target_48_GeneCard_ID:
Not Available

# Drug_Target_48_Gene_Name:
GLA

# Drug_Target_48_Gene_Sequence:
>1290 bp
ATGCAGCTGAGGAACCCAGAACTACATCTGGGCTGCGCGCTTGCGCTTCGCTTCCTGGCC
CTCGTTTCCTGGGACATCCCTGGGGCTAGAGCACTGGACAATGGATTGGCAAGGACGCCT
ACCATGGGCTGGCTGCACTGGGAGCGCTTCATGTGCAACCTTGACTGCCAGGAAGAGCCA
GATTCCTGCATCAGTGAGAAGCTCTTCATGGAGATGGCAGAGCTCATGGTCTCAGAAGGC
TGGAAGGATGCAGGTTATGAGTACCTCTGCATTGATGACTGTTGGATGGCTCCCCAAAGA
GATTCAGAAGGCAGACTTCAGGCAGACCCTCAGCGCTTTCCTCATGGGATTCGCCAGCTA
GCTAATTATGTTCACAGCAAAGGACTGAAGCTAGGGATTTATGCAGATGTTGGAAATAAA
ACCTGCGCAGGCTTCCCTGGGAGTTTTGGATACTACGACATTGATGCCCAGACCTTTGCT
GACTGGGGAGTAGATCTGCTAAAATTTGATGGTTGTTACTGTGACAGTTTGGAAAATTTG
GCAGATGGTTATAAGCACATGTCCTTGGCCCTGAATAGGACTGGCAGAAGCATTGTGTAC
TCCTGTGAGTGGCCTCTTTATATGTGGCCCTTTCAAAAGCCCAATTATACAGAAATCCGA
CAGTACTGCAATCACTGGCGAAATTTTGCTGACATTGATGATTCCTGGAAAAGTATAAAG
AGTATCTTGGACTGGACATCTTTTAACCAGGAGAGAATTGTTGATGTTGCTGGACCAGGG
GGTTGGAATGACCCAGATATGTTAGTGATTGGCAACTTTGGCCTCAGCTGGAATCAGCAA
GTAACTCAGATGGCCCTCTGGGCTATCATGGCTGCTCCTTTATTCATGTCTAATGACCTC
CGACACATCAGCCCTCAAGCCAAAGCTCTCCTTCAGGATAAGGACGTAATTGCCATCAAT
CAGGACCCCTTGGGCAAGCAAGGGTACCAGCTTAGACAGGGAGACAACTTTGAAGTGTGG
GAACGACCTCTCTCAGGCTTAGCCTGGGCTGTAGCTATGATAAACCGGCAGGAGATTGGT
GGACCTCGCTCTTATACCATCGCAGTTGCTTCCCTGGGTAAAGGAGTGGCCTGTAATCCT
GCCTGCTTCATCACACAGCTCCTCCCTGTGAAAAGGAAGCTAGGGTTCTATGAATGGACT
TCAAGGTTAAGAAGTCACATAAATCCCACAGGCACTGTTTTGCTTCAGCTAGAAAATACA
ATGCAGATGTCATTAAAAGACTTACTTTAA

# Drug_Target_48_General_Function:
Involved in catalytic activity

# Drug_Target_48_General_References:
2542896	Kornreich R, Desnick RJ, Bishop DF: Nucleotide sequence of the human alpha-galactosidase A gene. Nucleic Acids Res. 1989 Apr 25;17(8):3301-2.
2836863	Bishop DF, Kornreich R, Desnick RJ: Structural organization of the human alpha-galactosidase A gene: further evidence for the absence of a 3' untranslated region. Proc Natl Acad Sci U S A. 1988 Jun;85(11):3903-7.
2892762	Quinn M, Hantzopoulos P, Fidanza V, Calhoun DH: A genomic clone containing the promoter for the gene encoding the human lysosomal enzyme, alpha-galactosidase A. Gene. 1987;58(2-3):177-88.
3014515	Bishop DF, Calhoun DH, Bernstein HS, Hantzopoulos P, Quinn M, Desnick RJ: Human alpha-galactosidase A: nucleotide sequence of a cDNA clone encoding the mature enzyme. Proc Natl Acad Sci U S A. 1986 Jul;83(13):4859-63.
3036505	Tsuji S, Martin BM, Kaslow DC, Migeon BR, Choudary PV, Stubbleflied BK, Mayor JA, Murray GJ, Barranger JA, Ginns EI: Signal sequence and DNA-mediated expression of human lysosomal alpha-galactosidase A. Eur J Biochem. 1987 Jun 1;165(2):275-80.
7503918	Novo FJ, Kruszewski A, MacDermot KD, Goldspink G, Gorecki DC: Editing of human alpha-galactosidase RNA resulting in a pyrimidine to purine conversion. Nucleic Acids Res. 1995 Jul 25;23(14):2636-40.
7626884	Oeltjen JC, Liu X, Lu J, Allen RC, Muzny D, Belmont JW, Gibbs RA: Sixty-nine kilobases of contiguous human genomic sequence containing the alpha-galactosidase A and Bruton's tyrosine kinase loci. Mamm Genome. 1995 May;6(5):334-8.

# Drug_Target_48_HGNC_ID:
HGNC:4296

# Drug_Target_48_HPRD_ID:
Not Available

# Drug_Target_48_ID:
4189

# Drug_Target_48_Locus:
Xq22

# Drug_Target_48_Molecular_Weight:
48767

# Drug_Target_48_Name:
Alpha-galactosidase A

# Drug_Target_48_Number_of_Residues:
429

# Drug_Target_48_PDB_ID:
1R47

# Drug_Target_48_Pathway:
Not Available

# Drug_Target_48_Pfam_Domain_Function:
PF02065	Melibiase

# Drug_Target_48_Protein_Sequence:
>Alpha-galactosidase A
MQLRNPELHLGCALALRFLALVSWDIPGARALDNGLARTPTMGWLHWERFMCNLDCQEEP
DSCISEKLFMEMAELMVSEGWKDAGYEYLCIDDCWMAPQRDSEGRLQADPQRFPHGIRQL
ANYVHSKGLKLGIYADVGNKTCAGFPGSFGYYDIDAQTFADWGVDLLKFDGCYCDSLENL
ADGYKHMSLALNRTGRSIVYSCEWPLYMWPFQKPNYTEIRQYCNHWRNFADIDDSWKSIK
SILDWTSFNQERIVDVAGPGGWNDPDMLVIGNFGLSWNQQVTQMALWAIMAAPLFMSNDL
RHISPQAKALLQDKDVIAINQDPLGKQGYQLRQGDNFEVWERPLSGLAWAVAMINRQEIG
GPRSYTIAVASLGKGVACNPACFITQLLPVKRKLGFYEWTSRLRSHINPTGTVLLQLENT
MQMSLKDLL

# Drug_Target_48_Reaction:
Not Available

# Drug_Target_48_Signals:
1-31

# Drug_Target_48_Specific_Function:
Hydrolysis of terminal, non-reducing alpha-D- galactose residues in alpha-D-galactosides, including galactose oligosaccharides, galactomannans and galactohydrolase

# Drug_Target_48_SwissProt_ID:
P06280

# Drug_Target_48_SwissProt_Name:
AGAL_HUMAN

# Drug_Target_48_Synonyms:
Agalsidase alfa
Alpha-D- galactoside galactohydrolase
Alpha-D-galactosidase A
Alpha-galactosidase A precursor
EC 3.2.1.22
Melibiase

# Drug_Target_48_Theoretical_pI:
5.27

# Drug_Target_48_Transmembrane_Regions:
None

# Drug_Target_49_Cellular_Location:
Secreted

# Drug_Target_49_Chromosome_Location:
1

# Drug_Target_49_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_49_Essentiality:
Non-Essential

# Drug_Target_49_GenAtlas_ID:
Not Available

# Drug_Target_49_GenBank_ID_Gene:
AL928742

# Drug_Target_49_GenBank_ID_Protein:
Not Available

# Drug_Target_49_GeneCard_ID:
IGHG2

# Drug_Target_49_Gene_Name:
IGHG2

# Drug_Target_49_Gene_Sequence:
Not Available

# Drug_Target_49_General_Function:
Involved in antigen binding

# Drug_Target_49_General_References:
113060	Connell GE, Parr DM, Hofmann T: The amino acid sequences of the three heavy chain constant region domains of a human IgG2 myeloma protein. Can J Biochem. 1979 Jun;57(6):758-67.
118920	Hofmann T, Parr DM: A note of the amino acid sequence of residues 381--391 of human immunoglobulins gamma chains. Mol Immunol. 1979 Nov;16(11):923-5.
12508121	Heilig R, Eckenberg R, Petit JL, Fonknechten N, Da Silva C, Cattolico L, Levy M, Barbe V, de Berardinis V, Ureta-Vidal A, Pelletier E, Vico V, Anthouard V, Rowen L, Madan A, Qin S, Sun H, Du H, Pepin K, Artiguenave F, Robert C, Cruaud C, Bruls T, Jaillon O, Friedlander L, Samson G, Brottier P, Cure S, Segurens B, Aniere F, Samain S, Crespeau H, Abbasi N, Aiach N, Boscus D, Dickhoff R, Dors M, Dubois I, Friedman C, Gouyvenoux M, James R, Madan A, Mairey-Estrada B, Mangenot S, Martins N, Menard M, Oztas S, Ratcliffe A, Shaffer T, Trask B, Vacherie B, Bellemere C, Belser C, Besnard-Gonnet M, Bartol-Mavel D, Boutard M, Briez-Silla S, Combette S, Dufosse-Laurent V, Ferron C, Lechaplais C, Louesse C, Muselet D, Magdelenat G, Pateau E, Petit E, Sirvain-Trukniewicz P, Trybou A, Vega-Czarny N, Bataille E, Bluet E, Bordelais I, Dubois M, Dumont C, Guerin T, Haffray S, Hammadi R, Muanga J, Pellouin V, Robert D, Wunderle E, Gauguet G, Roy A, Sainte-Marthe L, Verdier J, Verdier-Discala C, Hillier L, Fulton L, McPherson J, Matsuda F, Wilson R, Scarpelli C, Gyapay G, Wincker P, Saurin W, Quetier F, Waterston R, Hood L, Weissenbach J: The DNA sequence and analysis of human chromosome 14. Nature. 2003 Feb 6;421(6923):601-7. Epub 2003 Jan 1.
4940472	Milstein C, Frangione B: Disulphide bridges of the heavy chain of human immunoglobulin G2. Biochem J. 1971 Jan;121(2):217-25.
6329676	Krawinkel U, Rabbitts TH: Comparison of the hinge-coding segments in human immunoglobulin gamma heavy chain genes and the linkage of the gamma 2 and gamma 4 subclass genes. EMBO J. 1982;1(4):403-7.
6774012	Wang AC, Tung E, Fudenberg HH: The primary structure of a human IgG2 heavy chain: genetic, evolutionary, and functional implications. J Immunol. 1980 Sep;125(3):1048-54.
6804948	Ellison J, Hood L: Linkage and sequence homology of two human immunoglobulin gamma heavy chain constant region genes. Proc Natl Acad Sci U S A. 1982 Mar;79(6):1984-8.
6811139	Takahashi N, Ueda S, Obata M, Nikaido T, Nakai S, Honjo T: Structure of human immunoglobulin gamma genes: implications for evolution of a gene family. Cell. 1982 Jun;29(2):671-9.
7737190	Stoppini M, Bellotti V, Negri A, Merlini G, Garver F, Ferri G: Characterization of the two unique human anti-flavin monoclonal immunoglobulins. Eur J Biochem. 1995 Mar 15;228(3):886-93.

# Drug_Target_49_HGNC_ID:
GNC:5526

# Drug_Target_49_HPRD_ID:
Not Available

# Drug_Target_49_ID:
6307

# Drug_Target_49_Locus:
14q32.33

# Drug_Target_49_Molecular_Weight:
35900.4

# Drug_Target_49_Name:
Ig gamma-2 chain C region

# Drug_Target_49_Number_of_Residues:
326

# Drug_Target_49_PDB_ID:
Not Available

# Drug_Target_49_Pathway:
Not Available

# Drug_Target_49_Pfam_Domain_Function:
PF07654	C1-set

# Drug_Target_49_Protein_Sequence:
>Ig gamma-2 chain C region
ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVF
LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFR
VVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKN
QVSLTCLVKGFYPSDISVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGN
VFSCSVMHEALHNHYTQKSLSLSPGK

# Drug_Target_49_Reaction:
Not Available

# Drug_Target_49_Signals:
None

# Drug_Target_49_Specific_Function:
Not Available

# Drug_Target_49_SwissProt_ID:
P01859

# Drug_Target_49_SwissProt_Name:
IGHG2_HUMAN

# Drug_Target_49_Synonyms:
Not Available

# Drug_Target_49_Theoretical_pI:
7.66

# Drug_Target_49_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Not Available

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
Not Available

# Drug_Target_4_GenBank_ID_Protein:
Not Available

# Drug_Target_4_GeneCard_ID:
Not Available

# Drug_Target_4_Gene_Name:
DNASE1

# Drug_Target_4_Gene_Sequence:
Not Available

# Drug_Target_4_General_Function:
Not Available

# Drug_Target_4_General_References:
Not Available

# Drug_Target_4_HGNC_ID:
Not Available

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
6966

# Drug_Target_4_Locus:
Not Available

# Drug_Target_4_Molecular_Weight:
Not Available

# Drug_Target_4_Name:
Deoxyribonuclease-1

# Drug_Target_4_Number_of_Residues:
0

# Drug_Target_4_PDB_ID:
Not Available

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
Not Available

# Drug_Target_4_Protein_Sequence:
Not Available

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
Not Available

# Drug_Target_4_Specific_Function:
Not Available

# Drug_Target_4_SwissProt_ID:
P24855

# Drug_Target_4_SwissProt_Name:
DNAS1_HUMAN

# Drug_Target_4_Synonyms:
Not Available

# Drug_Target_4_Theoretical_pI:
Not Available

# Drug_Target_4_Transmembrane_Regions:
Not Available

# Drug_Target_50_Cellular_Location:
Membrane

# Drug_Target_50_Chromosome_Location:
Not Available

# Drug_Target_50_Drug_References:
Not Available

# Drug_Target_50_Essentiality:
Non-Essential

# Drug_Target_50_GenAtlas_ID:
Not Available

# Drug_Target_50_GenBank_ID_Gene:
M24692

# Drug_Target_50_GenBank_ID_Protein:
Not Available

# Drug_Target_50_GeneCard_ID:
Not Available

# Drug_Target_50_Gene_Name:
F

# Drug_Target_50_Gene_Sequence:
>1662 bp
ATGGGCTCCAGATCTTCTACCAGGATCCCAGTACCTCTGATGCTGACCGTCCGAATCATG
TTGGCACTGAGTTGCGTCTGTCCGACCAGCTCCCTTGATGGCAGGCCTCTTGCAGCTGCA
GGGATTGTGGTAACAGGAGACAAAGCAGTCAACATATACACCTCATCTCAGACAGGGTCA
ATCATAATCAAGTTACTCCCAAATATGCCCAAGGATAAAGAGGCGTGTGCAAAAGCCCCA
TTGGAAGCATACAACAGGACATTGACTACTTTGCTCACCCCCCTTGGTGATTCTATCCGT
AGGATACAAGAGTCTGTGACCACATCCGGAGGAGGGAAACAGGGACGTCTTATAGGCGCC
ATTATCGGTGGTGTAGCTCTCGGGGTTGCAACCGCTGCACAGATAACAGCAGCCTCGGCT
CTGATACAAGCCAATCAAAATGCTGCCAACATCCTCCGGCTCAAAGAGAGCATTGCTGCA
ACCAATGAGGCTGTGCACGAGGTCACTGACGGATTATCACAACTAGCAGTGGCAGTTGGG
AAGATGCAGCAATTTGTTAATGACCAGTTTAATAAAACAGCTCAGGAATTGGACTGTATA
AAAATTACACAGCAGGTTGGTGTAGAACTCAACCTGTACCTAACTGAATTGACTACAGTA
TTCGGGCCACAAATCACTTCCCCTGCCTTAACTCAGCTGACTATCCAGGCGCTTTACAAT
CTAGCTGGTGGGAATATGGATTACTTGTTGACTAAGTTAGGTGTAGGAAACAACCAACTC
AGCTCATTAATTGGTAGTGGCCTGATTACCGGCAACCCTATCCTGTACGACTCACAGACT
CAACTCTTGGGTATACAGGTCACCCTACCCTCAGTCGGGAATCTAAATAATATGCGTGCC
ACCTACCTGGAAACCTTGTCTGTAAGTACAACCAAAGGATTTGCCTCAGCACTTGTCCCA
AAAGTAGTGACACAGGTTGGTTCCGTGATAGAAGAGCTTGACACCTCGTACTGTATCGAG
ACCGATTTGGACCTATATTGTACAAGAATAGTGACATTCCCTATGTCTCCTGGTATTTAT
TCCTGTTTGAGTGGCAATACATCTGCTTGCATGTATTCAAAGACTGAAGGCGCACTCACT
ACGCCGTATATGACCCTCAAAGGCTCAGTTATTGCCAACTGTAAGATGACAACATGTAGA
TGTGCAGACCCCCCGGGTATCATATCGCAGAATTATGGAGAAGCTGTGTCTCTAATAGAT
AGGCAATCATGCAATATCTTATCCTTAGACGGGATAACTTTGAGGCTCAGTGGGGAATTT
GATGCAACTTATCAAAAGAATATCTCAATACAAGATTCTCAAGTAATAGTTACAGGCAAT
CTTGACATCTCGACTGAGCTTGGGAATGTCAACAACTCGATAAGTAATGCTTTGGATAAG
TTAGAGGAAAGCAACAGCAAACTAGACAAGGTCAATGTTAAACTGACCAGCACATCCGCT
CTTATTACCTATATCTTTTTAACTGTCATATCTCTTGTATGTGGTATACTTAGCCTGGTT
CTAGCATGCTACCTGATGTACAAGCAAAAGGCGCAACAGAAGACCTTGTTGTGGCTTGGG
AATAATACCCTAGACCAGATGAGGGCCACTACAAAAATGTGA

# Drug_Target_50_General_Function:
Not Available

# Drug_Target_50_General_References:
11286892	Chen L, Gorman JJ, McKimm-Breschkin J, Lawrence LJ, Tulloch PA, Smith BJ, Colman PM, Lawrence MC: The structure of the fusion glycoprotein of Newcastle disease virus suggests a novel paradigm for the molecular mechanism of membrane fusion. Structure. 2001 Mar 7;9(3):255-66.
2705298	Toyoda T, Sakaguchi T, Hirota H, Gotoh B, Kuma K, Miyata T, Nagai Y: Newcastle disease virus evolution. II. Lack of gene recombination in generating virulent and avirulent strains. Virology. 1989 Apr;169(2):273-82.

# Drug_Target_50_HGNC_ID:
Not Available

# Drug_Target_50_HPRD_ID:
Not Available

# Drug_Target_50_ID:
4875

# Drug_Target_50_Locus:
Not Available

# Drug_Target_50_Molecular_Weight:
58893

# Drug_Target_50_Name:
Fusion glycoprotein F0

# Drug_Target_50_Number_of_Residues:
553

# Drug_Target_50_PDB_ID:
1G5G

# Drug_Target_50_Pathway:
Not Available

# Drug_Target_50_Pfam_Domain_Function:
PF00523	Fusion_gly

# Drug_Target_50_Protein_Sequence:
>Fusion glycoprotein F0
MGSRSSTRIPVPLMLTVRIMLALSCVCPTSSLDGRPLAAAGIVVTGDKAVNIYTSSQTGS
IIIKLLPNMPKDKEACAKAPLEAYNRTLTTLLTPLGDSIRRIQESVTTSGGGKQGRLIGA
IIGGVALGVATAAQITAASALIQANQNAANILRLKESIAATNEAVHEVTDGLSQLAVAVG
KMQQFVNDQFNKTAQELDCIKITQQVGVELNLYLTELTTVFGPQITSPALTQLTIQALYN
LAGGNMDYLLTKLGVGNNQLSSLIGSGLITGNPILYDSQTQLLGIQVTLPSVGNLNNMRA
TYLETLSVSTTKGFASALVPKVVTQVGSVIEELDTSYCIETDLDLYCTRIVTFPMSPGIY
SCLSGNTSACMYSKTEGALTTPYMTLKGSVIANCKMTTCRCADPPGIISQNYGEAVSLID
RQSCNILSLDGITLRLSGEFDATYQKNISIQDSQVIVTGNLDISTELGNVNNSISNALDK
LEESNSKLDKVNVKLTSTSALITYIFLTVISLVCGILSLVLACYLMYKQKAQQKTLLWLG
NNTLDQMRATTKM

# Drug_Target_50_Reaction:
Not Available

# Drug_Target_50_Signals:
1-31

# Drug_Target_50_Specific_Function:
Class I viral fusion protein. Under the current model, the protein has at least 3 conformational states:pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During viral and target cell membrane fusion, the heptad repeat (HR) regions assume a trimer-of-hairpins structure, positioning the fusion peptide in close proximity to the C- terminal region of the ectodomain. The formation of this structure appears to drive apposition and subsequent fusion of viral and target cell membranes. Directs fusion of viral and cellular membranes leading to delivery of the nucleocapsid into the cytoplasm. This fusion is pH independent and occurs directly at the outer cell membrane. The trimer of F1-F2 (F protein) probably interacts with HN at the virion surface. Upon HN binding to its cellular receptor, the hydrophobic fusion peptide is unmasked and interacts with the cellular membrane, inducing the fusion between cell and virion membranes. Later in infection, F proteins expressed at the plasma membrane of infected cells could mediate fusion with adjacent cells to form syncytia, a cytopathic effect that could lead to tissue necrosis (By similarity)

# Drug_Target_50_SwissProt_ID:
P35936

# Drug_Target_50_SwissProt_Name:
FUS_NDVD

# Drug_Target_50_Synonyms:
Fusion glycoprotein F0 precursor

# Drug_Target_50_Theoretical_pI:
6.87

# Drug_Target_50_Transmembrane_Regions:
501-521

# Drug_Target_51_Cellular_Location:
Cytoplasmic

# Drug_Target_51_Chromosome_Location:
Not Available

# Drug_Target_51_Drug_References:
Not Available

# Drug_Target_51_Essentiality:
Non-Essential

# Drug_Target_51_GenAtlas_ID:
Not Available

# Drug_Target_51_GenBank_ID_Gene:
AJ006227

# Drug_Target_51_GenBank_ID_Protein:
Not Available

# Drug_Target_51_GeneCard_ID:
Not Available

# Drug_Target_51_Gene_Name:
man

# Drug_Target_51_Gene_Sequence:
>837 bp
GGGCTGCATGTAAAGAACGGCCGCCTGTATGAGGCCAACGGGCAGGAGTTCATCATCCGT
GGCGTCAGCCACCCCCACAACTGGTACCCCCAGCACACCCAGGCGTTCGCCGACATCAAG
TCGCACGGCGCCAACACCGTCCGGGTGGTGCTGAGCAACGGTGTCCGGTGGAGCAAGAAC
GGTCCTTCTGACGTCGCCAACGTCATCTCCCTGTGCAAGCAGAACCGCCTTATCTGCATG
CTGGAGGTGCACGACACCACCGGCTACGGTGAGCAGAGCGGGGCCTCCACGCTCGACCAG
GCCGTCGACTACTGGATCGAGCTGAAGAGCGTGCTCCAGGGCGAGGAGGACTATGTCCTC
ATCAACATCGGCAACGAGCCCTACGGCAACGACTCCGCGACCGTCGCCGCTGGGGCGTGG
GACACCTCCGCCGCCATCCAGCGGCTGCGCGCCGCCGGATTCGAGCACACCCTCGTGGTG
GACGCCCCCAACTGGGGCCAGGACTGGACGAACACCATGCGGAACAACGCCGACCAGGTG
TACGCCAGCGACCCCACCGGCAACACCGTCTTCTCGATCCACATGTACGGCGTCTACTCC
CAGGCGTCCACGATCACCAGCTACCTGGAGCACTTCGTCAACGCGGGCCTGCCGCTCATC
ATCGGCGAGTTCGGCCACGACCACTCCGACGGCAACCCCGACGAGGACACGATCATGGCC
GAGGCCGAGCGGCTCAAGCTGGGCTACATCGGCTGGTCGTGGAGTGGCAACGGCGGCGGG
GTCGAGTACCTCGACATGGTGTACAACTTCGACGGCGACAACCTGAGCCCGTGGGGC

# Drug_Target_51_General_Function:
Involved in hydrolase activity, hydrolyzing O-glycosyl compounds

# Drug_Target_51_General_References:
9817845	Hilge M, Gloor SM, Rypniewski W, Sauer O, Heightman TD, Zimmermann W, Winterhalter K, Piontek K: High-resolution native and complex structures of thermostable beta-mannanase from Thermomonospora fusca - substrate specificity in glycosyl hydrolase family 5. Structure. 1998 Nov 15;6(11):1433-44.

# Drug_Target_51_HGNC_ID:
Not Available

# Drug_Target_51_HPRD_ID:
Not Available

# Drug_Target_51_ID:
4877

# Drug_Target_51_Locus:
Not Available

# Drug_Target_51_Molecular_Weight:
30657

# Drug_Target_51_Name:
Beta-mannanase

# Drug_Target_51_Number_of_Residues:
279

# Drug_Target_51_PDB_ID:
3MAN

# Drug_Target_51_Pathway:
Not Available

# Drug_Target_51_Pfam_Domain_Function:
PF00150	Cellulase

# Drug_Target_51_Protein_Sequence:
>Beta-mannanase
GLHVKNGRLYEANGQEFIIRGVSHPHNWYPQHTQAFADIKSHGANTVRVVLSNGVRWSKN
GPSDVANVISLCKQNRLICMLEVHDTTGYGEQSGASTLDQAVDYWIELKSVLQGEEDYVL
INIGNEPYGNDSATVAAGAWDTSAAIQRLRAAGFEHTLVVDAPNWGQDWTNTMRNNADQV
YASDPTGNTVFSIHMYGVYSQASTITSYLEHFVNAGLPLIIGEFGHDHSDGNPDEDTIMA
EAERLKLGYIGWSWSGNGGGVEYLDMVYNFDGDNLSPWG

# Drug_Target_51_Reaction:
Not Available

# Drug_Target_51_Signals:
None

# Drug_Target_51_Specific_Function:
Not Available

# Drug_Target_51_SwissProt_ID:
Q9ZF13

# Drug_Target_51_SwissProt_Name:
Q9ZF13_THEFU

# Drug_Target_51_Synonyms:
EC 3.2.1.78

# Drug_Target_51_Theoretical_pI:
4.51

# Drug_Target_51_Transmembrane_Regions:
None

# Drug_Target_52_Cellular_Location:
Secreted protein

# Drug_Target_52_Chromosome_Location:
Not Available

# Drug_Target_52_Drug_References:
Not Available

# Drug_Target_52_Essentiality:
Non-Essential

# Drug_Target_52_GenAtlas_ID:
CGA

# Drug_Target_52_GenBank_ID_Gene:
J00152

# Drug_Target_52_GenBank_ID_Protein:
Not Available

# Drug_Target_52_GeneCard_ID:
Not Available

# Drug_Target_52_Gene_Name:
CGA

# Drug_Target_52_Gene_Sequence:
>351 bp
ATGGATTACTACAGAAAATATGCAGCTATCTTTCTGGTCACATTGTCGGTGTTTCTGCAT
GTTCTCCATTCCGCTCCTGATGTGCAGGATTGCCCAGAATGCACGCTACAGGAAAACCCA
TTCTTCTCCCAGCCGGGTGCCCCAATACTTCAGTGCATGGGCTGCTGCTTCTCTAGAGCA
TATCCCACTCCACTAAGGTCCAAGAAGACGATGTTGGTCCAAAAGAACGTCACCTCAGAG
TCCACTTGCTGTGTAGCTAAATCATATAACAGGGTCACAGTAATGGGGGGTTTCAAAGTG
GAGAACCACACGGCGTGCCACTGCAGTACTTGTTATTATCACAAATCTTAA

# Drug_Target_52_General_Function:
Involved in hormone activity

# Drug_Target_52_General_References:
1158880	Rathnam P, Saxena BB: Primary amino acid sequence of follicle-stimulating hormone from human pituitary glands. I. alpha subunit. J Biol Chem. 1975 Sep 10;250(17):6735-46.
481597	Fiddes JC, Goodman HM: Isolation, cloning and sequence analysis of the cDNA for the alpha-subunit of human chorionic gonadotropin. Nature. 1979 Oct 4;281(5730):351-6.
4835135	Shome B, Parlow AF: Human follicle stimulating hormone (hFSH): first proposal for the amino acid sequence of the alpha-subunit (hFSHa) and first demonstration of its identity with the alpha-subunit of human luteinizing hormone (hLHa). J Clin Endocrinol Metab. 1974 Jul;39(1):199-202.
5065401	Sairam MR, Papkoff H, Li CH: Human pituitary interstitial cell stimulating hormone: primary structure of the subunit. Biochem Biophys Res Commun. 1972 Aug 7;48(3):530-7.
6286817	Fiddes JC, Goodman HM: The gene encoding the common alpha subunit of the four human glycoprotein hormones. J Mol Appl Genet. 1981;1(1):3-18.
7462224	Birken S, Fetherston J, Canfield R, Boime I: The amino acid sequences of the prepeptides contained in the alpha and beta subunits of human choriogonadotropin. J Biol Chem. 1981 Feb 25;256(4):1816-23.
8196184	Miyoshi I, Kasai N, Hayashizaki Y: [Structure and regulation of human thyroid-stimulating hormone (TSH) gene] Nippon Rinsho. 1994 Apr;52(4):940-7.
890569	Sairam MR, Li CH: Human pituitary thyrotropin. The primary structure of the alpha and beta subunits. Can J Biochem. 1977 Jul;55(7):755-60.

# Drug_Target_52_HGNC_ID:
HGNC:1885

# Drug_Target_52_HPRD_ID:
Not Available

# Drug_Target_52_ID:
4878

# Drug_Target_52_Locus:
6q12-q21

# Drug_Target_52_Molecular_Weight:
13075

# Drug_Target_52_Name:
Glycoprotein hormones alpha chain

# Drug_Target_52_Number_of_Residues:
116

# Drug_Target_52_PDB_ID:
1XWD

# Drug_Target_52_Pathway:
Not Available

# Drug_Target_52_Pfam_Domain_Function:
PF00236	Hormone_6

# Drug_Target_52_Protein_Sequence:
>Glycoprotein hormones alpha chain
MDYYRKYAAIFLVTLSVFLHVLHSAPDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRA
YPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS

# Drug_Target_52_Reaction:
Not Available

# Drug_Target_52_Signals:
1-24

# Drug_Target_52_Specific_Function:
Not Available

# Drug_Target_52_SwissProt_ID:
P01215

# Drug_Target_52_SwissProt_Name:
GLHA_HUMAN

# Drug_Target_52_Synonyms:
Anterior pituitary glycoprotein hormones common subunit alpha
CG-alpha
Choriogonadotropin alpha chain
Chorionic gonadotrophin alpha subunit
FSH-alpha
Follicle-stimulating hormone alpha chain
Follitropin alpha chain
Glycoprotein hormones alpha chain precursor
LSH-alpha
Luteinizing hormone alpha chain
Lutropin alpha chain
TSH-alpha
Thyroid-stimulating hormone alpha chain
Thyrotropin alpha chain

# Drug_Target_52_Theoretical_pI:
8.26

# Drug_Target_52_Transmembrane_Regions:
None

# Drug_Target_53_Cellular_Location:
Cytoplasmic

# Drug_Target_53_Chromosome_Location:
Not Available

# Drug_Target_53_Drug_References:
Not Available

# Drug_Target_53_Essentiality:
Non-Essential

# Drug_Target_53_GenAtlas_ID:
C1R

# Drug_Target_53_GenBank_ID_Gene:
X04701

# Drug_Target_53_GenBank_ID_Protein:
29539

# Drug_Target_53_GeneCard_ID:
C1R

# Drug_Target_53_Gene_Name:
C1R

# Drug_Target_53_Gene_Sequence:
>2118 bp
ATGTGGCTCTTGTACCTCCTGGTGCCGGCCCTGTTCTGCAGGGCAGGAGGCTCCATTCCC
ATCCCTCAGAAGTTATTTGGGGAGGTGACTTCCCCTCTGTTCCCCAAGCCTTACCCCAAC
AACTTTGAAACAACCACTGTGATCACAGTCCCCACGGGATACAGGGTGAAGCTCGTCTTC
CAGCAGTTTGACCTGGAGCCTTCTGAAGGCTGCTTCTATGATTATGTCAAGATCTCTGCT
GATAAGAAAAGCCTGGGGAGGTTCTGTGGGCAACTGGGTTCTCCACTGGGCAACCCCCCG
GGAAAGAAGGAATTTATGTCCCAAGGGAACAAGATGCTGCTGACCTTCCACACAGACTTC
TCCAACGAGGAGAATGGGACCATCATGTTCTACAAGGGCTTCCTGGCCTACTACCAAGCT
GTGGACCTTGATGAATGTGCTTCCCGGAGCAAATTAGGGGAGGAGGATCCCCAGCCCCAG
TGCCAGCACCTGTGTCACAACTACGTTGGAGGCTACTTCTGTTCCTGCCGTCCAGGCTAT
GAGCTTCAGGAAGACAGGCATTCCTGCCAGGCTGAGTGCAGCAGCGAGCTGTACACGGAG
GCATCAGGCTACATCTCCAGCCTGGAGTACCCTCGGTCCTACCCCCCTGACCTGCGCTGC
AACTACAGCATCCGGGTGGAGCGGGGCCTCACCCTGCACCTCAAGTTCCTGGAGCCTTTT
GATATTGATGACCACCAGCAAGTACACTGCCCCTATGACCAGCTACAGATCTATGCCAAC
GGGAAGAACATTGGCGAGTTCTGTGGGAAGCAAAGGCCCCCCGACCTCGACACCAGCAGC
AATGCTGTGGATCTGCTGTTCTTCACAGATGAGTCGGGGGACAGCCGGGGCTGGAAGCTG
CGCTACACCACCGAGATCATCAAGTGCCCCCAGCCCAAGACCCTAGACGAGTTCACCATC
ATCCAGAACCTGCAGCCTCAGTACCAGTTCCGTGACTACTTCATTGCTACCTGCAAGCAA
GGCTACCAGCTCATAGAGGGGAACCAGGTGCTGCATTCCTTCACAGCTGTCTGCCAGGAT
GATGGCACGTGGCATCGTGCCATGCCCAGATGCAAGATCAAGGACTGTGGGCAGCCCCGA
AACCTGCCTAATGGTGACTTCCGTTACACCACCACAATGGGAGTGAACACCTACAAGGCC
CGTATCCAGTACTACTGCCATGAGCCATATTACAAGATGCAGACCAGAGCTGGCAGCAGG
GAGTCTGAGCAAGGGGTGTACACCTGCACAGCACAGGGCATTTGGAAGAATGAACAGAAG
GGAGAGAAGATTCCTCGGTGCTTGCCAGTGTGTGGGAAGCCCGTGAACCCCGTGGAACAG
AGGCAGCGCATCATCGGAGGGCAAAAAGCCAAGATGGGCAACTTCCCCTGGCAGGTGTTC
ACCAACATCCACGGGCGCGGGGGCGGGGCCCTGCTGGGCGACCGCTGGATCCTCACAGCT
GCCCACACCCTGTATCCCAAGGAACACGAAGCGCAAAGCAACGCCTCTTTGGATGTGTTC
CTGGGCCACACAAATGTGGAAGAGCTCATGAAGCTAGGAAATCACCCCATCCGCAGGGTC
AGCGTCCACCCGGACTACCGTCAGGATGAGTCCTACAATTTTGAGGGGGACATCGCCCTG
CTGGAGCTGGAAAATAGTGTCACCCTGGGTCCCAACCTCCTCCCCATCTGCCTCCCTGAC
AACGATACCTTCTACGACCTGGGCTTGATGGGCTATGTCAGTGGCTTCGGGGTCATGGAG
GAGAAGATTGCTCATGACCTCAGGTTTGTCCGTCTGCCCGTAGCTAATCCACAGGCCTGT
GAGAACTGGCTCCGGGGAAAGAATAGGATGGATGTGTTCTCTCAAAACATGTTCTGTGCT
GGACACCCATCTCTAAAGCAGGACGCCTGCCAGGGGGATAGTGGGGGCGTTTTTGCAGTA
AGGGACCCGAACACTGATCGCTGGGTGGCCACGGGCATCGTGTCCTGGGGCATCGGGTGC
AGCAGGGGCTATGGCTTCTACACCAAAGTGCTCAACTACGTGGACTGGATCAAGAAAGAG
ATGGAGGAGGAGGACTGA

# Drug_Target_53_General_Function:
Not Available

# Drug_Target_53_General_References:
2820791	Arlaud GJ, Van Dorsselaer A, Bell A, Mancini M, Aude C, Gagnon J: Identification of erythro-beta-hydroxyasparagine in the EGF-like domain of human C1r. FEBS Lett. 1987 Sep 28;222(1):129-34.
3021205	Leytus SP, Kurachi K, Sakariassen KS, Davie EW: Nucleotide sequence of the cDNA coding for human complement C1r. Biochemistry. 1986 Aug 26;25(17):4855-63.
3030286	Journet A, Tosi M: Cloning and sequencing of full-length cDNA encoding the precursor of human complement component C1r. Biochem J. 1986 Dec 15;240(3):783-7.
3036070	Arlaud GJ, Willis AC, Gagnon J: Complete amino acid sequence of the A chain of human complement-classical-pathway enzyme C1r. Biochem J. 1987 Feb 1;241(3):711-20.
6303394	Arlaud GJ, Gagnon J: Complete amino acid sequence of the catalytic chain of human complement subcomponent C1-r. Biochemistry. 1983 Apr 12;22(8):1758-64.
8635594	Pelloux S, Thielens NM, Hudry-Clergeon G, Petillot Y, Filhol O, Arlaud GJ: Identification of a cryptic protein kinase CK2 phosphorylation site in human complement protease Clr, and its use to probe intramolecular interaction. FEBS Lett. 1996 May 13;386(1):15-20.
9477945	Bersch B, Hernandez JF, Marion D, Arlaud GJ: Solution structure of the epidermal growth factor (EGF)-like module of human complement protease C1r, an atypical member of the EGF family. Biochemistry. 1998 Feb 3;37(5):1204-14.

# Drug_Target_53_HGNC_ID:
HGNC:1246

# Drug_Target_53_HPRD_ID:
Not Available

# Drug_Target_53_ID:
3814

# Drug_Target_53_Locus:
12p13

# Drug_Target_53_Molecular_Weight:
80174

# Drug_Target_53_Name:
Complement C1r subcomponent

# Drug_Target_53_Number_of_Residues:
705

# Drug_Target_53_PDB_ID:
1GPZ

# Drug_Target_53_Pathway:
Not Available

# Drug_Target_53_Pfam_Domain_Function:
PF00084	Sushi
PF00089	Trypsin
PF00431	CUB
PF07645	EGF_CA

# Drug_Target_53_Protein_Sequence:
>Complement C1r subcomponent
MWLLYLLVPALFCRAGGSIPIPQKLFGEVTSPLFPKPYPNNFETTTVITVPTGYRVKLVF
QQFDLEPSEGCFYDYVKISADKKSLGRFCGQLGSPLGNPPGKKEFMSQGNKMLLTFHTDF
SNEENGTIMFYKGFLAYYQAVDLDECASRSKSGEEDPQPQCQHLCHNYVGGYFCSCRPGY
ELQEDRHSCQAECSSELYTEASGYISSLEYPRSYPPDLRCNYSIRVERGLTLHLKFLEPF
DIDDHQQVHCPYDQLQIYANGKNIGEFCGKQRPPDLDTSSNAVDLLFFTDESGDSRGWKL
RYTTEIIKCPQPKTLDEFTIIQNLQPQYQFRDYFIATCKQGYQLIEGNQVLHSFTAVCQD
DGTWHRAMPRCKIKDCGQPRNLPNGDFRYTTTMGVNTYKARIQYYCHEPYYKMQTRAGSR
ESEQGVYTCTAQGIWKNEQKGEKIPRCLPVCGKPVNPVEQRQRIIGGQKAKMGNFPWQVF
TNIHGRGGGALLGDRWILTAAHTLYPKEHEAQSNASLDVFLGHTNVEELMKLGNHPIRRV
SVHPDYRQDESYNFEGDIALLELENSVTLGPNLLPICLPDNDTFYDLGLMGYVSGFGVME
EKIAHDLRFVRLPVANPQACENWLRGKNRMDVFSQNMFCAGHPSLKQDACQGDSGGVFAV
RDPNTDRWVATGIVSWGIGCSRGYGFYTKVLNYVDWIKKEMEEED

# Drug_Target_53_Reaction:
Selective cleavage of Lys(or Arg)!Ile bond in complement subcomponent C1s to form C_overbar_1s_ (internal_xref(ec_num(3,4,21,42)))

# Drug_Target_53_Signals:
1-17

# Drug_Target_53_Specific_Function:
C1r B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system

# Drug_Target_53_SwissProt_ID:
P00736

# Drug_Target_53_SwissProt_Name:
C1R_HUMAN

# Drug_Target_53_Synonyms:
Complement C1r subcomponent precursor
Complement component 1, r subcomponent
EC 3.4.21.41

# Drug_Target_53_Theoretical_pI:
6.24

# Drug_Target_53_Transmembrane_Regions:
None

# Drug_Target_54_Cellular_Location:
Not Available

# Drug_Target_54_Chromosome_Location:
Not Available

# Drug_Target_54_Drug_References:
Not Available

# Drug_Target_54_Essentiality:
Non-Essential

# Drug_Target_54_GenAtlas_ID:
Not Available

# Drug_Target_54_GenBank_ID_Gene:
AE004091

# Drug_Target_54_GenBank_ID_Protein:
Not Available

# Drug_Target_54_GeneCard_ID:
Not Available

# Drug_Target_54_Gene_Name:
lecB

# Drug_Target_54_Gene_Sequence:
>348 bp
ATGGCAACACAAGGAGTGTTCACCCTTCCCGCCAACACCCGGTTCGGCGTCACCGCCTTC
GCCAACTCGTCCGGAACCCAGACGGTGAACGTGCTGGTCAACAACGAGACGGCCGCGACC
TTCAGCGGGCAAAGCACCAATAACGCCGTCATCGGCACCCAGGTGCTCAACTCCGGCAGC
AGTGGCAAGGTACAGGTCCAGGTCAGCGTCAACGGCCGCCCCTCGGATCTGGTCTCGGCA
CAGGTAATCCTGACCAACGAGCTGAACTTCGCCCTGGTCGGCTCTGAAGACGGCACCGAC
AACGACTACAACGACGCCGTCGTGGTGATCAACTGGCCGCTCGGCTAG

# Drug_Target_54_General_Function:
Not Available

# Drug_Target_54_General_References:
10984043	Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warrener P, Hickey MJ, Brinkman FS, Hufnagle WO, Kowalik DJ, Lagrou M, Garber RL, Goltry L, Tolentino E, Westbrock-Wadman S, Yuan Y, Brody LL, Coulter SN, Folger KR, Kas A, Larbig K, Lim R, Smith K, Spencer D, Wong GK, Wu Z, Paulsen IT, Reizer J, Saier MH, Hancock RE, Lory S, Olson MV: Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen. Nature. 2000 Aug 31;406(6799):959-64.
12415289	Mitchell E, Houles C, Sudakevitz D, Wimmerova M, Gautier C, Perez S, Wu AM, Gilboa-Garber N, Imberty A: Structural basis for oligosaccharide-mediated adhesion of Pseudomonas aeruginosa in the lungs of cystic fibrosis patients. Nat Struct Biol. 2002 Dec;9(12):918-21.
12909014	Loris R, Tielker D, Jaeger KE, Wyns L: Structural basis of carbohydrate recognition by the lectin LecB from Pseudomonas aeruginosa. J Mol Biol. 2003 Aug 22;331(4):861-70.

# Drug_Target_54_HGNC_ID:
Not Available

# Drug_Target_54_HPRD_ID:
Not Available

# Drug_Target_54_ID:
4666

# Drug_Target_54_Locus:
Not Available

# Drug_Target_54_Molecular_Weight:
11863

# Drug_Target_54_Name:
Fucose-binding lectin PA-IIL

# Drug_Target_54_Number_of_Residues:
115

# Drug_Target_54_PDB_ID:
1W8H

# Drug_Target_54_Pathway:
Not Available

# Drug_Target_54_Pfam_Domain_Function:
PF07472	PA-IIL

# Drug_Target_54_Protein_Sequence:
>Fucose-binding lectin PA-IIL
MATQGVFTLPANTRFGVTAFANSSGTQTVNVLVNNETAATFSGQSTNNAVIGTQVLNSGS
SGKVQVQVSVNGRPSDLVSAQVILTNELNFALVGSEDGTDNDYNDAVVVINWPLG

# Drug_Target_54_Reaction:
Not Available

# Drug_Target_54_Signals:
None

# Drug_Target_54_Specific_Function:
Not Available

# Drug_Target_54_SwissProt_ID:
Q9HYN5

# Drug_Target_54_SwissProt_Name:
Q9HYN5_PSEAE

# Drug_Target_54_Synonyms:
Not Available

# Drug_Target_54_Theoretical_pI:
3.83

# Drug_Target_54_Transmembrane_Regions:
None

# Drug_Target_55_Cellular_Location:
Acrosome

# Drug_Target_55_Chromosome_Location:
Not Available

# Drug_Target_55_Drug_References:
Not Available

# Drug_Target_55_Essentiality:
Non-Essential

# Drug_Target_55_GenAtlas_ID:
CD46

# Drug_Target_55_GenBank_ID_Gene:
Y00651

# Drug_Target_55_GenBank_ID_Protein:
Not Available

# Drug_Target_55_GeneCard_ID:
Not Available

# Drug_Target_55_Gene_Name:
CD46

# Drug_Target_55_Gene_Sequence:
>1155 bp
ATGGAGCCTCCCGGCCGCCGCGAGTGTCCCTTTCCTTCCTGGCGCTTTCCTGGGTTGCTT
CTGGCGGCCATGGTGTTGCTGCTGTACTCCTTCTCCGATGCCTGTGAGGAGCCACCAACA
TTTGAAGCTATGGAGCTCATTGGTAAACCAAAACCCTACTATGAGATTGGTGAACGAGTA
GATTATAAGTGTAAAAAAGGATACTTCTATATACCTCCTCTTGCCACCCATACTATTTGT
GATCGGAATCATACATGGCTACCTGTCTCAGATGACGCCTGTTATAGAGAAACATGTCCA
TATATACGGGATCCTTTAAATGGCCAAGCAGTCCCTGCAAATGGGACTTACGAGTTTGGT
TATCAGATGCACTTTATTTGTAATGAGGGTTATTACTTAATTGGTGAAGAAATTCTATAT
TGTGAACTTAAAGGATCAGTAGCAATTTGGAGCGGTAAGCCCCCAATATGTGAAAAGGTT
TTGTGTACACCACCTCCAAAAATAAAAAATGGAAAACACACCTTTAGTGAAGTAGAAGTA
TTTGAGTATCTTGATGCAGTAACTTATAGTTGTGATCCTGCACCTGGACCAGATCCATTT
TCACTTATTGGAGAGAGCACGATTTATTGTGGTGACAATTCAGTGTGGAGTCGTGCTGCT
CCAGAGTGTAAAGTGGTCAAATGTCGATTTCCAGTAGTCGAAAATGGAAAACAGATATCA
GGATTTGGAAAAAAATTTTACTACAAAGCAACAGTTATGTTTGAATGCGATAAGGGTTTT
TACCTCGATGGCAGCGACACAATTGTCTGTGACAGTAACAGTACTTGGGATCCCCCAGTT
CCAAAGTGTCTTAAAGTGTCGACTTCTTCCACTACAAAATCTCCAGCGTCCAGTGCCTCA
GGTCCTAGGCCTACTTACAAGCCTCCAGTCTCAAATTATCCAGGATATCCTAAACCTGAG
GAAGGAATACTTGACAGTTTGGATGTTTGGGTCATTGCTGTGATTGTTATTGCCATAGTT
GTTGGAGTTGCAGTAATTTGTGTTGTCCCGTACAGATATCTTCAAAGGAGGAAGAAGAAA
GGGAAAGCAGATGGTGGAGCTGAATATGCCACTTACCAGACTAAATCAACCACTCCAGCA
GAGCAGAGAGGCTGA

# Drug_Target_55_General_Function:
Not Available

# Drug_Target_55_General_References:
1711570	Post TW, Liszewski MK, Adams EM, Tedja I, Miller EA, Atkinson JP: Membrane cofactor protein of the complement system: alternative splicing of serine/threonine/proline-rich exons and cytoplasmic tails produces multiple isoforms that correlate with protein phenotype. J Exp Med. 1991 Jul 1;174(1):93-102.
2050389	Purcell DF, Russell SM, Deacon NJ, Brown MA, Hooker DJ, McKenzie IF: Alternatively spliced RNAs encode several isoforms of CD46 (MCP), a regulator of complement activation. Immunogenetics. 1991;33(5-6):335-44.
3260937	Lublin DM, Liszewski MK, Post TW, Arce MA, Le Beau MM, Rebentisch MB, Lemons LS, Seya T, Atkinson JP: Molecular cloning and chromosomal localization of human membrane cofactor protein (MCP). Evidence for inclusion in the multigene family of complement-regulatory proteins. J Exp Med. 1988 Jul 1;168(1):181-94.
8418811	Cervoni F, Fenichel P, Akhoundi C, Hsi BL, Rossi B: Characterization of a cDNA clone coding for human testis membrane cofactor protein (MCP, CD46). Mol Reprod Dev. 1993 Jan;34(1):107-13.

# Drug_Target_55_HGNC_ID:
HGNC:6953

# Drug_Target_55_HPRD_ID:
Not Available

# Drug_Target_55_ID:
4880

# Drug_Target_55_Locus:
1q32

# Drug_Target_55_Molecular_Weight:
43747

# Drug_Target_55_Name:
Membrane cofactor protein

# Drug_Target_55_Number_of_Residues:
392

# Drug_Target_55_PDB_ID:
1CKL

# Drug_Target_55_Pathway:
Not Available

# Drug_Target_55_Pfam_Domain_Function:
PF00084	Sushi

# Drug_Target_55_Protein_Sequence:
>Membrane cofactor protein
MEPPGRRECPFPSWRFPGLLLAAMVLLLYSFSDACEEPPTFEAMELIGKPKPYYEIGERV
DYKCKKGYFYIPPLATHTICDRNHTWLPVSDDACYRETCPYIRDPLNGQAVPANGTYEFG
YQMHFICNEGYYLIGEEILYCELKGSVAIWSGKPPICEKVLCTPPPKIKNGKHTFSEVEV
FEYLDAVTYSCDPAPGPDPFSLIGESTIYCGDNSVWSRAAPECKVVKCRFPVVENGKQIS
GFGKKFYYKATVMFECDKGFYLDGSDTIVCDSNSTWDPPVPKCLKVLPPSSTKPPALSHS
VSTSSTTKSPASSASGPRPTYKPPVSNYPGYPKPEEGILDSLDVWVIAVIVIAIVVGVAV
ICVVPYRYLQRRKKKGTYLTDETHREVKFTSL

# Drug_Target_55_Reaction:
Not Available

# Drug_Target_55_Signals:
1-34

# Drug_Target_55_Specific_Function:
Acts as a cofactor for complement factor I, a serine protease which protects autologous cells against complement- mediated injury by cleaving C3b and C4b deposited on host tissue. May be involved in the fusion of the spermatozoa with the oocyte during fertilization. Also acts as a co-stimulatory factor for T- cells which induces the differentiation of CD4+ into T-regulatory 1 cells. T-regulatory 1 cells suppress immune responses by secreting interleukin-10, and therefore are thought to prevent autoimmunity. A number of viral and bacterial pathogens seem to exploit this property and directly induce an immunosuppressive phenotype in T-cells by binding to CD46

# Drug_Target_55_SwissProt_ID:
P15529

# Drug_Target_55_SwissProt_Name:
MCP_HUMAN

# Drug_Target_55_Synonyms:
CD46 antigen
Membrane cofactor protein precursor
TLX
Trophoblast leukocyte common antigen

# Drug_Target_55_Theoretical_pI:
6.72

# Drug_Target_55_Transmembrane_Regions:
344-366

# Drug_Target_56_Cellular_Location:
Apical cell membrane

# Drug_Target_56_Chromosome_Location:
2

# Drug_Target_56_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_56_Essentiality:
Non-Essential

# Drug_Target_56_GenAtlas_ID:
Not Available

# Drug_Target_56_GenBank_ID_Gene:
X07994

# Drug_Target_56_GenBank_ID_Protein:
34400

# Drug_Target_56_GeneCard_ID:
LCT

# Drug_Target_56_Gene_Name:
LCT

# Drug_Target_56_Gene_Sequence:
>5784 bp
ATGGAGCTGTCTTGGCATGTAGTCTTTATTGCCCTGCTAAGTTTTTCATGCTGGGGGTCA
GACTGGGAGTCTGATAGAAATTTCATTTCCACCGCTGGTCCTCTAACCAATGACTTGCTG
CACAACCTGAGTGGTCTCCTGGGAGACCAGAGTTCTAACTTTGTAGCAGGGGACAAAGAC
ATGTATGTTTGTCACCAGCCACTGCCCACTTTCCTGCCAGAATACTTCAGCAGTCTCCAT
GCCAGTCAGATCACCCATTATAAGGTATTTCTGTCATGGGCACAGCTCCTCCCAGCAGGA
AGCACCCAGAATCCAGACGAGAAAACAGTGCAGTGCTACCGGCGACTCCTCAAGGCCCTC
AAGACTGCACGGCTTCAGCCCATGGTCATCCTGCACCACCAGACCCTCCCTGCCAGCACC
CTCCGGAGAACCGAAGCCTTTGCTGACCTCTTCGCCGACTATGCCACATTCGCCTTCCAC
TCCTTCGGGGACCTAGTTGGGATCTGGTTCACCTTCAGTGACTTGGAGGAAGTGATCAAG
GAGCTTCCCCACCAGGAATCAAGAGCGTCACAACTCCAGACCCTCAGTGATGCCCACAGA
AAAGCCTATGAGATTTACCACGAAAGCTATGCTTTTCAGGGCGGAAAACTCTCTGTTGTC
CTGCGAGCTGAAGATATCCCGGAGCTCCTGCTAGAACCACCCATATCTGCGCTTGCCCAG
GACACGGTCGATTTCCTCTCTCTTGATTTGTCTTATGAATGCCAAAATGAGGCAAGTCTG
CGGCAGAAGCTGAGTAAATTGCAGACCATTGAGCCAAAAGTGAAAGTTTTCATCTTCAAC
CTAAAACTCCCAGACTGCCCCTCCACCATGAAGAACCCAGCCAGTCTGCTCTTCAGCCTT
TTTGAAGCCATAAATAAAGACCAAGTGCTCACCATTGGGTTTGATATTAATGAGTTTCTG
AGTTGTTCATCAAGTTCCAAGAAAAGCATGTCTTGTTCTCTGACTGGCAGCCTGGCCCTT
CAGCCTGACCAGCAGCAGGACCACGAGACCACGGACTCCTCTCCTGCCTCTGCCTATCAG
AGAGTCTGGGAAGCATTTGCCAATCAGTCCAGAGCGGAAAGGGATGCCTTCCTGCAGGAT
ACTTTCCCTGAAGGCTTCCTCTGGGGTGCCTCCACAGGAGCCTTTAACGTGGAAGGAGGC
TGGGCCGAGGGTGGGAGAGGGGTGAGCATCTGGGATCCACGCAGGCCCCTGAACACCACT
GAGGGCCAAGCGACGCTGGAGGTGGCCAGCGACAGTTACCACAAGGTAGCCTCTGACGTC
GCCCTGCTTTGCGGCCTCCGGGCTCAGGTGTACAAGTTCTCCATCTCCTGGTCCCGGATC
TTCCCCATGGGGCACGGGAGCAGCCCCAGCCTCCCAGGCGTTGCCTACTACAACAAGCTG
ATTGACAGGCTACAGGATGCGGGCATCGAGCCCATGGCCACGCTGTTCCACTGGGACCTG
CCTCAGGCCCTGCAGGATCATGGTGGATGGCAGAATGAGAGCGTGGTGGATGCCTTCCTG
GACTATGCGGCCTTCTGCTTCTCCACATTTGGGGACCGTGTGAAGCTGTGGGTGACCTTC
CATGAGCCGTGGGTGATGAGCTACGCAGGCTATGGCACCGGCCAGCACCCTCCCGGCATC
TCTGACCCAGGAGTGGCCTCTTTTAAGGTGGCTCACTTGGTCCTCAAGGCTCATGCCAGA
ACTTGGCACCACTACAACAGCCATCATCGCCCACAGCAGCAGGGGCACGTGGGCATTGTG
CTGAACTCAGACTGGGCAGAACCCCTGTCTCCAGAGAGGCCTGAGGACCTGAGAGCCTCT
GAGCGCTTCTTGCACTTCATGCTGGGCTGGTTTGCACACCCCGTCTTTGTGGATGGAGAC
TACCCAGCCACCCTGAGGACCCAGATCCAACAGATGAACAGACAGTGCTCCCATCCTGTG
GCTCAACTCCCCGAGTTCACAGAGGCAGAGAAGCAGCTCCTGAAAGGCTCTGCTGATTTT
CTGGGTCTGTCGCATTACACCTCCCGCCTCATCAGCAACGCCCCACAAAACACCTGCATC
CCTAGCTATGATACCATTGGAGGCTTCTCCCAACACGTGAACCATGTGTGGCCCCAGACC
TCATCCTCTTGGATTCGTGTGGTGCCCTGGGGGATAAGGAGGCTGTTGCAGTTTGTATCC
CTGGAATACACAAGAGGAAAAGTTCCAATATACCTTGCCGGGAATGGCATGCCCATAGGG
GAAAGTGAAAATCTCTTTGATGATTCCTTAAGAGTAGACTACTTCAATCAATATATCAAT
GAGGTGCTCAAGGCTATCAAGGAAGACTCTGTGGATGTTCGTTCCTACATTGCTCGTTCC
CTCATTGATGGCTTCGAAGGCCCTTCTGGTTACAGCCAGCGGTTTGGCCTGCACCACGTC
AACTTCAGCGACAGCAGCAAGTCAAGGACTCCCAGGAAATCTGCCTACTTTTTCACTAGC
ATCATAGAAAAGAACGGTTTCCTCACCAAGGGGGCAAAAAGACTGCTACCACCTAATACA
GTAAACCTCCCCTCCAAAGTCAGAGCCTTCACTTTTCCATCTGAGGTGCCCTCCAAGGCT
AAAGTCGTTTGGGAAAAGTTCTCCAGCCAACCCAAGTTCGAAAGAGATTTGTTCTACCAC
GGGACGTTTCGGGATGACTTTCTGTGGGGCGTGTCCTCTTCCGCTTATCAGATTGAAGGC
GCGTGGGATGCCGATGGCAAAGGCCCCAGCATCTGGGATAACTTTACCCACACACCAGGG
AGCAATGTGAAAGACAATGCCACTGGAGACATCGCCTGTGACAGCTATCACCAGCTGGAT
GCCGATCTGAATATGCTCCGAGCTTTGAAGGTGAAGGCCTACCGCTTCTCTATCTCCTGG
TCTCGGATTTTCCCAACTGGGAGAAACAGCTCTATCAACAGTCATGGGGTTGATTATTAC
AACAGGCTGATCAATGGCTTGGTGGCAAGCAACATCTTTCCCATGGTGACATTGTTCCAT
TGGGACCTGCCCCAGGCCCTCCAGGATATCGGAGGCTGGGAGAATCCTGCCTTGATTGAC
TTGTTTGACAGCTACGCAGACTTTTGTTTCCAGACCTTTGGTGATAGAGTCAAGTTTTGG
ATGACTTTTAATGAGCCCATGTACCTGGCATGGCTAGGTTATGGCTCAGGGGAATTTCCC
CCAGGGGTGAAGGACCCAGGCTGGGCACCATATAGGATAGCCCACACCGTCATCAAAGCC
CATGCCAGAGTCTATCACACGTACGATGAGAAATACAGGCAGGAGCAGAAGGGGGTCATC
TCGCTGAGCCTCAGTACACACTGGGCAGAGCCCAAGTCACCAGGGGTCCCCAGAGATGTG
GAAGCCGCTGACCGAATGCTGCAGTTCTCCCTGGGCTGGTTTGCTCACCCCATTTTTAGA
AACGGAGACTATCCTGACACCATGAAGTGGAAAGTGGGGAACAGGAGTGAACTGCAGCAC
TTAGCCACCTCCCGCCTGCCAAGCTTCACTGAGGAAGAGAAGAGGTTCATCAGGGCGACG
GCCGACGTCTTCTGCCTCAACACGTACTACTCCAGAATCGTGCAGCACAAAACACCCAGG
CTAAACCCACCCTCCTACGAAGACGACCAGGAGATGGCTGAGGAGGAGGACCCTTCGTGG
CCTTCCACGGCAATGAACAGAGCTGCGCCCTGGGGGACGCGAAGGCTGCTGAACTGGATC
AAGGAAGAGTATGGTGACATCCCCATTTACATCACCGAAAACGGAGTGGGGCTGACCAAT
CCGAACACGGAGGATACTGATAGGATATTTTACCACAAAACCTACATCAATGAGGCTTTG
AAAGCCTACAGGCTCGATGGTATAGACCTTCGAGGGTATGTCGCCTGGTCTCTGATGGAC
AACTTTGAGTGGCTAAATGGCTACACGGTCAAGTTTGGACTGTACCATGTTGATTTCAAC
AACACGAACAGGCCTCGCACAGCAAGAGCCTCCGCCAGGTACTACACAGAGGTCATTACC
AACAACGGCATGCCACTGGCCAGGGAGGATGAGTTTCTGTACGGACGGTTTCCTGAGGGC
TTCATCTGGAGTGCAGCTTCTGCTGCATATCAGATTGAAGGTGCGTGGAGAGCAGATGGC
AAAGGACTCAGCATTTGGGACACGTTTTCTCACACACCACTGAGGGTTGAGAACGATGCC
ATTGGAGACGTGGCCTGTGACAGTTATCACAAGATTGCTGAGGATCTGGTCACCCTGCAG
AACCTGGGTGTGTCCCACTACCGTTTTTCCATCTCCTGGTCTCGCATCCTCCCTGATGGA
ACCACCAGGTACATCAATGAAGCGGGCCTGAACTACTACGTGAGGCTCATCGATACACTG
CTGGCCGCCAGCATCCAGCCCCAGGTGACCATTTACCACTGGGACCTACCACAGACGCTC
CAAGATGTAGGAGGCTGGGAGAATGAGACCATCGTGCAGCGGTTTAAGGAGTATGCAGAT
GTGCTCTTCCAGAGGCTGGGAGACAAGGTGAAGTTTTGGATCACGTTGAATGAGCCCTTT
GTCATTGCTTACCAGGGCTATGGCTACGGAACAGCAGCTCCAGGAGTCTCCAATAGGCCT
GGCACTGCCCCCTACATTGTTGGCCACAATCTAATAAAGGCTCATGCTGAGGCCTGGCAT
CTGTACAACGATGTGTACCGCGCCAGTCAAGGTGGCGTGATTTCCATCACCATCAGCAGT
GACTGGGCTGAACCCAGAGATCCCTCTAACCAGGAGGATGTGGAGGCAGCCAGGAGATAT
GTTCAGTTCATGGGAGGCTGGTTTGCACATCCTATTTTCAAGAATGGAGATTACAATGAG
GTGATGAAGACGCGGATCCGTGACAGGAGCTTGGCTGCAGGCCTCAACAAGTCTCGGCTG
CCAGAATTTACAGAGAGTGAGAAGAGGAGGATCAACGGCACCTATGACTTTTTTGGGTTC
AATCACTACACCACTGTCCTCGCCTACAACCTCAACTATGCCACTGCCATCTCTTCTTTT
GATGCAGACAGAGGAGTTGCTTCCATCGCAGATCGCTCGTGGCCAGACTCTGGCTCCTTC
TGGCTGAAGATGACGCCTTTTGGCTTCAGGAGGATCCTGAACTGGTTAAAGGAGGAATAC
AATGACCCTCCAATTTATGTCACAGAGAATGGAGTGTCCCAGCGGGAAGAAACAGACCTC
AATGACACTGCAAGGATCTACTACCTTCGGACTTACATCAATGAGGCCCTCAAAGCTGTG
CAGGACAAGGTGGACCTTCGAGGATACACAGTTTGGAGTGCGATGGACAATTTTGAGTGG
GCCACAGGCTTTTCAGAGAGATTTGGTCTGCATTTTGTGAACTACAGTGACCCTTCTCTG
CCAAGGATCCCCAAAGCATCAGCGAAGTTCTACGCCTCTGTGGTCCGATGCAATGGCTTC
CCTGACCCCGCTACAGGGCCTCACGCTTGTCTCCACCAGCCAGATGCTGGACCCACCATC
AGCCCCGTGAGACAGGAGGAGGTGCAGTTCCTGGGGCTAATGCTCGGCACCACAGAAGCA
CAGACAGCTTTGTACGTTCTCTTTTCTCTTGTGCTTCTTGGAGTCTGTGGCTTGGCATTT
CTGTCATACAAGTACTGCAAGCGCTCTAAGCAAGGGAAAACACAACGAAGCCAACAGGAA
TTGAGCCCGGTGTCTTCATTCTGA

# Drug_Target_56_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_56_General_References:
11788828	Enattah NS, Sahi T, Savilahti E, Terwilliger JD, Peltonen L, Jarvela I: Identification of a variant associated with adult-type hypolactasia. Nat Genet. 2002 Feb;30(2):233-7. Epub 2002 Jan 14.
15815621	Hillier LW, Graves TA, Fulton RS, Fulton LA, Pepin KH, Minx P, Wagner-McPherson C, Layman D, Wylie K, Sekhon M, Becker MC, Fewell GA, Delehaunty KD, Miner TL, Nash WE, Kremitzki C, Oddy L, Du H, Sun H, Bradshaw-Cordum H, Ali J, Carter J, Cordes M, Harris A, Isak A, van Brunt A, Nguyen C, Du F, Courtney L, Kalicki J, Ozersky P, Abbott S, Armstrong J, Belter EA, Caruso L, Cedroni M, Cotton M, Davidson T, Desai A, Elliott G, Erb T, Fronick C, Gaige T, Haakenson W, Haglund K, Holmes A, Harkins R, Kim K, Kruchowski SS, Strong CM, Grewal N, Goyea E, Hou S, Levy A, Martinka S, Mead K, McLellan MD, Meyer R, Randall-Maher J, Tomlinson C, Dauphin-Kohlberg S, Kozlowicz-Reilly A, Shah N, Swearengen-Shahid S, Snider J, Strong JT, Thompson J, Yoakum M, Leonard S, Pearman C, Trani L, Radionenko M, Waligorski JE, Wang C, Rock SM, Tin-Wollam AM, Maupin R, Latreille P, Wendl MC, Yang SP, Pohl C, Wallis JW, Spieth J, Bieri TA, Berkowicz N, Nelson JO, Osborne J, Ding L, Meyer R, Sabo A, Shotland Y, Sinha P, Wohldmann PE, Cook LL, Hickenbotham MT, Eldred J, Williams D, Jones TA, She X, Ciccarelli FD, Izaurralde E, Taylor J, Schmutz J, Myers RM, Cox DR, Huang X, McPherson JD, Mardis ER, Clifton SW, Warren WC, Chinwalla AT, Eddy SR, Marra MA, Ovcharenko I, Furey TS, Miller W, Eichler EE, Bork P, Suyama M, Torrents D, Waterston RH, Wilson RK: Generation and annotation of the DNA sequences of human chromosomes 2 and 4. Nature. 2005 Apr 7;434(7034):724-31.
16400612	Kuokkanen M, Kokkonen J, Enattah NS, Ylisaukko-Oja T, Komu H, Varilo T, Peltonen L, Savilahti E, Jarvela I: Mutations in the translated region of the lactase gene (LCT) underlie congenital lactase deficiency. Am J Hum Genet. 2006 Feb;78(2):339-44. Epub 2005 Dec 15.
17053785	Wang Y, Du D, Fang L, Yang G, Zhang C, Zeng R, Ullrich A, Lottspeich F, Chen Z: Tyrosine phosphorylated Par3 regulates epithelial tight junction assembly promoted by EGFR signaling. EMBO J. 2006 Nov 1;25(21):5058-70. Epub 2006 Oct 19.
1902057	Boll W, Wagner P, Mantei N: Structure of the chromosomal gene and cDNAs coding for lactase-phlorizin hydrolase in humans with adult-type hypolactasia or persistence of lactase. Am J Hum Genet. 1991 May;48(5):889-902.
2460343	Mantei N, Villa M, Enzler T, Wacker H, Boll W, James P, Hunziker W, Semenza G: Complete primary structure of human and rabbit lactase-phlorizin hydrolase: implications for biosynthesis, membrane anchoring and evolution of the enzyme. EMBO J. 1988 Sep;7(9):2705-13.

# Drug_Target_56_HGNC_ID:
GNC:6530

# Drug_Target_56_HPRD_ID:
Not Available

# Drug_Target_56_ID:
6847

# Drug_Target_56_Locus:
2q21

# Drug_Target_56_Molecular_Weight:
218570.8

# Drug_Target_56_Name:
Lactase-phlorizin hydrolase

# Drug_Target_56_Number_of_Residues:
1927

# Drug_Target_56_PDB_ID:
Not Available

# Drug_Target_56_Pathway:
Not Available

# Drug_Target_56_Pfam_Domain_Function:
PF00232	Glyco_hydro_1

# Drug_Target_56_Protein_Sequence:
>Lactase-phlorizin hydrolase
MELSWHVVFIALLSFSCWGSDWESDRNFISTAGPLTNDLLHNLSGLLGDQSSNFVAGDKD
MYVCHQPLPTFLPEYFSSLHASQITHYKVFLSWAQLLPAGSTQNPDEKTVQCYRRLLKAL
KTARLQPMVILHHQTLPASTLRRTEAFADLFADYATFAFHSFGDLVGIWFTFSDLEEVIK
ELPHQESRASQLQTLSDAHRKAYEIYHESYAFQGGKLSVVLRAEDIPELLLEPPISALAQ
DTVDFLSLDLSYECQNEASLRQKLSKLQTIEPKVKVFIFNLKLPDCPSTMKNPASLLFSL
FEAINKDQVLTIGFDINEFLSCSSSSKKSMSCSLTGSLALQPDQQQDHETTDSSPASAYQ
RVWEAFANQSRAERDAFLQDTFPEGFLWGASTGAFNVEGGWAEGGRGVSIWDPRRPLNTT
EGQATLEVASDSYHKVASDVALLCGLRAQVYKFSISWSRIFPMGHGSSPSLPGVAYYNKL
IDRLQDAGIEPMATLFHWDLPQALQDHGGWQNESVVDAFLDYAAFCFSTFGDRVKLWVTF
HEPWVMSYAGYGTGQHPPGISDPGVASFKVAHLVLKAHARTWHHYNSHHRPQQQGHVGIV
LNSDWAEPLSPERPEDLRASERFLHFMLGWFAHPVFVDGDYPATLRTQIQQMNRQCSHPV
AQLPEFTEAEKQLLKGSADFLGLSHYTSRLISNAPQNTCIPSYDTIGGFSQHVNHVWPQT
SSSWIRVVPWGIRRLLQFVSLEYTRGKVPIYLAGNGMPIGESENLFDDSLRVDYFNQYIN
EVLKAIKEDSVDVRSYIARSLIDGFEGPSGYSQRFGLHHVNFSDSSKSRTPRKSAYFFTS
IIEKNGFLTKGAKRLLPPNTVNLPSKVRAFTFPSEVPSKAKVVWEKFSSQPKFERDLFYH
GTFRDDFLWGVSSSAYQIEGAWDADGKGPSIWDNFTHTPGSNVKDNATGDIACDSYHQLD
ADLNMLRALKVKAYRFSISWSRIFPTGRNSSINSHGVDYYNRLINGLVASNIFPMVTLFH
WDLPQALQDIGGWENPALIDLFDSYADFCFQTFGDRVKFWMTFNEPMYLAWLGYGSGEFP
PGVKDPGWAPYRIAHAVIKAHARVYHTYDEKYRQEQKGVISLSLSTHWAEPKSPGVPRDV
EAADRMLQFSLGWFAHPIFRNGDYPDTMKWKVGNRSELQHLATSRLPSFTEEEKRFIRAT
ADVFCLNTYYSRIVQHKTPRLNPPSYEDDQEMAEEEDPSWPSTAMNRAAPWGTRRLLNWI
KEEYGDIPIYITENGVGLTNPNTEDTDRIFYHKTYINEALKAYRLDGIDLRGYVAWSLMD
NFEWLNGYTVKFGLYHVDFNNTNRPRTARASARYYTEVITNNGMPLAREDEFLYGRFPEG
FIWSAASAAYQIEGAWRADGKGLSIWDTFSHTPLRVENDAIGDVACDSYHKIAEDLVTLQ
NLGVSHYRFSISWSRILPDGTTRYINEAGLNYYVRLIDTLLAASIQPQVTIYHWDLPQTL
QDVGGWENETIVQRFKEYADVLFQRLGDKVKFWITLNEPFVIAYQGYGYGTAAPGVSNRP
GTAPYIVGHNLIKAHAEAWHLYNDVYRASQGGVISITISSDWAEPRDPSNQEDVEAARRY
VQFMGGWFAHPIFKNGDYNEVMKTRIRDRSLAAGLNKSRLPEFTESEKRRINGTYDFFGF
NHYTTVLAYNLNYATAISSFDADRGVASIADRSWPDSGSFWLKMTPFGFRRILNWLKEEY
NDPPIYVTENGVSQREETDLNDTARIYYLRTYINEALKAVQDKVDLRGYTVWSAMDNFEW
ATGFSERFGLHFVNYSDPSLPRIPKASAKFYASVVRCNGFPDPATGPHACLHQPDAGPTI
SPVRQEEVQFLGLMLGTTEAQTALYVLFSLVLLGVCGLAFLSYKYCKRSKQGKTQRSQQE
LSPVSSF

# Drug_Target_56_Reaction:
Not Available

# Drug_Target_56_Signals:
1-19

# Drug_Target_56_Specific_Function:
LPH splits lactose in the small intestine

# Drug_Target_56_SwissProt_ID:
P09848

# Drug_Target_56_SwissProt_Name:
LPH_HUMAN

# Drug_Target_56_Synonyms:
Lactase
Lactase-glycosylceramidase
Phlorizin hydrolase

# Drug_Target_56_Theoretical_pI:
6.30

# Drug_Target_56_Transmembrane_Regions:
1883-1901

# Drug_Target_57_Cellular_Location:
Membrane

# Drug_Target_57_Chromosome_Location:
Not Available

# Drug_Target_57_Drug_References:
Not Available

# Drug_Target_57_Essentiality:
Non-Essential

# Drug_Target_57_GenAtlas_ID:
DPP6

# Drug_Target_57_GenBank_ID_Gene:
M96859

# Drug_Target_57_GenBank_ID_Protein:
Not Available

# Drug_Target_57_GeneCard_ID:
Not Available

# Drug_Target_57_Gene_Name:
DPP6

# Drug_Target_57_Gene_Sequence:
>2598 bp
ATGGCTTCGCTGTACCAGAGGTTCACTGGCAAGATCAACACCTCGAGGTCCTTCCCCGCG
CCCCCGGAGGCGAGTCACCTCCTGGGCGGCCAGGGGCCCGAGGAGGACGGCGGTGCAGGA
GCCAAGCCCCTCGGCCCGCGGGCGCAGGCGGCGGCGCCCCGGGAGCGCGGCGGCGGCGGC
GGCGGCGCGGGTGGCCGGCCCCGGTTCCAGTACCAGGGCCGGAGCGATGGTGACGAGGAG
GACGAGCTGGTGGGGAGTAACCCTCCGCAGAGGAATTGGAAAGGAATAGCAATTGCACTG
CTTGTCATTCTGGTCATCTGCTCCTTGATCGTCACCTCGGTCATACTTCTGACACCAGCG
GAAGATAATAGTCTGTCTCAAAAGAAGAAGGTCACTGTAGAAGATCTCTTCAGTGAAGAC
TTCAAAATTCATGACCCCGAGGCTAAGTGGATAAGTGATACAGAATTCATCTACAGAGAA
CAGAAAGGAACAGTGAGACTGTGGAATGTTGAAACAAATACTTCTACTGTCTTAATAGAA
GGCAAAAAAATTGAATCATTAAGAGCCATCAGATATGAAATATCTCCAGATAGAGAGTAT
GCACTTTTTTCATACAATGTGGAACCCATATATCAACACTCGTATACTGGATATTATGTC
CTGAGCAAAATTCCTCATGGGGATCCTCAAAGTCTGGACCCACCAGAAGTCAGCAATGCA
AAGCTTCAGTATGCAGGATGGGGCCCTAAAGGCCAACAGCTGATATTTATTTTTGAAAAC
AATATCTACTACTGTGCACATGTCGGGAAACAGGCCATCCGTGTGGTCTCCACTGGCAAG
GAAGGTGTGATTTACAATGGCCTCAGTGACTGGCTGTATGAAGAGGAGATTTTGAAGACA
CACATCGCACACTGGTGGTCTCCGGATGGCACGAGACTCGCCTACGCCGCCATCAATGAT
TCCCGTGTCCCCATCATGGAGCTCCCAACTTACACCGGCTCCATCTACCCCACCGTGAAG
CCCTACCACTATCCCAAGGCTGGAAGTGAGAACCCCAGCATTTCCCTACACGTTATTGGC
TTAAATGGACCCACCCATGATCTGGAGATGATGCCGCCTGATGATCCACGGATGAGGGAG
TACTACATCACCATGGTGAAGTGGGCCACCAGCACCAAGGTCGCCGTGACCTGGCTGAAC
CGGGCGCAGAACGTGTCCATCCTCACCCTCTGCGACGCCACCACGGGGGTCTGCACGAAG
AAACACGAGGATGAAAGTGAGGCCTGGCTCCACAGACAGAATGAAGAACCTGTGTTCTCC
AAGGATGGCCGAAAGTTTTTCTTCATCAGAGCCATCCCCCAGGGAGGACGAGGGAAATTC
TATCACATCACGGTGTCCTCGTCCCAGCCCAACAGCAGCAACGACAACATCCAGTCCATC
ACCTCCGGGGACTGGGACGTGACCAAGATCCTAGCCTACGATGAGAAGGGGAATAAGATC
TACTTCCTGAGCACGGAGGACCTGCCTCGGAGACGACAACTCTACAGTGCCAACACGGAG
GGCAACTTCAACAGGCAGTGCCTCTCCTGTGACCTGGTTGAGAACTGCACCTACTTCAGC
GCTTCCTTCAGCCATAGCATGGACTTCTTCCTGCTCAAGTGCGAAGGTCCTGGTGTTCCT
ATGGTGACGGTGCACAACACAACAGATAAGAAAAAAATGTTTGACCTAGAAACAAATGAA
CATGTCAAGAAGGCCATAAATGACCGACAGATGCCTAAAGTGGAATACAGGGACATTGAG
ATTGATGATTACAACCTGCCCATGCAGATACTGAAGCCAGCAACCTTCACCGACACCACC
CACTACCCTCTGCTCCTGGTGGTGGATGGCACCCCGGGCAGCCAGAGTGTAGCTGAGAAG
TTCGAGGTGAGCTGGGAGACGGTGATGGTGAGCAGCCACGGCGCGGTGGTGGTAAAGTGT
GACGGCCGTGGCAGCGGCTTCCAAGGGACCAAGCTCCTGCACGAAGTGAGGCGGCGGCTG
GGCTTGCTGGAGGAGAAGGACCAGATGGAGGCCGTGCGGACGATGCTGAAGGAGCAGTAC
ATTGACAGGACGCGCGTGGCCGTGTTCGGGAAGGATTACGGTGGCTACCTGAGCACCTAC
ATCCTCCCAGCAAAGGGAGAAAATCAAGGCCAGACATTCACCTGCGGCTCTGCTCTCTCT
CCAATAACAGACTTCAAACTCTATGCCTCTGCGTTTTCCGAGAGGTACTTGGGCCTCCAT
GGACTTGACAACAGAGCATACGAGATGACCAAGGTAGCCCATCGAGTCTCCGCGCTGGAA
GAACAGCAGTTCCTGATCATTCATCCCACTGCCGATGAAAAAATTCATTTCCAGCACACA
GCAGAACTCATTACACAACTAATTAGGGGAAAGGCTAATTACAGCTTACAGATTTACCCG
GACGAAAGCCATTACTTTACCAGCTCCAGCCTCAAACAGCATCTGTACCGGTCCATCATC
AACTTCTTCGTGGAATGCTTCAGGATCCAGGACAAACTGCCGACAGTCACAGCGAAAGAG
GACGAGGAGGAGGACTAA

# Drug_Target_57_General_Function:
Involved in serine-type peptidase activity

# Drug_Target_57_General_References:
8103397	Yokotani N, Doi K, Wenthold RJ, Wada K: Non-conservation of a catalytic residue in a dipeptidyl aminopeptidase IV-related protein encoded by a gene on human chromosome 7. Hum Mol Genet. 1993 Jul;2(7):1037-9.

# Drug_Target_57_HGNC_ID:
HGNC:3010

# Drug_Target_57_HPRD_ID:
Not Available

# Drug_Target_57_ID:
4882

# Drug_Target_57_Locus:
7q36.2

# Drug_Target_57_Molecular_Weight:
97589

# Drug_Target_57_Name:
Dipeptidyl aminopeptidase-like protein 6

# Drug_Target_57_Number_of_Residues:
865

# Drug_Target_57_PDB_ID:
1XFD

# Drug_Target_57_Pathway:
Not Available

# Drug_Target_57_Pfam_Domain_Function:
PF00326	Peptidase_S9
PF00930	DPPIV_N

# Drug_Target_57_Protein_Sequence:
>Dipeptidyl aminopeptidase-like protein 6
MASLYQRFTGKINTSRSFPAPPEASHLLGGQGPEEDGGAGAKPLGPRAQAAAPRERGGGG
GGAGGRPRFQYQGRSDGDEEDELVGSNPPQRNWKGIAIALLVILVICSLIVTSVILLTPA
EDNSLSQKKKVTVEDLFSEDFKIHDPEAKWISDTEFIYREQKGTVRLWNVETNTSTVLIE
GKKIESLRAIRYEISPDREYALFSYNVEPIYQHSYTGYYVLSKIPHGDPQSLDPPEVSNA
KLQYAGWGPKGQQLIFIFENNIYYCAHVGKQAIRVVSTGKEGVIYNGLSDWLYEEEILKT
HIAHWWSPDGTRLAYAAINDSRVPIMELPTYTGSIYPTVKPYHYPKAGSENPSISLHVIG
LNGPTHDLEMMPPDDPRMREYYITMVKWATSTKVAVTWLNRAQNVSILTLCDATTGVCTK
KHEDESEAWLHRQNEEPVFSKDGRKFFFIRAIPQGGRGKFYHITVSSSQPNSSNDNIQSI
TSGDWDVTKILAYDEKGNKIYFLSTEDLPRRRQLYSANTEGNFNRQCLSCDLVENCTYFS
ASFSHSMDFFLLKCEGPGVPMVTVHNTTDKKKMFDLETNEHVKKAINDRQMPKVEYRDIE
IDDYNLPMQILKPATFTDTTHYPLLLVVDGTPGSQSVAEKFEVSWETVMVSSHGAVVVKC
DGRGSGFQGTKLLHEVRRRLGLLEEKDQMEAVRTMLKEQYIDRTRVAVFGKDYGGYLSTY
ILPAKGENQGQTFTCGSALSPITDFKLYASAFSERYLGLHGLDNRAYEMTKVAHRVSALE
EQQFLIIHPTADEKIHFQHTAELITQLIRGKANYSLQIYPDESHYFTSSSLKQHLYRSII
NFFVECFRIQDKLPTVTAKEDEEED

# Drug_Target_57_Reaction:
Not Available

# Drug_Target_57_Signals:
None

# Drug_Target_57_Specific_Function:
May be involved in the physiological processes of brain function. Has no dipeptidyl aminopeptidase activity. May modulate the cell surface expression and the activity of the potassium channel KCND2 (By similarity)

# Drug_Target_57_SwissProt_ID:
P42658

# Drug_Target_57_SwissProt_Name:
DPP6_HUMAN

# Drug_Target_57_Synonyms:
DPPX
Dipeptidyl aminopeptidase-related protein
Dipeptidyl peptidase IV-like protein
Dipeptidylpeptidase 6
Dipeptidylpeptidase VI

# Drug_Target_57_Theoretical_pI:
6.26

# Drug_Target_57_Transmembrane_Regions:
96-116

# Drug_Target_58_Cellular_Location:
Membrane

# Drug_Target_58_Chromosome_Location:
Not Available

# Drug_Target_58_Drug_References:
Not Available

# Drug_Target_58_Essentiality:
Non-Essential

# Drug_Target_58_GenAtlas_ID:
CSF2RB

# Drug_Target_58_GenBank_ID_Gene:
M59941

# Drug_Target_58_GenBank_ID_Protein:
487425

# Drug_Target_58_GeneCard_ID:
CSF2RB

# Drug_Target_58_Gene_Name:
CSF2RB

# Drug_Target_58_Gene_Sequence:
>2694 bp
ATGGTGCTGGCCCAGGGGCTGCTCTCCATGGCCCTGCTGGCCCTGTGCTGGGAGCGCAGC
CTGGCAGGGGCAGAAGAAACCATCCCGCTGCAGACCCTGCGCTGCTACAACGACTACACC
AGCCACATCACCTGCAGGTGGGCAGACACCCAGGATGCCCAGCGGCTCGTCAACGTGACC
CTCATTCGCCGGGTGAATGAGGACCTCCTGGAGCCAGTGTCCTGTGACCTCAGTGATGAC
ATGCCCTGGTCAGCCTGCCCCCATCCCCGCTGCGTGCCCAGGAGATGTGTCATTCCCTGC
CAGAGTTTTGTCGTCACTGACGTTGACTACTTCTCATTCCAACCAGACAGGCCTCTGGGC
ACCCGGCTCACCGTCACTCTGACCCAGCATGTCCAGCCTCCTGAGCCCAGGGACCTGCAG
ATCAGCACCGACCAGGACCACTTCCTGCTGACCTGGAGTGTGGCCCTTGGGAGTCCCCAG
AGCCACTGGTTGTCCCCAGGGGATCTGGAGTTTGAGGTGGTCTACAAGCGGCTTCAGGAC
TCTTGGGAGGACGCAGCCATCCTCCTCTCCAACACCTCCCAGGCCACCCTGGGGCCAGAG
CACCTCATGCCCAGCAGCACCTACGTGGCCCGAGTACGGACCCGCCTGGCCCCAGGTTCT
CGGCTCTCAGGACGTCCCAGCAAGTGGAGCCCAGAGGTTTGCTGGGACTCCCAGCCAGGG
GATGAGGCCCAGCCCCAGAACCTGGAGTGCTTCTTTGACGGGGCCGCCGTGCTCAGCTGC
TCCTGGGAGGTGAGGAAGGAGGTGGCCAGCTCGGTCTCCTTTGGCCTATTCTACAAGCCC
AGCCCAGATGCAGGGGAGGAAGAGTGCTCCCCAGTGCTGAGGGAGGGGCTCGGCAGCCTC
CACACCAGGCACCACTGCCAGATTCCCGTGCCCGACCCCGCGACCCACGGCCAATACATC
GTCTCTGTTCAGCCAAGGAGGGCAGAGAAACACATAAAGAGCTCAGTGAACATCCAGATG
GCCCCTCCATCCCTCAACGTGACCAAGGATGGAGACAGCTACAGCCTGCGCTGGGAAACA
ATGAAAATGCGATACGAACACATAGACCACACATTTGAGATCCAGTACAGGAAAGACACG
GCCACGTGGAAGGACAGCAAGACCGAGACCCTCCAGAACGCCCACAGCATGGCCCTGCCA
GCCCTGGAGCCCTCCACCAGGTACTGGGCCAGGGTGAGGGTCAGGACCTCCCGCACCGGC
TACAACGGGATCTGGAGCGAGTGGAGTGAGGCGCGCTCCTGGGACACCGAGTCGGTGCTG
CCTATGTGGGTGCTGGCCCTCATCGTGATCTTCCTCACCATCGCTGTGCTCCTGGCCCTC
CGCTTCTGTGGCATCTACGGGTACAGGCTGCGCAGAAAGTGGGAGGAGAAGATCCCCAAC
CCCAGCAAGAGCCACCTGTTCCAGAACGGGAGCGCAGAGCTTTGGCCCCCAGGCAGCATG
TCGGCCTTCACTAGCGGGAGTCCCCCACACCAGGGGCCGTGGGGCAGCCGCTTCCCTGAG
CTGGAGGGGGTGTTCCCTGTAGGATTCGGGGACAGCGAGGTGTCACCTCTCACCATAGAG
GACCCCAAGCATGTCTGTGATCCACCATCTGGGCCTGACACGACTCCAGCTGCCTCAGAT
CTACCCACAGAGCAGCCCCCCAGCCCCCAGCCAGGCCCGCCTGCCGCCTCCCACACACCT
GAGAAACAGGCTTCCAGCTTTGACTTCAATGGGCCCTACCTGGGGCCGCCCCACAGCCGC
TCCCTACCTGACATCCTGGGCCAGCCGGAGCCCCCACAGGAGGGTGGGAGCCAGAAGTCC
CCACCTCCAGGGTCCCTGGAGTACCTGTGTCTGCCTGCTGGGGGGCAGGTGCAACTGGTC
CCTCTGGCCCAGGCGATGGGACCGGGACAGGCCGTGGAAGTGGAGAGAAGGCCGAGCCAG
GGGGCTGCAGGGAGTCCCTCCCTGGAGTCCGGGGGAGGCCCTGCCCCTCCTGCTCTTGGG
CCAAGGGTGGGAGGACAGGACCAAAAGGACAGCCCTGTGGCTATACCCATGAGCTCTGGG
GACACTGAGGACCCTGGAGTGGCCTCTGGTTATGTCTCCTCTGCAGACCTGGTATTCACC
CCAAACTCAGGGGCCTCGTCTGTCTCCCTAGTTCCCTCTCTGGGCCTCCCCTCAGACCAG
ACCCCCAGCTTATGTCCTGGGCTGGCCAGTGGACCCCCTGGAGCCCCAGGCCCTGTGAAG
TCAGGGTTTGAGGGCTATGTGGAGCTCCCTCCAATTGAGGGCCGGTCCCCCAGGTCACCA
AGGAACAATCCTGTCCCCCCTGAGGCCAAAAGCCCTGTCCTGAACCCAGGGGAACGCCCG
GCAGATGTGTCCCCAACATCCCCACAGCCCGAGGGCCTCCTTGTCCTGCAGCAAGTGGGC
GACTATTGCTTCCTCCCCGGCCTGGGGCCCGGCCCTCTCTCGCTCCGGAGTAAACCTTCT
TCCCCGGGACCCGGTCCTGAGATCAAGAACCTAGACCAGGCTTTTCAAGTCAAGAAGCCC
CCAGGCCAGGCTGTGCCCCAGGTGCCCGTCATTCAGCTCTTCAAAGCCCTGAAGCAGCAG
GACTACCTGTCTCTGCCCCCTTGGGAGGTCAACAAGCCTGGGGAGGTGTGTTGA

# Drug_Target_58_General_Function:
Not Available

# Drug_Target_58_General_References:
10736232	Mulhern TD, Lopez AF, D'Andrea RJ, Gaunt C, Vandeleur L, Vadas MA, Booker GW, Bagley CJ: The solution structure of the cytokine-binding domain of the common beta-chain of the receptors for granulocyte-macrophage colony-stimulating factor, interleukin-3 and interleukin-5. J Mol Biol. 2000 Apr 7;297(4):989-1001.
10753826	Rossjohn J, McKinstry WJ, Woodcock JM, McClure BJ, Hercus TR, Parker MW, Lopez AF, Bagley CJ: Structure of the activation domain of the GM-CSF/IL-3/IL-5 receptor common beta-chain bound to an antagonist. Blood. 2000 Apr 15;95(8):2491-8.
11207369	Carr PD, Gustin SE, Church AP, Murphy JM, Ford SC, Mann DA, Woltring DM, Walker I, Ollis DL, Young IG: Structure of the complete extracellular domain of the common beta subunit of the human GM-CSF, IL-3, and IL-5 receptors reveals a novel dimer configuration. Cell. 2001 Jan 26;104(2):291-300.
1702217	Hayashida K, Kitamura T, Gorman DM, Arai K, Yokota T, Miyajima A: Molecular cloning of a second subunit of the receptor for human granulocyte-macrophage colony-stimulating factor (GM-CSF): reconstitution of a high-affinity GM-CSF receptor. Proc Natl Acad Sci U S A. 1990 Dec;87(24):9655-9.
9410898	Dirksen U, Nishinakamura R, Groneck P, Hattenhorst U, Nogee L, Murray R, Burdach S: Human pulmonary alveolar proteinosis associated with a defect in GM-CSF/IL-3/IL-5 receptor common beta chain expression. J Clin Invest. 1997 Nov 1;100(9):2211-7.

# Drug_Target_58_HGNC_ID:
HGNC:2436

# Drug_Target_58_HPRD_ID:
Not Available

# Drug_Target_58_ID:
3837

# Drug_Target_58_Locus:
22q13.1

# Drug_Target_58_Molecular_Weight:
97336

# Drug_Target_58_Name:
Cytokine receptor common beta chain

# Drug_Target_58_Number_of_Residues:
897

# Drug_Target_58_PDB_ID:
1GH7

# Drug_Target_58_Pathway:
Not Available

# Drug_Target_58_Pfam_Domain_Function:
PF00041	fn3

# Drug_Target_58_Protein_Sequence:
>Cytokine receptor common beta chain
MVLAQGLLSMALLALCWERSLAGAEETIPLQTLRCYNDYTSHITCRWADTQDAQRLVNVT
LIRRVNEDLLEPVSCDLSDDMPWSACPHPRCVPRRCVIPCQSFVVTDVDYFSFQPDRPLG
TRLTVTLTQHVQPPEPRDLQISTDQDHFLLTWSVALGSPQSHWLSPGDLEFEVVYKRLQD
SWEDAAILLSNTSQATLGPEHLMPSSTYVARVRTRLAPGSRLSGRPSKWSPEVCWDSQPG
DEAQPQNLECFFDGAAVLSCSWEVRKEVASSVSFGLFYKPSPDAGEEECSPVLREGLGSL
HTRHHCQIPVPDPATHGQYIVSVQPRRAEKHIKSSVNIQMAPPSLNVTKDGDSYSLRWET
MKMRYEHIDHTFEIQYRKDTATWKDSKTETLQNAHSMALPALEPSTRYWARVRVRTSRTG
YNGIWSEWSEARSWDTESVLPMWVLALIVIFLTIAVLLALRFCGIYGYRLRRKWEEKIPN
PSKSHLFQNGSAELWPPGSMSAFTSGSPPHQGPWGSRFPELEGVFPVGFGDSEVSPLTIE
DPKHVCDPPSGPDTTPAASDLPTEQPPSPQPGPPAASHTPEKQASSFDFNGPYLGPPHSR
SLPDILGQPEPPQEGGSQKSPPPGSLEYLCLPAGGQVQLVPLAQAMGPGQAVEVERRPSQ
GAAGSPSLESGGGPAPPALGPRVGGQDQKDSPVAIPMSSGDTEDPGVASGYVSSADLVFT
PNSGASSVSLVPSLGLPSDQTPSLCPGLASGPPGAPGPVKSGFEGYVELPPIEGRSPRSP
RNNPVPPEAKSPVLNPGERPADVSPTSPQPEGLLVLQQVGDYCFLPGLGPGPLSLRSKPS
SPGPGPEIKNLDQAFQVKKPPGQAVPQVPVIQLFKALKQQDYLSLPPWEVNKPGEVC

# Drug_Target_58_Reaction:
Not Available

# Drug_Target_58_Signals:
1-16

# Drug_Target_58_Specific_Function:
High affinity receptor for interleukin-3, interleukin-5 and granulocyte-macrophage colony-stimulating factor

# Drug_Target_58_SwissProt_ID:
P32927

# Drug_Target_58_SwissProt_Name:
IL3RB_HUMAN

# Drug_Target_58_Synonyms:
CD131 antigen
CDw131
Cytokine receptor common beta chain precursor
GM-CSF/IL-3/IL-5 receptor common beta-chain

# Drug_Target_58_Theoretical_pI:
5.21

# Drug_Target_58_Transmembrane_Regions:
444-460

# Drug_Target_59_Cellular_Location:
Not Available

# Drug_Target_59_Chromosome_Location:
Not Available

# Drug_Target_59_Drug_References:
Not Available

# Drug_Target_59_Essentiality:
Non-Essential

# Drug_Target_59_GenAtlas_ID:
IGHE

# Drug_Target_59_GenBank_ID_Gene:
Not Available

# Drug_Target_59_GenBank_ID_Protein:
Not Available

# Drug_Target_59_GeneCard_ID:
Not Available

# Drug_Target_59_Gene_Name:
IGHE

# Drug_Target_59_Gene_Sequence:
Not Available

# Drug_Target_59_General_Function:
Not Available

# Drug_Target_59_General_References:
3796618	Padlan EA, Davies DR: A model of the Fc of immunoglobulin E. Mol Immunol. 1986 Oct;23(10):1063-75.
6234164	Flanagan JG, Rabbitts TH: The sequence of a human immunoglobulin epsilon heavy chain constant region gene, and evidence for three non-allelic genes. EMBO J. 1982;1(5):655-60.
6288268	Max EE, Battey J, Ney R, Kirsch IR, Leder P: Duplication and deletion in the human immunoglobulin epsilon genes. Cell. 1982 Jun;29(2):691-9.
6300763	Seno M, Kurokawa T, Ono Y, Onda H, Sasada R, Igarashi K, Kikuchi M, Sugino Y, Nishida Y, Honjo T: Molecular cloning and nucleotide sequencing of human immunoglobulin epsilon chain cDNA. Nucleic Acids Res. 1983 Feb 11;11(3):719-26.
6327276	Ueda S, Nakai S, Nishida Y, Hisajima H, Honjo T: Long terminal repeat-like elements flank a human immunoglobulin epsilon pseudogene that lacks introns. EMBO J. 1982;1(12):1539-44.
6815656	Kenten JH, Molgaard HV, Houghton M, Derbyshire RB, Viney J, Bell LO, Gould HJ: Cloning and sequence determination of the gene for the human immunoglobulin epsilon chain expressed in a myeloma cell line. Proc Natl Acad Sci U S A. 1982 Nov;79(21):6661-5.

# Drug_Target_59_HGNC_ID:
HGNC:5522

# Drug_Target_59_HPRD_ID:
Not Available

# Drug_Target_59_ID:
4889

# Drug_Target_59_Locus:
14q32.33

# Drug_Target_59_Molecular_Weight:
47019

# Drug_Target_59_Name:
Ig epsilon chain C region

# Drug_Target_59_Number_of_Residues:
428

# Drug_Target_59_PDB_ID:
1O0V

# Drug_Target_59_Pathway:
Not Available

# Drug_Target_59_Pfam_Domain_Function:
PF00047	ig
PF07654	C1-set

# Drug_Target_59_Protein_Sequence:
>Ig epsilon chain C region
ASTQSPSVFPLTRCCKNIPSNATSVTLGCLATGYFPEPVMVTWDTGSLNGTTMTLPATTL
TLSGHYATISLLTVSGAWAKQMFTCRVAHTPSSTDWVDNKTFSVCSRDFTPPTVKILQSS
CDGGGHFPPTIQLLCLVSGYTPGTINITWLEDGQVMDVDLSTASTTQEGELASTQSELTL
SQKHWLSDRTYTCQVTYQGHTFEDSTKKCADSNPRGVSAYLSRPSPFDLFIRKSPTITCL
VVDLAPSKGTVNLTWSRASGKPVNHSTRKEEKQRNGTLTVTSTLPVGTRDWIEGETYQCR
VTHPHLPRALMRSTTKTSGPRAAPEVYAFATPEWPGSRDKRTLACLIQNFMPEDISVQWL
HNEVQLPDARHSTTQPRKTKGSGFFVFSRLEVTRAEWEQKDEFICRAVHEAASPSQTVQR
AVSVNPGK

# Drug_Target_59_Reaction:
Not Available

# Drug_Target_59_Signals:
None

# Drug_Target_59_Specific_Function:
Not Available

# Drug_Target_59_SwissProt_ID:
P01854

# Drug_Target_59_SwissProt_Name:
IGHE_HUMAN

# Drug_Target_59_Synonyms:
Not Available

# Drug_Target_59_Theoretical_pI:
8.13

# Drug_Target_59_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Lysosome

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
GUSB

# Drug_Target_5_GenBank_ID_Gene:
M15182

# Drug_Target_5_GenBank_ID_Protein:
183233

# Drug_Target_5_GeneCard_ID:
GUSB

# Drug_Target_5_Gene_Name:
GUSB

# Drug_Target_5_Gene_Sequence:
>1956 bp
ATGGCCCGGGGGTCGGCGGTTGCCTGGGCGGCGCTCGGGCCGTTGTTGTGGGGCTGCGCG
CTGGGGCTGCAGGGCGGGATGCTGTACCCCCAGGAGAGCCCGTCGCGGGAGTGCAAGGAG
CTGGACGGCCTCTGGAGCTTCCGCGCCGACTTCTCTGACAACCGACGCCGGGGCTTCGAG
GAGCAGTGGTACCGGCGGCCGCTGTGGGAGTCAGGCCCCACCGTGGACATGCCAGTTCCC
TCCAGCTTCAATGACATCAGCCAGGACTGGCGTCTGCGGCATTTTGTCGGCTGGGTGTGG
TACGAACGGGAGGTGATCCTGCCGGAGCGATGGACCCAGGACCTGCGCACAAGAGTGGTG
CTGAGGATTGGCAGTGCCCATTCCTATGCCATCGTGTGGGTGAATGGGGTCGACACGCTA
GAGCATGAGGGGGGCTACCTCCCCTTCGAGGCCGACATCAGCAACCTGGTCCAGGTGGGG
CCCCTGCCCTCCCGGCTCCGAATCACTATCGCCATCAACAACACACTCACCCCCACCACC
CTGCCACCAGGGACCATCCAATACCTGACTGACACCTCCAAGTATCCCAAGGGTTACTTT
GTCCAGAACACATATTTTGACTTTTTCAACTACGCTGGACTGCAGCGGTCTGTACTTCTG
TACACGACACCCACCACCTACATCGATGACATCACCGTCACCACCAGCGTGGAGCAAGAC
AGTGGGCTGGTGAATTACCAGATCTCTGTCAAGGGCAGTAACCTGTTCAAGTTGGAAGTG
CGTCTTTTGGATGCAGAAAACAAAGTCGTGGCGAATGGGACTGGGACCCAGGGCCAACTT
AAGGTGCCAGGTGTCAGCCTCTGGTGGCCGTACCTGATGCACGAACGCCCTGCCTATCTG
TATTCATTGGAGGTGCAGCTGACTGCACAGACGTCACTGGGGCCTGTGTCTGACTTCTAC
ACACTCCCTGTGGGGATCCGCACTGTGGCTGTCACCAAGAGCCAGTTCCTCATCAATGGG
AAACCTTTCTATTTCCACGGTGTCAACAAGCATGAGGATGCGGACATCCGAGGGAAGGGC
TTCGACTGGCCGCTGCTGGTGAAGGACTTCAACCTGCTTCGCTGGCTTGGTGCCAACGCT
TTCCGTACCAGCCACTACCCCTATGCAGAGGAAGTGATGCAGATGTGTGACCGCTATGGG
ATTGTGGTCATCGATGAGTGTCCCGGCGTGGGCCTGGCGCTGCCGCAGTTCTTCAACAAC
GTTTCTCTGCATCACCACATGCAGGTGATGGAAGAAGTGGTGCGTAGGGACAAGAACCAC
CCCGCGGTCGTGATGTGGTCTGTGGCCAACGAGCCTGCGTCCCACCTAGAATCTGCTGGC
TACTACTTGAAGATGGTGATCGCTCACACCAAATCCTTGGACCCCTCCCGGCCTGTGACC
TTTGTGAGCAACTCTAACTATGCAGCAGACAAGGGGGCTCCGTATGTGGATGTGATCTGT
TTGAACAGCTACTACTCTTGGTATCACGACTACGGGCACCTGGAGTTGATTCAGCTGCAG
CTGGCCACCCAGTTTGAGAACTGGTATAAGAAGTATCAGAAGCCCATTATTCAGAGCGAG
TATGGAGCAGAAACGATTGCAGGGTTTCACCAGGATCCACCTCTGATGTTCACTGAAGAG
TACCAGAAAAGTCTGCTAGAGCAGTACCATCTGGGTCTGGATCAAAAACGCAGAAAATAT
GTGGTTGGAGAGCTCATTTGGAATTTTGCCGATTTCATGACTGAACAGTCACCGACGAGA
GTGCTGGGGAATAAAAAGGGGATCTTCACTCGGCAGAGACAACCAAAAAGTGCAGCGTTC
CTTTTGCGAGAGAGATACTGGAAGATTGCCAATGAAACCAGGTATCCCCACTCAGTAGCC
AAGTCACAATGTTTGGAAAACAGCCCGTTTACTTGA

# Drug_Target_5_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_5_General_References:
12754519	Zhang H, Li XJ, Martin DB, Aebersold R: Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol. 2003 Jun;21(6):660-6. Epub 2003 May 18.
12853948	Hillier LW, Fulton RS, Fulton LA, Graves TA, Pepin KH, Wagner-McPherson C, Layman D, Maas J, Jaeger S, Walker R, Wylie K, Sekhon M, Becker MC, O'Laughlin MD, Schaller ME, Fewell GA, Delehaunty KD, Miner TL, Nash WE, Cordes M, Du H, Sun H, Edwards J, Bradshaw-Cordum H, Ali J, Andrews S, Isak A, Vanbrunt A, Nguyen C, Du F, Lamar B, Courtney L, Kalicki J, Ozersky P, Bielicki L, Scott K, Holmes A, Harkins R, Harris A, Strong CM, Hou S, Tomlinson C, Dauphin-Kohlberg S, Kozlowicz-Reilly A, Leonard S, Rohlfing T, Rock SM, Tin-Wollam AM, Abbott A, Minx P, Maupin R, Strowmatt C, Latreille P, Miller N, Johnson D, Murray J, Woessner JP, Wendl MC, Yang SP, Schultz BR, Wallis JW, Spieth J, Bieri TA, Nelson JO, Berkowicz N, Wohldmann PE, Cook LL, Hickenbotham MT, Eldred J, Williams D, Bedell JA, Mardis ER, Clifton SW, Chissoe SL, Marra MA, Raymond C, Haugen E, Gillett W, Zhou Y, James R, Phelps K, Iadanoto S, Bubb K, Simms E, Levy R, Clendenning J, Kaul R, Kent WJ, Furey TS, Baertsch RA, Brent MR, Keibler E, Flicek P, Bork P, Suyama M, Bailey JA, Portnoy ME, Torrents D, Chinwalla AT, Gish WR, Eddy SR, McPherson JD, Olson MV, Eichler EE, Green ED, Waterston RH, Wilson RK: The DNA sequence of human chromosome 7. Nature. 2003 Jul 10;424(6945):157-64.
1311180	Tanaka J, Gasa S, Sakurada K, Miyazaki T, Kasai M, Makita A: Characterization of the subunits and sugar moiety of human placental and leukemic beta-glucuronidase. Biol Chem Hoppe Seyler. 1992 Jan;373(1):57-62.
1702266	Tomatsu S, Fukuda S, Sukegawa K, Ikedo Y, Yamada S, Yamada Y, Sasaki T, Okamoto H, Kuwahara T, Yamaguchi S, et al.: Mucopolysaccharidosis type VII: characterization of mutations and molecular heterogeneity. Am J Hum Genet. 1991 Jan;48(1):89-96.
1916806	Shipley JM, Miller RD, Wu BM, Grubb JH, Christensen SG, Kyle JW, Sly WS: Analysis of the 5' flanking region of the human beta-glucuronidase gene. Genomics. 1991 Aug;10(4):1009-18.
3468507	Oshima A, Kyle JW, Miller RD, Hoffmann JW, Powell PP, Grubb JH, Sly WS, Tropak M, Guise KS, Gravel RA: Cloning, sequencing, and expression of cDNA for human beta-glucuronidase. Proc Natl Acad Sci U S A. 1987 Feb;84(3):685-9.
3924735	Guise KS, Korneluk RG, Waye J, Lamhonwah AM, Quan F, Palmer R, Ganschow RE, Sly WS, Gravel RA: Isolation and expression in Escherichia coli of a cDNA clone encoding human beta-glucuronidase. Gene. 1985;34(1):105-10.
7680524	Shipley JM, Klinkenberg M, Wu BM, Bachinsky DR, Grubb JH, Sly WS: Mutational analysis of a patient with mucopolysaccharidosis type VII, and identification of pseudogenes. Am J Hum Genet. 1993 Mar;52(3):517-26.
8111412	Vervoort R, Lissens W, Liebaers I: Molecular analysis of a patient with hydrops fetalis caused by beta-glucuronidase deficiency, and evidence for additional pseudogenes. Hum Mutat. 1993;2(6):443-5.
8111413	Wu BM, Sly WS: Mutational studies in a patient with the hydrops fetalis form of mucopolysaccharidosis type VII. Hum Mutat. 1993;2(6):446-57.
8599764	Jain S, Drendel WB, Chen ZW, Mathews FS, Sly WS, Grubb JH: Structure of human beta-glucuronidase reveals candidate lysosomal targeting and active-site motifs. Nat Struct Biol. 1996 Apr;3(4):375-81.

# Drug_Target_5_HGNC_ID:
HGNC:4696

# Drug_Target_5_HPRD_ID:
02018

# Drug_Target_5_ID:
1354

# Drug_Target_5_Locus:
7q21.11

# Drug_Target_5_Molecular_Weight:
74733

# Drug_Target_5_Name:
Beta-glucuronidase

# Drug_Target_5_Number_of_Residues:
651

# Drug_Target_5_PDB_ID:
1BHG

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF00703	Glyco_hydro_2
PF02836	Glyco_hydro_2_C
PF02837	Glyco_hydro_2_N

# Drug_Target_5_Protein_Sequence:
>Beta-glucuronidase precursor
MARGSAVAWAALGPLLWGCALGLQGGMLYPQESPSRECKELDGLWSFRADFSDNRRRGFE
EQWYRRPLWESGPTVDMPVPSSFNDISQDWRLRHFVGWVWYEREVILPERWTQDLRTRVV
LRIGSAHSYAIVWVNGVDTLEHEGGYLPFEADISNLVQVGPLPSRLRITIAINNTLTPTT
LPPGTIQYLTDTSKYPKGYFVQNTYFDFFNYAGLQRSVLLYTTPTTYIDDITVTTSVEQD
SGLVNYQISVKGSNLFKLEVRLLDAENKVVANGTGTQGQLKVPGVSLWWPYLMHERPAYL
YSLEVQLTAQTSLGPVSDFYTLPVGIRTVAVTKSQFLINGKPFYFHGVNKHEDADIRGKG
FDWPLLVKDFNLLRWLGANAFRTSHYPYAEEVMQMCDRYGIVVIDECPGVGLALPQFFNN
VSLHHHMQVMEEVVRRDKNHPAVVMWSVANEPASHLESAGYYLKMVIAHTKSLDPSRPVT
FVSNSNYAADKGAPYVDVICLNSYYSWYHDYGHLELIQLQLATQFENWYKKYQKPIIQSE
YGAETIAGFHQDPPLMFTEEYQKSLLEQYHLGLDQKRRKYVVGELIWNFADFMTEQSPTR
VLGNKKGIFTRQRQPKSAAFLLRERYWKIANETRYPHSVAKSQCLENSLFT

# Drug_Target_5_Reaction:
a beta-D-glucuronoside + H2O = D-glucuronate + an alcohol

# Drug_Target_5_Signals:
1-22

# Drug_Target_5_Specific_Function:
Plays an important role in the degradation of dermatan and keratan sulfates

# Drug_Target_5_SwissProt_ID:
P08236

# Drug_Target_5_SwissProt_Name:
BGLR_HUMAN

# Drug_Target_5_Synonyms:
Beta-G1
Beta-glucuronidase precursor
EC 3.2.1.31

# Drug_Target_5_Theoretical_pI:
7.02

# Drug_Target_5_Transmembrane_Regions:
None

# Drug_Target_60_Cellular_Location:
Cell membrane

# Drug_Target_60_Chromosome_Location:
Not Available

# Drug_Target_60_Drug_References:
Not Available

# Drug_Target_60_Essentiality:
Non-Essential

# Drug_Target_60_GenAtlas_ID:
Not Available

# Drug_Target_60_GenBank_ID_Gene:
J02090

# Drug_Target_60_GenBank_ID_Protein:
Not Available

# Drug_Target_60_GeneCard_ID:
Not Available

# Drug_Target_60_Gene_Name:
HA

# Drug_Target_60_Gene_Sequence:
>1701 bp
ATGAAGACCATCATTGCTTTGAGCTACATTTTCTGTCTGGCTCTCGGCCAAGACCTTCCA
GGAAATGACAACAGCACAGCAACGCTGTGCCTGGGACATCATGCGGTGCCAAACGGAACA
CTAGTGAAAACAATCACAGATGATCAGATTGAAGTGACTAATGCTACTGAGCTAGTTCAG
AGCTCCTCAACGGGGAAAATATGCAACAATCCTCATCGAATCCTTGATGGAATAGACTGC
ACACTGATAGATGCTCTATTGGGGGACCCTCATTGTGATGTTTTTCAAAATGAGACATGG
GACCTTTTCGTTGAACGCAGCAAAGCTTTCAGCAACTGTTACCCTTATGATGTGCCAGAT
TATGCCTCCCTTAGGTCACTAGTTGCCTCGTCAGGCACTCTGGAGTTTATCACTGAGGGT
TTCACTTGGACTGGGGTCACTCAGAATGGGGGAAGCAATGCTTGCAAAAGGGGACCTGGT
AGCGGTTTTTTCAGTAGACTGAACTGGTTGACCAAATCAGGAAGCACATATCCAGTGCTG
AACGTGACTATGCCAAACAATGACAATTTTGACAAACTATACATTTGGGGGATTCACCAC
CCGAGCACGAACCAAGAACAAACCAGCCTGTATGTTCAAGCATCAGGGAGAGTCACAGTC
TCTACCAGGAGAAGCCAGCAAACTATAATCCCGAATATCGGGTCCAGACCCTGGGTAAGG
GGTCTGTCTAGTAGAATAAGCATCTATTGGACAATAGTTAAGCCGGGAGACGTACTGGTA
ATTAATAGTAATGGGAACCTAATCGCTCCTCGGGGTTATTTCAAAATGCGCACTGGGAAA
AGCTCAATAATGAGGTCAGATGCACCTATTGATACCTGTATTTCTGAATGCATCACTCCA
AATGGAAGCATTCCCAATGACAAGCCCTTTCAAAACGTAAACAAGATCACATATGGAGCA
TGCCCCAAGTATGTTAAGCAAAACACCCTGAAGTTGGCAACAGGGATGCGGAATGTACCA
GAGAAACAAACTAGAGGCCTATTCGGCGCAATAGCAGGTTTCATAGAAAATGGTTGGGAG
GGAATGATAGACGGTTGGTACGGTTTCAGGCATCAAAATTCTGAGGGCACAGGACAAGCA
GCAGATCTTAAAAGCACTCAAGCAGCCATCGACCAAATCAATGGGAAATTGAACAGGGTA
ATCGAGAAGACGAACGAGAAATTCCATCAAATCGAAAAGGAATTCTCAGAAGTAGAAGGG
AGAATTCAGGACCTCGAGAAATACGTTGAAGACACTAAAATAGATCTCTGGTCTTACAAT
GCGGAGCTTCTTGTCGCTCTGGAGAATCAACATACAATTGACCTGACTGACTCGGAAATG
AACAAGCTGTTTGAAAAAACAAGGAGGCAACTGAGGGAAAATGCTGAAGAGATGGGCAAT
GGTTGCTTCAAAATATACCACAAATGTGACAACGCTTGCATAGAGTCAATCAGAAATGGT
ACTTATGACCATGATGTATACAGAGACGAAGCATTAAACAACCGGTTTCAGATCAAAGGT
GTTGAACTGAAGTCTGGATACAAAGACTGGATCCTGTGGATTTCCTTTGCCATATCATGC
TTTTTGCTTTGTGTTGTTTTGCTGGGGTTCATCATGTGGGCCTGCCAGAGAGGCAACATT
AGGTGCAACATTTGCATTTGA

# Drug_Target_60_General_Function:
Involved in host cell surface receptor binding

# Drug_Target_60_General_References:
2295311	Weis WI, Cusack SC, Brown JH, Daniels RS, Skehel JJ, Wiley DC: The structure of a membrane fusion mutant of the influenza virus haemagglutinin. EMBO J. 1990 Jan;9(1):17-24.
2329580	Weis WI, Brunger AT, Skehel JJ, Wiley DC: Refinement of the influenza virus hemagglutinin by simulated annealing. J Mol Biol. 1990 Apr 20;212(4):737-61.
3374584	Weis W, Brown JH, Cusack S, Paulson JC, Skehel JJ, Wiley DC: Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature. 1988 Jun 2;333(6172):426-31.
7402351	Verhoeyen M, Fang R, Jou WM, Devos R, Huylebroeck D, Saman E, Fiers W: Antigenic drift between the haemagglutinin of the Hong Kong influenza strains A/Aichi/2/68 and A/Victoria/3/75. Nature. 1980 Aug 21;286(5775):771-6.
7464906	Wilson IA, Skehel JJ, Wiley DC: Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature. 1981 Jan 29;289(5796):366-73.
8072525	Bullough PA, Hughson FM, Skehel JJ, Wiley DC: Structure of influenza haemagglutinin at the pH of membrane fusion. Nature. 1994 Sep 1;371(6492):37-43.
9461077	Fleury D, Wharton SA, Skehel JJ, Knossow M, Bizebard T: Antigen distortion allows influenza virus to escape neutralization. Nat Struct Biol. 1998 Feb;5(2):119-23.

# Drug_Target_60_HGNC_ID:
Not Available

# Drug_Target_60_HPRD_ID:
Not Available

# Drug_Target_60_ID:
4890

# Drug_Target_60_Locus:
Not Available

# Drug_Target_60_Molecular_Weight:
63416

# Drug_Target_60_Name:
Hemagglutinin

# Drug_Target_60_Number_of_Residues:
566

# Drug_Target_60_PDB_ID:
1HA0

# Drug_Target_60_Pathway:
Not Available

# Drug_Target_60_Pfam_Domain_Function:
PF00509	Hemagglutinin

# Drug_Target_60_Protein_Sequence:
>Hemagglutinin
MKTIIALSYIFCLALGQDLPGNDNSTATLCLGHHAVPNGTLVKTITDDQIEVTNATELVQ
SSSTGKICNNPHRILDGIDCTLIDALLGDPHCDVFQNETWDLFVERSKAFSNCYPYDVPD
YASLRSLVASSGTLEFITEGFTWTGVTQNGGSNACKRGPGSGFFSRLNWLTKSGSTYPVL
NVTMPNNDNFDKLYIWGIHHPSTNQEQTSLYVQASGRVTVSTRRSQQTIIPNIGSRPWVR
GLSSRISIYWTIVKPGDVLVINSNGNLIAPRGYFKMRTGKSSIMRSDAPIDTCISECITP
NGSIPNDKPFQNVNKITYGACPKYVKQNTLKLATGMRNVPEKQTRGLFGAIAGFIENGWE
GMIDGWYGFRHQNSEGTGQAADLKSTQAAIDQINGKLNRVIEKTNEKFHQIEKEFSEVEG
RIQDLEKYVEDTKIDLWSYNAELLVALENQHTIDLTDSEMNKLFEKTRRQLRENAEEMGN
GCFKIYHKCDNACIESIRNGTYDHDVYRDEALNNRFQIKGVELKSGYKDWILWISFAISC
FLLCVVLLGFIMWACQRGNIRCNICI

# Drug_Target_60_Reaction:
Not Available

# Drug_Target_60_Signals:
1-16

# Drug_Target_60_Specific_Function:
Binds to sialic acid-containing receptors on the cell surface, bringing about the attachment of the virus particle to the cell. Plays a major role in the determination of host range restriction and virulence. Class I viral fusion protein. Responsible for penetration of the virus into the cell cytoplasm by mediating the fusion of the membrane of the endocytosed virus particle with the endosomal membrane. Low pH in endosomes induce an irreversible conformational change in HA2, releasing the fusion hydrophobic peptide. Several trimers are required to form a competent fusion pore

# Drug_Target_60_SwissProt_ID:
P03437

# Drug_Target_60_SwissProt_Name:
HEMA_I68A0

# Drug_Target_60_Synonyms:
Hemagglutinin precursor

# Drug_Target_60_Theoretical_pI:
6.71

# Drug_Target_60_Transmembrane_Regions:
531-551

# Drug_Target_61_Cellular_Location:
Not Available

# Drug_Target_61_Chromosome_Location:
Not Available

# Drug_Target_61_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_61_Essentiality:
Non-Essential

# Drug_Target_61_GenAtlas_ID:
Not Available

# Drug_Target_61_GenBank_ID_Gene:
Not Available

# Drug_Target_61_GenBank_ID_Protein:
Not Available

# Drug_Target_61_GeneCard_ID:
Not Available

# Drug_Target_61_Gene_Name:
CHI3L1

# Drug_Target_61_Gene_Sequence:
Not Available

# Drug_Target_61_General_Function:
Not Available

# Drug_Target_61_General_References:
Not Available

# Drug_Target_61_HGNC_ID:
Not Available

# Drug_Target_61_HPRD_ID:
Not Available

# Drug_Target_61_ID:
7113

# Drug_Target_61_Locus:
Not Available

# Drug_Target_61_Molecular_Weight:
Not Available

# Drug_Target_61_Name:
Chitinase-3-like protein 1

# Drug_Target_61_Number_of_Residues:
0

# Drug_Target_61_PDB_ID:
Not Available

# Drug_Target_61_Pathway:
Not Available

# Drug_Target_61_Pfam_Domain_Function:
Not Available

# Drug_Target_61_Protein_Sequence:
Not Available

# Drug_Target_61_Reaction:
Not Available

# Drug_Target_61_Signals:
Not Available

# Drug_Target_61_Specific_Function:
Not Available

# Drug_Target_61_SwissProt_ID:
P36222

# Drug_Target_61_SwissProt_Name:
CH3L1_HUMAN

# Drug_Target_61_Synonyms:
Not Available

# Drug_Target_61_Theoretical_pI:
Not Available

# Drug_Target_61_Transmembrane_Regions:
Not Available

# Drug_Target_62_Cellular_Location:
Not Available

# Drug_Target_62_Chromosome_Location:
Not Available

# Drug_Target_62_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_62_Essentiality:
Non-Essential

# Drug_Target_62_GenAtlas_ID:
Not Available

# Drug_Target_62_GenBank_ID_Gene:
Not Available

# Drug_Target_62_GenBank_ID_Protein:
Not Available

# Drug_Target_62_GeneCard_ID:
Not Available

# Drug_Target_62_Gene_Name:
LGALS1

# Drug_Target_62_Gene_Sequence:
Not Available

# Drug_Target_62_General_Function:
Not Available

# Drug_Target_62_General_References:
Not Available

# Drug_Target_62_HGNC_ID:
Not Available

# Drug_Target_62_HPRD_ID:
Not Available

# Drug_Target_62_ID:
7003

# Drug_Target_62_Locus:
Not Available

# Drug_Target_62_Molecular_Weight:
Not Available

# Drug_Target_62_Name:
Galectin-1

# Drug_Target_62_Number_of_Residues:
0

# Drug_Target_62_PDB_ID:
Not Available

# Drug_Target_62_Pathway:
Not Available

# Drug_Target_62_Pfam_Domain_Function:
Not Available

# Drug_Target_62_Protein_Sequence:
Not Available

# Drug_Target_62_Reaction:
Not Available

# Drug_Target_62_Signals:
Not Available

# Drug_Target_62_Specific_Function:
Not Available

# Drug_Target_62_SwissProt_ID:
P09382

# Drug_Target_62_SwissProt_Name:
LEG1_HUMAN

# Drug_Target_62_Synonyms:
Not Available

# Drug_Target_62_Theoretical_pI:
Not Available

# Drug_Target_62_Transmembrane_Regions:
Not Available

# Drug_Target_63_Cellular_Location:
Capsid protein:Cytoplasm. p62:Cell membrane

# Drug_Target_63_Chromosome_Location:
Not Available

# Drug_Target_63_Drug_References:
Not Available

# Drug_Target_63_Essentiality:
Non-Essential

# Drug_Target_63_GenAtlas_ID:
Not Available

# Drug_Target_63_GenBank_ID_Gene:
Not Available

# Drug_Target_63_GenBank_ID_Protein:
Not Available

# Drug_Target_63_GeneCard_ID:
Not Available

# Drug_Target_63_Gene_Name:
Not Available

# Drug_Target_63_Gene_Sequence:
Not Available

# Drug_Target_63_General_Function:
Involved in structural molecule activity

# Drug_Target_63_General_References:
6087344	Bell JR, Kinney RM, Trent DW, Strauss EG, Strauss JH: An evolutionary tree relating eight alphaviruses, based on amino-terminal sequences of their glycoproteins. Proc Natl Acad Sci U S A. 1984 Aug;81(15):4702-6.
6935652	Garoff H, Frischauf AM, Simons K, Lehrach H, Delius H: The capsid protein of Semliki Forest virus has clusters of basic amino acids and prolines in its amino-terminal region. Proc Natl Acad Sci U S A. 1980 Nov;77(11):6376-80.
6985476	Garoff H, Frischauf AM, Simons K, Lehrach H, Delius H: Nucleotide sequence of cdna coding for Semliki Forest virus membrane glycoproteins. Nature. 1980 Nov 20;288(5788):236-41.

# Drug_Target_63_HGNC_ID:
Not Available

# Drug_Target_63_HPRD_ID:
Not Available

# Drug_Target_63_ID:
4892

# Drug_Target_63_Locus:
Not Available

# Drug_Target_63_Molecular_Weight:
138018

# Drug_Target_63_Name:
Structural polyprotein

# Drug_Target_63_Number_of_Residues:
1253

# Drug_Target_63_PDB_ID:
1RER

# Drug_Target_63_Pathway:
Not Available

# Drug_Target_63_Pfam_Domain_Function:
PF00943	Alpha_E2_glycop
PF00944	Peptidase_S3
PF01563	Alpha_E3_glycop
PF01589	Alpha_E1_glycop

# Drug_Target_63_Protein_Sequence:
>Structural polyprotein
MNYIPTQTFYGRRWRPRPAARPWPLQATPVAPVVPDFQAQQMQQLISAVNALTMRQNAIA
PARPPKPKKKKTTKPKPKTQPKKINGKTQQQKKKDKQADKKKKKPGKRERMCMKIENDCI
FEVKHEGKVTGYACLVGDKVMKPAHVKGVIDNADLAKLAFKKSSKYDLECAQIPVHMRSD
ASKYTHEKPEGHYNWHHGAVQYSGGRFTIPTGAGKPGDSGRPIFDNKGRVVAIVLGGANE
GSRTALSVVTWNKDMVTRVTPEGSEEWSAPLITAMCVLANATFPCFQPPCVPCCYENNAE
ATLRMLEDNVDRPGYYDLLQAALTCRNGTRHRRSVSQHFNVYKATRPYIAYCADCGAGHS
CHSPVAIEAVRSEATDGMLKIQFSAQIGIDKSDNHDYTKIRYADGHAIENAVRSSLKVAT
SGDCFVHGTMGHFILAKCPPGEFLQVSIQDTRNAVRACRIQYHHDPQPVGREKFTIRPHY
GKEIPCTTYQQTTAETVEEIDMHMPPDTPDRTLLSQQSGNVKITVGGKKVKYNCTCGTGN
VGTTNSDMTINTCLIEQCHVSVTDHKKWQFNSPFVPRADEPARKGKVHIPFPLDNITCRV
PMAREPTVIHGKREVTLHLHPDHPTLFSYRTLGEDPQYHEEWVTAAVERTIPVPVDGMEY
HWGNNDPVRLWSQLTTEGKPHGWPHQIVQYYYGLYPAATVSAVVGMSLLALISIFASCYM
LVAARSKCLTPYALTPGAAVPWTLGILCCAPRAHAASVAETMAYLWDQNQALFWLEFAAP
VACILIITYCLRNVLCCCKSLSFLVLLSLGATARAYEHSTVMPNVVGFPYKAHIERPGYS
PLTLQMQVVETSLEPTLNLEYITCEYKTVVPSPYVKCCGASECSTKEKPDYQCKVYTGVY
PFMWGGAYCFCDSENTQLSEAYVDRSDVCRHDHASAYKAHTASLKAKVRVMYGNVNQTVD
VYVNGDHAVTIGGTQFIFGPLSSAWTPFDNKIVVYKDEVFNQDFPPYGSGQPGRFGDIQS
RTVESNDLYANTALKLARPSPGMVHVPYTQTPSGFKYWLKEKGTALNTKAPFGCQIKTNP
VRAMNCAVGNIPVSMNLPDSAFTRIVEAPTIIDLTCTVATCTHSSDFGGVLTLTYKTNKN
GDCSVHSHSNVATLQEATAKVKTAGKVTLHFSTASASPSFVVSLCSARATCSASCEPPKD
HIVPYAASHSNVVFPDMSGTALSWVQKISGGLGAFAIGAILVLVVVTCIGLRR

# Drug_Target_63_Reaction:
Not Available

# Drug_Target_63_Signals:
268-282

# Drug_Target_63_Specific_Function:
E1 is a class II viral fusion protein. Fusion activity is inactive as long as E1 is bound to E2 in mature virion. After virus attachment to target cell and endocytosis, acidification of the endosome would induce dissociation of E1/E2 heterodimer and concomitant trimerization of the E1 subunits. This E1 trimer is fusion active, and promotes release of viral nucleocapsid in cytoplasm after cell and viral membrane fusion. Efficient fusion requires the presence of cholesterol and sphingolipid in the target membrane. Fusion is optimal at levels of about 1 molecule of cholesterol per 2 molecules of phospholipids, and is specific for sterols containing a 3beta-hydroxyl group

# Drug_Target_63_SwissProt_ID:
P03315

# Drug_Target_63_SwissProt_Name:
POLS_SFV

# Drug_Target_63_Synonyms:
p130

# Drug_Target_63_Theoretical_pI:
8.63

# Drug_Target_63_Transmembrane_Regions:
702-722
771-791
793-813
1231-1251

# Drug_Target_64_Cellular_Location:
Lysosome membrane

# Drug_Target_64_Chromosome_Location:
6

# Drug_Target_64_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_64_Essentiality:
Non-Essential

# Drug_Target_64_GenAtlas_ID:
Not Available

# Drug_Target_64_GenBank_ID_Gene:
Y00285

# Drug_Target_64_GenBank_ID_Protein:
33055

# Drug_Target_64_GeneCard_ID:
IGF2R

# Drug_Target_64_Gene_Name:
IGF2R

# Drug_Target_64_Gene_Sequence:
>7476 bp
ATGGGGGCCGCCGCCGGCCGGAGCCCCCACCTGGGGCCCGCGCCCGCCCGCCGCCCGCAG
CGCTCTCTGCTCCTGCTGCAGCTGCTGCTGCTCGTCGCTGCCCCGGGGTCCACGCAGGCC
CAGGCCGCCCCGTTCCCCGAGCTGTGCAGTTATACATGGGAAGCTGTTGATACCAAAAAT
AATGTACTTTATAAAATCAACATCTGTGGAAGTGTGGATATTGTCCAGTGCGGGCCATCA
AGTGCTGTTTGTATGCACGACTTGAAGACACGCACTTATCATTCAGTGGGTGACTCTGTT
TTGAGAAGTGCAACCAGATCTCTCCTGGAATTCAACACAACAGTGAGCTGTGACCAGCAA
GGCACAAATCACAGAGTCCAGAGCAGCATTGCCTTCCTGTGTGGGAAAACCCTGGGAACT
CCTGAATTTGTAACTGCAACAGAATGTGTGCACTACTTTGAGTGGAGGACCACTGCAGCC
TGCAAGAAAGACATATTTAAAGCAAATAAGGAGGTGCCATGCTATGTGTTTGATGAAGAG
TTGAGGAAGCATGATCTCAATCCTCTGATCAAGCTTAGTGGTGCCTACTTGGTGGATGAC
TCCGATCCGGACACTTCTCTATTCATCAATGTTTGTAGAGACATAGACACACTACGAGAC
CCAGGTTCACAGCTGCGGGCCTGTCCCCCCGGCACTGCCGCCTGCCTGGTAAGAGGACAC
CAGGCGTTTGATGTTGGCCAGCCCCGGGACGGACTGAAGCTGGTGCGCAAGGACAGGCTT
GTCCTGAGTTACGTGAGGGAAGAGGCAGGAAAGCTAGACTTTTGTGATGGTCACAGCCCT
GCGGTGACTATTACATTTGTTTGCCCGTCGGAGCGGAGAGAGGGCACCATTCCCAAACTC
ACAGCTAAATCCAACTGCCGCTATGAAATTGAGTGGATTACTGAGTATGCCTGCCACAGA
GATTACCTGGAAAGTAAAACTTGTTCTCTGAGCGGCGAGCAGCAGGATGTCTCCATAGAC
CTCACACCACTTGCCCAGAGCGGAGGTTCATCCTATATTTCAGATGGAAAAGAATATTTG
TTTTATTTGAATGTCTGTGGAGAAACTGAAATACAGTTCTGTAATAAAAAACAAGCTGCA
GTTTGCCAAGTGAAAAAGAGCGATACCTCTCAAGTCAAAGCAGCAGGAAGATACCACAAT
CAGACCCTCCGATATTCGGATGGAGACCTCACCTTGATATATTTTGGAGGTGATGAATGC
AGCTCAGGGTTTCAGCGGATGAGCGTCATAAACTTTGAGTGCAATAAAACCGCAGGTAAC
GATGGGAAAGGAACTCCTGTATTCACAGGGGAGGTTGACTGCACCTACTTCTTCACATGG
GACACGGAATACGCCTGTGTTAAGGAGAAGGAAGACCTCCTCTGCGGTGCCACCGACGGG
AAGAAGCGCTATGACCTGTCCGCGCTGGTCCGCCATGCAGAACCAGAGCAGAATTGGGAA
GCTGTGGATGGCAGTCAGACGGAAACAGAGAAGAAGCATTTTTTCATTAATATTTGTCAC
AGAGTGCTGCAGGAAGGCAAGGCACGAGGGTGTCCCGAGGACGCGGCAGTGTGTGCAGTG
GATAAAAATGGAAGTAAAAATCTGGGAAAATTTATTTCCTCTCCCATGAAAGAGAAAGGA
AACATTCAACTCTCTTATTCAGATGGTGATGATTGTGGTCATGGCAAGAAAATTAAAACT
AATATCACACTTGTATGCAAGCCAGGTGATCTGGAAAGTGCACCAGTGTTGAGAACTTCT
GGGGAAGGCGGTTGCTTTTATGAGTTTGAGTGGCGCACAGCTGCGGCCTGTGTGCTGTCT
AAGACAGAAGGGGAGAACTGCACGGTCTTTGACTCCCAGGCAGGGTTTTCTTTTGACTTA
TCACCTCTCACAAAGAAAAATGGTGCCTATAAAGTTGAGACAAAGAAGTATGACTTTTAT
ATAAATGTGTGTGGCCCGGTGTCTGTGAGCCCCTGTCAGCCAGACTCAGGAGCCTGCCAG
GTGGCAAAAAGTGATGAGAAGACTTGGAACTTGGGTCTGAGTAATGCGAAGCTTTCATAT
TATGATGGGATGATCCAACTGAACTACAGAGGCGGCACACCCTATAACAATGAAAGACAC
ACACCGAGAGCTACGCTCATCACCTTTCTCTGTGATCGAGACGCGGGAGTGGGCTTCCCT
GAATATCAGGAAGAGGATAACTCCACCTACAACTTCCGGTGGTACACCAGCTATGCCTGC
CCGGAGGAGCCCCTGGAATGCGTAGTGACCGACCCCTCCACGCTGGAGCAGTACGACCTC
TCCAGTCTGGCAAAATCTGAAGGTGGCCTTGGAGGAAACTGGTATGCCATGGACAACTCA
GGGGAACATGTCACGTGGAGGAAATACTACATTAACGTGTGTCGGCCTCTGAATCCAGTG
CCGGGCTGCAACCGATATGCATCGGCTTGCCAGATGAAGTATGAAAAAGATCAGGGCTCC
TTCACTGAAGTGGTTTCCATCAGTAACTTGGGAATGGCAAAGACCGGCCCGGTGGTTGAG
GACAGCGGCAGCCTCCTTCTGGAATACGTGAATGGGTCGGCCTGCACCACCAGCGATGGC
AGACAGACCACATATACCACGAGGATCCATCTCGTCTGCTCCAGGGGCAGGCTGAACAGC
CACCCCATCTTTTCTCTCAACTGGGAGTGTGTGGTCAGTTTCCTGTGGAACACAGAGGCT
GCCTGTCCCATTCAGACAACGACGGATACAGACCAGGCTTGCTCTATAAGGGATCCCAAC
AGTGGATTTGTGTTTAATCTTAATCCGCTAAACAGTTCGCAAGGATATAACGTCTCTGGC
ATTGGGAAGATTTTTATGTTTAATGTCTGCGGCACAATGCCTGTCTGTGGGACCATCCTG
GGAAAACCTGCTTCTGGCTGTGAGGCAGAAACCCAAACTGAAGAGCTCAAGAATTGGAAG
CCAGCAAGGCCAGTCGGAATTGAGAAAAGCCTCCAGCTGTCCACAGAGGGCTTCATCACT
CTGACCTACAAAGGGCCTCTCTCTGCCAAAGGTACCGCTGATGCTTTTATCGTCCGCTTT
GTTTGCAATGATGATGTTTACTCAGGGCCCCTCAAATTCCTGCATCAAGATATCGACTCT
GGGCAAGGGATCCGAAACACTTACTTTGAGTTTGAAACCGCGTTGGCCTGTGTTCCTTCT
CCAGTGGACTGCCAAGTCACCGACCTGGCTGGAAATGAGTACGACCTGACTGGCCTAAGC
ACAGTCAGGAAACCTTGGACGGCTGTTGACACCTCTGTCGATGGGAGAAAGAGGACTTTC
TATTTGAGCGTTTGCAATCCTCTCCCTTACATTCCTGGATGCCAGGGCAGCGCAGTGGGG
TCTTGCTTAGTGTCAGAAGGCAATAGCTGGAATCTGGGTGTGGTGCAGATGAGTCCCCAA
GCCGCGGCGAATGGATCTTTGAGCATCATGTATGTCAACGGTGACAAGTGTGGGAACCAG
CGCTTCTCCACCAGGATCACGTTTGAGTGTGCTCAGATATCGGGCTCACCAGCATTTCAG
CTTCAGGATGGTTGTGAGTACGTGTTTATCTGGAGAACTGTGGAAGCCTGTCCCGTTGTC
AGAGTGGAAGGGGACAACTGTGAGGTGAAAGACCCAAGGCATGGCAACTTGTATGACCTG
AAGCCCCTGGGCCTCAACGACACCATCGTGAGCGCTGGCGAATACACTTATTACTTCCGG
GTCTGTGGGAAGCTTTCCTCAGACGTCTGCCCCACAAGTGACAAGTCCAAGGTGGTCTCC
TCATGTCAGGAAAAGCGGGAACCGCAGGGATTTCACAAAGTGGCAGGTCTCCTGACTCAG
AAGCTAACTTATGAAAATGGCTTGTTAAAAATGAACTTCACGGGGGGGGACACTTGCCAT
AAGGTTTATCAGCGCTCCACAGCCATCTTCTTCTACTGTGACCGCGGCACCCAGCGGCCA
GTATTTCTAAAGGAGACTTCAGATTGTTCCTACTTGTTTGAGTGGCGAACGCAGTATGCC
TGCCCACCTTTCGATCTGACTGAATGTTCATTCAAAGATGGGGCTGGCAACTCCTTCGAC
CTCTCGTCCCTGTCAAGGTACAGTGACAACTGGGAAGCCATCACTGGGACGGGGGACCCG
GAGCACTACCTCATCAATGTCTGCAAGTCTCTGGCCCCGCAGGCTGGCACTGAGCCGTGC
CCTCCAGAAGCAGCCGCGTGTCTGCTGGGTGGCTCCAAGCCCGTGAACCTCGGCAGGGTA
AGGGACGGACCTCAGTGGAGAGATGGCATAATTGTCCTGAAATACGTTGATGGCGACTTA
TGTCCAGATGGGATTCGGAAAAAGTCAACCACCATCCGATTCACCTGCAGCGAGAGCCAA
GTGAACTCCAGGCCCATGTTCATCAGCGCCGTGGAGGACTGTGAGTACACCTTTGCCTGG
CCCACAGCCACAGCCTGTCCCATGAAGAGCAACGAGCATGATGACTGCCAGGTCACCAAC
CCAAGCACAGGACACCTGTTTGATCTGAGCTCCTTAAGTGGCAGGGCGGGATTCACAGCT
GCTTACAGCGAGAAGGGGTTGGTTTACATGAGCATCTGTGGGGAGAATGAAAACTGCCCT
CCTGGCGTGGGGGCCTGCTTTGGACAGACCAGGATTAGCGTGGGCAAGGCCAACAAGAGG
CTGAGATACGTGGACCAGGTCCTGCAGCTGGTGTACAAGGATGGGTCCCCTTGTCCCTCC
AAATCCGGCCTGAGCTATAAGAGTGTGATCAGTTTCGTGTGCAGGCCTGAGGCCGGGCCA
ACCAATAGGCCCATGCTCATCTCCCTGGACAAGCAGACATGCACTCTCTTCTTCTCCTGG
CACACGCCGCTGGCCTGCGAGCAAGCGACCGAATGTTCCGTGAGGAATGGAAGCTCTATT
GTTGACTTGTCTCCCCTTATTCATCGCACTGGTGGTTATGAGGCTTATGATGAGAGTGAG
GATGATGCCTCCGATACCAACCCTGATTTCTACATCAATATTTGTCAGCCACTAAATCCC
ATGCACGCAGTGCCCTGTCCTGCCGGAGCCGCTGTGTGCAAAGTTCCTATTGATGGTCCC
CCCATAGATATCGGCCGGGTAGCAGGACCACCAATACTCAATCCAATAGCAAATGAGATT
TACTTGAATTTTGAAAGCAGTACTCCTTGCTTAGCGGACAAGCATTTCAACTACACCTCG
CTCATCGCGTTTCACTGTAAGAGAGGTGTGAGCATGGGAACGCCTAAGCTGTTAAGGACC
AGCGAGTGCGACTTTGTGTTCGAATGGGAGACTCCTGTCGTCTGTCCTGATGAAGTGAGG
ATGGATGGCTGTACCCTGACAGATGAGCAGCTCCTCTACAGCTTCAACTTGTCCAGCCTT
TCCACGAGCACCTTTAAGGTGACTCGCGACTCGCGCACCTACAGCGTTGGGGTGTGCACC
TTTGCAGTCGGGCCAGAACAAGGAGGCTGTAAGGACGGAGGAGTCTGTCTGCTCTCAGGC
ACCAAGGGGGCATCCTTTGGACGGCTGCAATCAATGAAACTGGATTACAGGCACCAGGAT
GAAGCGGTCGTTTTAAGTTACGTGAATGGTGATCGTTGCCCTCCAGAAACCGATGACGGC
GTCCCCTGTGTCTTCCCCTTCATATTCAATGGGAAGAGCTACGAGGAGTGCATCATAGAG
AGCAGGGCGAAGCTGTGGTGTAGCACAACTGCGGACTACGACAGAGACCACGAGTGGGGC
TTCTGCAGACACTCAAACAGCTACCGGACATCCAGCATCATATTTAAGTGTGATGAAGAT
GAGGACATTGGGAGGCCACAAGTCTTCAGTGAAGTGCGTGGGTGTGATGTGACATTTGAG
TGGAAAACAAAAGTTGTCTGCCCTCCAAAGAAGTTGGAGTGCAAATTCGTCCAGAAACAC
AAAACCTACGACCTGCGGCTGCTCTCCTCTCTCACCGGGTCCTGGTCCCTGGTCCACAAC
GGAGTCTCGTACTATATAAATCTGTGCCAGAAAATATATAAAGGGCCCCTGGGCTGCTCT
GAAAGGGCCAGCATTTGCAGAAGGACCACAACTGGTGACGTCCAGGTCCTGGGACTCGTT
CACACGCAGAAGCTGGGTGTCATAGGTGACAAAGTTGTTGTCACGTACTCCAAAGGTTAT
CCGTGTGGTGGAAATAAGACCGCATCCTCCGTGATAGAATTGACCTGTACAAAGACGGTG
GGCAGACCTGCATTCAAGAGGTTTGATATCGACAGCTGCACTTACTACTTCAGCTGGGAC
TCCCGGGCTGCCTGCGCCGTGAAGCCTCAGGAGGTGCAGATGGTGAATGGGACCATCACC
AACCCTATAAATGGCAAGAGCTTCAGCCTCGGAGATATTTATTTTAAGCTGTTCAGAGCC
TCTGGGGACATGAGGACCAATGGGGACAACTACCTGTATGAGATCCAACTTTCCTCCATC
ACAAGCTCCAGAAACCCGGCGTGCTCTGGAGCCAACATATGCCAGGTGAAGCCCAACGAT
CAGCACTTCAGTCGGAAAGTTGGAACCTCTGACAAGACCAAGTACTACCTTCAAGACGGC
GATCTCGATGTCGTGTTTGCCTCTTCCTCTAAGTGCGGAAAGGATAAGACCAAGTCTGTT
TCTTCCACCATCTTCTTCCACTGTGACCCTCTGGTGGAGGACGGGATCCCCGAGTTCAGT
CACGAGACTGCCGACTGCCAGTACCTCTTCTCTTGGTACACCTCAGCCGTGTGTCCTCTG
GGGGTGGGCTTTGACAGCGAGAATCCCGGGGACGACGGGCAGATGCACAAGGGGCTGTCA
GAACGGAGCCAGGCAGTCGGCGCGGTGCTCAGCCTGCTGCTGGTGGCGCTCACCTGCTGC
CTGCTGGCCCTGTTGCTCTACAAGAAGGAGAGGAGGGAAACAGTGATAAGTAAGCTGACC
ACTTGCTGTAGGAGAAGTTCCAACGTGTCCTACAAATACTCAAAGGTGAATAAGGAAGAA
GAGACAGATGAGAATGAAACAGAGTGGCTGATGGAAGAGATCCAGCTGCCTCCTCCACGG
CAGGGAAAGGAAGGGCAGGAGAACGGCCATATTACCACCAAGTCAGTGAAAGCCCTCAGC
TCCCTGCATGGGGATGACCAGGACAGTGAGGATGAGGTTCTGACCATCCCAGAGGTGAAA
GTTCACTCGGGCAGGGGAGCTGGGGCAGAGAGCTCCCACCCAGTGAGAAACGCACAGAGC
AATGCCCTTCAGGAGCGTGAGGACGATAGGGTGGGGCTGGTCAGGGGTGAGAAGGCGAGG
AAAGGGAAGTCCAGCTCTGCACAGCAGAAGACAGTGAGCTCCACCAAGCTGGTGTCCTTC
CATGACGACAGCGACGAGGACCTCTTACACATCTGA

# Drug_Target_64_General_Function:
Involved in insulin-like growth factor receptor activity

# Drug_Target_64_General_References:
11387475	Puertollano R, Aguilar RC, Gorshkova I, Crouch RJ, Bonifacino JS: Sorting of mannose 6-phosphate receptors mediated by the GGAs. Science. 2001 Jun 1;292(5522):1712-6.
12754519	Zhang H, Li XJ, Martin DB, Aebersold R: Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol. 2003 Jun;21(6):660-6. Epub 2003 May 18.
14574404	Mungall AJ, Palmer SA, Sims SK, Edwards CA, Ashurst JL, Wilming L, Jones MC, Horton R, Hunt SE, Scott CE, Gilbert JG, Clamp ME, Bethel G, Milne S, Ainscough R, Almeida JP, Ambrose KD, Andrews TD, Ashwell RI, Babbage AK, Bagguley CL, Bailey J, Banerjee R, Barker DJ, Barlow KF, Bates K, Beare DM, Beasley H, Beasley O, Bird CP, Blakey S, Bray-Allen S, Brook J, Brown AJ, Brown JY, Burford DC, Burrill W, Burton J, Carder C, Carter NP, Chapman JC, Clark SY, Clark G, Clee CM, Clegg S, Cobley V, Collier RE, Collins JE, Colman LK, Corby NR, Coville GJ, Culley KM, Dhami P, Davies J, Dunn M, Earthrowl ME, Ellington AE, Evans KA, Faulkner L, Francis MD, Frankish A, Frankland J, French L, Garner P, Garnett J, Ghori MJ, Gilby LM, Gillson CJ, Glithero RJ, Grafham DV, Grant M, Gribble S, Griffiths C, Griffiths M, Hall R, Halls KS, Hammond S, Harley JL, Hart EA, Heath PD, Heathcott R, Holmes SJ, Howden PJ, Howe KL, Howell GR, Huckle E, Humphray SJ, Humphries MD, Hunt AR, Johnson CM, Joy AA, Kay M, Keenan SJ, Kimberley AM, King A, Laird GK, Langford C, Lawlor S, Leongamornlert DA, Leversha M, Lloyd CR, Lloyd DM, Loveland JE, Lovell J, Martin S, Mashreghi-Mohammadi M, Maslen GL, Matthews L, McCann OT, McLaren SJ, McLay K, McMurray A, Moore MJ, Mullikin JC, Niblett D, Nickerson T, Novik KL, Oliver K, Overton-Larty EK, Parker A, Patel R, Pearce AV, Peck AI, Phillimore B, Phillips S, Plumb RW, Porter KM, Ramsey Y, Ranby SA, Rice CM, Ross MT, Searle SM, Sehra HK, Sheridan E, Skuce CD, Smith S, Smith M, Spraggon L, Squares SL, Steward CA, Sycamore N, Tamlyn-Hall G, Tester J, Theaker AJ, Thomas DW, Thorpe A, Tracey A, Tromans A, Tubby B, Wall M, Wallis JM, West AP, White SS, Whitehead SL, Whittaker H, Wild A, Willey DJ, Wilmer TE, Wood JM, Wray PW, Wyatt JC, Young L, Younger RM, Bentley DR, Coulson A, Durbin R, Hubbard T, Sulston JE, Dunham I, Rogers J, Beck S: The DNA sequence and analysis of human chromosome 6. Nature. 2003 Oct 23;425(6960):805-11.
17081983	Olsen JV, Blagoev B, Gnad F, Macek B, Kumar C, Mortensen P, Mann M: Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell. 2006 Nov 3;127(3):635-48.
17487921	Giorgianni F, Zhao Y, Desiderio DM, Beranova-Giorgianni S: Toward a global characterization of the phosphoproteome in prostate cancer cells: identification of phosphoproteins in the LNCaP cell line. Electrophoresis. 2007 Jun;28(12):2027-34.
2957598	Morgan DO, Edman JC, Standring DN, Fried VA, Smith MC, Roth RA, Rutter WJ: Insulin-like growth factor II receptor as a multifunctional binding protein. Nature. 1987 Sep 24-30;329(6137):301-7.
2963003	Oshima A, Nolan CM, Kyle JW, Grubb JH, Sly WS: The human cation-independent mannose 6-phosphate receptor. Cloning and sequence of the full-length cDNA and expression of functional receptor in COS cells. J Biol Chem. 1988 Feb 15;263(5):2553-62.
9892739	Killian JK, Jirtle RL: Genomic structure of the human M6P/IGF2 receptor. Mamm Genome. 1999 Jan;10(1):74-7.

# Drug_Target_64_HGNC_ID:
GNC:5467

# Drug_Target_64_HPRD_ID:
Not Available

# Drug_Target_64_ID:
6120

# Drug_Target_64_Locus:
6q26

# Drug_Target_64_Molecular_Weight:
274273.3

# Drug_Target_64_Name:
Cation-independent mannose-6-phosphate receptor

# Drug_Target_64_Number_of_Residues:
2491

# Drug_Target_64_PDB_ID:
Not Available

# Drug_Target_64_Pathway:
Not Available

# Drug_Target_64_Pfam_Domain_Function:
PF00040	fn2
PF00878	CIMR

# Drug_Target_64_Protein_Sequence:
>Cation-independent mannose-6-phosphate receptor
MGAAAGRSPHLGPAPARRPQRSLLLLQLLLLVAAPGSTQAQAAPFPELCSYTWEAVDTKN
NVLYKINICGSVDIVQCGPSSAVCMHDLKTRTYHSVGDSVLRSATRSLLEFNTTVSCDQQ
GTNHRVQSSIAFLCGKTLGTPEFVTATECVHYFEWRTTAACKKDIFKANKEVPCYVFDEE
LRKHDLNPLIKLSGAYLVDDSDPDTSLFINVCRDIDTLRDPGSQLRACPPGTAACLVRGH
QAFDVGQPRDGLKLVRKDRLVLSYVREEAGKLDFCDGHSPAVTITFVCPSERREGTIPKL
TAKSNCRYEIEWITEYACHRDYLESKTCSLSGEQQDVSIDLTPLAQSGGSSYISDGKEYL
FYLNVCGETEIQFCNKKQAAVCQVKKSDTSQVKAAGRYHNQTLRYSDGDLTLIYFGGDEC
SSGFQRMSVINFECNKTAGNDGKGTPVFTGEVDCTYFFTWDTEYACVKEKEDLLCGATDG
KKRYDLSALVRHAEPEQNWEAVDGSQTETEKKHFFINICHRVLQEGKARGCPEDAAVCAV
DKNGSKNLGKFISSPMKEKGNIQLSYSDGDDCGHGKKIKTNITLVCKPGDLESAPVLRTS
GEGGCFYEFEWHTAAACVLSKTEGENCTVFDSQAGFSFDLSPLTKKNGAYKVETKKYDFY
INVCGPVSVSPCQPDSGACQVAKSDEKTWNLGLSNAKLSYYDGMIQLNYRGGTPYNNERH
TPRATLITFLCDRDAGVGFPEYQEEDNSTYNFRWYTSYACPEEPLECVVTDPSTLEQYDL
SSLAKSEGGLGGNWYAMDNSGEHVTWRKYYINVCRPLNPVPGCNRYASACQMKYEKDQGS
FTEVVSISNLGMAKTGPVVEDSGSLLLEYVNGSACTTSDGRQTTYTTRIHLVCSRGRLNS
HPIFSLNWECVVSFLWNTEAACPIQTTTDTDQACSIRDPNSGFVFNLNPLNSSQGYNVSG
IGKIFMFNVCGTMPVCGTILGKPASGCEAETQTEELKNWKPARPVGIEKSLQLSTEGFIT
LTYKGPLSAKGTADAFIVRFVCNDDVYSGPLKFLHQDIDSGQGIRNTYFEFETALACVPS
PVDCQVTDLAGNEYDLTGLSTVRKPWTAVDTSVDGRKRTFYLSVCNPLPYIPGCQGSAVG
SCLVSEGNSWNLGVVQMSPQAAANGSLSIMYVNGDKCGNQRFSTRITFECAQISGSPAFQ
LQDGCEYVFIWRTVEACPVVRVEGDNCEVKDPRHGNLYDLKPLGLNDTIVSAGEYTYYFR
VCGKLSSDVCPTSDKSKVVSSCQEKREPQGFHKVAGLLTQKLTYENGLLKMNFTGGDTCH
KVYQRSTAIFFYCDRGTQRPVFLKETSDCSYLFEWRTQYACPPFDLTECSFKDGAGNSFD
LSSLSRYSDNWEAITGTGDPEHYLINVCKSLAPQAGTEPCPPEAAACLLGGSKPVNLGRV
RDGPQWRDGIIVLKYVDGDLCPDGIRKKSTTIRFTCSESQVNSRPMFISAVEDCEYTFAW
PTATACPMKSNEHDDCQVTNPSTGHLFDLSSLSGRAGFTAAYSEKGLVYMSICGENENCP
PGVGACFGQTRISVGKANKRLRYVDQVLQLVYKDGSPCPSKSGLSYKSVISFVCRPEAGP
TNRPMLISLDKQTCTLFFSWHTPLACEQATECSVRNGSSIVDLSPLIHRTGGYEAYDESE
DDASDTNPDFYINICQPLNPMHGVPCPAGAAVCKVPIDGPPIDIGRVAGPPILNPIANEI
YLNFESSTPCLADKHFNYTSLIAFHCKRGVSMGTPKLLRTSECDFVFEWETPVVCPDEVR
MDGCTLTDEQLLYSFNLSSLSTSTFKVTRDSRTYSVGVCTFAVGPEQGGCKDGGVCLLSG
TKGASFGRLQSMKLDYRHQDEAVVLSYVNGDRCPPETDDGVPCVFPFIFNGKSYEECIIE
SRAKLWCSTTADYDRDHEWGFCRHSNSYRTSSIIFKCDEDEDIGRPQVFSEVRGCDVTFE
WKTKVVCPPKKLECKFVQKHKTYDLRLLSSLTGSWSLVHNGVSYYINLCQKIYKGPLGCS
ERASICRRTTTGDVQVLGLVHTQKLGVIGDKVVVTYSKGYPCGGNKTASSVIELTCTKTV
GRPAFKRFDIDSCTYYFSWDSRAACAVKPQEVQMVNGTITNPINGKSFSLGDIYFKLFRA
SGDMRTNGDNYLYEIQLSSITSSRNPACSGANICQVKPNDQHFSRKVGTSDKTKYYLQDG
DLDVVFASSSKCGKDKTKSVSSTIFFHCDPLVEDGIPEFSHETADCQYLFSWYTSAVCPL
GVGFDSENPGDDGQMHKGLSERSQAVGAVLSLLLVALTCCLLALLLYKKERRETVISKLT
TCCRRSSNVSYKYSKVNKEEETDENETEWLMEEIQLPPPRQGKEGQENGHITTKSVKALS
SLHGDDQDSEDEVLTIPEVKVHSGRGAGAESSHPVRNAQSNALQEREDDRVGLVRGEKAR
KGKSSSAQQKTVSSTKLVSFHDDSDEDLLHI

# Drug_Target_64_Reaction:
Not Available

# Drug_Target_64_Signals:
1-40

# Drug_Target_64_Specific_Function:
Transport of phosphorylated lysosomal enzymes from the Golgi complex and the cell surface to lysosomes. Lysosomal enzymes bearing phosphomannosyl residues bind specifically to mannose-6- phosphate receptors in the Golgi apparatus and the resulting receptor-ligand complex is transported to an acidic prelyosomal compartment where the low pH mediates the dissociation of the complex. This receptor also binds IGF2

# Drug_Target_64_SwissProt_ID:
P11717

# Drug_Target_64_SwissProt_Name:
MPRI_HUMAN

# Drug_Target_64_Synonyms:
300 kDa mannose 6-phosphate receptor
CD222 antigen
CI Man-6-P receptor
CI-MPR
IGF-II receptor
Insulin-like growth factor 2 receptor
Insulin-like growth factor II receptor
M6P/IGF2 receptor
M6P/IGF2R
M6PR
MPR 300

# Drug_Target_64_Theoretical_pI:
5.71

# Drug_Target_64_Transmembrane_Regions:
2305-2327

# Drug_Target_65_Cellular_Location:
Not Available

# Drug_Target_65_Chromosome_Location:
Not Available

# Drug_Target_65_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_65_Essentiality:
Non-Essential

# Drug_Target_65_GenAtlas_ID:
Not Available

# Drug_Target_65_GenBank_ID_Gene:
Not Available

# Drug_Target_65_GenBank_ID_Protein:
Not Available

# Drug_Target_65_GeneCard_ID:
Not Available

# Drug_Target_65_Gene_Name:
CPD

# Drug_Target_65_Gene_Sequence:
Not Available

# Drug_Target_65_General_Function:
Not Available

# Drug_Target_65_General_References:
Not Available

# Drug_Target_65_HGNC_ID:
Not Available

# Drug_Target_65_HPRD_ID:
Not Available

# Drug_Target_65_ID:
7078

# Drug_Target_65_Locus:
Not Available

# Drug_Target_65_Molecular_Weight:
Not Available

# Drug_Target_65_Name:
Carboxypeptidase D

# Drug_Target_65_Number_of_Residues:
0

# Drug_Target_65_PDB_ID:
Not Available

# Drug_Target_65_Pathway:
Not Available

# Drug_Target_65_Pfam_Domain_Function:
Not Available

# Drug_Target_65_Protein_Sequence:
Not Available

# Drug_Target_65_Reaction:
Not Available

# Drug_Target_65_Signals:
Not Available

# Drug_Target_65_Specific_Function:
Not Available

# Drug_Target_65_SwissProt_ID:
O75976

# Drug_Target_65_SwissProt_Name:
CBPD_HUMAN

# Drug_Target_65_Synonyms:
Not Available

# Drug_Target_65_Theoretical_pI:
Not Available

# Drug_Target_65_Transmembrane_Regions:
Not Available

# Drug_Target_66_Cellular_Location:
Endoplasmic reticulum

# Drug_Target_66_Chromosome_Location:
Not Available

# Drug_Target_66_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_66_Essentiality:
Non-Essential

# Drug_Target_66_GenAtlas_ID:
CES1

# Drug_Target_66_GenBank_ID_Gene:
M73499

# Drug_Target_66_GenBank_ID_Protein:
Not Available

# Drug_Target_66_GeneCard_ID:
Not Available

# Drug_Target_66_Gene_Name:
CES1

# Drug_Target_66_Gene_Sequence:
>1704 bp
ATGTGGCTCCGTGCCTTTATCCTGGCCACTCTCTCTGCTTCCGCGGCTTGGGGGCATCCG
TCCTCGCCACCTGTGGTGGACACCGTGCATGGCAAAGTGCTGGGGAAGTTCGTCAGCTTA
GAAGGATTTGCACAGCCTGTGGCCATTTTCCTGGGAATCCCTTTTGCCAAGCCGCCTCTT
GGACCCCTGAGGTTTACTCCACCGCAGCCTGCAGAACCATGGAGCTTTGTGAAGAATGCC
ACCTCGTACCCTCCTATGTGCACCCAAGATCCCAAGGCGGGGCAGTTACTCTCAGAGCTA
TTTACAAACCGAAAGGAGAACATTCCTCTCAAGCTTTCTGAAGACTGTCTTTACCTCAAT
ATTTACACTCCTGCTGACTTGACCAAGAAAAACAGGCTGCCGGTGATGGTGTGGATCCAC
GGAGGGGGGCTGATGGTGGGTGCGGCATCAACCTATGATGGGCTGGCCCTTGCTGCCCAT
GAAAACGTGGTGGTGGTGACCATTCAATATCGCCTGGGCATCTGGGGATTCTTCAGCACA
GGGGATGAACACAGCCGGGGGAACTGGGGTCACCTGGACCAGGTGGCTGCCCTGCGCTGG
GTCCAGGACAACATTGCCAGCTTTGGAGGGAACCCAGGCTCTGTGACCATCTTTGGAGAG
TCAGCGGGAGGAGAAAGTGTCTCTGTTCTTGTTTTGTCTCCATTGGCCAAGAACCTCTTC
CACCGGGCCATTTCTGAGAGTGGCGTGGCCCTCACTTCTGTTCTGGTGAAGAAAGGTGAT
GTCAAGCCCTTGGCTGAGCAAATTGCTATCACTGCTGGGTGCAAAACCACCACCTCTGCT
GTCATGGTTCACTGCCTGCGACAGAAGACGGAAGAGGAGCTCTTGGAGACGACATTGAAA
ATGAAATTCTTATCTCTGGACTTACAGGGAGACCCCAGAGAGAGTCAACCCCTTCTGGGC
ACTGTGATTGATGGGATGCTGCTGCTGAAAACACCTGAAGAGCTTCAAGCTGAAAGGAAT
TTCCACACTGTCCCCTACATGGTCGGAATTAACAAGCAGGAGTTTGGCTGGTTGATTCCA
ATGCAGTTGATGAGCTATCCACTCTCCGAAGGGCAACTGGACCAGAAGACAGCCATGTCA
CTCCTGTGGAAGTCCTATCCCCTTGTTTGCATTGCTAAGGAACTGATTCCAGAAGCCACT
GAGAAATACTTAGGAGGAACAGACGACACTGTCAAAAAGAAAGACCTGTTCCTGGACTTG
ATAGCAGATGTGATGTTTGGTGTCCCATCTGTGATTGTGGCCCGGAACCACAGAGATGCT
GGAGCACCCACCTACATGTATGAGTTTCAGTACCGTCCAAGCTTCTCATCAGACATGAAA
CCCAAGACGGTGATAGGAGACCACGGGGATGAGCTCTTCTCCGTCTTTGGGGCCCCATTT
TTAAAAGAGGGTGCCTCAGAAGAGGAGATCAGACTTAGCAAGATGGTGATGAAATTCTGG
GCCAACTTTGCTCGCAATGGAAACCCCAATGGGGAAGGGCTGCCCCACTGGCCAGAGTAC
AACCAGAAGGAAGGGTATCTGCAGATTGGTGCCAACACCCAGGCGGCCCAGAAGCTGAAG
GACAAAGAAGTAGCTTTCTGGACCAACCTCTTTGCCAAGAAGGCAGTGGAGAAGCCACCC
CAGACAGAACACATAGAGCTGTGA

# Drug_Target_66_General_Function:
Lipid transport and metabolism

# Drug_Target_66_General_References:
10518925	Mori M, Hosokawa M, Ogasawara Y, Tsukada E, Chiba K: cDNA cloning, characterization and stable expression of novel human brain carboxylesterase. FEBS Lett. 1999 Sep 10;458(1):17-22.
11015575	Ghosh S: Cholesteryl ester hydrolase in human monocyte/macrophage: cloning, sequencing, and expression of full-length cDNA. Physiol Genomics. 2000 Jan 24;2(1):1-8.
1918003	Munger JS, Shi GP, Mark EA, Chin DT, Gerard C, Chapman HA: A serine esterase released by human alveolar macrophages is closely related to liver microsomal carboxylesterases. J Biol Chem. 1991 Oct 5;266(28):18832-8.
1997784	Long RM, Calabrese MR, Martin BM, Pohl LR: Cloning and sequencing of a human liver carboxylesterase isoenzyme. Life Sci. 1991;48(11):PL43-9.
8049197	Becker A, Bottcher A, Lackner KJ, Fehringer P, Notka F, Aslanidis C, Schmitz G: Purification, cloning, and expression of a human enzyme with acyl coenzyme A: cholesterol acyltransferase activity, which is identical to liver carboxylesterase. Arterioscler Thromb. 1994 Aug;14(8):1346-55.
8218228	Kroetz DL, McBride OW, Gonzalez FJ: Glycosylation-dependent activity of baculovirus-expressed human liver carboxylesterases: cDNA cloning and characterization of two highly similar enzyme forms. Biochemistry. 1993 Nov 2;32(43):11606-17.
8406473	Shibata F, Takagi Y, Kitajima M, Kuroda T, Omura T: Molecular cloning and characterization of a human carboxylesterase gene. Genomics. 1993 Jul;17(1):76-82.

# Drug_Target_66_HGNC_ID:
HGNC:1863

# Drug_Target_66_HPRD_ID:
Not Available

# Drug_Target_66_ID:
4604

# Drug_Target_66_Locus:
16q13-q22.1

# Drug_Target_66_Molecular_Weight:
62522

# Drug_Target_66_Name:
Liver carboxylesterase 1

# Drug_Target_66_Number_of_Residues:
567

# Drug_Target_66_PDB_ID:
1MX1

# Drug_Target_66_Pathway:
Capecitabine Pathway	SMP00469
Heroin Pathway	SMP00407
Irinotecan Pathway	SMP00433

# Drug_Target_66_Pfam_Domain_Function:
PF00135	COesterase

# Drug_Target_66_Protein_Sequence:
>Liver carboxylesterase 1
MWLRAFILATLSASAAWGHPSSPPVVDTVHGKVLGKFVSLEGFAQPVAIFLGIPFAKPPL
GPLRFTPPQPAEPWSFVKNATSYPPMCTQDPKAGQLLSELFTNRKENIPLKLSEDCLYLN
IYTPADLTKKNRLPVMVWIHGGGLMVGAASTYDGLALAAHENVVVVTIQYRLGIWGFFST
GDEHSRGNWGHLDQVAALRWVQDNIASFGGNPGSVTIFGESAGGESVSVLVLSPLAKNLF
HRAISESGVALTSVLVKKGDVKPLAEQIAITAGCKTTTSAVMVHCLRQKTEEELLETTLK
MKFLSLDLQGDPRESQPLLGTVIDGMLLLKTPEELQAERNFHTVPYMVGINKQEFGWLIP
MQLMSYPLSEGQLDQKTAMSLLWKSYPLVCIAKELIPEATEKYLGGTDDTVKKKDLFLDL
IADVMFGVPSVIVARNHRDAGAPTYMYEFQYRPSFSSDMKPKTVIGDHGDELFSVFGAPF
LKEGASEEEIRLSKMVMKFWANFARNGNPNGEGLPHWPEYNQKEGYLQIGANTQAAQKLK
DKEVAFWTNLFAKKAVEKPPQTEHIEL

# Drug_Target_66_Reaction:
Not Available

# Drug_Target_66_Signals:
1-18

# Drug_Target_66_Specific_Function:
Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acyl CoA ester

# Drug_Target_66_SwissProt_ID:
P23141

# Drug_Target_66_SwissProt_Name:
EST1_HUMAN

# Drug_Target_66_Synonyms:
ACAT
Acyl coenzyme A:cholesterol acyltransferase
Brain carboxylesterase hBr1
EC 3.1.1.1
Egasyn
HMSE
Liver carboxylesterase 1 precursor
Monocyte/macrophage serine esterase
Serine esterase 1
TGH
Triacylglycerol hydrolase

# Drug_Target_66_Theoretical_pI:
6.58

# Drug_Target_66_Transmembrane_Regions:
None

# Drug_Target_67_Cellular_Location:
Endoplasmic reticulum
endoplasmic reticulum membrane
single-pass type II membrane protein

# Drug_Target_67_Chromosome_Location:
Not Available

# Drug_Target_67_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_67_Essentiality:
Non-Essential

# Drug_Target_67_GenAtlas_ID:
MAN1B1

# Drug_Target_67_GenBank_ID_Gene:
AF148509

# Drug_Target_67_GenBank_ID_Protein:
6066222

# Drug_Target_67_GeneCard_ID:
MAN1B1

# Drug_Target_67_Gene_Name:
MAN1B1

# Drug_Target_67_Gene_Sequence:
>2100 bp
ATGGCTGCCTGCGAGGGCAGGAGAAGCGGAGCTCTCGGTTCCTCTCAGTCGGACTTCCTG
ACGCCGCCAGTGGGCGGGGCCCCTTGGGCCGTCGCCACCACTGTAGTCATGTACCCACCG
CCGCCGCCGCCGCCTCATCGGGACTTCATCTCGGTGACGCTGAGCTTTGGCGAGAGCTAT
GACAACAGCAAGAGTTGGCGGCGGCGCTCGTGCTGGAGGAAATGGAAGCAACTGTCGAGA
TTGCAGCGGAATATGATTCTCTTCCTCCTTGCCTTTCTGCTTTTCTGTGGACTCCTCTTC
TACATCAACTTGGCTGACCATTGGAAAGCTCTGGCTTTCAGGCTAGAGGAAGAGCAGAAG
ATGAGGCCAGAAATTGCTGGGTTAAAACCAGCAAATCCACCCGTCTTACCAGCTCCTCAG
AAGGCGGACACCGACCCTGAGAACTTACCTGAGATTTCGTCACAGAAGACACAAAGACAC
ATCCAGCGGGGACCACCTCACCTGCAGATTAGACCCCCAAGCCAAGACCTGAAGGATGGG
ACCCAGGAGGAGGCCACAAAAAGGCAAGAAGCCCCTGTGGATCCCCGCCCGGAAGGAGAT
CCGCAGAGGACAGTCATCAGCTGGAGGGGAGCGGTGATCGAGCCTGAGCAGGGCACCGAG
CTCCCTTCAAGAAGAGCAGAAGTGCCCACCAAGCCTCCCCTGCCACCGGCCAGGACACAG
GGCACACCAGTGCATCTGAACTATCGCCAGAAGGGCGTGATTGACGTCTTCCTGCATGCA
TGGAAAGGATACCGCAAGTTTGCATGGGGCCATGACGAGCTGAAGCCTGTGTCCAGGTCC
TTCAGTGAGTGGTTTGGCCTCGGTCTCACACTGATCGACGCGCTGGACACCATGTGGATC
TTGGGTCTGAGGAAAGAATTTGAGGAAGCCAGGAAGTGGGTGTCGAAGAAGTTACACTTT
GAAAAGGACGTGGACGTCAACCTGTTTGAGAGCACGATCCGCATCCTGGGGGGGCTCCTG
AGTGCCTACCACCTGTCTGGGGACAGCCTCTTCCTGAGGAAAGCTGAGGATTTTGGAAAT
CGGCTAATGCCTGCCTTCAGAACACCATCCAAGATTCCTTACTCGGATGTGAACATCGGT
ACTGGAGTTGCCCACCCGCCACGGTGGACCTCCGACAGCACTGTGGCCGAGGTGACCAGC
ATTCAGCTGGAGTTCCGGGAGCTCTCCCGTCTCACAGGGGATAAGAAGTTTCAGGAGGCA
GTGGAGAAGGTGACACAGCACATCCACGGCCTGTCTGGGAAGAAGGATGGGCTGGTGCCC
ATGTTCATCAATACCCACAGTGGCCTCTTCACCCACCTGGGCGTATTCACGCTGGGCGCC
AGGGCCGACAGCTACTATGAGTACCTGCTGAAGCAGTGGATCCAGGGCGGGAAGCAGGAG
ACACAGCTGCTGGAAGACTACGTGGAAGCCATCGAGGGTGTCAGAACGCACCTGCTGCGG
CACTCCGAGCCCAGTAAGCTCACCTTTGTGGGGGAGCTTGCCCACGGCCGCTTCAGTGCC
AAGATGGACCACCTGGTGTGCTTCCTGCCAGGGACGCTGGCTCTGGGCGTCTACCACGGC
CTGCCCGCCAGCCACATGGAGCTGGCCCAGGAGCTCATGGAGACTTGTTACCAGATGAAC
CGGCAGATGGAGACGGGGCTGAGTCCCGAGATCGTGCACTTCAACCTTTACCCCCAGCCG
GGCCGTCGGGACGTGGAGGTCAAGCCAGCAGACAGGCACAACCTGCTGCGGCCAGAGACC
GTGGAGAGCCTGTTCTACCTGTACCGCGTCACAGGGGACCGCAAATACCAGGACTGGGGC
TGGGAGATTCTGCAGAGCTTCAGCCGATTCACACGGGTCCCCTCGGGTGGCTATTCTTCC
ATCAACAATGTCCAGGATCCTCAGAAGCCCGAGCCTAGGGACAAGATGGAGAGCTTCTTC
CTGGGGGAGACGCTCAAGTATCTGTTCTTGCTCTTCTCCGATGACCCAAACCTGCTCAGC
CTGGACGCCTACGTGTTCAACACCGAAGCCCACCCTCTGCCTATCTGGACCCCTGCCTAG

# Drug_Target_67_General_Function:
Involved in mannosyl-oligosaccharide 1,2-alpha-mannosidase activity

# Drug_Target_67_General_References:
10409699	Gonzalez DS, Karaveg K, Vandersall-Nairn AS, Lal A, Moremen KW: Identification, expression, and characterization of a cDNA encoding human endoplasmic reticulum mannosidase I, the enzyme that catalyzes the first mannose trimming step in mammalian Asn-linked oligosaccharide biosynthesis. J Biol Chem. 1999 Jul 23;274(30):21375-86.
10521544	Tremblay LO, Herscovics A: Cloning and expression of a specific human alpha 1,2-mannosidase that trims Man9GlcNAc2 to Man8GlcNAc2 isomer B during N-glycan biosynthesis. Glycobiology. 1999 Oct;9(10):1073-8.
12975309	Clark HF, Gurney AL, Abaya E, Baker K, Baldwin D, Brush J, Chen J, Chow B, Chui C, Crowley C, Currell B, Deuel B, Dowd P, Eaton D, Foster J, Grimaldi C, Gu Q, Hass PE, Heldens S, Huang A, Kim HS, Klimowski L, Jin Y, Johnson S, Lee J, Lewis L, Liao D, Mark M, Robbie E, Sanchez C, Schoenfeld J, Seshagiri S, Simmons L, Singh J, Smith V, Stinson J, Vagts A, Vandlen R, Watanabe C, Wieand D, Woods K, Xie MH, Yansura D, Yi S, Yu G, Yuan J, Zhang M, Zhang Z, Goddard A, Wood WI, Godowski P, Gray A: The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res. 2003 Oct;13(10):2265-70. Epub 2003 Sep 15.

# Drug_Target_67_HGNC_ID:
HGNC:6823

# Drug_Target_67_HPRD_ID:
05068

# Drug_Target_67_ID:
2577

# Drug_Target_67_Locus:
9q34

# Drug_Target_67_Molecular_Weight:
79581

# Drug_Target_67_Name:
Endoplasmic reticulum mannosyl-oligosaccharide 1,2-alpha-mannosidase

# Drug_Target_67_Number_of_Residues:
699

# Drug_Target_67_PDB_ID:
1X9D

# Drug_Target_67_Pathway:
Not Available

# Drug_Target_67_Pfam_Domain_Function:
PF01532	Glyco_hydro_47

# Drug_Target_67_Protein_Sequence:
>Endoplasmic reticulum mannosyl-oligosaccharide 1,2-alpha-mannosidase
MAACEGRRSGALGSSQSDFLTPPVGGAPWAVATTVVMYPPPPPPPHRDFISVTLSFGENY
DNSKSWRRRSCWRKWKQLSRLQRNMILFLLAFLLFCGLLFYINLADHWKALAFRLEEEQK
MRPEIAGLKPANPPVLPAPQKADTDPENLPEISSQKTQRHIQRGPPHLQIRPPSQDLKDG
TQEEATKRQEAPVDPRPEGDPQRTVISWRGAVIEPEQGTELPSRRAEVPTKPPLPPARTQ
GTPVHLNYRQKGVIDVFLHAWKGYRKFAWGHDELKPVSRSFSEWFGLGLTLIDALDTMWI
LGLRKEFEEARKWVSKKLHFEKDVDVNLFESTIRILGGLLSAYHLSGDSLFLRKAEDFGN
RLMPAFRTPSKIPYSDVNIGTGVAHPPRWTSDSTVAEVTSIQLEFRELSRLTGDKKFQEA
VEKVTQHIHGLSGKKDGLVPMFINTHSGLFTHLGVFTLGARADSYYEYLLKQWIQGGKQE
TQLLEDYVEAIEGVRTHLLRHSEPSKLTFVGELAHGRFSAKMDHLVCFLPGTLALGVYHG
LPASHMELAQELMETCYQMNRQMETGLSPEIVHFNLYPQPGRRDVEVKPADRHNLLRPET
VESLFYLYRVTGDRKYQDWGWEILQSFSRFTRVPSGGYSSINNVQDPQKPEPRDKMESFF
LGETLKYLFLLFSDDPNLLSLDAYVFNTEAHPLPIWTPA

# Drug_Target_67_Reaction:
Hydrolysis of the terminal 1,2-linked alpha-D-mannose residues in the oligo-mannose oligosaccharide Man9(GlcNAc)2 ALL_REAC (other) R05982(G) R06722(G)

# Drug_Target_67_Signals:
None

# Drug_Target_67_Specific_Function:
Involved in the maturation of Asn-linked oligosaccharides. Trim a single alpha-1,2-linked mannose residue from Man(9)GlcNAc(2) to produce Man(8)GlcNAc(2). The only product is the Man(8)GlcNAc(2) isomer B, the form lacking the middle-arm terminal alpha 1,2-mannose. It may be involved in glycoprotein quality control since it is important to target misfolded glycoproteins for degradation

# Drug_Target_67_SwissProt_ID:
Q9UKM7

# Drug_Target_67_SwissProt_Name:
MA1B1_HUMAN

# Drug_Target_67_Synonyms:
EC 3.2.1.113
ER alpha-1,2-mannosidase
Man9GlcNAc2-specific-processing alpha-mannosidase
Mannosidase alpha class 1B member 1

# Drug_Target_67_Theoretical_pI:
7.80

# Drug_Target_67_Transmembrane_Regions:
85-105

# Drug_Target_68_Cellular_Location:
Virion
apical cell membrane
single-pass type II membrane protein (
virion membrane. Cell membrane

# Drug_Target_68_Chromosome_Location:
Not Available

# Drug_Target_68_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_68_Essentiality:
Non-Essential

# Drug_Target_68_GenAtlas_ID:
Not Available

# Drug_Target_68_GenBank_ID_Gene:
M11445

# Drug_Target_68_GenBank_ID_Protein:
324416

# Drug_Target_68_GeneCard_ID:
Not Available

# Drug_Target_68_Gene_Name:
NA

# Drug_Target_68_Gene_Sequence:
>1413 bp
ATGAATCCAAATCAGAAGATTCTATGCACTTCTGCCACTGCTCTCGTAATAGGCACAATT
GCAGTACTCATAGGAATAACGAACTTAGGATTGAACATAGGACTACATCTGAAACCGAGC
TGCAATTGCTCACACTCACAACCCGAAGCAACCAATGCAAGCCAAACAATAATAAATAAC
TATTATAATGACACAAACATCACCCAGATAAGTAATACCAACATTCAGGTAGAGGAAAGG
GCAATTAGAGATTTCAATAACTTGACCAAAGGGCTCTGTACTATAAATTCATGGCACATA
TATGGGAAAGACAATGCGGTGAGAATTGGGGAGGACTCAGATGTTTTAGTCACAAGAGAA
CCCTATGTCTCCTGTGACCCAGATGAGTGCAGGTTCTATGCTCTCAGCCAAGGGACAACA
ATCAGAGGAAAACACTCAAATGGAACAATACACGATAGGTCTCAATATCGTGCCCTGATA
AGCTGGCCATTGTCATCACCGCCCACAGTATACAACAGCAGAGTGGAATGCATTGGATGG
TCAAGTACTAGTTGTCATGATGGCAAAACCAGGATGTCAATATGCATATCAGGCCCGAAC
AATAACGCATCAGCAGTGATCTGGTACAATAGAAGGCCTGTGACAGAAATCAACACATGG
GCCCGAAACATACTAAGGACACAAGAATCTGAATGCGTATGCCACAACGGTGTCTGCCCG
GTAGTGTTCACAGATGGGTCTGCCACTGGACCTGCAGAAACAAGAATATACTATTTTAAA
GAAGGGAAGATCTTAAAATGGGAACCTCTGGCTGGAACTGCTAAGCATATCGAAGAATGC
TCATGCTACGGAGAGCGAGCAGAGATTACTTGCACGTGTAGGGATAATTGGCAAGGCTCA
AATAGACCAGTAATTCGGATAGATCCAGTGGCGATGACACATACTAGTCAGTATATATGT
AGCCCTGTTCTCACAGATAACCCCCGACCGAATGACCCAACTGTAGGTAAGTGTAACGAC
CCTTATCCAGGCAATAACAACAATGGGGTCAAAGGGTTTTCATATCTGGATGGAGTTAAT
ACTTGGCTAGGGAGGACAATAAGCATAGCTTCAAGATCCGGATATGAGATGCTAAAGGTG
CCAAATGCATTGACAGACGATAAGTCAAAGCCCACTCAAGGTCAGACAATCGTCTTAAAC
ACTGACTGGAGTGGTTACAGTGGGTCCTTCATGGACTATTGGGCTGAGGGGGAATGCTAC
CGAGCGTGTTTTTACGTGGAGTTAATACGTGGGAGACCTAAGGAGGATAAAGTGTGGTGG
ACCAGTAATAGTATAGTATCGATGTGTTCCAGCACAGAATTCCTTGGACAATGGGACTGG
CCTGATGGGGCTAAAATAGAGTACTTCCTCTAA

# Drug_Target_68_General_Function:
Not Available

# Drug_Target_68_General_References:
3447170	Baker AT, Varghese JN, Laver WG, Air GM, Colman PM: Three-dimensional structure of neuraminidase of subtype N9 from an avian influenza virus. Proteins. 1987;2(2):111-7.
3660585	Air GM, Webster RG, Colman PM, Laver WG: Distribution of sequence differences in influenza N9 neuraminidase of tern and whale viruses and crystallization of the whale neuraminidase complexed with antibodies. Virology. 1987 Oct;160(2):346-54.
4013081	Air GM, Ritchie LR, Laver WG, Colman PM: Gene and protein sequence of an influenza neuraminidase with hemagglutinin activity. Virology. 1985 Aug;145(1):117-22.
8371267	Bossart-Whitaker P, Carson M, Babu YS, Smith CD, Laver WG, Air GM: Three-dimensional structure of influenza A N9 neuraminidase and its complex with the inhibitor 2-deoxy 2,3-dehydro-N-acetyl neuraminic acid. J Mol Biol. 1993 Aug 20;232(4):1069-83.
9342319	Varghese JN, Colman PM, van Donkelaar A, Blick TJ, Sahasrabudhe A, McKimm-Breschkin JL: Structural evidence for a second sialic acid binding site in avian influenza virus neuraminidases. Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):11808-12.

# Drug_Target_68_HGNC_ID:
Not Available

# Drug_Target_68_HPRD_ID:
Not Available

# Drug_Target_68_ID:
3026

# Drug_Target_68_Locus:
Not Available

# Drug_Target_68_Molecular_Weight:
52469

# Drug_Target_68_Name:
Neuraminidase

# Drug_Target_68_Number_of_Residues:
470

# Drug_Target_68_PDB_ID:
1NMB

# Drug_Target_68_Pathway:
Not Available

# Drug_Target_68_Pfam_Domain_Function:
PF00064	Neur

# Drug_Target_68_Protein_Sequence:
>Neuraminidase
MNPNQKILCTSATALVIGTIAVLIGITNLGLNIGLHLKPSCNCSHSQPEATNASQTIINN
YYNDTNITQISNTNIQVEERAIRDFNNLTKGLCTINSWHIYGKDNAVRIGEDSDVLVTRE
PYVSCDPDECRFYALSQGTTIRGKHSNGTIHDRSQYRALISWPLSSPPTVYNSRVECIGW
SSTSCHDGKTRMSICISGPNNNASAVIWYNRRPVTEINTWARNILRTQESECVCHNGVCP
VVFTDGSATGPAETRIYYFKEGKILKWEPLAGTAKHIEECSCYGERAEITCTCRDNWQGS
NRPVIRIDPVAMTHTSQYICSPVLTDNPRPNDPTVGKCNDPYPGNNNNGVKGFSYLDGVN
TWLGRTISIASRSGYEMLKVPNALTDDKSKPTQGQTIVLNTDWSGYSGSFMDYWAEGECY
RACFYVELIRGRPKEDKVWWTSNSIVSMCSSTEFLGQWDWPDGAKIEYFL

# Drug_Target_68_Reaction:
Hydrolysis of alpha-(2->3)-, alpha-(2->6)-, alpha-(2->8)- glycosidic linkages of terminal sialic acid residues in oligosaccharides, glycoproteins, glycolipids, colominic acid and synthetic substrates ALL_REAC (other) R03491 R04018 R04634 R04650 R05115 R05117 R05996(G) R05998(G) R05999(G) R06012(G) R06147(G) R06253(G) INHIBITOR 2-Deoxy-2,3-dehydro-N-acetylneuraminic acid

# Drug_Target_68_Signals:
None

# Drug_Target_68_Specific_Function:
Catalyzes the removal of terminal sialic acid residues from viral and cellular glycoconjugates. Cleaves off the terminal sialic acids on the glycosylated HA during virus budding to facilitate virus release. Additionally helps virus spread through the circulation by further removing sialic acids from the cell surface. These cleavages prevent self-aggregation and ensure the efficient spread of the progeny virus from cell to cell. Otherwise, infection would be limited to one round of replication. Described as a receptor-destroying enzyme because it cleaves a terminal sialic acid from the cellular receptors. May facilitate viral invasion of the upper airways by cleaving the sialic acid moities on the mucin of the airway epithelial cells. Likely to plays a role in the budding process through its association with lipid rafts during intracellular transport. May additionally display a raft-association independent effect on budding. Plays a role in the determination of host range restriction on replication and virulence. Sialidase activity in late endosome/lysosome traffic seems to enhance virus replication

# Drug_Target_68_SwissProt_ID:
P03472

# Drug_Target_68_SwissProt_Name:
NRAM_I75A5

# Drug_Target_68_Synonyms:
EC 3.2.1.18

# Drug_Target_68_Theoretical_pI:
6.57

# Drug_Target_68_Transmembrane_Regions:
7-35

# Drug_Target_69_Cellular_Location:
Membrane
single-pass type II membrane protein

# Drug_Target_69_Chromosome_Location:
Not Available

# Drug_Target_69_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_69_Essentiality:
Non-Essential

# Drug_Target_69_GenAtlas_ID:
Not Available

# Drug_Target_69_GenBank_ID_Gene:
M18764

# Drug_Target_69_GenBank_ID_Protein:
332715

# Drug_Target_69_GeneCard_ID:
Not Available

# Drug_Target_69_Gene_Name:
HN

# Drug_Target_69_Gene_Sequence:
>1719 bp
ATGGAATACTGGAAGCATACCAATCACGGAAAGGATGCTGGTAATGAGCTGGAGACGTCC
ATGGCTACTCATGGCAACAAGCTCACTAATAAGATAATATACATATTATGGACAATAATC
CTGGTGTTATTATCAATAGTCTTCATCATAGTGCTAATCAATTCCATCAAAAGTGAAAAG
GCCCACGAATCATTGCTGCGAGACATAAACAATGAGTTTATGGAAATTACAGGAAAGATC
CAAATGGCATCGGATAATACCAATGATCTAATACAGTCAGGAGTGAATACAAGGCTTCTT
ACAATTCAGAGTCATGTCCAGAATTACATACCAATATCATTGACACAACAGATGTCAGAT
CTTAGGAAATTCATTAGTGAAATTACAATTAGAAATGATAATCAAGAAGTGCTGCCGCAA
AGAATAACACATGATGTAGGTATAAAACCTTTAAATCCAGATGATTTTTGGAGATGCACG
TCTGGTCTTCCATCTTTAATGAAAACTCCAAAAATAAGGTTAATGCCAGGGCCGGGGTTA
TTAGCTATGCCAACGACTGATGATGGCTGTATTAGAACTCCGTCTTTAGTTATAAATGAT
CTGATTTATGCTTATACCTCAAATCTAATTACTCGAGGTTGTCAGGATATAGGAAAATCA
TATCAAGTCTTACAGATAGGGATAATAACTGTAAACTCAGACTTGGTACCTGACTTAAAT
CCTAGGATCTCTCATACTTTCAACATAAATGACAATAGGAAGTCATGCTCTCTAGCACTC
CTAAATACAGATGTATATCAACTGTGTTCAACTCCCAAAGTTGATGAAAGATCAGATTAT
GCATCATCAGGCATAGAAGATATTGTACTTGATATTGTCAATTATGATGGCTCAATCTCA
ACAACAAGATTTAAGAATAATAACATAAGCTTTGATCAACCATATGCTGCGCTATACCCA
TCTGTTGGACCAGGGATATACTACAAAGGCAAAATAATATTTCTCGGATATGGAGGTCTT
GAACATCCAATAAATGAGAATGTAATCTGCAATACAACTGGGTGTCCCGGGAAAACACAG
AGAGACTGTAATCAAGCGTCTCATAGTCCATGGTTTTCAGATAGGAGGATGGTCAACTCC
ATCATTGTTGTTGACAAAGGCTTAAACTCAACTCCAAAATTGAAGGTATGGACGATATCT
ATGCGACAAAATTACTGGGGGTCAGAAGGAAGGTTACTTCTACTAGGTAACAAGATCTAT
ATATATACAAGATCTACAAGTTGGCATAGCAAGTTACAATTAGGAATAATTGATATTACT
GATTACAGTGATATAAGGATAAAATGGACATGGCATAATGTGCTATCAAGACCAGGAAAC
AATGAATGTCCATGGGGACATTCATGTCCAGATGGATGTATAACAGGAGTATATACTGAT
GCATATCCACTCAATCCCACAGGGAGCATTGTGTCATCTGTCATATTAGACTCACAAAAA
TCGAGAGTGAACCCAGTCATAACTTACTCAACAGCAACCGAAAGAGTAAACGAGCTGGCC
ATCCGAAACAGAACACTCTCAGCTGGATATACAACAACAAGCTGCATTACACACTATAAC
AAAGGATATTGTTTTCATATAGTAGAAATAAATCATAAAAGCTTAAACACATTTCAACCC
ATGTTGTTCAAAACAGAGATTCCAAAAAGCTGCAGTTAA

# Drug_Target_69_General_Function:
Not Available

# Drug_Target_69_General_References:
2827373	van Wyke Coelingh KL, Winter CC, Murphy BR: Nucleotide and deduced amino acid sequence of hemagglutinin-neuraminidase genes of human type 3 parainfluenza viruses isolated from 1957 to 1983. Virology. 1988 Jan;162(1):137-43.

# Drug_Target_69_HGNC_ID:
Not Available

# Drug_Target_69_HPRD_ID:
Not Available

# Drug_Target_69_ID:
3140

# Drug_Target_69_Locus:
Not Available

# Drug_Target_69_Molecular_Weight:
64331

# Drug_Target_69_Name:
Hemagglutinin-neuraminidase

# Drug_Target_69_Number_of_Residues:
572

# Drug_Target_69_PDB_ID:
1V3E

# Drug_Target_69_Pathway:
Not Available

# Drug_Target_69_Pfam_Domain_Function:
PF00423	HN

# Drug_Target_69_Protein_Sequence:
>Hemagglutinin-neuraminidase
MEYWKHTNHGKDAGNELETSMATHGNKLTNKIIYILWTIILVLLSIVFIIVLINSIKSEK
AHESLLRDINNEFMEITGKIQMASDNTNDLIQSGVNTRLLTIQSHVQNYIPISLTQQMSD
LRKFISEITIRNDNQEVLPQRITHDVGIKPLNPDDFWRCTSGLPSLMKTPKIRLMPGPGL
LAMPTTDDGCIRTPSLVINDLIYAYTSNLITRGCQDIGKSYQVLQIGIITVNSDLVPDLN
PRISHTFNINDNRKSCSLALLNTDVYQLCSTPKVDERSDYASSGIEDIVLDIVNYDGSIS
TTRFKNNNISFDQPYAALYPSVGPGIYYKGKIIFLGYGGLEHPINENVICNTTGCPGKTQ
RDCNQASHSPWFSDRRMVNSIIVVDKGLNSTPKLKVWTISMRQNYWGSEGRLLLLGNKIY
IYTRSTSWHSKLQLGIIDITDYSDIRIKWTWHNVLSRPGNNECPWGHSCPDGCITGVYTD
AYPLNPTGSIVSSVILDSQKSRVNPVITYSTATERVNELAIRNRTLSAGYTTTSCITHYN
KGYCFHIVEINHKSLNTFQPMLFKTEIPKSCS

# Drug_Target_69_Reaction:
Hydrolysis of alpha-(2->3)-, alpha-(2->6)-, alpha-(2->8)- glycosidic linkages of terminal sialic acid residues in oligosaccharides, glycoproteins, glycolipids, colominic acid and synthetic substrates ALL_REAC (other) R03491 R04018 R04634 R04650 R05115 R05117 R05996(G) R05998(G) R05999(G) R06012(G) R06147(G) R06253(G) INHIBITOR 2-Deoxy-2,3-dehydro-N-acetylneuraminic acid

# Drug_Target_69_Signals:
None

# Drug_Target_69_Specific_Function:
Neuraminidase activity ensures the efficient spread of the virus by dissociating the mature virions from the neuraminic acid containing glycoproteins

# Drug_Target_69_SwissProt_ID:
P12564

# Drug_Target_69_SwissProt_Name:
HN_PI3HV

# Drug_Target_69_Synonyms:
EC 3.2.1.18

# Drug_Target_69_Theoretical_pI:
7.96

# Drug_Target_69_Transmembrane_Regions:
32-52

# Drug_Target_6_Cellular_Location:
Membrane

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
Not Available

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
ADAM33

# Drug_Target_6_GenBank_ID_Gene:
AB055891

# Drug_Target_6_GenBank_ID_Protein:
Not Available

# Drug_Target_6_GeneCard_ID:
Not Available

# Drug_Target_6_Gene_Name:
ADAM33

# Drug_Target_6_Gene_Sequence:
>2442 bp
ATGGGCTGGAGGCCCCGGAGAGCTCGGGGGACCCCGTTGCTGCTGCTGCTACTACTGCTG
CTGCTCTGGCCAGTGCCAGGCGCCGGGGTGCTTCAAGGACATATCCCTGGGCAGCCAGTC
ACCCCGCACTGGGTCCTGGATGGACAACCCTGGCGCACCGTCAGCCTGGAGGAGCCGGTC
TCGAAGCCAGACATGGGGCTGGTGGCCCTGGAGGCTGAAGGCCAGGAGCTCCTGCTTGAG
CTGGAGAAGAACCACAGGCTGCTGGCCCCAGGATACATAGAAACCCACTACGGCCCAGAT
GGGCAGCCAGTGGTGCTGGCCCCCAACCACACGGATCATTGCCACTACCAAGGGCGAGTA
AGGGGCTTCCCCGACTCCTGGGTAGTCCTCTGCACCTGCTCTGGGATGAGTGGCCTGATC
ACCCTCAGCAGGAATGCCAGCTATTATCTGCGTCCCTGGCCACCCCGGGGCTCCAAGGAC
TTCTCAACCCACGAGATCTTTCGGATGGAGCAGCTGCTCACCTGGAAAGGAACCTGTGGC
CACAGGGATCCTGGGAACAAAGCGGGCATGACCAGCCTTCCTGGTGGTCCCCAGAGCAGG
GGCAGGCGGGAAGCGCGCAGGACCCGGAAGTACCTGGAACTGTACATTGTGGCAGACCAC
ACCCTGTTCTTGACTCGGCACCGAAACTTGAACCACACCAAACAGCGTCTCCTGGAAGTC
GCCAACTACGTGGACCAGCTTCTCAGGACTCTGGACATTCAGGTGGCGCTGACCGGCCTG
GAGGTGTGGACCGAGCGGGACCGCAGCCGCGTCACGCAGGACGCCAACGCCACGCTCTGG
GCCTTCCTGCAGTGGCGCCGGGGGCTGTGGGCGCAGCGGCCCCACGACTCCGCGCAGCTG
CTCACGGGCCGCGCCTTCCAGGGCGCCACAGTGGGCCTGGCGCCCGTCGAGGGCATGTGC
CGCGCCGAGAGCTCGGGAGGCGTGAGCACGGACCACTCGGAGCTCCCCATCGGCGCCGCA
GCCACCATGGCCCATGAGATCGGCCACAGCCTCGGCCTCAGCCACGACCCCGACGGCTGC
TGCGTGGAGGCTGCGGCCGAGTCCGGAGGCTGCGTCATGGCTGCGGCCACCGGGCACCCG
TTTCCGCGCGTGTTCAGCGCCTGCAGCCGCCGCCAGCTGCGCGCCTTCTTCCGCAAGGGG
GGCGGCGCTTGCCTCTCCAATGCCCCGGACCCCGGACTCCCGGTGCCGCCGGCGCTCTGC
GGGAACGGCTTCGTGGAAGCGGGCGAGGAGTGTGACTGCGGCCCTGGCCAGGAGTGCCGC
GACCTCTGCTGCTTTGCTCACAACTGCTCGCTGCGCCCGGGGGCCCAGTGCGCCCACGGG
GACTGCTGCGTGCGCTGCCTGCTGAAGCCGGCTGGAGCGCTGTGCCGCCAGGCCATGGGT
GACTGTGACCTCCCTGAGTTTTGCACGGGCACCTCCTCCCACTGTCCCCCAGACGTTTAC
CTACTGGACGGCTCACCCTGTGCCAGGGGCAGTGGCTACTGCTGGGATGGCGCATGTCCC
ACGCTGGAGCAGCAGTGCCAGCAGCTCTGGGGGCCTGGCTCCCACCCAGCTCCCGAGGCC
TGTTTCCAGGTGGTGAACTCTGCGGGAGATGCTCATGGAAACTGCGGCCAGGACAGCGAG
GGCCACTTCCTGCCCTGTGCAGGGAGGGATGCCCTGTGTGGGAAGCTGCAGTGCCAGGGT
GGAAAGCCCAGCCTGCTCGCACCGCACATGGTGCCAGTGGACTCTACCGTTCACCTAGAT
GGCCAGGAAGTGACTTGTCGGGGAGCCTTGGCACTCCCCAGTGCCCAGCTGGACCTGCTT
GGCCTGGGCCTGGTAGAGCCAGGCACCCAGTGTGGACCTAGAATGGTGTGCCAGAGCAGG
CGCTGCAGGAAGAATGCCTTCCAGGAGCTTCAGCGCTGCCTGACTGCCTGCCACAGCCAC
GGGGTTTGCAATAGCAACCATAACTGCCACTGTGCTCCAGGCTGGGCTCCACCCTTCTGT
GACAAGCCAGGCTTTGGTGGCAGCATGGACAGTGGCCCTGTGCAGGCTGAAAACCATGAC
ACCTTCCTGCTGGCCATGCTCCTCAGCGTCCTGCTGCCTCTGCTCCCAGGGGCCGGCCTG
GCCTGGTGTTGCTACCGACTCCCAGGAGCCCATCTGCAGCGATGCAGCTGGGGCTGCAGA
AGGGACCCTGCGTGCAGTGGCCCCAAAGATGGCCCACACAGGGACCACCCCCTGGGCGGC
GTTCACCCCATGGAGTTGGGCCCCACAGCCACTGGACAGCCCTGGCCCCTGGACCCTGAG
AACTCTCATGAGCCCAGCAGCCACCCTGAGAAGCCTCTGCCAGCAGTCTCGCCTGACCCC
CAAGCAGATCAAGTCCAGATGCCAAGATCCTGCCTCTGGTGA

# Drug_Target_6_General_Function:
Involved in metalloendopeptidase activity

# Drug_Target_6_General_References:
11780052	Deloukas P, Matthews LH, Ashurst J, Burton J, Gilbert JG, Jones M, Stavrides G, Almeida JP, Babbage AK, Bagguley CL, Bailey J, Barlow KF, Bates KN, Beard LM, Beare DM, Beasley OP, Bird CP, Blakey SE, Bridgeman AM, Brown AJ, Buck D, Burrill W, Butler AP, Carder C, Carter NP, Chapman JC, Clamp M, Clark G, Clark LN, Clark SY, Clee CM, Clegg S, Cobley VE, Collier RE, Connor R, Corby NR, Coulson A, Coville GJ, Deadman R, Dhami P, Dunn M, Ellington AG, Frankland JA, Fraser A, French L, Garner P, Grafham DV, Griffiths C, Griffiths MN, Gwilliam R, Hall RE, Hammond S, Harley JL, Heath PD, Ho S, Holden JL, Howden PJ, Huckle E, Hunt AR, Hunt SE, Jekosch K, Johnson CM, Johnson D, Kay MP, Kimberley AM, King A, Knights A, Laird GK, Lawlor S, Lehvaslaiho MH, Leversha M, Lloyd C, Lloyd DM, Lovell JD, Marsh VL, Martin SL, McConnachie LJ, McLay K, McMurray AA, Milne S, Mistry D, Moore MJ, Mullikin JC, Nickerson T, Oliver K, Parker A, Patel R, Pearce TA, Peck AI, Phillimore BJ, Prathalingam SR, Plumb RW, Ramsay H, Rice CM, Ross MT, Scott CE, Sehra HK, Shownkeen R, Sims S, Skuce CD, Smith ML, Soderlund C, Steward CA, Sulston JE, Swann M, Sycamore N, Taylor R, Tee L, Thomas DW, Thorpe A, Tracey A, Tromans AC, Vaudin M, Wall M, Wallis JM, Whitehead SL, Whittaker P, Willey DL, Williams L, Williams SA, Wilming L, Wray PW, Hubbard T, Durbin RM, Bentley DR, Beck S, Rogers J: The DNA sequence and comparative analysis of human chromosome 20. Nature. 2001 Dec 20-27;414(6866):865-71.
11814695	Yoshinaka T, Nishii K, Yamada K, Sawada H, Nishiwaki E, Smith K, Yoshino K, Ishiguro H, Higashiyama S: Identification and characterization of novel mouse and human ADAM33s with potential metalloprotease activity. Gene. 2002 Jan 9;282(1-2):227-36.
12110844	Van Eerdewegh P, Little RD, Dupuis J, Del Mastro RG, Falls K, Simon J, Torrey D, Pandit S, McKenny J, Braunschweiger K, Walsh A, Liu Z, Hayward B, Folz C, Manning SP, Bawa A, Saracino L, Thackston M, Benchekroun Y, Capparell N, Wang M, Adair R, Feng Y, Dubois J, FitzGerald MG, Huang H, Gibson R, Allen KM, Pedan A, Danzig MR, Umland SP, Egan RW, Cuss FM, Rorke S, Clough JB, Holloway JW, Holgate ST, Keith TP: Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature. 2002 Jul 25;418(6896):426-30. Epub 2002 Jul 10.
12975309	Clark HF, Gurney AL, Abaya E, Baker K, Baldwin D, Brush J, Chen J, Chow B, Chui C, Crowley C, Currell B, Deuel B, Dowd P, Eaton D, Foster J, Grimaldi C, Gu Q, Hass PE, Heldens S, Huang A, Kim HS, Klimowski L, Jin Y, Johnson S, Lee J, Lewis L, Liao D, Mark M, Robbie E, Sanchez C, Schoenfeld J, Seshagiri S, Simmons L, Singh J, Smith V, Stinson J, Vagts A, Vandlen R, Watanabe C, Wieand D, Woods K, Xie MH, Yansura D, Yi S, Yu G, Yuan J, Zhang M, Zhang Z, Goddard A, Wood WI, Godowski P, Gray A: The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res. 2003 Oct;13(10):2265-70. Epub 2003 Sep 15.

# Drug_Target_6_HGNC_ID:
HGNC:15478

# Drug_Target_6_HPRD_ID:
Not Available

# Drug_Target_6_ID:
4845

# Drug_Target_6_Locus:
20p13

# Drug_Target_6_Molecular_Weight:
87740

# Drug_Target_6_Name:
ADAM 33

# Drug_Target_6_Number_of_Residues:
813

# Drug_Target_6_PDB_ID:
1R55

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF00200	Disintegrin
PF01421	Reprolysin
PF01562	Pep_M12B_propep
PF07974	EGF_2
PF08516	ADAM_CR

# Drug_Target_6_Protein_Sequence:
>ADAM 33
MGWRPRRARGTPLLLLLLLLLLWPVPGAGVLQGHIPGQPVTPHWVLDGQPWRTVSLEEPV
SKPDMGLVALEAEGQELLLELEKNHRLLAPGYIETHYGPDGQPVVLAPNHTDHCHYQGRV
RGFPDSWVVLCTCSGMSGLITLSRNASYYLRPWPPRGSKDFSTHEIFRMEQLLTWKGTCG
HRDPGNKAGMTSLPGGPQSRGRREARRTRKYLELYIVADHTLFLTRHRNLNHTKQRLLEV
ANYVDQLLRTLDIQVALTGLEVWTERDRSRVTQDANATLWAFLQWRRGLWAQRPHDSAQL
LTGRAFQGATVGLAPVEGMCRAESSGGVSTDHSELPIGAAATMAHEIGHSLGLSHDPDGC
CVEAAAESGGCVMAAATGHPFPRVFSACSRRQLRAFFRKGGGACLSNAPDPGLPVPPALC
GNGFVEAGEECDCGPGQECRDLCCFAHNCSLRPGAQCAHGDCCVRCLLKPAGALCRQAMG
DCDLPEFCTGTSSHCPPDVYLLDGSPCARGSGYCWDGACPTLEQQCQQLWGPGSHPAPEA
CFQVVNSAGDAHGNCGQDSEGHFLPCAGRDALCGKLQCQGGKPSLLAPHMVPVDSTVHLD
GQEVTCRGALALPSAQLDLLGLGLVEPGTQCGPRMVCQSRRCRKNAFQELQRCLTACHSH
GVCNSNHNCHCAPGWAPPFCDKPGFGGSMDSGPVQAENHDTFLLAMLLSVLLPLLPGAGL
AWCCYRLPGAHLQRCSWGCRRDPACSGPKDGPHRDHPLGGVHPMELGPTATGQPWPLDPE
NSHEPSSHPEKPLPAVSPDPQADQVQMPRSCLW

# Drug_Target_6_Reaction:
Not Available

# Drug_Target_6_Signals:
1-29

# Drug_Target_6_Specific_Function:
Not Available

# Drug_Target_6_SwissProt_ID:
Q9BZ11

# Drug_Target_6_SwissProt_Name:
ADA33_HUMAN

# Drug_Target_6_Synonyms:
A disintegrin and metalloproteinase domain 33
ADAM 33 precursor
EC 3.4.24.-

# Drug_Target_6_Theoretical_pI:
6.97

# Drug_Target_6_Transmembrane_Regions:
702-722

# Drug_Target_70_Cellular_Location:
Membrane
single-pass type I membrane protein

# Drug_Target_70_Chromosome_Location:
Not Available

# Drug_Target_70_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_70_Essentiality:
Non-Essential

# Drug_Target_70_GenAtlas_ID:
SIGLEC7

# Drug_Target_70_GenBank_ID_Gene:
AF170485

# Drug_Target_70_GenBank_ID_Protein:
6466012

# Drug_Target_70_GeneCard_ID:
SIGLEC7

# Drug_Target_70_Gene_Name:
SIGLEC7

# Drug_Target_70_Gene_Sequence:
>1404 bp
ATGCTGCTGCTGCTGCTGCTGCCCCTGCTCTGGGGGAGGGAGAGGGTGGAAGGACAGAAG
AGTAACCGGAAGGATTACTCGCTGACGATGCAGAGTTCCGTGACCGTGCAAGAGGGCATG
TGTGTCCATGTGCGCTGCTCCTTCTCCTACCCAGTGGACAGCCAGACTGACTCTGACCCA
GTTCATGGCTACTGGTTCCGGGCAGGGAATGATATAAGCTGGAAGGCTCCAGTGGCCACA
AACAACCCAGCTTGGGCAGTGCAGGAGGAAACTCGGGACCGATTCCACCTCCTTGGGGAC
CCACAGACCAAAAATTGCACCCTGAGCATCAGAGATGCCAGAATGAGTGATGCGGGGAGA
TACTTCTTTCGTATGGAGAAAGGAAATATAAAATGGAATTATAAATATGACCAGCTCTCT
GTGAACGTGACAGCCTTGACCCACAGGCCCAACATCCTTATCCCCGGTACCCTGGAGTCT
GGCTGCTTCCAGAATCTGACCTGCTCTGTGCCCTGGGCCTGTGAGCAGGGGACGCCCCCT
ATGATCTCCTGGATGGGGACCTCTGTGTCCCCCCTGCACCCCTCCACCACCCGCTCCTCA
GTGCTCACCCTCATCCCACAGCCCCAGCACCACGGCACCAGCCTCACCTGTCAGGTGACC
TTGCCTGGGGCCGGCGTGACCACGAACAGGACCATCCAACTCAATGTGTCCTACCCTCCT
CAGAACTTGACTGTGACTGTCTTCCAAGGAGAAGGCACAGCATCCACAGCTCTGGGGAAC
AGCTCATCTCTTTCAGTCCTAGAGGGCCAGTCTCTGCGCTTGGTCTGTGCTGTTGACAGC
AATCCCCCTGCCAGGCTGAGCTGGACCTGGAGGAGTCTGACCCTGTACCCCTCACAGCCC
TCAAACCCTCTGGTACTGGAGCTGCAAGTGCACCTGGGGGATGAAGGGGAATTCACCTGT
CGAGCTCAGAACTCTCTGGGTTCCCAGCACGTTTCCCTGAACCTCTCCCTGCAACAGGAG
TACACAGGCAAAATGAGGCCTGTATCAGGAGTGTTGCTGGGGGCGGTCGGGGGAGCTGGA
GCCACAGCCCTGGTCTTCCTCTCCTTCTGTGTCATCTTCATTGTAGTGAGGTCCTGCAGG
AAGAAATCGGCAAGGCCAGCAGCGGACGTGGGAGACATAGGCATGAAGGATGCAAACACC
ATCAGGGGCTCAGCCTCTCAGGGTAACCTGACTGAGTCCTGGGCAGATGATAACCCCCGA
CACCATGGCCTGGCTGCCCACTCCTCAGGGGAGGAAAGAGAGATCCAGTATGCACCCCTC
AGCTTTCATAAGGGGGAGCCTCAGGACCTATCAGGTCAAGAAGCCACCAACAATGAGTAC
TCAGAGATCAAGATCCCCAAGTAA

# Drug_Target_70_General_Function:
Involved in sugar binding activity

# Drug_Target_70_General_References:
10499918	Falco M, Biassoni R, Bottino C, Vitale M, Sivori S, Augugliaro R, Moretta L, Moretta A: Identification and molecular cloning of p75/AIRM1, a novel member of the sialoadhesin family that functions as an inhibitory receptor in human natural killer cells. J Exp Med. 1999 Sep 20;190(6):793-802.
10567377	Nicoll G, Ni J, Liu D, Klenerman P, Munday J, Dubock S, Mattei MG, Crocker PR: Identification and characterization of a novel siglec, siglec-7, expressed by human natural killer cells and monocytes. J Biol Chem. 1999 Nov 26;274(48):34089-95.
10611343	Vitale C, Romagnani C, Falco M, Ponte M, Vitale M, Moretta A, Bacigalupo A, Moretta L, Mingari MC: Engagement of p75/AIRM1 or CD33 inhibits the proliferation of normal or leukemic myeloid cells. Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15091-6.
10764831	Angata T, Varki A: Siglec-7: a sialic acid-binding lectin of the immunoglobulin superfamily. Glycobiology. 2000 Apr;10(4):431-8.
11389909	Ito A, Handa K, Withers DA, Satoh M, Hakomori S: Binding specificity of siglec7 to disialogangliosides of renal cell carcinoma: possible role of disialogangliosides in tumor progression. FEBS Lett. 2001 Jun 1;498(1):116-20.

# Drug_Target_70_HGNC_ID:
HGNC:10876

# Drug_Target_70_HPRD_ID:
05102

# Drug_Target_70_ID:
2998

# Drug_Target_70_Locus:
19q13.3

# Drug_Target_70_Molecular_Weight:
51143

# Drug_Target_70_Name:
Sialic acid-binding Ig-like lectin 7

# Drug_Target_70_Number_of_Residues:
467

# Drug_Target_70_PDB_ID:
1NKO

# Drug_Target_70_Pathway:
Not Available

# Drug_Target_70_Pfam_Domain_Function:
PF00047	ig
PF07686	V-set
PF08205	C2-set_2

# Drug_Target_70_Protein_Sequence:
>Sialic acid-binding Ig-like lectin 7 precursor
MLLLLLLPLLWGRERVEGQKSNRKDYSLTMQSSVTVQEGMCVHVRCSFSYPVDSQTDSDP
VHGYWFRAGNDISWKAPVATNNPAWAVQEETRDRFHLLGDPQTKNCTLSIRDARMSDAGR
YFFRMEKGNIKWNYKYDQLSVNVTALTHRPNILIPGTLESGCFQNLTCSVPWACEQGTPP
MISWMGTSVSPLHPSTTRSSVLTLIPQPQHHGTSLTCQVTLPGAGVTTNRTIQLNVSYPP
QNLTVTVFQGEGTASTALGNSSSLSVLEGQSLRLVCAVDSNPPARLSWTWRSLTLYPSQP
SNPLVLELQVHLGDEGEFTCRAQNSLGSQHVSLNLSLQQEYTGKMRPVSGVLLGAVGGAG
ATALVFLSFCVIFIVVRSCRKKSARPAADVGDIGMKDANTIRGSASQGNLTESWADDNPR
HHGLAAHSSGEEREIQYAPLSFHKGEPQDLSGQEATNNEYSEIKIPK

# Drug_Target_70_Reaction:
Not Available

# Drug_Target_70_Signals:
1-18

# Drug_Target_70_Specific_Function:
Putative adhesion molecule that mediates sialic-acid dependent binding to cells. Preferentially binds to alpha2,3 and alpha2,6-linked sialic acid. Also binds disialogangliosides (disialogalactosyl globoside, disialyl lactotetraosylceramide and disialyl GalNAc lactotetraoslylceramide). The sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface. In the immune response, may act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 domain(s) that block signal transduction through dephosphorylation of signaling molecules. Mediates inhibition of natural killer cells cytotoxicity. May play a role in hemopoiesis. Inhibits differentiation of CD34+ cell precursors towards myelomonocytic cell lineage and proliferation of leukemic myeloid cells (in vitro)

# Drug_Target_70_SwissProt_ID:
Q9Y286

# Drug_Target_70_SwissProt_Name:
SIGL7_HUMAN

# Drug_Target_70_Synonyms:
AIRM-1
Adhesion inhibitory receptor molecule 1
CD328 antigen
CDw328
D-siglec
QA79 membrane protein
Sialic acid-binding Ig-like lectin 7 precursor
Siglec-7
p75

# Drug_Target_70_Theoretical_pI:
7.32

# Drug_Target_70_Transmembrane_Regions:
354-376

# Drug_Target_71_Cellular_Location:
Cytoplasmic

# Drug_Target_71_Chromosome_Location:
Not Available

# Drug_Target_71_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_71_Essentiality:
Non-Essential

# Drug_Target_71_GenAtlas_ID:
Not Available

# Drug_Target_71_GenBank_ID_Gene:
X82179

# Drug_Target_71_GenBank_ID_Protein:
14594858

# Drug_Target_71_GeneCard_ID:
Not Available

# Drug_Target_71_Gene_Name:
manA

# Drug_Target_71_Gene_Sequence:
>1272 bp
ATGAAAACTATTACCACTGCACGCCTTCCATGGGCTGCGCAGAGCTTTGCCTTGGGCATT
TGCCTGATAGCGCTGTTGGGTTGTAATCACGCCGCTAATAAATCATCGGCATCCAGGGCA
GATGTCAAACCTGTTACGGTCAAACTGGTCGATTCCCAGGCGACCATGGAAACCCGTTCC
CTGTTTGCGTTTATGCAGGAGCAGCGCAGACATTCCATTATGTTTGGGCACCAGCACGAA
ACAACCCAGGGACTCACTATTACCCGCACAGATGGTACCCAATCCGATACCTTTAATGCC
GTTGGTGATTTTGCAGCGGTCTATGGTTGGGACACGCTGTCTATTGTTGCCCCTAAAGCG
GAGGGCGATATTGTCGCCCAAGTAAAAAAGGCTTATGCGCGCGGGGGCATCATTACGGTG
AGCTCGCATTTTGATAATCCAAAAACCGATACCCAAAAGGGCGTATGGCCCGTTGGCACT
TCCTGGGATCAAACCCCGGCTGTTGTGGATTCCCTGCCTGGAGGCGCCTATAACCCGGTA
TTAAATGGCTATCTCGACCAGGTGGCCGAGTGGGCCAATAACCTGAAAGACGAGCAGGGG
CGGCTGATACCGGTCATCTTTCGCCTGTACCACGAAAATACCGGCAGTTGGTTCTGGTGG
GGAGATAAGCAATCAACCCCTGAACAATACAAGCAATTGTTCCGCTATTCCGTCGAGTAT
TTGCGCGATGTGAAAGGTGTGCGCAATTTCCTGTATGCCTATTCGCCCAACAACTTTTGG
GACGTGACCGAGGCCAATTACCTGGAGCGTTATCCGGGGGATGAGTGGGTGGATGTACTG
GGATTTGATACCTATGGCCCGGTGGCGGACAACGCTGACTGGTTCCGCAATGTGGTGGCC
AATGCGGCCTTGGTTGCCCGCATGGCGGAAGCGCGGGGCAAAATACCGGTGATCTCCGAG
ATAGGTATACGCGCTCCCGACATTGAAGCCGGGCTCTATGATAACCAGTGGTATCGCAAG
CTTATCTCCGGCCTCAAGGCCGATCCGGATGCACGCGAGATTGCCTTCCTGCTGGTATGG
CGCAATGCCCCGCAGGGAGTTCCTGGCCCCAATGGCACCCAGGTTCCCCATTATTGGGTG
CCTGCTAACCGCCCGGAGAATATCAACAATGGCACCCTGGAGGACTTCCAGGCCTTTTAT
GCCGATGAATTCACAGCGTTCAATCGCGACATCGAGCAGGTCTATCAGCGTCCGACCCTG
ATAGTTAAATAG

# Drug_Target_71_General_Function:
Involved in mannan endo-1,4-beta-mannosidase activity

# Drug_Target_71_General_References:
7848261	Braithwaite KL, Black GW, Hazlewood GP, Ali BR, Gilbert HJ: A non-modular endo-beta-1,4-mannanase from Pseudomonas fluorescens subspecies cellulosa. Biochem J. 1995 Feb 1;305 ( Pt 3):1005-10.

# Drug_Target_71_HGNC_ID:
Not Available

# Drug_Target_71_HPRD_ID:
Not Available

# Drug_Target_71_ID:
3480

# Drug_Target_71_Locus:
Not Available

# Drug_Target_71_Molecular_Weight:
47488

# Drug_Target_71_Name:
Mannan endo-1,4-beta-mannosidase

# Drug_Target_71_Number_of_Residues:
423

# Drug_Target_71_PDB_ID:
1R7O

# Drug_Target_71_Pathway:
Not Available

# Drug_Target_71_Pfam_Domain_Function:
PF02156	Glyco_hydro_26

# Drug_Target_71_Protein_Sequence:
>Mannan endo-1,4-beta-mannosidase precursor
MKTITTARLPWAAQSFALGICLIALLGCNHAANKSSASRADVKPVTVKLVDSQATMETRS
LFAFMQEQRRHSIMFGHQHETTQGLTITRTDGTQSDTFNAVGDFAAVYGWDTLSIVAPKA
EGDIVAQVKKAYARGGIITVSSHFDNPKTDTQKGVWPVGTSWDQTPAVVDSLPGGAYNPV
LNGYLDQVAEWANNLKDEQGRLIPVIFRLYHENTGSWFWWGDKQSTPEQYKQLFRYSVEY
LRDVKGVRNFLYAYSPNNFWDVTEANYLERYPGDEWVDVLGFDTYGPVADNADWFRNVVA
NAALVARMAEARGKIPVISEIGIRAPDIEAGLYDNQWYRKLISGLKADPDAREIAFLLVW
RNAPQGVPGPNGTQVPHYWVPANRPENINNGTLEDFQAFYADEFTAFNRDIEQVYQRPTL
IVK

# Drug_Target_71_Reaction:
Random hydrolysis of 1,4-beta-D-mannosidic linkages in mannans, galactomannans and glucomannans ALL_REAC (other) R01332 R06207(G) REFERENCE 1 AUTHORS Eriksson, A.F.V. TITLE Purification and characterisation of a fungal beta-mannanase. JOURNAL Acta Chem. Scand. 22 (1968) 1924-1934. ORGANISM Aspergillus niger REFERENCE 2 AUTHORS Reese, E.T. TITLE beta-Mannanases of fungi. JOURNAL Can. J. Microbiol. 11 (1965) 167-183. ORGANISM Paecilomyces variotii, Penicillium funiculosum, Penicillium wortmanni, Penicillium verruculosum, Penicillium ochro-chloron, Fusicoccum sp., Aspergillus luchuensis, Aspergillus giganteus, Paecilomyces variotii

# Drug_Target_71_Signals:
1-31

# Drug_Target_71_Specific_Function:
Hydrolyzes mannan and galactomannan, but displays little activity towards other polysaccharides located in the plant cell wall. Preferentially hydrolyzes the larger oligosaccharides

# Drug_Target_71_SwissProt_ID:
P49424

# Drug_Target_71_SwissProt_Name:
MANA_CELJU

# Drug_Target_71_Synonyms:
EC 3.2.1.78
Mannan endo-1,4-beta-mannosidase precursor
Mannanase A

# Drug_Target_71_Theoretical_pI:
5.46

# Drug_Target_71_Transmembrane_Regions:
None

# Drug_Target_72_Cellular_Location:
Secreted protein

# Drug_Target_72_Chromosome_Location:
Not Available

# Drug_Target_72_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_72_Essentiality:
Non-Essential

# Drug_Target_72_GenAtlas_ID:
Not Available

# Drug_Target_72_GenBank_ID_Gene:
D45839

# Drug_Target_72_GenBank_ID_Protein:
987684

# Drug_Target_72_GeneCard_ID:
Not Available

# Drug_Target_72_Gene_Name:
MSDC

# Drug_Target_72_Gene_Sequence:
>1536 bp
ATGCGTCTTCCAGTGTCATTCCCTCTGACAGTTCTGAGCTTGTTGGGCTCGACAATTGCT
CATCCCTATGGCGAGACCGAGGCTGTTTTGCGAAGTGAGCCTAAGAGTAACCAAGCCAAA
GCCGACGCTGTCAAAGAGGCCTTCCAGCACGCGTGGAATGGATACATGAAATATGCCTTC
CCTCATGACGAGTTGACTCCTGTCAGCAATGGTCATGCCGACTCTAGAAATGGATGGGGG
GCCTCAGCAGTTGACGCGCTTTCCACGGCCGTGATTATGGGCAAAGCGGATGTTGTGAAT
GCCATTCTCGAGCATGTCGCCGACATTGACTTCTCGAAGACCTCGGATACCGTCAGTCTT
TTCGAAACAACCATTCGTTACTTGGCGGGTATGCTATCGGGTTACGATCTGCTTCAGGGA
CCTGCCAAGAATTTGGTCGATAACCAAGACCTCATTGACGGATTACTGGACCAGTCAAGA
AACCTGGCCGATGTTCTGAAATTTGCTTTCGATACCCCTTCGGGTGTCCCCTATAATAAC
ATCAACATCACCTCGCACGGAAATGACGGCGCAACCACTAATGGCCTCGCTGTGACTGGC
ACACTGGTTCTGGAATGGACTCGTCTTTCTGATCTGACAGGTGATGAAGAGTATGCCAAA
TTAAGCCAGAAGGCCGAGTCTTATCTGCTCAAGCCGCAGCCATCGAGCAGCGAGCCTTTC
CCTGGTCTCGTAGGCAGCTCGATTAATATCAACGATGGTCAATTTGCCGACTCCAGAGTC
TCTTGGAATGGAGGTGACGATTCATTCTATGAGTACCTGATCAAGATGTACGTGTACGAC
CCTAAGCGGTTTGAGACATACAAGGATCGCTGGGTCCTGGCAGCCGAGTCGACTATCAAG
CATCTCAAGTCGCACCCGAAGTCCCGCCCGGACTTGACGTTCCTGTCTTCCTACAGTAAC
AGGAATTATGATCTCAGCTCGCAGCACCTGACTTGCTTCGATGGCGGTAGTTTTCTTCTG
GGCGGTACCGTTCTGGACCGCCAGGACTTCATTGATTTTGGTCTGGAGCTTGTTGACGGC
TGTGAGGCTACCTACAATTCTACTCTGACCAAGATCGGTCCAGACTCGTGGGGCTGGGAC
CCAAAGAAGGTCCCCAGTGACCAGAAAGAATTCTATGAAAAAGCTGGCTTCTATATCAGT
AGTGGTTCGTACGTCCTCCGCCCCGAGGTGATTGAAAGTTTTTACTACGCGCACCGCGTT
ACTGGAAAGGAAATTTACCGTGACTGGGTTTGGAATGCGTTCGTTGCAATTAACTCGACC
TGCCGTACCGACTCTGGTTTCGCTGCTGTATCCGACGTCAACAAGGCGAACGGTGGCTCC
AAGTACGACAACCAAGAGAGTTTCCTCTTCGCCGAGGTCATGAAGTACTCATATCTCGCT
CATTCCGAGGATGCTGCATGGCAAGTCCAGAAGGGTGGCAAGAATACCTTCGTGTACAAC
ACTGAGGCTCACCCGATTAGCGTCGCACGCAACTAA

# Drug_Target_72_General_Function:
Involved in mannosyl-oligosaccharide 1,2-alpha-mannosidase activity

# Drug_Target_72_General_References:
7640307	Yoshida T, Ichishima E: Molecular cloning and nucleotide sequence of the genomic DNA for 1,2-alpha-D-mannosidase gene, msdC from Penicillium citrinum. Biochim Biophys Acta. 1995 Aug 22;1263(2):159-62.
8452520	Yoshida T, Inoue T, Ichishima E: 1,2-alpha-D-mannosidase from Penicillium citrinum: molecular and enzymic properties of two isoenzymes. Biochem J. 1993 Mar 1;290 ( Pt 2):349-54.

# Drug_Target_72_HGNC_ID:
Not Available

# Drug_Target_72_HPRD_ID:
Not Available

# Drug_Target_72_ID:
3258

# Drug_Target_72_Locus:
Not Available

# Drug_Target_72_Molecular_Weight:
56570

# Drug_Target_72_Name:
Mannosyl-oligosaccharide alpha-1,2-mannosidase

# Drug_Target_72_Number_of_Residues:
511

# Drug_Target_72_PDB_ID:
1KKT

# Drug_Target_72_Pathway:
Not Available

# Drug_Target_72_Pfam_Domain_Function:
PF01532	Glyco_hydro_47

# Drug_Target_72_Protein_Sequence:
>Mannosyl-oligosaccharide alpha-1,2-mannosidase precursor
MRLPVSFPLTVLSLLGSTIAHPYGETEAVLRSEPKSNQAKADAVKEAFQHAWNGYMKYAF
PHDELTPVSNGHADSRNGWGASAVDALSTAVIMGKADVVNAILEHVADIDFSKTSDTVSL
FETTIRYLAGMLSGYDLLQGPAKNLVDNQDLIDGLLDQSRNLADVLKFAFDTPSGVPYNN
INITSHGNDGATTNGLAVTGTLVLEWTRLSDLTGDEEYAKLSQKAESYLLKPQPSSSEPF
PGLVGSSININDGQFADSRVSWNGGDDSFYEYLIKMYVYDPKRFETYKDRWVLAAESTIK
HLKSHPKSRPDLTFLSSYSNRNYDLSSQHLTCFDGGSFLLGGTVLDRQDFIDFGLELVDG
CEATYNSTLTKIGPDSWGWDPKKVPSDQKEFYEKAGFYISSGSYVLRPEVIESFYYAHRV
TGKEIYRDWVWNAFVAINSTCRTDSGFAAVSDVNKANGGSKYDNQESFLFAEVMKYSYLA
HSEDAAWQVQKGGKNTFVYNTEAHPISVARN

# Drug_Target_72_Reaction:
Hydrolysis of the terminal 1,2-linked alpha-D-mannose residues in the oligo-mannose oligosaccharide Man9(GlcNAc)2 ALL_REAC (other) R05982(G) R06722(G)

# Drug_Target_72_Signals:
1-35

# Drug_Target_72_Specific_Function:
Involved in the maturation of Asn-linked oligosaccharides. Progressively trim alpha-1,2-linked mannose residues from Man(9)GlcNAc(2) to produce Man(5)GlcNAc(2)

# Drug_Target_72_SwissProt_ID:
P31723

# Drug_Target_72_SwissProt_Name:
MAN12_PENCI

# Drug_Target_72_Synonyms:
EC 3.2.1.113
Man(9)-alpha-mannosidase
Mannosyl-oligosaccharide alpha-1,2-mannosidase precursor

# Drug_Target_72_Theoretical_pI:
4.83

# Drug_Target_72_Transmembrane_Regions:
None

# Drug_Target_73_Cellular_Location:
Not Available

# Drug_Target_73_Chromosome_Location:
Not Available

# Drug_Target_73_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_73_Essentiality:
Non-Essential

# Drug_Target_73_GenAtlas_ID:
Not Available

# Drug_Target_73_GenBank_ID_Gene:
Not Available

# Drug_Target_73_GenBank_ID_Protein:
Not Available

# Drug_Target_73_GeneCard_ID:
Not Available

# Drug_Target_73_Gene_Name:
Not Available

# Drug_Target_73_Gene_Sequence:
Not Available

# Drug_Target_73_General_Function:
Not Available

# Drug_Target_73_General_References:
10329150	Yang F, Bewley CA, Louis JM, Gustafson KR, Boyd MR, Gronenborn AM, Clore GM, Wlodawer A: Crystal structure of cyanovirin-N, a potent HIV-inactivating protein, shows unexpected domain swapping. J Mol Biol. 1999 May 7;288(3):403-12.
9210678	Boyd MR, Gustafson KR, McMahon JB, Shoemaker RH, O'Keefe BR, Mori T, Gulakowski RJ, Wu L, Rivera MI, Laurencot CM, Currens MJ, Cardellina JH 2nd, Buckheit RW Jr, Nara PL, Pannell LK, Sowder RC 2nd, Henderson LE: Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob Agents Chemother. 1997 Jul;41(7):1521-30.
9299483	Gustafson KR, Sowder RC 2nd, Henderson LE, Cardellina JH 2nd, McMahon JB, Rajamani U, Pannell LK, Boyd MR: Isolation, primary sequence determination, and disulfide bond structure of cyanovirin-N, an anti-HIV (human immunodeficiency virus) protein from the cyanobacterium Nostoc ellipsosporum. Biochem Biophys Res Commun. 1997 Sep 8;238(1):223-8.
9665171	Bewley CA, Gustafson KR, Boyd MR, Covell DG, Bax A, Clore GM, Gronenborn AM: Solution structure of cyanovirin-N, a potent HIV-inactivating protein. Nat Struct Biol. 1998 Jul;5(7):571-8.

# Drug_Target_73_HGNC_ID:
Not Available

# Drug_Target_73_HPRD_ID:
Not Available

# Drug_Target_73_ID:
3444

# Drug_Target_73_Locus:
Not Available

# Drug_Target_73_Molecular_Weight:
11013

# Drug_Target_73_Name:
Cyanovirin-N

# Drug_Target_73_Number_of_Residues:
101

# Drug_Target_73_PDB_ID:
1M5M

# Drug_Target_73_Pathway:
Not Available

# Drug_Target_73_Pfam_Domain_Function:
PF08881	CNVH

# Drug_Target_73_Protein_Sequence:
>Cyanovirin-N
LGKFSQTCYNSAIQGSVLTSTCERTNGGYNTSSIDLNSVIENVDGSLKWQPSNFIETCRN
TQLAGSSELAAECKTRAQQFVSTKINLDDHIANIDGTLKYE

# Drug_Target_73_Reaction:
Not Available

# Drug_Target_73_Signals:
None

# Drug_Target_73_Specific_Function:
Unknown

# Drug_Target_73_SwissProt_ID:
P81180

# Drug_Target_73_SwissProt_Name:
CVN_NOSEL

# Drug_Target_73_Synonyms:
CV-N

# Drug_Target_73_Theoretical_pI:
4.69

# Drug_Target_73_Transmembrane_Regions:
None

# Drug_Target_74_Cellular_Location:
Not Available

# Drug_Target_74_Chromosome_Location:
Not Available

# Drug_Target_74_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_74_Essentiality:
Non-Essential

# Drug_Target_74_GenAtlas_ID:
Not Available

# Drug_Target_74_GenBank_ID_Gene:
Not Available

# Drug_Target_74_GenBank_ID_Protein:
Not Available

# Drug_Target_74_GeneCard_ID:
Not Available

# Drug_Target_74_Gene_Name:
LYZ

# Drug_Target_74_Gene_Sequence:
Not Available

# Drug_Target_74_General_Function:
Not Available

# Drug_Target_74_General_References:
Not Available

# Drug_Target_74_HGNC_ID:
Not Available

# Drug_Target_74_HPRD_ID:
Not Available

# Drug_Target_74_ID:
6252

# Drug_Target_74_Locus:
Not Available

# Drug_Target_74_Molecular_Weight:
Not Available

# Drug_Target_74_Name:
Lysozyme C

# Drug_Target_74_Number_of_Residues:
0

# Drug_Target_74_PDB_ID:
Not Available

# Drug_Target_74_Pathway:
Not Available

# Drug_Target_74_Pfam_Domain_Function:
Not Available

# Drug_Target_74_Protein_Sequence:
Not Available

# Drug_Target_74_Reaction:
Not Available

# Drug_Target_74_Signals:
Not Available

# Drug_Target_74_Specific_Function:
Not Available

# Drug_Target_74_SwissProt_ID:
P61626

# Drug_Target_74_SwissProt_Name:
LYSC_HUMAN

# Drug_Target_74_Synonyms:
Not Available

# Drug_Target_74_Theoretical_pI:
Not Available

# Drug_Target_74_Transmembrane_Regions:
Not Available

# Drug_Target_75_Cellular_Location:
Secreted

# Drug_Target_75_Chromosome_Location:
1

# Drug_Target_75_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_75_Essentiality:
Non-Essential

# Drug_Target_75_GenAtlas_ID:
Not Available

# Drug_Target_75_GenBank_ID_Gene:
M21054

# Drug_Target_75_GenBank_ID_Protein:
190013

# Drug_Target_75_GeneCard_ID:
PLA2G1B

# Drug_Target_75_Gene_Name:
PLA2G1B

# Drug_Target_75_Gene_Sequence:
>447 bp
ATGAAACTCCTTGTGCTAGCTGTGCTGCTCACAGTGGCCGCCGCCGACAGCGGCATCAGC
CCTCGGGCCGTGTGGCAGTTCCGCAAAATGATCAAGTGCGTGATCCCGGGGAGTGACCCC
TTCTTGGAATACAACAACTACGGCTGCTACTGTGGCTTGGGGGGCTCAGGCACCCCCGTG
GATGAACTGGACAAGTGCTGCCAGACACATGACAACTGCTATGACCAGGCCAAGAAGCTG
GACAGCTGTAAATTTCTGCTGGACAACCCGTACACCCACACCTATTCATACTCGTGCTCT
GGCTCGGCAATCACCTGTAGCAGCAAAAACAAAGAGTGTGAGGCCTTCATTTGCAACTGC
GACCGCAACGCTGCCATCTGCTTTTCAAAAGCTCCATATAACAAGGCACACAAGAACCTG
GACACCAAGAAGTATTGTCAGAGTTGA

# Drug_Target_75_General_Function:
Involved in bile acid binding

# Drug_Target_75_General_References:
14702039	Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21.
15489334	Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.
16541075	Scherer SE, Muzny DM, Buhay CJ, Chen R, Cree A, Ding Y, Dugan-Rocha S, Gill R, Gunaratne P, Harris RA, Hawes AC, Hernandez J, Hodgson AV, Hume J, Jackson A, Khan ZM, Kovar-Smith C, Lewis LR, Lozado RJ, Metzker ML, Milosavljevic A, Miner GR, Montgomery KT, Morgan MB, Nazareth LV, Scott G, Sodergren E, Song XZ, Steffen D, Lovering RC, Wheeler DA, Worley KC, Yuan Y, Zhang Z, Adams CQ, Ansari-Lari MA, Ayele M, Brown MJ, Chen G, Chen Z, Clerc-Blankenburg KP, Davis C, Delgado O, Dinh HH, Draper H, Gonzalez-Garay ML, Havlak P, Jackson LR, Jacob LS, Kelly SH, Li L, Li Z, Liu J, Liu W, Lu J, Maheshwari M, Nguyen BV, Okwuonu GO, Pasternak S, Perez LM, Plopper FJ, Santibanez J, Shen H, Tabor PE, Verduzco D, Waldron L, Wang Q, Williams GA, Zhang J, Zhou J, Allen CC, Amin AG, Anyalebechi V, Bailey M, Barbaria JA, Bimage KE, Bryant NP, Burch PE, Burkett CE, Burrell KL, Calderon E, Cardenas V, Carter K, Casias K, Cavazos I, Cavazos SR, Ceasar H, Chacko J, Chan SN, Chavez D, Christopoulos C, Chu J, Cockrell R, Cox CD, Dang M, Dathorne SR, David R, Davis CM, Davy-Carroll L, Deshazo DR, Donlin JE, D'Souza L, Eaves KA, Egan A, Emery-Cohen AJ, Escotto M, Flagg N, Forbes LD, Gabisi AM, Garza M, Hamilton C, Henderson N, Hernandez O, Hines S, Hogues ME, Huang M, Idlebird DG, Johnson R, Jolivet A, Jones S, Kagan R, King LM, Leal B, Lebow H, Lee S, LeVan JM, Lewis LC, London P, Lorensuhewa LM, Loulseged H, Lovett DA, Lucier A, Lucier RL, Ma J, Madu RC, Mapua P, Martindale AD, Martinez E, Massey E, Mawhiney S, Meador MG, Mendez S, Mercado C, Mercado IC, Merritt CE, Miner ZL, Minja E, Mitchell T, Mohabbat F, Mohabbat K, Montgomery B, Moore N, Morris S, Munidasa M, Ngo RN, Nguyen NB, Nickerson E, Nwaokelemeh OO, Nwokenkwo S, Obregon M, Oguh M, Oragunye N, Oviedo RJ, Parish BJ, Parker DN, Parrish J, Parks KL, Paul HA, Payton BA, Perez A, Perrin W, Pickens A, Primus EL, Pu LL, Puazo M, Quiles MM, Quiroz JB, Rabata D, Reeves K, Ruiz SJ, Shao H, Sisson I, Sonaike T, Sorelle RP, Sutton AE, Svatek AF, Svetz LA, Tamerisa KS, Taylor TR, Teague B, Thomas N, Thorn RD, Trejos ZY, Trevino BK, Ukegbu ON, Urban JB, Vasquez LI, Vera VA, Villasana DM, Wang L, Ward-Moore S, Warren JT, Wei X, White F, Williamson AL, Wleczyk R, Wooden HS, Wooden SH, Yen J, Yoon L, Yoon V, Zorrilla SE, Nelson D, Kucherlapati R, Weinstock G, Gibbs RA: The finished DNA sequence of human chromosome 12. Nature. 2006 Mar 16;440(7082):346-51.
3028739	Seilhamer JJ, Randall TL, Yamanaka M, Johnson LK: Pancreatic phospholipase A2: isolation of the human gene and cDNAs from porcine pancreas and human lung. DNA. 1986 Dec;5(6):519-27.
6349696	Verheij HM, Westerman J, Sternby B, De Haas GH: The complete primary structure of phospholipase A2 from human pancreas. Biochim Biophys Acta. 1983 Sep 14;747(1-2):93-9.
7060561	Grataroli R, Dijkman R, Dutilh CE, van der Ouderaa F, De Haas GH, Figarella C: Studies on prophospholipase A2 and its enzyme from human pancreatic juice. Catalytic properties and sequence of the N-terminal region. Eur J Biochem. 1982 Feb;122(1):111-7.

# Drug_Target_75_HGNC_ID:
GNC:9030

# Drug_Target_75_HPRD_ID:
Not Available

# Drug_Target_75_ID:
6500

# Drug_Target_75_Locus:
12q23-q24.1

# Drug_Target_75_Molecular_Weight:
16359.5

# Drug_Target_75_Name:
Phospholipase A2

# Drug_Target_75_Number_of_Residues:
148

# Drug_Target_75_PDB_ID:
Not Available

# Drug_Target_75_Pathway:
Not Available

# Drug_Target_75_Pfam_Domain_Function:
PF00068	Phospholip_A2_1

# Drug_Target_75_Protein_Sequence:
>Phospholipase A2
MKLLVLAVLLTVAAADSGISPRAVWQFRKMIKCVIPGSDPFLEYNNYGCYCGLGGSGTPV
DELDKCCQTHDNCYDQAKKLDSCKFLLDNPYTHTYSYSCSGSAITCSSKNKECEAFICNC
DRNAAICFSKAPYNKAHKNLDTKKYCQS

# Drug_Target_75_Reaction:
Not Available

# Drug_Target_75_Signals:
1-15

# Drug_Target_75_Specific_Function:
PA2 catalyzes the calcium-dependent hydrolysis of the 2- acyl groups in 3-sn-phosphoglycerides

# Drug_Target_75_SwissProt_ID:
P04054

# Drug_Target_75_SwissProt_Name:
PA21B_HUMAN

# Drug_Target_75_Synonyms:
Group IB phospholipase A2
Phosphatidylcholine 2-acylhydrolase

# Drug_Target_75_Theoretical_pI:
7.91

# Drug_Target_75_Transmembrane_Regions:
None

# Drug_Target_76_Cellular_Location:
TM:Virion

# Drug_Target_76_Chromosome_Location:
Not Available

# Drug_Target_76_Drug_References:
Not Available

# Drug_Target_76_Essentiality:
Non-Essential

# Drug_Target_76_GenAtlas_ID:
Not Available

# Drug_Target_76_GenBank_ID_Gene:
Not Available

# Drug_Target_76_GenBank_ID_Protein:
Not Available

# Drug_Target_76_GeneCard_ID:
Not Available

# Drug_Target_76_Gene_Name:
env

# Drug_Target_76_Gene_Sequence:
Not Available

# Drug_Target_76_General_Function:
Involved in structural molecule activity

# Drug_Target_76_General_References:
3497350	Franchini G, Gurgo C, Guo HG, Gallo RC, Collalti E, Fargnoli KA, Hall LF, Wong-Staal F, Reitz MS Jr: Sequence of simian immunodeficiency virus and its relationship to the human immunodeficiency viruses. Nature. 1987 Aug 6-12;328(6130):539-43.

# Drug_Target_76_HGNC_ID:
Not Available

# Drug_Target_76_HPRD_ID:
Not Available

# Drug_Target_76_ID:
4787

# Drug_Target_76_Locus:
Not Available

# Drug_Target_76_Molecular_Weight:
101132

# Drug_Target_76_Name:
Envelope glycoprotein gp160

# Drug_Target_76_Number_of_Residues:
881

# Drug_Target_76_PDB_ID:
Not Available

# Drug_Target_76_Pathway:
Not Available

# Drug_Target_76_Pfam_Domain_Function:
PF00516	GP120
PF00517	GP41

# Drug_Target_76_Protein_Sequence:
>Envelope glycoprotein gp160
MGCLGNQLLIAILLLSVYGIYCTQYVTVFYGVPAWRNATIPLFCATKNRDTWGTTQCLPD
NGDYSELALNVTESFDAWENTVTEQAIEDVWQLFETSIKPCVKLSPLCITMRCNKSETDR
WGLTKSSTTITTAAPTSAPVSEKIDMVNETSSCIAQNNCTGLEQEQMISCKFTMTGLKRD
KTKEYNETWYSTDLVCEQGNSTDNESRCYMNHCNTSVIQESCDKHYWDTIRFRYCAPPGY
ALLRCNDTNYSGFMPKCSKVVVSSCTRMMETQTSTWFGFNGTRAENRTYIYWHGRDNRTI
ISLNKYYNLTMKCRRPGNKTVLPVTIMSGLVFHSQPLTDRPKQAWCWFGGKWKDAIKEVK
QTIVKHPRYTGTNNTDKINLTAPGGGDPEVTFMWTNCRGEFLYCKMNWFLNWVEDRDVTT
QRPKERHRRNYVPCHIRQIINTWHKVGKNVYLPPREGDLTCNSTVTSLIANIDWTDGNQT
SITMSAEVAELYRLELGDYKLVEITPIGLAPTDVKRYTTGGTSRNKRGVFVLGFLGFLAT
AGSAMGAASFRLTAQSRTLLAGIVQQQQQLLGVVKRQQELLRLTVWGTKNLQTRVTAIEK
YLEDQAQLNAWGCAFRQVCHTTVPWPNASLTPDWNNDTWQEWERKVDFLEENITALLEEA
QIQQEKNMYELQKLNSWDVFGNWFDLASWIKYIQYGIYVVVGVILLRIVIYIVQMLAKLR
QGYRPVFSSPPSYFQXTHTQQDPALPTREGKEGDGGEGGGNSSWPWQIEYIHFLIRQLIR
LLTWLFSNCRTLLSRAYQILQPILQRLSATLRRIREVLRTELTYLQYGWSYFHEAVQAGW
RSATETLAGAWGDLWETLRRGGRWILAIPRRIRQGLELTLL

# Drug_Target_76_Reaction:
Not Available

# Drug_Target_76_Signals:
1-19

# Drug_Target_76_Specific_Function:
Allows rapid transcytosis of the virus through CD4 negative cells such as simple epithelial monolayers of the intestinal, rectal and endocervical epithelial barriers. Both gp120 and gp41 specifically recognize glycosphingolipids galactosyl-ceramide (GalCer) or 3' sulfo-galactosyl-ceramide (GalS) present in the lipid rafts structures of epithelial cells. Binding to these alternative receptors allows the rapid transcytosis of the virus through the epithelial cells. This transcytotic vesicle-mediated transport of virions from the apical side to the basolateral side of the epithelial cells does not involve infection of the cells themselves (By similarity)

# Drug_Target_76_SwissProt_ID:
P05884

# Drug_Target_76_SwissProt_Name:
ENV_SIVMK

# Drug_Target_76_Synonyms:
Env polyprotein
Envelope glycoprotein gp160 precursor

# Drug_Target_76_Theoretical_pI:
8.40

# Drug_Target_76_Transmembrane_Regions:
697-717

# Drug_Target_7_Cellular_Location:
Secreted protein

# Drug_Target_7_Chromosome_Location:
Not Available

# Drug_Target_7_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_7_Essentiality:
Non-Essential

# Drug_Target_7_GenAtlas_ID:
IL12B

# Drug_Target_7_GenBank_ID_Gene:
M65272

# Drug_Target_7_GenBank_ID_Protein:
180626

# Drug_Target_7_GeneCard_ID:
IL12B

# Drug_Target_7_Gene_Name:
IL12B

# Drug_Target_7_Gene_Sequence:
>987 bp
ATGTGTCACCAGCAGTTGGTCATCTCTTGGTTTTCCCTGGTTTTTCTGGCATCTCCCCTC
GTGGCCATATGGGAACTGAAGAAAGATGTTTATGTCGTAGAATTGGATTGGTATCCGGAT
GCCCCTGGAGAAATGGTGGTCCTCACCTGTGACACCCCTGAAGAAGATGGTATCACCTGG
ACCTTGGACCAGAGCAGTGAGGTCTTAGGCTCTGGCAAAACCCTGACCATCCAAGTCAAA
GAGTTTGGAGATGCTGGCCAGTACACCTGTCACAAAGGAGGCGAGGTTCTAAGCCATTCG
CTCCTGCTGCTTCACAAAAAGGAAGATGGAATTTGGTCCACTGATATTTTAAAGGACCAG
AAAGAACCCAAAAATAAGACCTTTCTAAGATGCGAGGCCAAGAATTATTCTGGACGTTTC
ACCTGCTGGTGGCTGACGACAATCAGTACTGATTTGACATTCAGTGTCAAAAGCAGCAGA
GGCTCTTCTGACCCCCAAGGGGTGACGTGCGGAGCTGCTACACTCTCTGCAGAGAGAGTC
AGAGGGGACAACAAGGAGTATGAGTACTCAGTGGAGTGCCAGGAGGACAGTGCCTGCCCA
GCTGCTGAGGAGAGTCTGCCCATTGAGGTCATGGTGGATGCCGTTCACAAGCTCAAGTAT
GAAAACTACACCAGCAGCTTCTTCATCAGGGACATCATCAAACCTGACCCACCCAAGAAC
TTGCAGCTGAAGCCATTAAAGAATTCTCGGCAGGTGGAGGTCAGCTGGGAGTACCCTGAC
ACCTGGAGTACTCCACATTCCTACTTCTCCCTGACATTCTGCGTTCAGGTCCAGGGCAAG
AGCAAGAGAGAAAAGAAAGATAGAGTCTTCACGGACAAGACCTCAGCCACGGTCATCTGC
CGCAAAAATGCCAGCATTAGCGTGCGGGCCCAGGACCGCTACTATAGCTCATCTTGGAGC
GAATGGGCATCTGTGCCCTGCAGTTAG

# Drug_Target_7_General_Function:
Involved in hematopoietin/interferon-class (D200-domain) cytokine receptor activity

# Drug_Target_7_General_References:
10207176	Doucey MA, Hess D, Blommers MJ, Hofsteenge J: Recombinant human interleukin-12 is the second example of a C-mannosylated protein. Glycobiology. 1999 May;9(5):435-41.
11114383	Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, Vega F, Yu N, Wang J, Singh K, Zonin F, Vaisberg E, Churakova T, Liu M, Gorman D, Wagner J, Zurawski S, Liu Y, Abrams JS, Moore KW, Rennick D, de Waal-Malefyt R, Hannum C, Bazan JF, Kastelein RA: Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000 Nov;13(5):715-25.
11197695	Huang D, Cancilla MR, Morahan G: Complete primary structure, chromosomal localisation, and definition of polymorphisms of the gene encoding the human interleukin-12 p40 subunit. Genes Immun. 2000 Dec;1(8):515-20.
11753820	Picard C, Fieschi C, Altare F, Al-Jumaah S, Al-Hajjar S, Feinberg J, Dupuis S, Soudais C, Al-Mohsen IZ, Genin E, Lammas D, Kumararatne DS, Leclerc T, Rafii A, Frayha H, Murugasu B, Wah LB, Sinniah R, Loubser M, Okamoto E, Al-Ghonaium A, Tufenkeji H, Abel L, Casanova JL: Inherited interleukin-12 deficiency: IL12B genotype and clinical phenotype of 13 patients from six kindreds. Am J Hum Genet. 2002 Feb;70(2):336-48. Epub 2001 Dec 17.
1673147	Wolf SF, Temple PA, Kobayashi M, Young D, Dicig M, Lowe L, Dzialo R, Fitz L, Ferenz C, Hewick RM, et al.: Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol. 1991 May 1;146(9):3074-81.
1674604	Gubler U, Chua AO, Schoenhaut DS, Dwyer CM, McComas W, Motyka R, Nabavi N, Wolitzky AG, Quinn PM, Familletti PC, et al.: Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc Natl Acad Sci U S A. 1991 May 15;88(10):4143-7.
2070420	Gearing DP, Cosman D: Homology of the p40 subunit of natural killer cell stimulatory factor (NKSF) with the extracellular domain of the interleukin-6 receptor. Cell. 1991 Jul 12;66(1):9-10.
2204066	Stern AS, Podlaski FJ, Hulmes JD, Pan YC, Quinn PM, Wolitzky AG, Familletti PC, Stremlo DL, Truitt T, Chizzonite R, et al.: Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci U S A. 1990 Sep;87(17):6808-12.
9854038	Altare F, Lammas D, Revy P, Jouanguy E, Doffinger R, Lamhamedi S, Drysdale P, Scheel-Toellner D, Girdlestone J, Darbyshire P, Wadhwa M, Dockrell H, Salmon M, Fischer A, Durandy A, Casanova JL, Kumararatne DS: Inherited interleukin 12 deficiency in a child with bacille Calmette-Guerin and Salmonella enteritidis disseminated infection. J Clin Invest. 1998 Dec 15;102(12):2035-40.

# Drug_Target_7_HGNC_ID:
HGNC:5970

# Drug_Target_7_HPRD_ID:
01194

# Drug_Target_7_ID:
1379

# Drug_Target_7_Locus:
5q31.1-q33.1

# Drug_Target_7_Molecular_Weight:
37169

# Drug_Target_7_Name:
Interleukin-12 subunit beta

# Drug_Target_7_Number_of_Residues:
328

# Drug_Target_7_PDB_ID:
1F45

# Drug_Target_7_Pathway:
Not Available

# Drug_Target_7_Pfam_Domain_Function:
PF00041	fn3

# Drug_Target_7_Protein_Sequence:
>Interleukin-12 subunit beta precursor
MCHQQLVISWFSLVFLASPLVAIWELKKDVYVVELDWYPDAPGEMVVLTCDTPEEDGITW
TLDQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKDQ
KEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTCGAATLSAERV
RGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYTSSFFIRDIIKPDPPKN
LQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFCVQVQGKSKREKKDRVFTDKTSATVIC
RKNASISVRAQDRYYSSSWSEWASVPCS

# Drug_Target_7_Reaction:
Not Available

# Drug_Target_7_Signals:
1-22

# Drug_Target_7_Specific_Function:
Associates with IL23A to form the IL-23 interleukin, an heterodimeric cytokine which functions in innate and adaptive immunity. IL-23 may constitute with IL-17 an acute response to infection in peripheral tissues. IL-23 binds to an heterodimeric receptor complex composed of IL12RB1 and IL23R, activates the Jak- Stat signaling cascade, stimulates memory rather than naive T- cells and promotes production of proinflammatory cytokines. IL-23 induces autoimmune inflammation and thus may be responsible for autoimmune inflammatory diseases and may be important for tumorigenesis

# Drug_Target_7_SwissProt_ID:
P29460

# Drug_Target_7_SwissProt_Name:
IL12B_HUMAN

# Drug_Target_7_Synonyms:
CLMF p40
Cytotoxic lymphocyte maturation factor 40 kDa subunit
IL-12 subunit p40
IL-12B
Interleukin-12 subunit beta precursor
NK cell stimulatory factor chain 2
NKSF2

# Drug_Target_7_Theoretical_pI:
5.47

# Drug_Target_7_Transmembrane_Regions:
None

# Drug_Target_8_Cellular_Location:
Cytoplasmic

# Drug_Target_8_Chromosome_Location:
Not Available

# Drug_Target_8_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_8_Essentiality:
Non-Essential

# Drug_Target_8_GenAtlas_ID:
BCHE

# Drug_Target_8_GenBank_ID_Gene:
M32391

# Drug_Target_8_GenBank_ID_Protein:
1311630

# Drug_Target_8_GeneCard_ID:
BCHE

# Drug_Target_8_Gene_Name:
BCHE

# Drug_Target_8_Gene_Sequence:
>1809 bp
ATGCATAGCAAAGTCACAATCATATGCATCAGATTTCTCTTTTGGTTTCTTTTGCTCTGC
ATGCTTATTGGGAAGTCACATACTGAAGATGACATCATAATTGCAACAAAGAATGGAAAA
GTCAGAGGGATGAACTTGACAGTTTTTGGTGGCACGGTAACAGCCTTTCTTGGAATTCCC
TATGCACAGCCACCTCTTGGTAGACTTCGATTCAAAAAGCCACAGTCTCTGACCAAGTGG
TCTGATATTTGGAATGCCACAAAATATGCAAATTCTTGCTGTCAGAACATAGATCAAAGT
TTTCCAGGCTTCCATGGATCAGAGATGTGGAACCCAAACACTGACCTCAGTGAAGACTGT
TTATATCTAAATGTATGGATTCCAGCACCTAAACCAAAAAATGCCACTGTATTGATATGG
ATTTATGGTGGTGGTTTTCAAACTGGAACATCATCTTTACATGTTTATGATGGCAAGTTT
CTGGCTCGGGTTGAAAGAGTTATTGTAGTGTCAATGAACTATAGGGTGGGTGCCCTAGGA
TTCTTAGCTTTGCCAGGAAATCCTGAGGCTCCAGGGAACATGGGTTTATTTGATCAACAG
TTGGCTCTTCAGTGGGTTCAAAAAAATATAGCAGCCTTTGGTGGAAATCCTAAAAGTGTA
ACTCTCTTTGGAGAAAGTGCAGGAGCAGCTTCAGTTAGCCTGCATTTGCTTTCTCCTGGA
AGCCATTCATTGTTCACCAGAGCCATTCTGCAAAGTGGATCCTTTAATGCTCCTTGGGCG
GTAACATCTCTTTATGAAGCTAGGAACAGAACGTTGAACTTAGCTAAATTGACTGGTTGC
TCTAGAGAGAATGAGACTGAAATAATCAAGTGTCTTAGAAATAAAGATCCCCAAGAAATT
CTTCTGAATGAAGCATTTGTTGTCCCCTATGGGACTCCTTTGTCAGTAAACTTTGGTCCG
ACCGTGGATGGTGATTTTCTCACTGACATGCCAGACATATTACTTGAACTTGGACAATTT
AAAAAAACCCAGATTTTGGTGGGTGTTAATAAAGATGAAGGGACAGCTTTTTTAGTCTAT
GGTGCTCCTGGCTTCAGCAAAGATAACAATAGTATCATAACTAGAAAAGAATTTCAGGAA
GGTTTAAAAATATTTTTTCCAGGAGTGAGTGAGTTTGGAAAGGAATCCATCCTTTTTCAT
TACACAGACTGGGTAGATGATCAGAGACCTGAAAACTACCGTGAGGCCTTGGGTGATGTT
GTTGGGGATTATAATTTCATATGCCCTGCCTTGGAGTTCACCAAGAAGTTCTCAGAATGG
GGAAATAATGCCTTTTTCTACTATTTTGAACACCGATCCTCCAAACTTCCGTGGCCAGAA
TGGATGGGAGTGATGCATGGCTATGAAATTGAATTTGTCTTTGGTTTACCTCTGGAAAGA
AGAGATAATTACACAAAAGCCGAGGAAATTTTGAGTAGATCCATAGTGAAACGTTGGGCA
AATTTTGCAAAATATGGGAATCCAAATGAGACTCAGAACAATAGCACAAGCTGGCCTGTC
TTCAAAAGCACTGAACAAAAATATCTAACCTTGAATACAGAGTCAACAAGAATAATGACG
AAACTACGTGCTCAACAATGTCGATTCTGGACATCATTTTTTCCAAAAGTCTTGGAAATG
ACAGGAAATATTGATGAAGCAGAATGGGAGTGGAAAGCAGGATTCCATCGCTGGAACAAT
TACATGATGGACTGGAAAAATCAATTTAACGATTACACTAGCAAGAAAGAAAGTTGTGTG
GGTCTCTAA

# Drug_Target_8_General_Function:
Lipid transport and metabolism

# Drug_Target_8_General_References:
2322535	Arpagaus M, Kott M, Vatsis KP, Bartels CF, La Du BN, Lockridge O: Structure of the gene for human butyrylcholinesterase. Evidence for a single copy. Biochemistry. 1990 Jan 9;29(1):124-31.
2915989	McGuire MC, Nogueira CP, Bartels CF, Lightstone H, Hajra A, Van der Spek AF, Lockridge O, La Du BN: Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase. Proc Natl Acad Sci U S A. 1989 Feb;86(3):953-7.
3035536	Prody CA, Zevin-Sonkin D, Gnatt A, Goldberg O, Soreq H: Isolation and characterization of full-length cDNA clones coding for cholinesterase from fetal human tissues. Proc Natl Acad Sci U S A. 1987 Jun;84(11):3555-9.
3067729	Lockridge O: Structure of human serum cholinesterase. Bioessays. 1988 Oct;9(4):125-8.
3115973	Lockridge O, Adkins S, La Du BN: Location of disulfide bonds within the sequence of human serum cholinesterase. J Biol Chem. 1987 Sep 25;262(27):12945-52.
3477799	McTiernan C, Adkins S, Chatonnet A, Vaughan TA, Bartels CF, Kott M, Rosenberry TL, La Du BN, Lockridge O: Brain cDNA clone for human cholinesterase. Proc Natl Acad Sci U S A. 1987 Oct;84(19):6682-6.
3542989	Lockridge O, Bartels CF, Vaughan TA, Wong CK, Norton SE, Johnson LL: Complete amino acid sequence of human serum cholinesterase. J Biol Chem. 1987 Jan 15;262(2):549-57.

# Drug_Target_8_HGNC_ID:
HGNC:983

# Drug_Target_8_HPRD_ID:
01519

# Drug_Target_8_ID:
3923

# Drug_Target_8_Locus:
3q26.1-q26.2

# Drug_Target_8_Molecular_Weight:
68419

# Drug_Target_8_Name:
Cholinesterase

# Drug_Target_8_Number_of_Residues:
602

# Drug_Target_8_PDB_ID:
1P0Q

# Drug_Target_8_Pathway:
Heroin Pathway	SMP00407
Irinotecan Pathway	SMP00433

# Drug_Target_8_Pfam_Domain_Function:
PF00135	COesterase
PF08674	AChE_tetra

# Drug_Target_8_Protein_Sequence:
>Cholinesterase
MHSKVTIICIRFLFWFLLLCMLIGKSHTEDDIIIATKNGKVRGMNLTVFGGTVTAFLGIP
YAQPPLGRLRFKKPQSLTKWSDIWNATKYANSCCQNIDQSFPGFHGSEMWNPNTDLSEDC
LYLNVWIPAPKPKNATVLIWIYGGGFQTGTSSLHVYDGKFLARVERVIVVSMNYRVGALG
FLALPGNPEAPGNMGLFDQQLALQWVQKNIAAFGGNPKSVTLFGESAGAASVSLHLLSPG
SHSLFTRAILQSGSFNAPWAVTSLYEARNRTLNLAKLTGCSRENETEIIKCLRNKDPQEI
LLNEAFVVPYGTPLSVNFGPTVDGDFLTDMPDILLELGQFKKTQILVGVNKDEGTAFLVY
GAPGFSKDNNSIITRKEFQEGLKIFFPGVSEFGKESILFHYTDWVDDQRPENYREALGDV
VGDYNFICPALEFTKKFSEWGNNAFFYYFEHRSSKLPWPEWMGVMHGYEIEFVFGLPLER
RDNYTKAEEILSRSIVKRWANFAKYGNPNETQNNSTSWPVFKSTEQKYLTLNTESTRIMT
KLRAQQCRFWTSFFPKVLEMTGNIDEAEWEWKAGFHRWNNYMMDWKNQFNDYTSKKESCV
GL

# Drug_Target_8_Reaction:
an acylcholine + H2O = choline + a carboxylate

# Drug_Target_8_Signals:
1-28

# Drug_Target_8_Specific_Function:
An acylcholine + H(2)O = choline + a carboxylate

# Drug_Target_8_SwissProt_ID:
P06276

# Drug_Target_8_SwissProt_Name:
CHLE_HUMAN

# Drug_Target_8_Synonyms:
Acylcholine acylhydrolase
Butyrylcholine esterase
Choline esterase II
Cholinesterase precursor
EC 3.1.1.8
Pseudocholinesterase

# Drug_Target_8_Theoretical_pI:
7.47

# Drug_Target_8_Transmembrane_Regions:
None

# Drug_Target_9_Cellular_Location:
Not Available

# Drug_Target_9_Chromosome_Location:
Not Available

# Drug_Target_9_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_9_Essentiality:
Non-Essential

# Drug_Target_9_GenAtlas_ID:
Not Available

# Drug_Target_9_GenBank_ID_Gene:
U27583

# Drug_Target_9_GenBank_ID_Protein:
1002525

# Drug_Target_9_GeneCard_ID:
Not Available

# Drug_Target_9_Gene_Name:
cslA

# Drug_Target_9_Gene_Sequence:
>2103 bp
ATGAAGAAATTATTTGTAACCTGTATAGTCTTTTTCTCTATTTTAAGTCCTGCTCTGCTT
ATTGCACAGCAGACCGGTACTGCAGAACTGATTATGAAGCGGGTGATGCTGGACCTTAAA
AAGCCTTTGCGCAATATGGATAAGGTGGCGGAAAAGAACCTGAATACGCTGCAGCCTGAC
GGTAGCTGGAAGGATGTGCCTTATAAAGATGATGCCATGACCAATTGGTTGCCAAACAAC
CACCTGCTACAATTGGAAACTATTATACAGGCTTATATTGAAAAAGATAGTCACTATTAT
GGCGACGATAAAGTGTTTGACCAGATTTCCAAAGCTTTTAAGTATTGGTATGACAGCGAC
CCGAAAAGCCGCAACTGGTGGCACAATGAAATTGCCACTCCGCAGGCCCTTGGTGAAATG
CTGATCCTGATGCGTTACGGTAAAAAGCCGCTTGATGAAGCATTGGTGCATAAATTGACC
GAAAGAATGAAGCGGGGCGAACCGGAGAAGAAAACGGGGGCCAACAAAACAGATATCGCC
CTGCATTACTTTTATCGTGCTTTGTTAACGTCTGATGAGGCTTTGCTTTCCTTCGCCGTA
AAAGAATTGTTTTATCCCGTACAGTTTGTACACTATGAGGAAGGCCTGCAATACGATTAT
TCCTACCTGCAGCACGGTCCGCAATTACAGATATCGAGCTACGGTGCCGTATTTATTACC
GGGGTACTGAAACTTGCCAATTACGTTAGGGATACCCCTTATGCTTTAAGTACCGAGAAA
CTGGCTATATTTTCAAAGTATTACCGCGACAGTTATCTGAAAGCTATCCGTGGAAGTTAT
ATGGATTTTAACGTAGAAGGCCGCGGAGTAAGCCGGCCAGACATTCTAAATAAAAAGGCA
GAAAAAAAGAGGTTGCTGGTGGCGAAGATGATCGATCTTAAGCATACTGAAGAATGGGCT
GATGCGATAGCCAGGACAGATAGCACAGTTGCGGCCGGCTATAAGATTGAGCCCTATCAC
CATCAGTTCTGGAATGGTGATTATGTGCAACATTTAAGACCTGCCTATTCTTTTAATGTT
CGTATGGTGAGTAAGCGGACCCGACGCAGTGAATCCGGCAATAAAGAAAACCTGCTGGGC
AGGTATTTATCTGATGGGGCTACTAACATACAATTGCGCGGACCAGAATACTATAACATT
ATGCCGGTATGGGAATGGGACAAGATTCCTGGCATAACCAGCCGTGATTATTTAACCGAC
AGACCTTTGACGAAGCTTTGGGGAGAGCAGGGGAGCAATGACTTTGCAGGAGGGGTGTCT
GATGGTGTATACGGGGCCAGTGCCTACGCATTGGATTACGATAGCTTACAGGCAAAGAAA
GCCTGGTTCTTTTTTGACAAAGAGATTGTATGTCTTGGTGCCGGTATCAACAGCAATGCC
CCTGAAAACATTACCACTACCCTTAACCAGAGCTGGTTAAATGGCCCGGTTATAAGTACT
GCAGGTAAAACCGGCCGGGGTAAAATAACAACGTTTAAAGCACAGGGACAGTTCTGGTTG
TTGCACGATGCGATTGGTTATTACTTTCCTGAAGGGGCCAACCTTAGTCTGAGTACCCAG
TCGCAAAAAGGCAATTGGTTCCACATCAACAATTCACATTCAAAAGATGAAGTTTCTGGT
GATGTATTTAAGCTTTGGATCAACCATGGTGCCAGGCCAGAAAATGCGCAGTATGCTTAT
ATCGTTTTGCCGGGAATAAACAAGCCGGAAGAAATTAAAAAATATAATGGAACGGCACCG
AAAGTCCTTGCCAATACCAACCAGCTGCAGGCAGTTTATCATCAGCAGTTAGATATGGTA
CAGGCTATCTTCTATACAGCTGGAAAATTAAGCGTAGCGGGCATAGAAATTGAAACAGAT
AAGCCATGTGCAGTGCTGATCAAGCACATCAATGGCAAGCAGGTAATTTGGGCTGCCGAT
CCATTGCAAAAAGAAAAGACTGCAGTGTTGAGCATCAGGGATTTAAAAACAGGAAAAACA
AATCGGGTAAAAATTGATTTTCCGCAACAGGAATTTGCAGGTGCAACGGTTGAACTGAAA
TAG

# Drug_Target_9_General_Function:
Involved in catalytic activity

# Drug_Target_9_General_References:
10329169	Fethiere J, Eggimann B, Cygler M: Crystal structure of chondroitin AC lyase, a representative of a family of glycosaminoglycan degrading enzymes. J Mol Biol. 1999 May 14;288(4):635-47.
10618199	Tkalec AL, Fink D, Blain F, Zhang-Sun G, Laliberte M, Bennett DC, Gu K, Zimmermann JJ, Su H: Isolation and expression in Escherichia coli of cslA and cslB, genes coding for the chondroitin sulfate-degrading enzymes chondroitinase AC and chondroitinase B, respectively, from Flavobacterium heparinum. Appl Environ Microbiol. 2000 Jan;66(1):29-35.
11327856	Huang W, Boju L, Tkalec L, Su H, Yang HO, Gunay NS, Linhardt RJ, Kim YS, Matte A, Cygler M: Active site of chondroitin AC lyase revealed by the structure of enzyme-oligosaccharide complexes and mutagenesis. Biochemistry. 2001 Feb 27;40(8):2359-72.

# Drug_Target_9_HGNC_ID:
Not Available

# Drug_Target_9_HPRD_ID:
Not Available

# Drug_Target_9_ID:
2581

# Drug_Target_9_Locus:
Not Available

# Drug_Target_9_Molecular_Weight:
79695

# Drug_Target_9_Name:
Chondroitinase AC

# Drug_Target_9_Number_of_Residues:
700

# Drug_Target_9_PDB_ID:
1HMW

# Drug_Target_9_Pathway:
Not Available

# Drug_Target_9_Pfam_Domain_Function:
PF02278	Lyase_8
PF02884	Lyase_8_C
PF08124	Lyase_8_N

# Drug_Target_9_Protein_Sequence:
>Chondroitinase AC precursor
MKKLFVTCIVFFSILSPALLIAQQTGTAELIMKRVMLDLKKPLRNMDKVAEKNLNTLQPD
GSWKDVPYKDDAMTNWLPNNHLLQLETIIQAYIEKDSHYYGDDKVFDQISKAFKYWYDSD
PKSRNWWHNEIATPQALGEMLILMRYGKKPLDEALVHKLTERMKRGEPEKKTGANKTDIA
LHYFYRALLTSDEALLSFAVKELFYPVQFVHYEEGLQYDYSYLQHGPQLQISSYGAVFIT
GVLKLANYVRDTPYALSTEKLAIFSKYYRDSYLKAIRGSYMDFNVEGRGVSRPDILNKKA
EKKRLLVAKMIDLKHTEEWADAIARTDSTVAAGYKIEPYHHQFWNGDYVQHLRPAYSFNV
RMVSKRTRRSESGNKENLLGRYLSDGATNIQLRGPEYYNIMPVWEWDKIPGITSRDYLTD
RPLTKLWGEQGSNDFAGGVSDGVYGASAYALDYDSLQAKKAWFFFDKEIVCLGAGINSNA
PENITTTLNQSWLNGPVISTAGKTGRGKITTFKAQGQFWLLHDAIGYYFPEGANLSLSTQ
SQKGNWFHINNSHSKDEVSGDVFKLWINHGARPENAQYAYIVLPGINKPEEIKKYNGTAP
KVLANTNQLQAVYHQQLDMVQAIFYTAGKLSVAGIEIETDKPCAVLIKHINGKQVIWAAD
PLQKEKTAVLSIRDLKTGKTNRVKIDFPQQEFAGATVELK

# Drug_Target_9_Reaction:
Eliminative degradation of polysaccharides containing 1,4-beta-D-hexosaminyl and 1,3-beta-D-glucuronosyl linkages to disaccharides containing 4-deoxy-beta-D-gluc-4-enuronosyl groups

# Drug_Target_9_Signals:
1-22

# Drug_Target_9_Specific_Function:
Eliminative degradation of polysaccharides containing 1,4-beta-D-hexosaminyl and 1,3-beta-D-glucuronosyl linkages to disaccharides containing 4-deoxy-beta-D-gluc-4- enuronosyl groups

# Drug_Target_9_SwissProt_ID:
Q59288

# Drug_Target_9_SwissProt_Name:
CSLA_PEDHD

# Drug_Target_9_Synonyms:
Chondroitin AC eliminase
Chondroitin AC lyase
Chondroitin sulfate AC lyase
Chondroitinase AC precursor
EC 4.2.2.5

# Drug_Target_9_Theoretical_pI:
9.19

# Drug_Target_9_Transmembrane_Regions:
None

#END_DRUGCARD DB02944
